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Abstract 
 
Biotechnology, an umbrella term describing combinations of engineering and scientific 
knowledge from an array of disciplines used to produce products and processes from 
living organisms, has been identified as a key sector for future economic developments 
among industrialised and industrialising nations as it blurs traditional boundaries 
between various industries. The Irish Government has introduced a series of initiatives 
to facilitate the development of an internationally competitive indigenous biotechnology 
sector since the late 1990s, yet no in-depth analysis of the sector relative to international 
sectoral characteristics, structures, or policy themes have informed their design or 
implementation. This thesis analyses the Irish sector in the context of global sectoral 
developments by studying the Post-Fordist organisational structure of the international 
sector, where biotechnology firms interact with various actors at different stages of the 
sectoral value chain in a variety of innovative networks determined by place specific 
actor and institution endowments that form local knowledge communities. Through 
qualitatively investigating the Irish sector's actors and collaborative network structure, 
the thesis analyses the implications of the nature and character of these elements for the 
sector's future sustainability and development, and appraises existing Government 
policies relating to sectoral developments. The thesis found that the on-going initiatives 
have facilitated significant advances, yet have not addressed the legacy of pre-initiative 
resource and skill capacity weaknesses, while the sectoral value chain is fragmented as 
actors have developed poor networking arrangements due to their conservative natures, 
and the relative absence of key sector actors, skills and resources. These issues 
demonstrate that a complex overarching policy framework is required so as to engender 
the long-term development of a regionally tailored, systems-based support ecosystem 
which addresses existing structural weaknesses, and which facilitates and drives 
entrepreneurial and innovative activities throughout the sector's value chain.  
 
 
ACKNOWLEDGEMENTS 
 
I would like to thank a long list of people for the endless help, encouragement and 
guidance that I received during the course of this project. To do this justice would 
take several pages, the following are those whose help I am particularly indebted to. 
 
I would like to thank my supervisor Prof. Mark Boyle for his support, guidance and 
help, without which this thesis would not have been completed.  
 
I would like to thank all the participants in the questionnaire survey and interviews, 
their participation is greatly appreciated. 
 
To my family, I would like to say a big thank you for the numerous ways in which 
you helped, supported and tolerated me throughout this long experience. I owe you 
all so much in terms of moral, mental, and financial support (and much much 
more). 
 
I was incredibly fortunate to have a number of very good friends who helped me 
through this project. The entire project would have been unimaginable without their 
support and ability to put the experiences of thesis life into perspective. In particular 
I would like to thank Conor McCaffery, Nicola Brennan, Brian Conway, Dr. James 
Monagle, Simone Klapper, and Dr. Deirdre Quinn. I would also like to thank Aidan 
McGuire for giving me the first (and best) piece of Ph.D. related advice I received.  
 
Finally, I would also like to thank the following people: Prof. Rob Kitchin, all in 
NIRSA, all in the Department of Geography, Darren Riedy, Officer T.J. Whyte, 
Damien Byrne, Mr. and Mrs. Klapper, Regina Klapper, Stavros Vasarmidis, and 
Waldemar Reger.  
 
 
 
 
 
 
 
This thesis was funded by the Irish Research Council for the Humanities and the 
Social Sciences and the National Institute for Regional and Spatial Analysis 
(NIRSA). 
 
 
 
 
 
 
 
 
  
 
 
This thesis is dedicated to the memories of  
Aoife Begley, Ed O’Malley, Andrea Klapper and Jim Campion. 
 
 i 
Table of Contents 
 
CHAPTER 1:  
INTRODUCTION 
 
1.1 SETTING THE SCENE        1 
   1.1.1 The development of biotechnology      1 
   1.1.2 The development of the biotechnology industry      2 
   1.1.3 The unique structure of the international biotechnology industry   5 
1.2 FOCUS OF THE THESIS        6 
1.3 STRUCTURE OF THE THESIS       7 
 
CHAPTER 2:  
THE STRUCTURES AND DEVELOPMENT OF POST-FORDIST INDUSTRIAL  
NETWORKS AND CLUSTERS 
 
2.1 INTRODUCTION         10 
2.2 FROM FORDIST TO POST-FORDIST PRODUCTION SYSTEMS   10 
   2.2.1 The Fordist system of production      10 
   2.2.2 The emergence and development of the Post-Fordist production system  13 
2.3 NETWORKS          18 
2.4 INDUSTRIAL CLUSTERS        21 
   2.4.1 The concept of industrial clustering      22 
   2.4.2 Porter’s theory of industrial clusters       25 
   2.4.3 Cluster policy issues and formulation approaches    27 
   2.4.4 Cluster specific policy themes       33 
   2.4.5 Cluster specific entrepreneurial and innovative functional resource themes 38 
   2.4.6 Cluster informed policy themes       54 
2.5 CONCLUSION         55 
 
CHAPTER 3:  
THE ORGANISATIONAL STRUCTURES OF THE INTERNATIONAL 
BIOTECHNOLOGY INDUSTRY 
 
3.1 INTRODUCTION         57 
3.2 CLUSTERS IN THE INTERNATIONAL BIOTECHNOLOGY INDUSTRY  58 
   3.2.1 Bio-cluster development themes       59 
      3.2.1.1 General development themes of the US bio-clusters    59 
      3.2.1.2 General development themes of the European Union-based bio-clusters 66 
   3.2.2 PBC system development issues        69 
      3.2.2.1 Key PBC systemic and structural weakness     69 
3.3 ACTOR AND NETWORK TYPOLOGIES IN THE BIOTECHNOLOGY  
      INDUSTRY         71 
   3.3.1 Sectoral Actor Typologies       71 
   3.3.2 Formal and informal network typologies in the bio-sector   71 
      3.3.2.1 Typology of formal inter-actor networks in the biotechnology industry 72 
      3.3.2.2 The main inter-actor network types in bio-sector value chains  72 
      3.3.2.3 Networking patterns in the PBCs      83 
3.4 BIOTECHNOLOGY CLUSTER POLICY THEMES AND TEMPLATE  84 
   3.4.1 Bio-cluster development policy themes       84 
      3.4.1.1 The role of Government initiatives in the emergence of the international  
      bio-clusters         84 
      3.4.1.2 PBC cluster specific policy issue themes     88 
   3.4.2 Cluster specific policy themes to facilitate bio-cluster developments  91 
      3.4.2.1 Knowledge infrastructure, resources and skills    92 
      3.4.2.2 Entrepreneurial infrastructure, resources and skills    94 
      3.4.2.3 Inter-actor networks        96 
 ii 
      3.4.2.4 Market information exchange resources     97 
      3.4.2.5 Actor and institutional density, and skill, competence and resource depth 100 
3.5 CONCLUSION         102 
 
CHAPTER 4:  
METHODOLOGY 
 
4.1 INTRODUCTION         105 
4.2 THE RESEARCH QUESTION       105 
4.3 METHODOLOGY EMPLOYED IN CONSTRUCTING THE SECTORAL  
      PROFILE          105 
   4.3.1 Analysis of secondary documentation      105 
   4.3.2 Questionnaire of bio-firms       108 
      4.3.2.1 Questionnaire administration      109 
      4.3.2.2 Questionnaire analysis       110 
   4.3.3 In-depth interviews         111 
      4.3.3.1 Organisation of the interview process     111 
      4.3.3.2 The interview approach       113 
      4.3.3.3 Problems encountered       113 
      4.3.3.4 Interview analysis        114 
4.4 SUMMARY ACCOUNT OF INFORMATION FROM THE DIFFERENT  
      RESEARCH STAGES        115 
 
CHAPTER 5:  
A REVIEW OF IRELAND'S ECONOMIC DEVELOPMENT AND OF THE 
EVOLUTION OF THE IRISH GOVERNMENT'S BIOTECHNOLOGY-RELATED 
POLICIES 
 
5.1 INTRODUCTION         117 
5.2 IRELAND’S ECONOMIC DEVELOPMENT SINCE THE 1920s   117 
   5.2.1 Independence and the Protectionist era      117 
   5.2.2 Open Market Policies and Foreign Direct Investment    121 
   5.2.3 The development of “jobless growth” and steps towards recovery  124 
   5.2.4 The “Celtic Tiger” era        127 
   5.2.5 The post “Celtic Tiger” economy      133 
5.3 THE DEVELOPMENT OF GOVERNMENT POLICIES RELATING  
      TO BIOTECHNOLOGY        134 
   5.3.1 Measures to promote Science, Technology & Innovation, and the indigenous  
            bio-sector         134 
   5.3.2 Government measures to promote indigenous networks and clusters  140 
5.4 DISCUSSION         147 
   5.4.1 Irish industrial and STI policies       147 
   5.4.2 Network- and Cluster-related policies      149 
   5.4.3 Biotechnology specific policies       151 
 
CHAPTER 6:  
ACTOR TYPOLOGIES IN IRELAND’S INDIGENOUS BIOTECHNOLOGY SECTOR 
 
6.1 INTRODUCTION         153 
6.2 ACTOR TYPES IN THE IRISH BIO-SECTOR     153 
   6.2.1 Public Research and Education Organisations     153 
      6.2.1.1 Universities         154 
      6.2.1.2 Institutes of Technology       156 
      6.2.1.3 Public Research Institutes       156 
      6.2.1.4 Research Hospitals        157 
      6.2.1.5 The commercial orientation of Irish PREOs     157 
   6.2.2 Biotechnology firms        161 
 iii 
   6.2.3 Investors         163 
   6.2.4 Diversified Transnational Corporations      165 
   6.2.5 Irish Government departments and agencies     167 
      6.2.5.1 The Department of Enterprise, Trade and Innovation    169 
         6.2.5.1.1 Forfás         169 
         6.2.5.1.2 Science Foundation Ireland      169 
         6.2.5.1.3 The Industrial Development Agency Ireland    170 
         6.2.5.1.4 Enterprise Ireland       171 
         6.2.5.1.5 Enterprise Ireland’s Bioresearch Directorate    173 
          6.2.5.1.6 The Advisory Council for Science, Technology and Innovation  173 
      6.2.5.2 The Department of Education and Science      173 
         6.2.5.2.1 The Higher Education Authority and the Programme for Research  
                         in Third Level Institutions      174 
      6.2.5.3 The Department of Agriculture and Food      174 
         5.2.5.3.1 Teagasc         174 
      6.2.5.4 The Department of the Environment, Heritage and Local Government  174 
         6.2.5.4.1 The Environmental Protection Agency     175 
      6.2.5.5 The Department of Health and Children      175      
   6.2.6 Additional actor types        176 
      6.2.6.1 Suppliers of Goods and Services      176 
      6.2.6.2 Sub-national Biotechnology Centres      176 
      6.2.6.3 Trade Associations        177 
         6.2.6.3.1 InterTradeIreland       177 
         6.2.6.3.2 The Irish BioIndustry Association     178 
         6.2.6.3.3 Bioconnect Ireland       178 
         6.2.6.3.4 Biolink USA-Ireland       178 
         6.2.6.3.5 Biolink Canada-Ireland       178 
         6.2.6.3.6 TechLink UK-Ireland       178 
      6.2.6.4 Private Research Institutes       179 
      6.2.6.5 Repositories (Gene Banks)        179 
6.3 DISCUSSION         179 
 
CHAPTER 7:  
FORMAL AND INFORMAL INTER-ACTOR NETWORKS IN THE INDIGENOUS 
BIOTECHNOLOGY SECTOR 
 
7.1 INTRODUCTION         186 
7.2 INTER-ACTOR NETWORKS IN THE INDIGENOUS BIO-SECTOR  186 
   7.2.1 PREO-based research networks       187 
   7.2.2 PREO networks with commercial actors  (Bio-firms and TNCs)   192 
   7.2.3 Upstream bio-firm networks with PREOs     198 
   7.2.4 Downstream Bio-firm networks with commercial actors        200 
   7.2.5 Sectoral support actor networks       204 
7.3 DISCUSSION ON THE IRISH BIO-SECTOR'S NETWORK STRUCTURE 206 
 
CHAPTER 8:  
POLICY PROPOSALS FOR THE DEVELOPMENT OF THE INDIGENOUS  
BIOTECHNOLOGY SECTOR 
 
8.1 INTRODUCTION         210 
8.2 A REVIEW OF THE INDIGENOUS BIO-SECTOR'S GENERAL STRENGTHS  
      AND WEAKNESSES        210 
   8.2.1 General sectoral strengths       210 
   8.2.2 General sectoral weaknesses       212 
      8.2.2.1 PREO-based weaknesses       212 
         8.2.2.1.1 Basic research funding weaknesses     213 
         8.2.2.1.2 Key skills weaknesses       214 
 iv 
         8.2.2.1.3 Cross disciplinary structural weaknesses     215 
         8.2.2.1.4 The weak commercial orientation of administrators, academics  
           and students        216 
         8.2.2.1.5 PREO commercial support and intermediary actor weaknesses  218 
         8.2.2.1.6 Limited commercial “marketing” by PREOs    220 
      8.2.2.2 Bio-firm weaknesses       221 
      8.2.2.3 Entrepreneurial development skills and investor actor weaknesses  222 
      8.2.2.4 TNC-related weaknesses       224 
8.3 SECTORAL DEVELOPMENT POLICY PROPOSALS    226 
   8.3.1 Knowledge base infrastructure, resources and skills    230 
   8.3.2 Entrepreneurial infrastructures, resources and skills    233 
   8.3.3 An inter-actor network development programme     240 
   8.3.4 Market information exchange resources      241 
   8.3.5 Actor and institutional density, and skill, competence and resource depth  244 
8.5 CONCLUSION         248 
 
CHAPTER 9:  
A COMPARATIVE ANALYSIS BETWEEN THE IRISH AND INTERNATIONAL 
BIOTECHNOLOGY SECTORS 
 
9.1 INTRODUCTION         250 
9.2 ANALYSIS OF THE INTERNATIONAL CASE STUDIES AND  
      THE IRISH BIO-SECTOR        250 
   9.2.1 An analysis of the actor typologies of the international case studies and the  
Irish bio-sector         251 
   9.2.2 An analysis of the network typologies of the international case studies and the  
Irish bio-sector         255 
9.2.3 An analysis of agglomerations in the bio-cluster case studies and the  
Irish bio-sector         258 
   9.2.4 An analysis of the policy themes of the international case studies and the  
Irish bio-sector         260 
9.3 DISCUSSION         263 
 
Chapter 10:  
CONCLUSION 
 
10.1 INTRODUCTION         268 
10.2 SUMMARY OF THE MAIN FINDINGS OF THE THESIS   268 
10.3 POLICY IMPLICATIONS AND RECOMMENDATIONS    278 
10.4 CONTRIBUTION TO THE LITERATURE     280 
 
Bibliography          285 
 
Appendix A          327 
 
Appendix B          339 
 
Appendix C          347 
 
Appendix D          355 
 
 
 
 
 
 
 
 v 
List of Figures 
Figure 1.1: Structure of the Deoxyribose Nucleic Acid (DNA) double helix  2 
Figure 2.1: Porter’s Complete System      26 
Figure 5.1: Timeline of key events and publications relating to the development  
       of public industrial and science, technology and innovation policies 104 
Figure 6.1: Irish Third Level Institutions      159 
Figure 6.2: Ireland’s Main Research Hospitals     160 
 
List of Tables 
Table 2.1: Defining characteristics of networks      19 
Table 2.2: Characteristic differences between networks and clusters   23 
Table 2.3: A selection of industrial agglomeration theories    24 
Table 2.4: The four determinants and the two influencing factors of the national  
     diamond         29 
Table 2.5: Examples of cluster induced 'lock-in'.     32 
Table 2.6: Proto-cluster emergence and development stage themes   34 
Table 2.7: Instances when direct government policy intervention(s) should occur  
     in a PC system        38 
Table 2.8: Sample Knowledge Infrastructure, Resources and Skills SWOT  
     Questions         41 
Table 2.9: Different forms of entrepreneurial developments    45 
Table 2.10: Sample Entrepreneurial Resource and Skill SWOT Questions  45 
Table 2.11: Issues undermining network developments    47 
Table 2.12: Sample Network SWOT Questions     48 
Table 2.13: Sample Market Information Exchange SWOT Questions  50 
Table 2.14: Sample Actor Thickness and Institutional Depth and Density  
       SWOT Questions        49 
Table 3.1: The bio-sector actor typologies      73 
Table 3.2: Formal inter-actor network typologies in the biotechnology industry 74 
Table 3.3: The four phases of the clinical research trial process   79 
Table 3.4: 'Hard' entrepreneurial sectoral supports     96 
Table 4.1: Survey respondents activity focus      111 
Table 4.2: Interview respondents and activities     115 
Table 6.1: The bio-sector actor typologies      155 
Table 6.2: Activity focus of the Irish bio-sector's bio-firms    163 
Table 6.3: Regional endowments of pre-initiative sectoral actors   182 
Table 6.4:  Comparison of pre- and post-initiative regional endowments of  
      sectoral actors        184 
Table 9.1: The main contributions of the international bio-sector's actor analysis  
     to the Irish bio-sector       251 
Table 9.2: The main contributions of the analysis of the international bio-sector's  
     network structure to the Irish bio-sector     256 
Table 9.3: The main contributions of the international bio-sector's bio-cluster  
     analysis to the Irish bio-sector      259 
Table 9.4: Review of the international bio-sector's policy themes   261 
 
 
 
 
 
 
 
 
 
 
 
 
 vi 
List of Acronyms  
 
 
 
 
 ACSTI: The Advisory Council for Science, Technology  
   and Innovation  
 AUA: The Atlantic University Alliance  
 CSETs: The Centres for Science, Engineering & Technology  
 DES: The Department of Education and Skills  
 DETI: The Department of Enterprise, Trade and Innovation  
 DMMC: The Dublin Molecular Medicine Centre  
 DNA: Deoxyribonucleic Acid  
 EEC: The European Economic Community  
 EI: Enterprise Ireland 
 EIFR: Entrepreneurial and Innovative Functional Resource  
 EIBD: Enterprise Ireland's Biotechnology Directorate 
 EPA: The Environmental Protection Agency 
 EU: The European Union 
 FDI: Foreign Direct Investment 
 FPs: Framework Programmes  
 GATT: The General Agreement on Tariffs and Trade  
 GDA: The Greater Dublin Area 
 GDP: Gross Domestic Product  
 GMOs: Genetically Modified Organisms 
 HEA: The Higher Education Authority 
 HRB: The Health Research Board 
 HSE: The Heath Service Executive 
 IBEC: The Irish Businesses and Employers Confederation  
 IBIA: The Irish BioIndustry Association  
 ICSTI: The Irish Council for Science, Technology and  
   Innovation  
 IFSC: The International Financial Services Centre  
 ILOs: Industrial Liaison Offices  
 IP: Intellectual Property 
 IPO: Initial Public Offering 
 IoTs: Institutes of Technology  
 JIT: Just in Time delivery  
 NAMA: The National Asset Management Agency  
 NBP: The National Biotechnology Programme  
 NBST: The National Board for Science and Technology  
 NCP: Network Cooperation Programme  
 NDP: The National Development Plan  
 NESC: The National Economic and Social Council  
 NICTs: New Information and Communication Technologies 
 NIH: National Institutes of Health 
 NSS: The National Spatial Strategy 
 NTMA: The National Treasury Management Agency  
 NUIM: National University of Ireland, Maynooth 
 OECD: The Organisation for Economic Co-operation and 
Development 
 PBCs: Proto Biotechnology Clusters 
 PC: Proto Cluster 
 PCR: Polymerase Chain Reaction  
 PCT: A Patent Co-operation Treaty  
 PREOs: Public Research and Education Organisation 
 PRTLI: The Programme for Research in Third Level Institutions  
 rDNA: Recombinant Deoxyribonucleic Acid  
 R&D: Research and Development 
 RHs: Research Hospitals 
 RIs: Research Institutes 
 RTCs: The Regional Technical Colleges 
 RTDI: The Research, Technological Development  
     and Innovation fund  
 SFI: Science Foundation Ireland 
 SME: Small and Medium Enterprise  
 STI: Science, Technology and Innovation 
 STIAC: The Science, Technology and Innovation 
Advisory Council  
 SV: Silicon Valley 
 SWOT: Strengths, Weaknesses, Opportunities and 
Threats analysis  
 TFF: The Technology Foresight Fund  
 TNC: Transnational Corporations 
 TTOs: Technology Transfer Office 
 UK: The United Kingdom 
 UL: The University of Limerick 
 VCs: Venture Capitalists  
 
 1 
CHAPTER 1: 
INTRODUCTION 
 
1.1 SETTING THE SCENE 
Biotechnology is an umbrella term used to describe a combination of engineering and 
scientific knowledge and techniques derived from advances across a large array of 
disciplines and sub-technologies (including cellular and molecular biology, chemistry, 
physics, and information science) to produce new or improved products, processes and 
services from living organisms (Downey, 1979; Kenney 1986; Panetta, 2006). 
 
Due to its wide scientific base, biotechnology impacts on a variety of established 
industries, particularly through facilitating innovative developments across industries by 
blurring traditional boundaries which exist between them. As such, biotechnology has 
been identified as one of the key sectors for future economic developments among 
industrialised and industrialising nations (Massachusetts Biotechnology Council, 2002; 
European Commission, 2012). 
 
This chapter is divided into three sections. The remainder of the following section 
places the thesis into its proper context in relation to the development of biotechnology, 
and the development of the international biotechnology sector. The second section 
details the specific focus of the thesis. The structure of the thesis is presented in the final 
section. 
 
1.1.1 The development of biotechnology 
Biotechnology is based on a series of laboratory-based scientific advances which have 
occurred since the second half of the 20th century. The foundation of modern 
biotechnology can be traced to 1940, when Oswald Avery (of the Rockefeller Institute, 
New York) demonstrated that deoxyribonucleic acid (DNA) was the transferring factor 
in genetic information, and was the fundamental component of genetic material (Evers, 
2002; Biotechnology Industry Organization, 2001; Europa, 2006; Wallman, 1997).   
 
The second, but more important breakthrough, occurred in 1953 when Francis Crick 
and James Watson (of Cambridge University) and Rosalind Franklin (of King’s College, 
London) discovered the genetic code by which the DNA double helix (Figure 1.1), the 
basic structure of life, governs the reproduction of cells in all living organisms (Access 
Excellence, 2002a; Time.com, 2000).  
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This discovery subsequently initiated the microbiology revolution, and was followed by 
further breakthroughs which played central roles in the subsequent development of the 
modern biotechnology industry, in particular:  
 
 the development of recombinant DNA (rDNA) technologies in 1973, by Stanley 
Cohen (of Stanford University) and Herbert Boyer (of the University of 
California, San Francisco). This development facilitated genetic engineering, i.e. 
scientists could now alter the genetic coding of DNA to give micro-organisms 
specific qualities not ordinarily found in nature, and; 
 the development of the Polymerase Chain Reaction (PCR) technique in 1983 by 
a team of scientists led by Kary B. Mullis (of the Cetus Corporation, Berkley, 
California). PCR deciphers the genetic material of organisms and analyses the 
functions of genes, facilitating the analysis of the genetic causes behind 
infections, cancers and genetic disorders (Chiron Corporation, 2002; Kayvon et 
al., 2002b; Feldman and Francis, 2003). 
 
 
Figure 1.1.: Structure of the Deoxyribose Nucleic Acid (DNA) double helix  
(After Watson and Crick, 1953). 
 
1.1.2 The development of the biotechnology industry 
The origins of the modern biotechnology industry can be traced to the San Francisco 
Bay Area in 1975. Robert Swanson, a Silicon Valley-based venture capitalist who had a 
background in chemistry, had come to the conclusion that the many laboratory-based 
microbiological research projects conducted in US universities/research centres had 
latent commercial promise. Swanson interviewed researchers to determine whether such 
research could be commercialised in a viable manner. A casual meeting with Herbert 
Boyer, the co-developer of rDNA in 1973, confirmed Swanson’s suspicions about the 
commercial potential of biotechnology research (Access Excellence, 2002b, 2002e; The 
Bancroft Library, 2002; Zhang and Patel, 2005; Delerue and Lejeune, 2011).  
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Swanson and Boyer subsequently established Genentech, the world’s first 'new' 
biotechnology firm (bio-firm), in 1976 to create a synthesis of human insulin. 
Genentech successfully licensed its human insulin technology to pharmaceutical 
Transnational Corporation (TNC) Eli Lilly in 1978, and became the first bio-firm to 
float on the US stock market in 1980, raising a record breaking $35 million with its 
initial public offering. Due to its sustained success, Genentech attracted strong interest 
from TNCs, culminating in Swiss-based Hoffman La Roche purchasing a majority stake 
in 1990, followed by an outright purchase in 1999 (Roche, 2000, 2002; Genentech, 
2002a; 2002b).  
 
The manner of Genentech's formation and rapid development created a bio-firm 
development 'template' for the international biotechnology sector (bio-sector). This can 
be summarised as follows; academic researchers commercialise their research by 
establishing a bio-firm through venture capital (VC) support, the bio-firm's business 
activities are optimised through the advice and guidance of the VC firm, and 
subsequently the bio-firm is floated on the stock market and/or strategic alliances with a 
TNC are sought so as to access the necessary knowledge sets and revenues required in 
developing products or processes, and to continue generating high quality research 
(Krafft et al., 2011).  
 
In the wake of Genentech's establishment, the international bio-sector quickly 
developed through major governmental support and funding, as the potential range and 
impact of biotechnology-derived applications were recognised as being a major engine 
for economic growth. The various technologies used in biotechnology have 
subsequently been introduced in most developed and underdeveloped regions as the 
'raw materials' needed to successfully develop a bio-sector, i.e. high quality scientific 
research and sums of intelligently-invested money, are not the sole province of a single 
country or region (Abate, 2001).  
 
It must be noted that bio-sectors, internationally, have been fashioned after various 
development patterns evident in the US bio-sector, while they have also idiosyncratic 
versions of US institutions and organisational structures (Biotechnology Industry 
Organization, 2002: 2007). 
 
The global spread of biotechnology has also been driven by the significant support and 
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funding of TNCs. While there have been consistent problems in turning scientific 
biotechnology advances into marketable products for a variety of reasons, including 
ethical and political issues, one clear exception is that of biotechnology-derived 
pharmaceutical products. Due to their enormous commercial value, research on new 
pharmaceutical drugs, therapies and diagnostics has grown rapidly due to massive 
investments from pharmaceutical TNCs. TNCs have increasingly focused on 
biotechnology as it complements their core activities, while also replacing the 
traditional chemical knowledge base upon which pharmaceutical products were 
previously developed (this issue is detailed further in chapter 2) (Irish Council for 
Science Technology & Innovation, 2005).  
 
There are presently two 'main' foci in the biopharmaceutical sector: 
  
 diagnostic products, i.e. procedures, devices and chemicals that screen, detect, 
diagnose and monitor diseases, which are relatively quick to develop for the 
market place, and;  
 biotechnology-derived pharmaceutical drugs, i.e. pharmaceutical drugs 
developed through genetic engineering, which are targeted towards specific 
diseases or conditions (Panetta, 2006; Dodgson et al., 2008). 
 
Biotechnology's importance for the global pharmaceutical industry continues to deepen 
as the science and its possible industrial applications expand into new areas. This 
expansion has been driven by the completion of the human genome project in 2001. 
This project has the potential to revolutionise all aspects of the biotechnology industry, 
and expand its reach and impact into areas previously unimagined. Indeed, most of the 
technological advances in pharmaceuticals over the last ten years have developed from 
genomic research:  
 
"...genomics has caught the attention of the traditional pharmaceutical industry to a 
greater extent than any other early-stage technology in the biotechnology industry's 
history. Companies are vying to stake out patent-protected territory in what they believe 
will be the therapeutic battlefield of the 21st Century: the human genome." (Author 
unknown, quoted in ETC Group, 1994). 
 
Genomic research represents the next phase of biotechnological development by further 
blurring the boundaries between the pharmaceutical, agricultural, chemical, 
environmental, energy and computer industries (Donnelly and Smyth, 2001; Human 
Genome Project Information, 2002b, 2002c). 
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1.1.3 The unique structure of the international biotechnology industry 
The modern bio-sector is a structurally-complex post-Fordist industry. Post-Fordism 
emerged in the late 1960s/early 1970s, superseding the previous dominant industrial 
structure of the 20
th
 century, the vertically-integrated, mass assembly production line-
based Fordist model of industrial organisation (these organisational forms are detailed 
further in chapter 2) (Dicken, 1998).  
 
Post-Fordist firms are characterised as being small, flexible, and highly 
adaptable/sensitive to market changes and demands. Their development was facilitated 
by the impact of globalisation and advances in new information and communication 
technologies (NICTs) which allowed production structures to fragment as individual 
firms focused on specific niche markets through specialising in specific areas of 
expertise. The resultant fragmentation of markets and production processes has led to 
the economies of industrialised countries moving away from traditional forms of 
industrial manufacturing towards service- and knowledge-intensive economic sectors, 
such as biotechnology (Capello, 1996; Dicken, 1998).  
 
Additionally, Post-Fordism, globalisation (e.g. borderless markets), and the 
hypermobility of finance have emphasised regional economic distinctions in relation to 
place specific concentrations of specialised skills, knowledge, institutions, and 
businesses. Such agglomerations allow firms to benefit from both market and non-
market externalities/spillovers, which increase local endogenous innovation and 
productivity. In effect, “regional economies, not national economies, are now the salient 
foci of wealth creation and world trade” (Martin and Sunley, 2001: 3). 
 
The biotechnology industry's complex Post-Fordist value chain can be characterised as 
being formed around different inter-actor relationships found between third level-based 
researchers who seek to commercialise research through establishing a bio-firm and 
forming alliances with VCs and/or TNCs, i.e. the 'template' created by Genentech, as 
detailed above (these different actors and relationships are detailed further in chapter 3). 
Such developments are supported by Government agencies through the creation of a 
positive and supportive policy environment, and other sectoral support actors, such as 
specialist supply and service firms.  
 
As the international bio-sector has evolved, the inter-actor networked structure of the 
 6 
bio-sector and its value chain, have grown in complexity, leading to the international 
bio-sector being labelled the training ground of corporations in the 21
st
 century (Boje, 
2001; Harrison, 1997). 
 
However, networks are not solely at the heart of the development of bio-sectors, as they 
form and emerge from distinct geographic roots; “...geography played a key role in the 
industry’s evolution and remains an important feature even today” (Owen-Smith and 
Powell, 2007: 63). Many of the actors and organisations that forged, and continue to 
support the complex relationships found in the international bio-sector are located in 
close geographic proximity to each other, meaning these networks are spatially 
concentrated in what are identified as industrial clusters (detailed further in chapter 2) 
(Visser and Boschma, 2002; Romanelli and Feldman, 2007). 
 
The industrial organisation of such a complex structured sector poses significant issues 
for policy makers, as the various roles and demands of different actors, networks, and 
clusters in the development of a bio-sector require multi-faceted and inter-related policy 
approaches. Many Governments wishing to develop indigenous bio-sectors have 
struggled to develop and maintain adequate policy coverage due to the rapid advances 
and developments of bio-sectors at local and global levels. This is reflected in the very 
limited number of hub bio-sectors that have emerged internationally, as detailed further 
in chapter 3 (Wolfe, 2005; Feldman and Braunerhjelm, 2007). 
 
1.2 FOCUS OF THE THESIS 
The Irish Government first identified biotechnology as a key sector for Ireland’s future 
economic development in the late 1970s. However, concerted efforts to facilitate the 
development of an internationally competitive indigenous bio-sector have only occurred 
since the late 1990s through a series of investment programmes which have mainly 
focused on addressing decades of underinvestment and underdevelopment in many 
areas of the sector's value chain, in particular through addressing infrastructural- and 
skills-related issues in the country's third-level institutions (this is detailed further in 
chapters 5 and 6). These issues have impacted on the development of the 
characteristically complex, network dependent sectoral value chain (as detailed above) 
within the Irish bio-sector (this is detailed further in chapters 7 and 8) (Burke et al., 
2003; Cogan and McDevitt, 2000).  
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This thesis qualitatively investigates the structure of the Irish bio-sector, in comparison 
to the structures found in the international bio-sector's key hubs, to determine the 
strengths and weaknesses of the inter-actor networking arrangements which have 
developed among the bio-sector's actors, and how they are impacting on the 
development of the indigenous bio-sector. This research has an important theoretical 
dimension in seeking to locate the networking configuration of the Irish bio-sector in 
the context of general global developments. It also seeks to develop policy proposals to 
indigenously replicate the complex structures and supports, such as inter-actor networks 
and industrial clusters, which have underpinned the successful development of the 
international industry's key bio-sectors.  
 
The overall aim of this thesis is to explore: 
 
 the configurations of the collaborative network structures among the Irish bio-
sector's actors, and;  
 the implications of these structures for the future sustainability and development 
of the indigenous bio-sector. 
 
In particular the thesis: 
 
1. identifies sectoral actors in the Irish biotechnology sector, 
2. examines inter-actor networks and interactions, and reflects on their uniqueness 
to Ireland; 
3. appraises the functions, performances, and weaknesses of inter-actor sectoral 
networks and clusters in Ireland in comparison to their international 
counterparts, and; 
4. appraises existing Irish Government policies relating to the indigenous bio-
sector. 
  
1.3 STRUCTURE OF THE THESIS 
The dissertation is divided into ten chapters.  
 
Chapter 2 details how Post-Fordist firms superseded Fordist industrial structures 
through their ability to rapidly respond to market changes due to their fragmented, 
though integrated production process which are coordinated through inter-actor 
networks. This chapter details what inter-actors networks are, their key features, what 
motivates actors to form networks, the role of inter-actor networks in facilitating 
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innovative developments, as well as how their form and behaviour are determined by 
the spatial contexts and social relationships in which they develop. This chapter then 
details the theory of industrial clusters, i.e. more advanced forms of industrial 
organisation which are inherently organised/based on inter-actor networks. Finally, the 
chapter discusses Government policy measures which seek to facilitate new cluster 
developments, and to optimise the development of existing clusters, derived from 
international case studies. This chapter, ultimately, lays the theoretical foundation from 
which the remainder of the thesis is constructed.  
 
Chapter 3 applies the theoretical descriptions of Post-Fordist institutional and 
geographic organisation, i.e. inter-actor networks and industrial clustering (as detailed in 
chapter 2), to the international bio-sector to create the theoretical foundation upon 
which the subsequent analytical chapters are based. The chapter presents a typology of 
the main sectoral actors found in the international bio-sector, which is derived from 
observations of key bio-sectors, and a template of the key formal and informal inter-
actor networks found throughout the biotechnology innovation process, using the 
previously detailed actor typologies. The chapter discusses the international bio-sector's 
tendency towards industrial clustering, and then presents an analysis of cluster policy 
measures that seek to engender and support new and existing biotechnology cluster 
development. 
 
Chapter 4 outlines the methodological approach used to conduct the empirical research 
on the Irish bio-sector and its network structure, based upon the sectoral actor and 
network typologies presented in Chapter 3. This methodology informs the remainder of 
the thesis. 
 
Chapter 5 places the remaining analytical chapters into their proper context by 
presenting a general review of Ireland’s economic development since the early 1920s, 
and discusses the evolution, and interconnectedness, of policies relating to the 
indigenous bio-sector, including the government's industrial, Science, Technology and 
Innovation policies, as well as the evolution of policy thinking in relation to networks 
and clusters.  
 
Chapter 6 applies the actor typologies detailed in chapter 3 to the Irish bio-sector to 
provide a comparative overview of the indigenous bio-sector’s key actors. This 
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overview is derived from the sectoral review, survey, and actor interviews detailed in 
chapter 4.  
 
Chapter 7 applies the inter-actor network typologies found in the international bio-
sector, as presented in chapter 3, to the Irish bio-sector, using the actor typologies 
presented in chapter 6. The chapter also analyses the development and evolving nature 
of the bio-sector's network arrangements, and their regional characteristics. 
 
Chapter 8 presents a comprehensive range of systems-based policy areas that address 
the existing issues that undermine the indigenous bio-sector's development, so as to 
facilitate the development of an advanced, highly entrepreneurial and innovative bio-
sector. These policy suggestions are derived from an analysis of structural strengths that 
are evident in the indigenous bio-sector, upon which on-going efforts to develop the 
bio-sector can build, as well various obstacles that exist in the bio-sector's value chain 
which will undermine and impinge on future sectoral development efforts. This analysis 
emerges from and builds upon the findings of chapters 5, 6 and 7, while the policies are 
derived using the bio-system policy template developed in chapter 3.  
 
Chapter 9 presents a comparative analysis between Ireland and the international hub and 
non-hub bio-sectors. This analysis focuses on the core areas of this study, so as to place 
the findings of the previous analysis chapters into their proper contexts, and to identify 
the contributions of the Irish bio-sector's analysis to advancing our understanding of the 
international bio-sector.  
 
Chapter 10 concludes the thesis, presents the main argument of the thesis, and its 
findings. Additionally, the research project's contribution to current research is also 
discussed. 
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CHAPTER 2: 
THE STRUCTURES AND DEVELOPMENT OF POST-FORDIST 
INDUSTRIAL NETWORKS AND CLUSTERS 
 
2.1 INTRODUCTION 
This chapter details advanced forms of industrial organisation which are increasingly 
important for regional economic development and technology intensive industrial 
sectors, i.e. inter-actor networks and industrial clusters. The chapter details how Post-
Fordism has changed the economic geographic distribution of production through 
superseding Fordist industrial structures. These structures are characterised by the 
spatial fragmentation of production processes, through advanced and spatially 
integrated production processes that are coordinated through different forms of inter-
actor networks. Networks are crucial elements in facilitating innovative developments 
in knowledge intensive high-tech sectors, their form and behaviour are determined by 
the spatial contexts and social relationships in which they develop. Where spatial 
agglomeration of actors and networks occur, industrial clusters may develop. Clusters 
are highly advanced and localised industrial systems that are inherently organised/based 
on networks, and contribute to the innovation and competitiveness of their constituent 
actors. Clusters are defining characteristics of modern high-tech industrial sectors. 
 
This chapter is divided into four sections. The first section traces the emergence and 
development of the Post-Fordist production system since the late 1960s/early 1970s, 
and the development of inter-actor networks. The second section presents a theoretical 
analysis of the structures and functions of inter-actor networks, how collaborative 
networks facilitate innovative activities, and how geography and social relationships 
impact on their formation, structures and functions. The third section discusses how 
networks develop into 'networks of networks' i.e. industrial clusters. This section details 
Porter's (1998) cluster model, and presents the four determinants of competitive 
advantage which determine the context in which clusters emerge. This section also 
discusses the complexities of promoting industrial clusters through policy actions, in 
relation to efforts seeking to facilitate a cluster's emergence, and also in relation to 
optimising an existing cluster's development trajectory. The conclusions are presented in 
the final section. 
 
2.2 FROM FORDIST TO POST-FORDIST PRODUCTION SYSTEMS 
2.2.1 The Fordist system of production 
In the decades following World War II, prior to the 1970s, the dominant firm structure 
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in advanced Western economies was that of Fordism. Initially coined to describe the 
moving assembly line method of mass production employed by Henry Ford’s US 
automobile factories, Fordism refers to an organisational form of production, modelled 
on Ford’s production method, that is characterised by long-run assembly-line production 
accompanying mass (bulk) production of standardised goods (Sheppard & Barnes, 
2003).  
 
The Fordist production model was based upon Fredrick Taylor’s Principles of Scientific 
Management (1911). Taylor devised a business process that differed from the industrial 
revolution's rationally organised mechanised production systems, which involved 
mechanised subdivided production of standardised products based upon exploitative 
labour practices, and the unequal redistribution of capital-gains, i.e. workers received 
minimal pay for maximum effort, with profits being retained by the firm’s owner(s) 
(Besson, 2000; Rupert, 2000; Boyer and Julliard, 2001).  
 
Taylor’s business process (Taylorism) was developed through time and motion studies 
involving disciplined workshop organisation, e.g. tool and implement standardisation, 
and labour activity subdivision ('parcelisation) through defined task allocation. 
Taylorism increased production through the parcelisation of labour activities, and the 
implementation of a wage incentive bonus system to encourage high productivity 
(Fischer, 2007; Thompson, 2005). 
 
Fordism moved beyond Taylorism, reorganising the entire production process through a 
greater division and deskilling of manual labour, implementing standardised 
components in standardised production processes to produce standardised products. The 
Fordist assembly line method reorganised production by breaking it into many smaller 
and simpler tasks, i.e. low skilled repetitive tasks that were performed in a specified 
time period. This 'parcelisation' of the assembly line meant that the rate of production 
was dictated by the assembly line's speed, a defining characteristic of Fordism, and 
allowed Fordist firms to employ more unskilled then skilled employees through 
dramatically reducing the required level of employee training. The assembly line's 
unskilled nature meant employees could be replaced more easily, meaning Fordist firms’ 
required large supplies of relatively cheap unskilled labour. As such, Fordist firms 
located production process aspects at (often overseas) locations with cheap labour 
pools, creating non-autonomous integrated branch plant operations (Oberhauser, 1990; 
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Delerue and Lejeune, 2011). 
 
All aspects and stages of the Fordist production process, from product design through to 
marketing and retailing, were conducted in-house, thus facilitating fixed production 
runs in relation to both the length of the production cycle and the type of product. Due 
to the scale of production, i.e. large volumes of mass produced standardised consumer 
goods for increasingly-affluent mass consumer markets, Fordist firms could derive 
substantial economies of scale by producing inputs internally. This mass production 
aspect meant that large stockpiles of components were required to prevent input 
shortages stopping the whole assembly line, which resulted in the development of 
extensive warehouse management facilities (Capello, 1996; Dicken, 1998; Thompson, 
2005).   
 
In order to secure cheap inputs, Fordist firms created dispersed (resource) branch plant 
operations, again in areas with cheap input costs. Where relationships with outside sub-
suppliers developed, they were price-determined contract-based relationships in which 
relatively little interaction occurred; supply agreements would involve fixed quantities 
of a particular input, whose exact specifications were determined by the Fordist firm 
awarding the contract, to be supplied over a certain period of time, after which the 
process was repeated (Oberhauser, 1990).  
 
The vertically-integrated, hierarchical structured Fordist production processes required a 
rigidly defined management structure to coordinate the different and sometimes 
geographically dispersed elements of the production process. As such, Fordist firms 
were characterised as being bureaucratic and organisationally inflexible (Manicas, 1997; 
Thompson, 2005).  
 
The Fordist production model predated the Great Depression and World War II, yet both 
events altered the socio-political landscape of industrialised nations leading to the post-
war emergence and dominance of Fordism.  
 
The Great Depression exposed failings in classical (laissez-fâire) economic theory, 
which had become the prevalent economic model in many industrialised nations 
following the First World War. Under classic economic theory, government involvement 
in markets was kept to a minimum which allowed monopolies to dominate the markets. 
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This resulted in significant social inequality, partly through the suppression of trade 
unions (Thompson, 2005, Manicas, 1997; Rupert, 2004; New Deal Network, 2003).  
 
In efforts to reverse the Great Depression during the 1930s, the economic theories of 
John Maynard Keynes gained popularity, most noticeably with then US President 
Franklin D. Roosevelt. Keynes, in his 'The General Theory of Employment, Interest and 
Money' (1936), promoted direct government involvement in the management of 
national economic performance, including the stimulation of economic performance 
through active fiscal policy based on interest rate reductions and investments in capital 
goods, e.g. infrastructural investments. Keynes advocated a more equitable 
redistribution of capital through increased purchasing power to stimulate consumer 
demand so as to further strengthen economic performance (Thompson, 2005, Manicas, 
1997; Rupert, 2004).  
 
Following World War II, partly due to the US government's adoption of Keynesian 
policies during the war being perceived as ending the Great Depression, Keynesianism 
became the dominant economic policy of industrialised nations. Keynesian 
interventionist economic policies complemented Fordism in several ways. Firstly, as an 
economic philosophy, Fordism/Keynesianism suggested that widespread prosperity and 
high corporate profits could be achieved by high wages that allowed workers to 
purchase the output they produced themselves. These high wages were secured through 
the development of strong trade unions, another Fordist characteristic, whose 
development was facilitated by Governments seeking to implement their Keynesian 
policies. High wages meant that the high-output Fordist firms’ production levels were 
matched by the increased purchasing power of their workforce (Manicas, 1997; Rupert, 
2004).  
 
Secondly, the Bretton Woods international monetary system, created in 1944 to avoid 
the economic instability of the 1930s perceived to have created the preconditions of 
WWII, controlled international trade and finance through fixed exchange rates to 
minimise international market fluctuations. This meant Fordist produced consumer 
items were sold in protected domestic markets (Manicas, 1997; Cohen, 2001).  
 
2.2.2 The emergence and development of the Post-Fordist production system 
In part, Keynesianism facilitated a post-war period of economic expansion, particularly 
among industrialised nations, which lasted until the early 1970s. However, a series of 
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events which emerged in the 1960s, and whose effects subsequently deepened during 
the 1970s and 1980s, led to Governments replacing Keynesian policies with more neo-
liberal open market policies. Additionally, the competitiveness and dominance of 
Fordism came under increasing pressure and competition (Rupert, 2004; Harvey, 2005).  
 
During this period, a series of global economic shocks exposed the inflexibility of 
Fordist structures and undermined the effectiveness of Keynesian policies. These shocks 
caused a protracted period of poor economic performance amongst most industrialised 
nations, the decline of established industrial areas, and significant market volatility 
(Rupert, 2004).  
 
The international financial system experienced significant unrest due to fluctuations in 
currency markets and gold prices, which ultimately caused the Bretton Woods monetary 
system to collapse in 1971. This resulted in significant market turmoil; a period of high 
inflation was followed by a global recession characterised by 'stagflation' i.e. inflation 
combined with economic stagnation and high unemployment levels. Additionally, two 
oil pricing crises, triggered by the Arab oil embargo in 1973 and the outbreak of the 
Iranian Revolution in 1978, had significant impacts on global inflation rates during this 
period (Bruno and Sachs, 1985; Olson, 1985; OPEC, 2000; NESC, 1996; Harvey, 
2005). 
 
Leading industrial nations also faced rising competition from foreign markets, e.g. 
South East Asia, due to economic globalisation; to avail of cheap labour costs, industrial 
manufacturing increasingly moved to second- and third-world countries, while 
advanced industrial economies shifted towards knowledge-based service activities 
facilitated by rapid advances in new information and communication technologies 
(NICTs). During this period, industrialised nations began entering a post-industrial 
'Informational Age' in which information/knowledge began to play a similar economic 
role as energy/fuel played in the industrial age (Castells, 2000; Acheson, and Lambkin, 
2009; Krafft et al., 2011). 
   
Also during this period, increased market fragmentation and segmentation emerged in 
industrial nations; due to a post-World War II baby boom, and the various social 
movements from the 1960s onwards, affluent 'baby boom' consumers became 
increasingly fashion-conscious and demanded more product variety and choice. As 
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such, market demand and trends became more specialised and altered too quickly for 
Fordist structured firms to adequately respond to the changing market conditions 
(Jessop, 2006).  
 
This inflexibility allowed small, innovative information-based Post-Fordist firms to 
challenge the dominance of Fordism, and gain competitive advantage in key industrial 
sectors. This development was possible through the emergence of flexible specialised 
production processes based on the application of NICTs, i.e. applying technologically 
advanced numerically controlled machines and robots to production process, and the 
development of flexible organisational forms that facilitated the fragmenting of 
production processes through outsourcing and the adoption of just-in-time (JIT) 
delivery systems, which involve suppliers delivering the necessary quantity of specified 
low-volume inputs to a customer firm's assembly plant on a just-in-time basis  
 
In combination, these elements continue to provide Post-Fordist firms with a flexible 
manufacturing process. Instead of mass-produced generic products, they have greater 
ability to respond to rapidly changing market segments by being able to rapidly 
diversify the type and amount of a product they make to produce diverse product lines 
targeted at different consumer groups (Dicken, 1998; Oberhauser, 1990; Essletzbichler, 
2003; Piore and Sabel, 1984).  
 
Post-Fordist manufacturing flexibility takes different, sometimes interlinking forms, i.e. 
flexibility within firms, and flexibility through supply-based linkages with outside 
firms/actors. Flexibility within firms is achieved through intra-firm fragmentation. 
Instead of a largely unskilled workforce engaged in parcelised production tasks, the 
different intra-firm operating units of Post-Fordist firms can be organised autonomously, 
i.e. units may operate in different locations and specialise in producing different 
components, which are then brought together for final assembly. These units may also 
have functional flexibility, i.e. they are responsible for numerous production process 
tasks, meaning Post-Fordist firms utilise combinations of low-skilled workers, e.g. in 
maintenance and menial positions, and highly skilled engineers and machine operators 
to oversee their computer automated production processes (Oberhauser, 1990; 
Vercellone, 2007).  
 
The tendency of Post-Fordist firms towards input externalisation/outsourcing from sub-
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suppliers is due to their changing batch production run input requirements. Unlike 
Fordist firms, the quantities required in their production runs are too small to deliver 
economies of scale. Yet economies of scale can be achieved through outsourcing, i.e. 
inputs can be purchased cheaply from a supplier that itself specialises on a particular 
activity, and by simultaneously supplying a number of client firms achieves economies 
of scale in its own operations (NESC, 1996).  
 
Subcontracting provides greater flexibility in various areas, including:  
  
 where cyclical or seasonal variations in demand, or demand for a particular 
product line is insufficient for continuous mass production;  
 where firms seek to control labour costs by taking advantage of cheap labour 
through awarding contracts to the lowest bidders;  
 where firms seek to maintain flexibility over variable capital by placing 
employee benefit responsibilities upon contractors, and subcontract to small 
non-unionised firms to retain labour process managerial control, and; 
 where firms seek to access scarce specialist labour skills (Holmes, 1986; Piore 
and Sabel, 1984). 
 
Furthermore, outsourcing from specialist suppliers also allows firms greater flexibility 
in responding to technological changes, i.e. where adopting new production 
technologies may put efficiency and output at risk, or where the maintenance of older 
technologies may reduce production capabilities. Essentially, the rapid pace of 
technological change means it is uneconomical for firms to try and keep up-to-date with 
development trends, therefore they increasingly rely on specialist suppliers who, due to 
their narrow activity focus, are dedicated to tracking and absorbing technological 
advances. For example, firms seek to by-pass the substantial costs of conducting 
research (e.g. resource, personnel and equipment costs) through sourcing research 
externally. The introduction of new organisational forms, in particular the JIT delivery 
system and new forms of logistics informed by NICT developments have facilitated 
these different forms of flexibility (Harrison, 1994; Capello, 1996; Dicken, 1998; 
Oberhauser, 1990; Piore and Sabel, 1984).  
 
Rapid NICT developments have facilitated network and strategic alliance developments 
between firms at an international scale, by removing traditional constraints such as 
distance. These alliances are managed through sophisticated logistic operations, as firms 
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seek to co-ordinate and organise diverse production networks among suppliers, 
subcontractors and distributors (Harrison, 1994; Dicken, 1998).  
 
Post-Fordism has resulted in separate, yet related trends in the spatial division of labour 
and production organisation, i.e. the spatial dispersal and reintegration of production. 
The spatial dispersal of production has occurred as, unlike Fordism (where a single firm 
operates and controls the entire assembly line process), the Post-Fordist production 
process is fragmented, i.e. the conception and execution of production are differentiated 
on a global scale, causing a deepening division of labour (Capello, 1996; Dicken, 1998).  
 
Additionally, the rapidly changing needs and requirements of Post-Fordist firms means 
that they have much deeper relationships with their suppliers then Fordist firms, as they 
will seek to ensure input quality, reliability and supply. This can lead to inter-firm 
strategic alliances developing, i.e. sub-suppliers themselves outsource work to other 
sub-suppliers. In some industries, several ‘tiers’ of sub-suppliers form, which results in 
the spatial reintegration of production, i.e. horizontal networks of inter-related specialist 
subcontracting firms which display strong geographic localisation tendencies, as close 
proximity is required (in part) to respond optimally to the changing demands of client 
firms. The spatial reintegration of production has resulted in spatial agglomerations 
emerging, i.e. concentrations of production activities and corresponding labour 
processes in regional complexes (NESC, 1996; Harrison, 1994; Dicken, 1998; 
Oberhauser, 1990; Piore and Sabel, 1984). 
 
Over time, due to the high interaction levels, the nature of these relationships may shift 
from purely commercial market-based relationships, to being based on trust and mutual 
benefit, i.e. relationships develop past formal contracts. The development of tiers of 
subcontractors in a particular location can mean that, where trust-based inter-firm 
relationships develop, they can extend beyond individual relationships to an entire 
industrial sector (Easton, 1992; Dicken, 1998; Lundberg and Andresen, 2012).  
 
In response to these developments, Fordist firms began restructuring themselves to 
mirror the Post-Fordist organisational form by introducing fragmented production 
processes to achieve improved flexibility and higher levels of responsiveness. This 
restructuring included the introduction of more horizontal management structures, the 
granting of greater autonomy to operating units, and the increased outsourcing of 
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material and service input production to independent suppliers (Sabel, 1994; Reich, 
1991).  
 
As a result, the operational characteristics of both flexible Post-Fordist and restructured 
Fordist firms have become increasingly enmeshed in:   
  
“…external networks of relationships with a myriad of other firms: transnational and 
domestic, large and small, public and private. Such inter-relationships between firms of 
different sizes and types increasingly span national boundaries to create a set of 
geographically nested relationships from local to global scales…new forms of 
collaboration are emerging which are embedded within much flatter and looser network 
structures or webs of enterprise” (Dicken, 1998: 223). (Italics authors own) 
 
The Post-Fordist organisational structure of horizontal alliances of interrelated specialist 
actors means it is increasingly difficult to clearly define the boundaries of a firm’s 
structure in comparison to the vertical structures and more defined boundaries of Fordist 
firms (Dicken, 1998; Visser and Boschuma, 2002; Pitt et al., 2006).  
 
2.3 NETWORKS  
There are many definitions of networks, depending on the sector being studied. 
Common elements of these definitions, and key characteristics of networks are detailed 
in Table 2.1.  
 
Where a region achieves dense inter-actor networks and significant innovative activity, 
a regional 'brand' can form, making its innovative capacities more visible. Branding 
strengthens a network's density and capabilities through attracting additional actors, 
labour and support structures into a region. This enhances information flows, assists 
actors in building global linkages, and improves the innovative capacities among 
existing actors and new actors, e.g. new firms set up to pursue new possibilities in terms 
of new products and techniques (Porter, 1998; Compete, 2005; OECD, 2004; 
Kolympirisa et al., 2011).  
 
Density can create a more extensive region-specific skilled labour base by attracting and 
integrating different and related labour skills, expertise and know-how, relative to the 
network's core activities,  
into a local  labour market.  This reinforces  network  density,  as a specialist  labour 
pool facilitates increased knowledge generation. Where different knowledge is 
combined, it opens the possibility of vertical and horizontal specialisation “and the 
development of adequate organisational devices for the integration of...relevant 
knowledge” (Orsenigo, 2007: 201), thus enhancing the filter aspect of networks 
(Krugman, 1991; Delerue and Lejeune, 2011).  
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Table 2.1: Defining characteristics of networks 
Networks form when existing stable collaborative commercial relationships shift to trust- and reciprocity-based relationships. This shift occurs 
through self-organisation, i.e. actors choose to engage in implicit and open-ended co-operative and collaborative transactions/exchanges to secure 
specific business objectives they cannot achieve through simple bilateral exchanges. Networks facilitate exchanges of resources and knowledge 
among network members only, and allow advanced specialisation and/or increased operational flexibility. 
Networks are either formal or informal relationships, both have restricted memberships: 
 Formal networks are rigid agreements on common business goals so as to achieve more sophisticated business practices. They involve exchanges 
of codified knowledge and information, i.e. knowledge/information embodied in machinery and equipment, codified through (for example) patents. 
Only the members of a network can benefit from these alliances due to their (sometimes) contractual nature.  
 Informal networks are loose social connections primarily involving knowledge/information transfers through face-to-face interactions. They 
involve tacit knowledge diffusion, i.e. privately held knowledge/information accumulated by technical and research personnel through practice and 
experience at the interface between organisations. Such transfers are optimised through geographic proximity and relational norms. 
Trust and reciprocity are central and interwoven aspects of how formal and informal networks function:  
 Trust is a product of the degree and nature of economic relationships in social contexts, which builds and consolidates through members 
demonstrating their reliability and trustworthiness to each other over a period of time. Networks develop with restricted memberships because of 
this. Trust determines the willingness/openness of network members to exchange information/knowledge and/or resources by establishing mutual 
confidence, through a social 'contract', that members will not (for example) exploit vulnerabilities or act opportunistically.   
 Reciprocity is a mutually contingent exchange of benefits that involves actors reciprocating each other's actions/services. The level of service 
between actors depends on the level each receives from the other.  
The importance and intensity of these elements relates to the features of the industry, and the collaborations actors engage in. Both aspects are 
important in bringing stability in uncertain, technology intensive sectors. 
Two principle benefits to networking can be identified; exchanges of resources and knowledge, irrespective of the flows between members. These 
benefits inform the principle interlinked and/or parallel motives underpinning networks:  
 Economisation motives, where firms seek to achieve increased flexibility and additional capacity through the division of production activities 
among members, and to share the costs and/or risks of activities that are too excessive for them to absorb alone, e.g. joint research programmes. 
 Strategisation allows members to access the technical capabilities of other members, and to augment their innovative capacities by improving 
their internal competencies and problem solving abilities. Improved response times, flexibility and resilience to evolving markets can be 
engendered through developing 'resource packages' as a result. It also facilitates codified and tacit knowledge transfers, allowing members access 
different knowledge bases to improve their capabilities through organisational learning. Furthermore, formal strategic alliances can allow small 
firms achieve relationship 'asymmetry' with larger firms, improve perceptions of reputation and image, and to address legal and/or regulatory 
requirements by accessing the resources of other members.  
Accompanying and underlying these motives, actors seeking to exploit and explore the knowledge bases and resources of other members to achieve 
improvements, refinements and extensions to their own competences, technologies and paradigms. This can result in innovative developments by 
allowing actors compare their relative strengths and weaknesses, facilitate increased levels of trust, and encourage the formation of more complex 
alliances. 
Close social relationships among actors in close proximity optimise networks through channelling information and resource within a defined social 
structure that emphasises trust and reciprocity.  Social relationships are vital due to the social character of tacit knowledge transfers and the 
importance of trust and reciprocity in networks. An area's social customs mean networks are spatially idiosyncratic, while close proximity reduces 
transaction costs and insecurities, facilitating common cultural rules and routines which limit knowledge group fragmentation and deter harmful 
actions. 
Regional endowments of firms, institutions, and the non-structural underpinnings of behavioural characteristics and social regulations (i.e. the 
features influencing how actors interact, the nature and character of transactions, and collective learning capabilities) are not homogeneous and can 
be region specific. Actors can have non-reproducible, regional specific organisational forms/targets that form a local knowledge community or 
organisational field, which determines the innovative capabilities and development trajectory of a sector. 
Networks allow members observe each others internal routines and operating procedures. Those observed as being most efficient and effective are 
diffused, fine-tuned and replicated among members, gradually becoming accepted routines and procedures. This drives density by facilitating the 
development of close social relationships and organisational proximity as structural similarities arising through the adoption of organisational forms 
improve perceptions of trustworthiness among the wider network structure. This is termed mimetic isomorphism. 
Regional specific forms and characteristics are influenced by the presence, or absence of a dominant actor type, i.e. the main/largest connected 
component of a network, whose institutional characteristics influences (formal or informal) networks within a wider network structure:  
 Networks dominated by (a) commercial actor(s), e.g. manufacturing-based industries, are predominantly formal and codified in nature as such 
actors derive competitive advantages from possessing advanced forms of resources and knowledge over their competitors. Alliances with 
external actors are formal and contractual to contain knowledge or innovation developments and exchanges, and to internalise their innovative 
developments to minimise 'leaks'. The degree of centrality (i.e. the relative trust and geographic proximity) 'junior' actors have to the dominant 
actor determines their ability to access closed information flows. Centrality makes a dominant actor an obligatory passage point for transfers. 
Perceptions of trust are therefore crucial, further engraining the formal nature of such alliances.  
 Networks dominated by non-commercial actors, e.g. public research and education organisations (PREOs), are informal in nature as they are 
less concerned with market demands. PREO-generated knowledge is spatially 'sticky', due to its predominantly tacit nature, meaning such 
networks are spatially concentrated. This concentration has deepened due to the importance of information/knowledge in the 'information age', 
and by government's seeking to engender commercial developments from PREOs through commercialisation supports that create a collaborative 
environment between commercial and public actors. PREO-based scientific research is increasingly crucial for modern high-tech industries, e.g. 
biotechnology. The innovative intensity of a region's high-tech firms positively relates to the quality of a region's PREOs and the knowledge 
they generate. Relative proximity and social inclusiveness to PREOs determines how members engender informal relationships to access 
commercially related and 'filtered' PREO-based tacit research knowledge. This also impacts on formal networks, as the earlier a technology is 
licensed, the greater exclusivity firms gain. 
A regional specific network structure is usually a function of a specific industrial setting, while (paradoxically) the structure and functioning of 
networks influences the way an industry's technology evolves. Different dominant actors can co-exist in a wider network structure, playing particular 
roles as a sector develops and evolves. The changing nature of innovation in a maturing industry means that as firms develop, their demands will 
change, e.g. the dominant actor can shift from an open to a closed actor type due to changing resource needs. Formal arrangements can dominate as 
technological fields stabilize and innovation becomes less radical. 
Based on (Rosenfeld, 2001; Owen-Smith and Powell, 2004; Compete, 2005; Lia and 
Gengb, 2012; Daskalakis and Kauffeld-Monz, 2007; Simon and Tellier, 2011; Visser 
and Boschma, 2002; Gertler and Levitte, 2005; Soh and Roberts, 2000; Kogut, 2000; 
Graf and Krüger, 2011; Chiaroni and Chiesa, 2006; Ahrweiler et al., 2011; Malecki, 
1997). 
 
A specialist labour pool can further drive density through facilitating information 
spillovers, i.e. localised informal knowledge transactions on innovations, production 
refinements, and business conditions can develop with actors not specifically 
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included/integrated into a specific network agreement. Spillovers occur where tacit 
practices and routines mingle with tacit components of knowledge encountered 
elsewhere through informal and formal networks, e.g. social meetings, and the mobility 
of local science and engineering labour through research/product alliances 
(MacPherson, 1998; Feldmann, 2000; Gertler and Levitte, 2005; Engel and Del-Palacio, 
2011; Delerue and Lejeune, 2011).  
 
As detailed above, Post-Fordist workers are increasingly involved in the conception and 
execution of tasks, meaning they develop/generate substantial levels of tacit knowledge, 
i.e. “the secrets of industry may not be floating freely in the air, but they are situated in 
informal communities of practice that constitute a local technology labor market” 
(Owen-Smith and Powell, 2004: 7). Through such interactions, different (codified) 
knowledge can be combined, facilitating exploitation, and resulting in spillovers which 
encourage innovative and commercial developments through the assimilation, 
adaptation or accommodation of the previous practices. This further deepens regional 
network density (MacPherson, 1998; Owen-Smith and Powell, 2004; Compete, 2005; 
Kolympirisa et al., 2011). 
 
Such localised informal transactions are key features of knowledge intensive sectors, 
such as biotechnology, particularly as they encourage new commercial developments 
and facilitate the formation of collaborative business support services that are tailored to 
the demands and requirements of the overall network structure. New commercial 
developments can also contribute to the generation and application of new knowledge, 
and the development of innovative technologies and products, by stimulating market 
structure changes and entrepreneurial agreements. Such developments can deliver 
higher productivity and comparative advantages, and also strengthen a region's 
competitiveness (Compete, 2005; MacPherson, 1998).  
 
In alliance with support service developments, new commercial developments can boost 
a region's 'brand'. Essentially, positive feedback events occur which deepens network 
density and further engrains the non-reproducible, regional specific characteristics of 
the network's structure.  Once network density reaches a certain critical mass, it 
becomes self-expanding due to the mutually reinforcing or symbiotic relations which 
develop. Critical mass is a fluid notion, determined by situation and circumstance, yet it 
refers to a variety of assets that are subject to economies of scale and scope, including 
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skill-sets, derived from densities of interactions, combinations, learning and innovation 
processes. Critical mass is important as it impacts on a location's future industrial 
performance/growth trajectory, e.g. it may increase a network structure's resistance to 
external and internal forces, such as technological discontinuities (Forfás, 2004; Porter, 
1998; Siegel et al., 2003; Anderson et al., 2004). 
 
Yet, differences in actor characteristics, particularly the dominant actor type, can 
prevent regions developing significant network density or critical mass, i.e. limited 
actor numbers and market size can inhibit labour mobility and spillovers, limit 
innovative developments by preventing user/producer interactions, and can also 
undermine information dissemination (Malecki, 1997; Graf and Krüger, 2011; 
Eisingerich et al, 2012). 
 
Formal networks are important in such areas, as they can substitute for advantages 
bestowed by agglomeration. Regional limitations in the supports and resources actors 
can access, relative to more densely networked and resource endowed regions, compel 
actors to form alliances with non-local actors in more endowed locations so as to by-
pass their regional limitations and to enhance their capabilities and optimise their long 
term developments, i.e. actors develop alternative forms of proximity, such as ‘distant 
networking’ strategies, to by-pass structural weaknesses (Gilding, 2008; Wilhelmsson, 
2007; Ozman, 2006; Lundberg and Andresen, 2012; Delerue and Lejeune, 2011). 
 
Yet the effectiveness of such strategies can be limited by the nature of the relationships 
they seek to develop, and the character of the actor(s) with which they seek to develop 
alliances. For example, private investor actors typically seek informal alliances with 
actors located in close proximity due to the importance of information in such alliances. 
This means that actors from less endowed regions will struggle to engender such 
relationships. As such, less endowed regions experience cumulative disadvantages, and 
fall further behind, relative to the more endowed regions (Gilding, 2008; Ozman, 2006; 
Chen at al., 2011; Morris, 2011).  
 
2.4 INDUSTRIAL CLUSTERS 
Geography can significantly impact the form, functioning, and development of 
networks, as: 
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 regional endowments of actors, and their institutional and non-institutional 
characteristics, are not homogenous;  
 where close social relationships develop amongst actors in close geographic 
proximity to each other, the effects/benefits of formal and informal networks 
may be optimised and emphasised. Proximity can result in trusting relationships 
developing by facilitating common cultural rule and routine developments, and 
the adoption of organisational forms that reduce transaction costs and 
insecurities (through mimetic isomorphism), and; 
 critical masses of actors and networks can drive the formation of self-supporting 
regional agglomerations. This can engrain a region's network structure and 
sectoral supports, and result in extensive external alliances forming through a 
branding effect that facilitates access to, and attracts in alternative and 
international sources of labour, knowledge, resources and finance (Barley et al., 
1992; Malecki, 1997; Gertler and Levitte, 2005; Rowley et al., 2000; Huggins et 
al., 2012). 
 
Where dense agglomerations of networks and actors form, the concept of cluster 
building may develop among the more interlinked partners. The “…concepts of 
networks and clusters overlap. A group of firms which network to collaborate…might 
well be part of a larger cluster” (Cooke, 1996: 21), yet there are noticeable differences 
between both concepts (see Table 2.2).  
 
Network density can facilitate cluster formation in several ways, primarily through 
creating the preconditions which result in cluster emergence, particularly through 
supporting the development of “relationships and routines [i.e. learned, regular and 
collective patterns of interacting] among the partners…[in which] the capabilities of 
clusters are found” (Compete, 2005). While networks are important aspects of clusters, 
cluster emergence occurs due to a wide variety of case and sector specific reasons. 
These issues are discussed in the following sections.  
 
2.4.1 The concept of industrial clustering 
Defining the key characteristics of a 'cluster' is complicated as it is a somewhat 
nebulous concept. No single unifying interpretation of what constitutes a cluster exists, 
i.e. there is “no overriding cluster theory per se…clusters are generally viewed as an 
economic development process rather than a definite development theory” (Brown, 
2000: 13). 
 23 
 
However, through reviewing a wide variety of cluster definitions, several commonalities 
can be identified. A cluster can be conceived as a mode of organisation of a productive 
system that contributes to the innovation and competitiveness of its constituent actors. 
The linkages between, and the interdependencies/collaborative arrangements among 
actors are at the core of the concept. Clusters have no membership limits, they are 
voluntary, non-contractual systematic relationship arrangements based on trust in which 
actors collaborate and compete to facilitate acquisitions of wider competencies and to 
build competitive advantage in a local system of specialised sub-supply, service 
providers and institutes (Rosenfeld, 1997; Porter 1998; Visser and Boschma, 2002; 
NESC, 1996; vom Hofe and Chen, 2006; Engel and Del-Palacio, 2011). 
 
Table 2.2: Characteristic differences between networks and clusters 
Networks have restricted membership. Clusters have open membership. 
Networks facilitate common business goals. Clusters facilitate open business goals/shared visions. 
Networks facilitate more sophisticated business practices. Clusters facilitate the acquisition of wider competencies. 
Based on (Rosenfeld, 2001; O’Doherty, 1998). 
 
The cluster concept was introduced by Michael Porter in 1990, however the discipline 
of agglomeration economics has a long history. Geographical concentrations of 
industries in urban areas have featured in advanced economies since the industrial age.  
 
Alfred Marshall, in his Principles of Economics (Marshall, 1890), termed industrial 
agglomerations 'industrial districts', based on his observations of how related industries 
concentrated in particular localities in Lancashire and Sheffield, and were typically made 
up of highly specialised producers in a certain industry exchanging products, which 
allowed firms to achieve a high level of economies of specialisation (Iammarion and 
McCann, 2006; Piore and Sabel, 1984; Ingley, 1999; Erden and von Krogh, 2011).  
 
Marshall identified several factors underpinning the processes that determine industrial 
district formation. These included the development and availability of specialist input 
suppliers, industry-specific skills, a skilled labour pool that all firms draw from, and the 
circulation of industry-specific information and knowledge facilitated by a distinct 
industrial culture and set of norms that regulated firm behaviour, and facilitate inter-firm 
trust that formed and was optimised by the regional concentration of firms. This meant 
that the social depth of the firm and the role of governance were important in 
determining the success of an industrial district (Cooke, 2002; Krugman, 1991; 
Malecki, 1997; Brett and Roe, 2006; Zhang and Haiyang, 2011; Erden and von Krogh, 
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2011). 
 
Following Marshall, a wide range of theories focused on industrial agglomerations using 
different spatial ranges, while some focused mainly on the economic relations that develop 
between inter-linked firms. However, these theories essentially focused on the same thing, 
i.e. the benefits which can be derived from groupings of connected or related firms through 
(for example) customer/supplier relations, competitive rivalry and the development of 
specialised labour pools. A small selection of these theories is detailed in Table 2.3. 
 
Table 2.3: A selection of industrial agglomeration theories 
Alfred Weber’s (1909) concept of agglomeration economies: firms derived savings locating in close proximity to other firms within an 
agglomeration. Weber distinguished between regional location factors, i.e. factors of production availability and transportation costs, 
and agglomeration factors, i.e. the scale of operations in an area. 
Francois Perroux’s growth pole concept (1950): a non-spatial theory where groups of firms clustered around central propulsive 
(related) industries constituted growth poles by undergoing long-term expansion. 
Jacques Boudeville’s growth centre concept (1960): agglomerations of linked industries concentrate in particular, mainly urban, 
regions. This was essentially a spatial application of Perroux’s concept. 
Henderson's (1974) concept emphasised the agglomerative effects of positive spillovers between firms in geographic proximity. 
After (vom Hofe and Chen, 2006; McCann, 2001). 
 
The industrial districts concept received renewed interest in the 1970s due to the 
emergence and considerable economic success of regions dominated by specialist 
industrial agglomerations of small-firms. These regions were, and remain, associated 
with high levels of flexibility and innovation, and included:  
 
 the electronics agglomeration of 'Silicon Valley' in California;  
 the traditional industry agglomerations of the 'third Italy' region in the Northeast 
of Italy, centred on the regions of Emilia Romagna and Tuscany, and;  
 'Toyota City' in Aichi, near Nagoya, Japan (NESC, 1996; Owen-Smith and 
Powell, 2004).  
 
Aside from 'Toyota City', where layers of small subcontracted firms agglomerate around 
a major client automobile firm, the 'neo-Marshallian Industrial districts' are 
characterised as highly localised, Small and Medium Enterprise (SME) dominated 
mono-industrial production systems, where firms specialise in various stages of a 
product's production, i.e. firms interact through dense networks of sub-contracting, with 
a highly differentiated division of labour. The presence of long-term linkages between 
suppliers and end-users, and a sense of community and common interest, enhanced by 
proximity, create a communal sense of trust which fosters a culture of information-sharing, 
and learning, and enhances innovation and restricts opportunistic behaviour (NESC, 
1996; Visser and Boschma, 2002; Dicken, 2003). 
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The factors Marshall identified as determining industrial district formation processes 
remain relevant in the modern era. However the conditions which create such 
agglomerations have altered somewhat. Many older industrial agglomerations formed 
due to historic 'accidents', e.g. metal working developing in an area rich in iron ore 
reserves. While this retains some relevance, today’s high-technology clusters are more 
likely to have developed due to less fortuitous reasons, such as the existence of a pool of 
highly skilled and specialist researchers, and policy developments (Cooke, 2002; 
Krugman, 1991; Brett and Roe, 2006; Zhang and Haiyang, 2011; Lee, 2012). 
 
Additionally, differences can be noted between the characteristics which typify 
traditional and modern clusters/agglomerations. Traditional agglomerations typically 
formed among horizontally (formally) networked firms operating in the same end 
product market/industry group. They were characterised as relying on incremental 
innovation and developments to products and processes. Modern clusters are 
characterised by different actors in a variety of long-term relationship types, i.e. formal 
and informal relationships, and are highly innovative as radical innovation processes 
augment organisational structures and product and process developments. The complex 
nature of the “internal social dynamics” (Feldman and Braunerhjelm, 2007: 4) of 
modern clusters separates them from traditional agglomerations (Owen-Smith and 
Powell, 2007; Enright and Roberts, 2001). 
 
2.4.2 Porter’s theory of industrial clusters  
The industrial cluster concept was developed by Michael Porter in his Competitive 
Advantage of Nations (1990), through his analysis of the factors determining national 
competitiveness: “The basic unit of analysis for understanding National Competitive 
Advantage is the industry. Nations succeed not in isolated industries...but in clusters of 
industries connected through vertical and horizontal relationships” (Porter, 1998: 73). 
Italics authors own.  
 
Porter initially argued that individual nations gain competitive advantage in particular 
industrial sectors that compete internationally, and that successful sectors portray strong 
tendencies to concentrate within particular regions. In a revised edition (1998), Porter 
adjusted his geographic focus to include non-internationally competitive regional 
industries. At a national level, Porter conceived clusters as broad industry groups linked 
within the overall macro economy. At the regional level, the constituent elements share 
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common regional locations, including urban areas, labour markets, and/or other 
functional economic units (Porter, 1990, 1998).  
 
Porter defines clusters as “geographic concentrations of interconnected companies, 
specialist suppliers, service providers, firms in industry, and associated institutions, (e.g. 
universities, standard agencies, trade associations) in a particular field that compete but 
also co-operate” (Porter, 1998; 197). The interconnections are characterised by vertical, 
i.e. supply chain, and horizontal relationships, e.g. the presence of common customers, 
and technology. The linkages and interdependencies among actors in value chain 
activities are at the centre of the concept (Porter, 1998; Enright and Roberts, 2001). 
 
Porter focuses on the importance of close proximity in facilitating synergistic 
interactions between actors that generate innovations. Proximity stimulates innovation 
by facilitating information/knowledge and technology transfers through repeated trust-
based exchanges, i.e. networks. Only through constant innovation, improvement and 
upgrading, including product, process and organisational methods innovation, can 
competitive advantage be attained and sustained. The nature and sources of competitive 
advantage differ widely amongst industries, and cannot simply be equated with 
economies of scale or labour cost differences (De Witt, 2001).  
 
Porter proposed a 'diamond' (Figure 2.1) of four broad determinants of national 
competitive advantage, i.e. Factor Conditions, Demand Conditions, Related and 
Supporting Industries, and Firm Strategy, Structure and Rivalry. 
 
 
Figure 2.1 Porter’s Complete System (After Porter, 1998 and Dagmar, 2001) 
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The interaction of these determinants, and the influence of two additional factors 
(Chance, and the Role of Government), create the context, individually and as a system, 
in which firms are created and compete. Essentially, the 'diamond' is a mutually 
reinforcing system where the effects and influence of one determinant is dependent on 
the state of the other determinants, i.e. “...the role of any determinant cannot be viewed 
in isolation” (Porter, 1998; 99). For example, factor input deployment is related to firm 
strategy and structure, while a lack of supporting industries might limit a firm's ability 
to respond to changing market demands.  
 
How the four determinants of the national diamond manifest themselves at a local level 
reflect the diverse and place specific elements of a nation and its resources. They 
determine why particular locations develop clusters and others do not, due (for example) to 
the uneven spatial distribution of resources, and place specific historical traditions and 
cultures.  
 
The sources of competitive advantage among different industries differ widely. Porter 
comments that for knowledge-intensive industries, competitive advantage is required in all 
diamond attributes as the “interplay of advantage in many determinants yields self-
reinforcing benefits that are extremely hard for foreign rivals to nullify or replicate” 
(Porter, 1998; 73). Essentially, where an industry's competitive advantage relies on one or 
two attributes, its competitive advantage is less sustainable and can be more easily 
superseded (Rosenfeld, 2000). The determinants and the influencing factors are detailed in 
Table 2.4.  
 
2.4.3 Cluster policy issues and formulation approaches 
Clusters are place specific in character, yet a number of common visible/perceived 
advantages and features, predominately associated with modern high-tech sectors, of 
identifiable clusters have encouraged authorities in industrialised nations to develop 
cluster promotion policies. Among the observed features are identifiable network-
related 'hard' and 'soft' benefits (Wolfe and Gertler, 2007; Lee, 2012; Lia and Gengb, 
2012).   
 
Observable 'hard' benefits are tangible in nature, and occur through more efficient 
business transactions, i.e. strategic and economising network-related benefits. 
Observable 'soft' benefits are intangible, knowledge-based benefits derived from actor 
interaction, i.e. explorative and exploitative network-related benefits.  
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Yet, it is important to note that clustering is not an economic development 'panacea' for 
a variety of reasons. There is much about the concept that is problematic, while 
introducing cluster elements to industrial development policy/policies pre-empts many 
fundamental conceptual, theoretical and empirical questions, which impact on cluster 
policy. 
 
The cluster concept, and what it constitutes, suffers from definitional and theoretical 
fuzziness. No single definition exists as to what constitutes a cluster in academic 
literature. Different authors use different features, characteristics, and activity foci of 
clusters, and various geographic levels to develop definitions. Indeed, Porter's concept, 
itself, is a highly generic and indistinct. It admits a very wide spectrum of industrial 
groupings, e.g. clusters can consist primarily of SMEs and/or Transnational 
Corporations (TNCs), various specialisations, from footwear clusters to biotechnology 
clusters, different demand-supply linkage types, factor conditions, and institutional set-
ups (Porter, 1998; Amin, 1989; Sabel, 1993).  
 
Porter never defines ‘geographical proximity’, and it is presented as a highly elastic 
term. Clusters are found at different spatial aggregation levels, including large and small 
economies, rural and urban/metropolitan regions, states, nations and beyond.  
Additionally, Porter notes that cluster boundaries continuously evolve as new firms and 
industries emerge, and as established ones shrink or decline.  
 
Porter also comments that boundaries “rarely conform to standard industrial 
classification systems” (Porter, 1998: 204), yet even when they do, standard 
classifications can fail to capture many important aspects, e.g. inter-industry linkages. 
This geographical fuzziness means there is an almost unlimited scope to the concept's 
definition and application (Porter, 1998; Martin and Sunley, 2001).  
 
Ffowcs-Williams (2000) comments that these ambiguities prevent precise empirical 
delimitation that restricts the development of a suitable cluster identification 
methodology. Indeed, no agreed approach for identifying and mapping clusters exists, in 
terms of the key variables that should be measured, or in relation to the procedures to 
determine the geographical boundaries of clusters. This methodological 'fuzziness' 
directly impacts on cluster policy formulation and implementation (vom Hofe and 
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Chen, 2006; Martin and Sunley, 2001).  
 
 
 
 
 
 
ies continuously  evolve as new firms and industries emerge, and as established ones shrin 
Table 2.4: The four determinants and the two influencing factors of the national diamond 
Factor conditions: Traditional economic theory states countries have different endowments of land, labour, capital, and 
infrastructure. Porter notes these factors now play more complex and complicated roles, i.e. competitive advantage is determined 
by how they are created, upgraded and made more specialised to a particular industry, as traditional disadvantages can be 
mitigated through outsourcing. Nations now create factors of production through processes determined by country specific social 
and political values, and the influence of history. Factor creation requires continual investment and innovation to upgrade and 
improve them so as to optimally meet the particular needs of a nation’s industries. 
Porter groups these factors into five general headings:  
 the quantity, cost, work ethic and skill sets of human resources;  
 the quality, cost, abundance, and accessibility of physical resources relative to other nations;   
 the knowledge resources (i.e. stock of scientific knowledge) in PREOs, trade associations, and government agencies;  
 the amount, variety and cost of capital resources, as idiosyncratic differences remain between countries despite market 
globalisation, and; 
 the type, quality, and cost of a country's infrastructure, e.g. communications infrastructure, and cultural institutions. 
Porter states there is a hierarchy, relating to the industry activities factors are used in: 
 Basic and generalised factors, e.g. natural resources and semi-skilled labour, are possibly inherited factors support rudimentary 
types of competitive advantage, require modest private and social investments, and can be easily nullified. 
 Advanced and specialised factors, e.g. digital data infrastructures, are crucial in securing more durable competitive advantage, 
they require sustained private and social investments in human and physical capital, and facilitate constant and sustained factor 
upgrading and innovation. Advanced factors are often specialised factors, though not exclusively. 
Demand conditions: the nature and character of a home market’s demand for an industry’s product/service determines 
competitive advantage by influencing economies of scale, conferring static efficiencies, and shapes the rate and character of 
innovation and improvement among firms. Porter identifies three key features:  
 the composition, segment structure, and nature, mix and character of home demand: despite globalisation, a home markets 
demand composition can disproportionately affect how companies perceive, interpret, and respond to buyer needs, particularly 
where sophisticated and demanding buyers require high quality, feature and service standards;  
 the size and growth patterns of domestic demand facilitate economies of scale, or learning through increased information 
dissemination, which can persuade firms to enter a market, and existing firms to invest in facilities and technical 
developments. Early market saturation, resulting from home demand developments driving foreign markets to react, also 
forces firms to innovate/upgrade due to increased demand for performance and features, and;  
 the internationalisation of domestic demand. Where domestic buyers are mobile and/or transnational, the local market is 
essentially comprised of domestic and foreign buyers, e.g. TNCs typically remain loyal to domestic suppliers by using the 
same inputs in all areas of their operations. This presents local supply firms with opportunities to sell abroad. Also, foreign 
workers entering industrial/scientific training placements transmit domestic needs and/or requirements to foreign buyers 
through a 'learning from others' effect. This transfers local approaches, values and skills to foreign markets. 
Related and supporting industries: the principle tool in understanding and determining competitive advantage is a sector's value 
chain. This refers to how the performance of one firm-based activity influences the cost or effectiveness of other activities. Inter-
related activities often create trade-offs, such as institutional/transaction costs, and require coordinated logistic activities and 
supply chain management. Where close geographic and institutional proximity exists, linkages with supply firms can be 
managed optimally. Proximity and cultural similarity facilitates open information flows, reduces transaction costs, improves the 
perception of new opportunities, allowing firms to develop joint-activities which increase the rate and pace of innovation and 
upgrading. The presence or absence of internationally competitive suppliers or industries directly and indirectly influences 
competitive advantage. Suppliers that achieve competitive advantage themselves can confer advantages to customers. Buyers can 
gain quick insight into and can access information on supply developments, thereby influencing supply firm developments. 
Exchanges can lead sellers to form joint problem solving and R&D programmes that enhance product/process innovation and 
upgrading for suppliers and buyers, yet they must actively engage in such exchanges. 
Firm strategy, structure and rivalry: The conditions governing how companies are created, structured, and managed, varies 
among nations, as does the nature of domestic rivalry. These determine competitive advantage, as inter-firm competition drives 
cluster development. Firm strategy is determined by the nature of firm ownership, i.e. public or private ownership, which is 
influenced by the nature of corporate governance and the ownership of debt. A public firm reflects the idiosyncratic 
characteristics and influences of national public capital markets, which have different goals for different industries and remain 
important despite capital market globalisation, while the goals of private firms are derived through complex factors, such as 
pride and the desire to succeed in business. Inter-firm rivalry impacts on domestic innovation and drives firm creation through 
generating demand for related industries, leading to cost reductions and increased demand for new and improved products and 
processes, and opening market segments established firms may not have observed or considered. 
Influencing factors on the diamond:  
 Chance developments have little to do with a nation's circumstances, and are outside the control of firms and governments, e.g. 
technological discontinuities, external political developments, and foreign demand shifts. They cause competitive advantage 
shifts, altering diamond conditions by reshaping or unfreezing industry structures through discontinuities, while also creating 
opportunities for a nation’s firms to supplant one another. Chance does not mean an industry development is unpredictable, as 
apparent chance occurrences can exist due to national environment differences. Nations with a favourable diamond will 
convert chance events into competitive advantage via an environment that exploits new/potential competitive advantage 
sources. 
Government influence the determinants, which themselves can influence policy. Governments cannot be fully aware how all 
policies impact on a diamond, yet they should be aware of possible impacts. Policy either supports and reinforces competitive 
advantage, or produces results contrary to their intended impact(s), typically by being poorly designed. 
After (Porter, 1998; De Witt, 2001; Lee, 2012; Brett and Roe, 2006; Visser and 
Boschma, 2002; Europa, 2003; Lundberg and Andresen, 2012).  
 
'Traditional' top down industrial development policies typically emphasise infrastructural 
investment, and the provision of firm supports and incentives to stimulate sectoral activity, 
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e.g. to attract TNC Foreign Direct Investment (FDI) and/or facilitating developments 
among existing firms. While such approaches can play a role in developing 
agglomerations, the complex influences of chance and serendipity in a cluster system's 
development and emergence limits the ability of such policies to fully account for 
unpredictable occurrences, and unintended policy impacts. This does not mean policy is 
inconsequential, as chance/serendipitous events occur within a limited historical and 
geographical context, i.e. without suitable conditions being in place, chance events won’t 
engage with existing elements (Brown, 2000; Anderson et al., 2004; Orsenigo, 2007; 
Feldman and Francis, 2002).  
 
Due to these issues, critics of cluster policies contend that Governments, in seeking to 
develop the observable 'hard' and 'soft' benefits associated with clusters, often derive 
measures from 'snapshots' of successful clusters and their sectors. Such an approach is 
problematic as clusters are unique due, for example, to their socio-cultural, historical, 
and spatial specificity, and also due to the evolutionary processes which influence their 
internal structures and development. In essence, 'snapshot' policies isolate a cluster from 
its economic landscape, ignore other forms of regional and local economic 
development, ignore the dynamics of the inter-regional system as a whole, and ignore 
the evolutionary trajectories, interdependencies and dynamics of firms inside a cluster 
relative to those outside (Martin and Sunley, 2001; Amin, 1989; Sabel, 1993; Staber, 
1996; Malecki, 1997; Lia and Gengb, 2012).  
 
Deriving policies from initiatives found in successful clusters also fails to acknowledge 
that many initiatives promoting clusters often have long histories predating explicit 
cluster development strategies. Rosenfeld (2002) notes that policies can play a role in 
agglomeration developments, yet often such policies are rarely implemented with the 
intent of starting a cluster (Scott, 2007; Kenny and Patton, 2007; Carlsson, 2007; Lia 
and Gengb, 2012).   
 
Martin and Sunley (2001) comment that clustering has become a ‘chaotic concept’ due 
to the variety of meanings and connotations governments associate with it. In part, this 
issue is due to the concept's definitional and methodological fuzziness, but it is also due 
to a limited understanding of the concept's fundamentals among public actors. This is 
reflected in governments introducing 'cluster' policies to promote political strategies, 
such as decentralisation programmes, and not as economic development tools. 
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Additionally, policies have been applied at unsuitable geographic levels due to political 
pressure to avoid offending regional interests. For example, the Sainsbury report on 
Biotechnology clusters in the UK (DTI, 1999) identified clusters in almost every UK 
region, even though many lacked key/fundamental features of clusters (vom Hofe and 
Chen, 2006; Enright and Ffowcs-Williams, 2001; Asheim and Coenen, 2004). 
 
Governments also predominately associate clusters with high-technology, knowledge-
based economic activities, i.e. industries with a high dependence on knowledge 
generated and contained in industry- and PREO-based research laboratories, and whose 
labour skills, technological know-how, and innovative activities are optimised through 
geographic proximity. However, it is unlikely that all regions can rely on the same 
knowledge-intensive sectors, as the benefits realised from clustering appear specific to 
certain industries, and are only realised under particular conditions (Martin and Sunley, 
2001; Audretsch and Feldman, 1996; Audretsch, 1998; Keeble and Wilkinson, 2000; 
Glasmeier, 2000; Ahrweiler et al., 2011; Lee, 2012).  
 
Indeed, Amin (1989) questions whether new clusters can develop through public or private 
sector intervention in locations where a few basic conditions required for cluster formation 
are found. Effectively, cluster policies are unlikely to successfully create 'new' clusters in 
poorly endowed regions, and are more appropriate where a diverse economic base that can 
support new markets and diversification already exists (Feldman and Braunerhjelm, 2007; 
Maggioni, 2007; Wolfe and Gertler, 2007; Morris, 2011; Ahrweiler et al., 2011).  
 
Critics also contend that governments seem unaware that cluster policies can actually 
introduce and embed regional vulnerabilities through promoting a specialised economic 
activity focus. Uzzi (1997) comments that the processes which create embeddedness 
develop due to a 'specific' cluster environment, and that sources of inertia and 
inflexibility, i.e. 'lock-in', relative to firms and industries outside a cluster, can develop 
over time. Essentially, the same processes which facilitate cluster formation may 
paradoxically reduce a cluster's ability to evolve and/or adapt to system shocks. 
Examples of cluster induced 'lock-in' are presented in Table 2.5 (Forfás, 2004; Porter, 
1998; Silvia, 2009; Malecki, 1997; Howells and Edler, 2011). 
 
Cluster policies can also reinforce regional inequalities, particularly where they are 
implemented uniformly (spatially), as more resource and competence rich locations will 
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better absorb resource investments, relative to less endowed locations, due to their 
greater capacity levels (Morris, 2011).  
 
Table 2.5: Examples of cluster induced 'lock-in' 
 a cluster with a specialised focus becoming resistant to new and different information sources which differ drastically from its 
established core skills, expertise, and/or supplier bases, i.e. its established paradigm;  
 the development of a high skilled specialised labour pool driving out lower skilled jobs and firms, which potentially creates an 
inability for the cluster members to react to external shocks and/or technological changes, and; 
 where a cluster relies on the activities of a large firm, the cluster may fail if the dominant actor moves from the system, even if 
it remains competitive. 
After (Martin and Sunley, 2001; vom Hofe and Chen, 2006; Ingley, 1999; Eisingerich et 
al, 2012) 
 
This issue relates to the 'innovation paradox', as identified by Oughton et al. (2002). 
Such a paradox emerges where actors in poorly endowed regions do not (and cannot) 
engage in significant innovative activities as they typically underinvest in R&D, which 
means they cannot (and do not) engage in significant innovative activities. Such actors 
would also lack an interactive learning tradition due to an established absence of inter-
actor cooperation caused, for example, by the presence of 'closed' vertically structured 
dominant actors and/or the prevalence of conservative business models, which would 
undermine potential opportunities to exploit synergies and facilitate spillovers (Asheim 
and Isaksen, 2002; Anderson et al, 2004; Giesecke, 2000; Leydesdorff at al., 2002; 
Morris, 2011; Eisingerich et al, 2012). 
 
Due to these definitional, conceptual and methodological issues, it is tempting to 
conclude that the notion of clusters, ultimately, has no real significance for policy 
measures. Yet, Brown (2000) comments that clusters should be viewed more as an 
economic development process rather than a definite development theory.  
 
Effectively, the cluster concept can be conceptualised as an umbrella term, or 'brand', 
which Governments can apply to different aspects of economic activities in different 
manners. The brand, at its core, is based on an image of a highly productive, 
knowledge-rich, decentralised, entrepreneurial and socially progressive economy, rather 
then as a coherent and carefully defined set of ideas and practices. Using the cluster 
'brand' as a policy focus can engender better coordination between different policy 
themes relating to cluster development, while initiatives can be optimally tailored 
towards regional specific processes and developments by orientating all relevant 
stakeholders towards cluster development, thus (for example) minimising the 
introduction of 'lock-in' events (Martin and Sunley, 2001; Wolfe and Gertler, 2007; Graf 
and Krüger, 2011; Howells and Edler, 2011). 
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Porter (1998) and other commentators argue that cluster policies should be geared to 
industrial sectors, and should avoid firm-specific actions in favour of a systems-based 
approach, as individual firms, for example, are part of a larger industrial system. A 
systems-based approach is also required as innovation does not occur in a chain link 
development process, but occurs through multiple reciprocal relationships at different 
stages of the innovation process between different public and private actors, and different 
sector segments (Brown, 2000; Anderson et al., 2004; Wolfe and Gertler, 2007; Giesecke, 
2000; Orsenigo, 2007; Feldman and Francis, 2002). 
 
Essentially, it is the process by which clusters form and emerge, not the final 'result', 
which is important in relation to policy measures. This means that policies can be 
developed to facilitate cluster development in the long-term by being used in a 
facilitator role, and not as a constructor. The rationale behind this approach, which is 
detailed further in the following sections, fundamentally differs from top down 'snap 
shot' derived policies (Anderson et al., 2004; Martin and Sunley, 2001). 
 
Through a review of various cluster case studies from different countries, industries, and 
Governments, two broad cluster development and evolution stages can be identified, as 
detailed in Table 2.6. It must be noted that this 'divide' is simply for presentation 
purposes only, as the border between both stages is fluid.   
 
These stages directly influence the approach, formulation and implementation of cluster 
policies. As such, two broad approaches to cluster policies can be detailed:  
 
 cluster-specific strategies, which are designed to facilitate 'new' cluster 
emergence in an area where one does not exist, or has not yet emerged, and;  
 cluster-informed strategies, which are introduced following a clusters emergence 
to optimise its development trajectory.  
 
2.4.4 Cluster specific policy themes 
Where Governments seek to develop a cluster where one has not formed/does not exist, 
their policy approach is termed 'cluster specific'. Such policies challenge conventional 
thinking about how national, regional and local governments promote economic 
development and prosperity, particularly where characteristic aspects of cluster systems 
are not present (Brown, 2000; Anderson et al., 2004; Wolfe and Gertler, 2007).  
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Table 2.6: Proto-cluster emergence and development stage themes 
The processes facilitating cluster development are complex and region specific. Economic systems evolve over time, through complex and 
idiosyncratic  “processes of construction of competencies, supporting institutions, [and] organisational structures” (Orsenigo, 2007: 204), under 
variable natural, cultural, social and economic conditions “shaped and constrained by past decisions, chance events, and accidents of history” 
(Wolfe and Gertler, 2007: 244), and which involve complex inter-actions of heterogeneous public and private actors. 
Proto-cluster (PC) developments are determined by the factor pre-conditions and seeds which exist prior to their emergence. There is a subtle 
difference between these elements:  
 Pre-conditions are a region's specific, non-reproducible asset base, including its accumulated local stock of knowledge, experiences, resources, 
institutions and infrastructures, which form prior to a PC's evolution (examples include naturally occurring factor endowments, such as existing 
ore reserves, and an area's climate, quality of life and living conditions), and the presence of existing agglomerated competences in similar or 
related industry/industries that actors in emerging sectors can exploit. 
 PC seeds/seedings are assets introduced to an area through deliberate actions by actors, such as (though not limited to) Government actors. Seeds 
can form due to intended impacts from intentional acts, or due to unintentional impacts from deliberate acts. 
Pre-conditions and seeds facilitate cluster emergence, yet are not sufficient to solely facilitate cluster emergence. 
Cluster emergence is determined by complex processes building upon and priming pre-conditions and seeds, i.e. a trigger process, and a critical 
mass of entrepreneurial and innovative activity which directly leads to a cluster's emergence, i.e. a trigger event. Both part of the same process, and 
are presented here separately for explanation purposes only.  
PC trigger process: As a cluster is a system. Different feedback forms develop at different points, and at different stages of a trigger process. 
Feedback determines a cluster's nature and character forms. A PC's trigger process is determined by the nature and character of a system's path 
dependence and development trajectory, and the presence of inter-actor knowledge/information spillovers;  
 PC system path dependence and development trajectory: development trajectory is determined by established cumulative formations, 
interactions and trade-offs of various hard and soft infrastructures, resources, skills, and actors. Strong associations exist between past 
investments in hard and soft infrastructures and a system's economic performance, while existing structures and routines mean rigidities and 
trajectories prevail in innovations. These elements form a system's path dependence, influencing and determining the innovative capabilities and 
resources of actors. Path dependence influences systemic spillovers by impacting on the interactive environment in which actors operate, 
meaning it determines and influences the generation, filtering, and dissemination of information. For a cluster to emerge, positive externalities 
must occur during a trigger process to build upon existing systemic strengths and to address systemic weaknesses. Key determinants of such 
externalities are entrepreneurship and innovation, i.e. new firms, products and processes which create positive feedback that addresses lock-in 
and technological discontinuities, which is facilitated and determined by the presence of skilled labour and an entrepreneurial support 
'ecosystem' that both facilitates and encourages innovative developments. The factors characterising an ecosystem are fundamentally linked, and 
are strongly influenced by a PC's pre-conditions/path dependence, and development trajectory. Different supports play different roles in the 
technological and regional dynamics of a PC, yet they are “mutually determined in a complex web of circular cumulative causation” (Feldman 
and Braunerhjelm, 2007: 10) which continuously alters through system specific feedback. 
 Information spillovers: A cluster's competitive advantage is determined through its value chain, which means a key factor determining cluster 
emergence is how actors in a system interact. Where localised knowledge transactions occur through informal and formal networks, 
combinations of tacit practices and routines with new knowledge components facilitate information spillovers. These determine, and are 
fundamentally determined by the characteristics of a PC system's actors and their networks. Spillovers, particularly where positive pre-
conditions/seeds exist, drive a PC's development trajectory through positive feedback inputs, and encourage innovative and entrepreneurial 
developments that drive network density and facilitate complex networking arrangements through mimetic isomorphism.  
PC trigger event: A trigger event occurs through the formation of a critical mass of entrepreneurial and innovative activity that emerges through a 
PC's trigger process. Critical mass develops over an extended period of time, and depends on the nature and character of a system's support 
ecosystem and information spillovers. A trigger event's character determines the nature of a cluster's structure, and influences the entrepreneurial 
and innovative features of its constituent actors and their business structures. Three principle categories can be identified:  
 Spontaneous trigger events occur in an absence of policy interventions through local actors proactively seeking to exploit actual and/or potential 
synergies in a PC's system. Actors proactively organise, i.e. they move away from spontaneous forms of agglomerated interactions towards a 
more organised and co-ordinated territorial system whose internal functions stratify organically. Such clusters are characterised as being 
intensely entrepreneurial and innovative in nature. 
 Trigger events can occur through (direct and indirect) policy interventions that seek/facilitate a system's emergence through creating an 
entrepreneurial and innovative support ecosystem that facilitate spillovers and the development of a positive development trajectory.  
 hybrid trigger event processes occur through a mix of spontaneous and policy driven developments. Hybrid systems initially form through 
proactive actor driven developments, yet later experience significant positive systemic inputs due to direct or indirect policy actions which 
ultimately facilitate a cluster system's emergence.  
Due to the 'constructed' aspects of planned and hybrid clusters, their entrepreneurship, innovation activities and internal organisation are less 
aggressive in nature then spontaneous systems. 
A cluster's long-term sustainability, i.e. how it extends and consolidates its competitive advantage(s), is determined by its system being subject to a 
continual, structured and self-reinforcing process of growth and development through on-going innovative and entrepreneurial activities. Due to the case 
specific nature of clusters, few cluster emergence and development themes can be detailed. However, two key interlinked determinants of a cluster's 
long-term positive development trajectory can be identified: 
 Second generation (spin-off) firm developments occur in the context of an established innovative and entrepreneurial culture and ecosystem that 
proactively encourages and facilitates entrepreneurial developments by lowering entry barriers and addressing risk perceptions associated with 
new developments. The skills and experiences of first generation firms act as reservoirs of knowledge relating to successful firm development, which 
encourage and facilitate second generation developments, shaping them through mimetic isomorphism. This allows spin-off firms to access existing 
supports, as they are perceived as system 'insiders'. Spin-out firm innovations are typically path-breaking, and open new sub-markets due to their origin. 
This drives a system's positive development trajectory by adding to its asset base, deepening networks, and facilitating systemic externalities and 
spillovers. 
 Non-local actors enter a system to access/exploit its highly developed support ecosystem, particularly after the development of spin-out firms. 
They facilitate increased spillovers through mixing new and old competences. Yet, spillover effects differ for new and existing actors. Existing 
actors predominately engage in incremental innovation based on an existing paradigm, while new actors are likely to drive radical innovation 
(which indicates a technological discontinuity for established actors). By increasing systemic activity and engendering positive feedback, new 
technological upsets are absorbed by both new and old firms, resulting in the improved technological capabilities and depth of the entire system. 
Such developments can address technological/trajectory 'lock-in', enhance a system's entrepreneurial and innovative 'brand', increase a system's 
depth and density, and attract in additional actors and their embedded tacit skills, competences, and resources, from less asset rich systems. 
After (Cooke, 2002; Owen-Smith and Powell, 2004, 2007; Wolfe and Gertler, 2007; 
Carlsson, 2007; Romanelli and Feldman’s, 2007; European Commission, 2006; Porter, 
1998; Gertler and Levitte, 2005; Scott, 2007; Kenny and Patton, 2007; Zhang and 
Haiyang, 2011; Graf and Krüger, 2011; Eisingerich et al, 2012). 
 
Government policies fall between these two broad approaches, meaning the nature and 
character of cluster policies ultimately depends on what Governments wish to achieve 
(Feser, 1998; Brown, 2000; Wolfe and Gertler, 2007). 
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Cluster policies should be tailored towards building on pre-existing competences and 
productive systems, which may be embryonic or latent, in a specific sector, rather than aim 
to create new systems, as “without the presence of underlying national circumstances...the 
best policies will fail” (Porter, 1998: 617). Additionally, key features of a cluster's internal 
structure, and many of the determinants of a cluster's development and emergence, 
cannot be developed solely through policy actions, e.g. the inherent trust-based nature 
of networks (Malecki, 1997; Scott, 2007; Anderson et al., 2004; Wolfe and Gertler, 
2007). 
 
A PC's formation is a long, complex and dynamic process. Porter (1998) notes that 
numerous studies suggests cluster emergence can take decades, e.g. Silicon Valley's 
foundations formed in the 1930s, yet it flourished from the 1960s onwards. This means 
that no one policy, or series of policies, can fully account for a system's evolving nature, 
i.e. cluster specific policies must develop and evolve over sequential processes, and be 
adaptive and highly responsive in nature so as to create the conditions which facilitate, 
support and reinforce a PC system's positive development trajectory (Porter, 1998; 
Maskell and Kebir, 2005; Scott, 2007; Anderson et al., 2004; Wolfe and Gertler, 2007) 
 
Yet, a decade is an eternity in politics, as demonstrated by 'traditional' industrial 
development policies, which typically seek short term benefits to fit election cycles. This 
approach can retard innovation in the long-term through, for example, introducing 
systemic 'lock-in'. As such, cluster specific policies must transcend short-term business 
cycle approaches, as “...the most potent influences of government in advanced nations are 
often slow and indirect” (Porter, 1998: 619; Carlsson, 2007; White, 2000; Graf and Krüger, 
2011).  
 
The complex interlinked nature of the themes which facilitate a PC's emergence means 
a suitably complex policy framework is required to address the relevant policy themes, 
particularly technology and industrial themes, as a whole, and in a coherent/convergent 
manner. Optimally, such a framework involves direct interventions to target the creation 
of required infrastructure and resources, e.g. regulatory initiatives to support 
entrepreneurship, and indirect interventions which play a facilitator role, e.g. market 
research assistance and prototype testing (vom Hofe and Chen, 2006; Europa, 2003; 
Oughton et al., 2002).  
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Scott (1997) states that cluster specific policies should focus on micro-economic 
measures, as within “...successful clusters there is a degree of self-organisation 
that...reflects an underlying complex social process. If policies fail to understand the 
dynamics of clusters emergence...[there is a significant] risk that a nascent cluster will 
decline” (Scott, 2007: 11). Additionally, Governments are often directly removed from 
market forces, meaning policy measures are at best reactive, addressing issues some 
time after their emergence (Breschi et al., 2001; Anderson et al., 2004; Eisingerich et al, 
2012).  
 
The geographic 'borders' of cluster systems are often larger, or smaller, then Geographic 
units of governance. As such, existing Government and non-Government institutional 
structures and jurisdictional boundaries may inhibit suitable policy developments by 
failing to capture key aspects of a PC system's internal dynamics. Indeed Porter (1998) 
comments that as the basis for competitive advantage is often locally concentrated, “the 
role of state and local [regional] government is potentially as great or greater” (Porter, 
1998: 622) than National or Federal government in developing tailored policies, by being 
relatively more attuned and responsive to a sector's needs (Steiner, 1998; Brown, 2000; 
Wolfe and Gertler, 2007; Europe Innova, 2008).  
 
Additionally, close co-ordination between the regional branches of development agencies 
and local authorities is also required for a uniform policy approach towards industrial and 
economic development. Yet, in the context of their typically limited resources, it is 
unrealistic to expect local and regional authorities to be able to fully detect how a PC 
system develops due to its complex and evolving nature, or to continually anticipate 
changing service requirements (Ffowcs-Williams, 2000; Wolfe and Gertler, 2004; 
Giesecke, 2000; Krugman, 1991; Anderson et al., 2004; Eisingerich et al, 2012).  
 
As such, to combat information weaknesses and to tailor suitable initiatives for a PC 
system, the formulation and implementation of cluster specific policy/policies should 
optimally involve the key public and private actors in a particular system, through a 
system-specific actor council or organisation. Essentially, this entails the development of a 
distinctly new cluster-specific associative governance structure that includes all relevant 
stakeholders in a PC/cluster system that influence, or may be affected by cluster 
activities, including:   
 
 37 
 National, Federal, Regional and Local government;  
 Development agencies; 
 Small and large firms in the specific sector, including SMEs and TNCs, and 
service provides;   
 Local PREOs;  
 Chambers of Commerce, Industry and Trade Associations, and enterprise boards, 
and; 
 Speculative investors, including venture capitalists (VCs) (Anderson et al., 2004; 
White, 2000; Asheim and Coenen, 2004; Cooke, 2002). 
 
Integrating a system's public and private actors and institutions into policy decision 
processes can be a significant challenge for highly-regulated/vertically structured 
Governments. Yet, such a process is required to optimally tailor initiatives to the specifics 
of a sector, by establishing a socio-economic dynamic that is based on open discussion and 
consensus-building through a complex range of interactive settings (including working 
groups, seminars, interviews, audits and surveys) so as to identify weakness, build on 
strengths and avoid laziness/complacency. Due to the evolutionary nature of a PC's system, 
this collective dialogue must be both continuous and open to new stakeholders to join and 
influence, so as to optimise a system in the context of current and future trends (Anderson 
et al., 2004; Wolfe and Gertler, 2007; Ffowcs-Williams, 2000; Giesecke, 2000; 
Eisingerich et al, 2012).  
 
Such elements can be facilitated through introducing a systems integrator, i.e. an actor, 
or council of key actors recognised by a system's actors, to manage and coordinate the 
dialogue. An integrator actor/council facilitates the formation of a 'cluster consciousness' 
by stimulating a sense of communal ownership among actors, aligning the various interests 
of the different stakeholders, and/or discouraging opportunistic acts which would result in 
the process' fragmentation. Additionally, a consensus driven dialogue removes/reduces the 
effect of election cycles on policy developments, and maintains and encourages private 
sector involvement in a PC's development (Europe Innova, 2008; Ffowcs-Williams, 
2000; Maskell and Kebir, 2005).  
 
A suitable systems integrator actor/council crucially creates confidence among the 
various stakeholders during the early stages of a dialogue process, and also prevents the 
development of a weak or exclusive leadership, e.g. an elite few which prevents new 
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members entering the process. An integrator actor/council also addresses complacency due 
to cluster success, and prevents vested interests or dominant actors, such as monopolies, 
placing pressure on Governments to protect an existing paradigm which may become 
outmoded due to new innovative developments. Essentially, it is important that all 
stakeholders focus on the long-term facilitation of innovation and entrepreneurship, 
regardless of the 'costs' and system shake outs which may occur, so as to avoid negative 
feedback inputs/systemic 'lock-in' events forming in the system (Giesecke, 2000; Europa, 
2003; Porter, 1998; Casper, 2007; Graf and Krüger, 2011). 
 
A public/private consensus is important for a PC's evolution in relation to the nature of its 
trigger event, i.e. a PC system's modus operandi should be more in keeping with the 
private sector with regards to the regulations and conventions governing the operation of 
capital markets, forms of corporate governance, R&D, and other relevant factors. Private 
sector actors, ultimately, must be the dominant investors in a system's development, 
resource and finance wise, and should therefore have a substantial input into the 
formulation of policy measures (Anderson et al., 2004; Rosenfeld, 1997; Martin and 
Sunley, 2001; Wolfe and Gertler, 2007; Oughton et al., 2002; Lundberg and Andresen, 
2012). 
 
Therefore, Porter (1998) comments that direct government policy intervention(s) into a PC 
system, sidestepping private actor involvement, should occur only in specific instances, as 
detailed in Table 2.7. 
 
2.7: Instances when direct government policy intervention(s) should occur in a PC system 
Market failures: where a market underperforms and cannot address these issues independently, policies may be introduced to 
motivate specific system developments, e.g. increased public R&D spending, while alterations can also be made to public 
procurement policies.   
Government policy failures: where an existing policy or policies cause system weaknesses, e.g. the presence of underdeveloped 
PREOs. 
Systemic failures: where structural inconsistencies/mismatches develop between interrelated institutions or organisations, e.g. poor 
Government jurisdictional and/or agency coordination. 
 
 
(Metcalfe, 1995; Porter, 1998; Howells and Edler, 2011).  
 
2.4.5 Cluster specific entrepreneurial and innovative functional resource themes 
The long-term challenge for cluster specific initiatives is to facilitate the emergence of a 
competitive, internationally focused PC system through seeding and developing the 
necessary elements that facilitate a positive trigger process, and ultimately the 
development of a trigger event. A complex approach is required to introduce the relevant 
'hard' and 'soft' infrastructures, skills, resources and supports. Essentially, a support 
'ecosystem' that facilitates and drives entrepreneurial and innovative developments 
throughout a PC system should be sought, one which optimally builds upon strengths, and 
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addresses weaknesses present in the four determinants of competitive advantage (Feldman 
and Braunerhjelm, 2007; Porter, 1998; Anderson et al., 2004). 
 
Due to the unique characteristics of PC systems, and also in the context of the issues of 
deriving 'snapshot' policies from established cluster systems, the following sections do not 
prescribe a series of detailed policy actions, but detail five inter-connected entrepreneurial 
and innovative functional resource (EIFR) requirements that have been identified 
through a review of international cluster and PC case studies, and which draw from 
Anderson et al. (2004). The EIFRs are: 
 
 Knowledge infrastructure, resources and skills (EIFR 1); 
 Entrepreneurial infrastructure, resources and skills (EIFR 2) 
 Inter-actor networks (EIFR 3); 
 Market information exchange resources (EIFR 4), and;  
 Actor and institutional density, and skill, competence and resource depth (EIFR 
5) (Ffowcs-Williams, 2000; Casper, 2007; Anderson et al., 2004; Carlsson, 2004).  
 
The EIFRs facilitate the development of a PC system's 'ecosystem' that feed into the 
development of the four determinants of national competitive advantage. They also 
represent the key themes around which a PC's public/private dialogue process, and the 
formulation of cluster specific policy initiatives, should be orientated.  
 
Prior to the formulation of cluster specific initiatives, a formal mapping exercise, i.e. a 
Strengths, Weaknesses, Opportunities and Threats (SWOT) analysis, is required to 
identify the idiosyncratic sectoral/system strengths and weaknesses, and to identify 
opportunities to exploit a PC's pre-conditions and seedings. Such an analysis is best 
viewed as a general mode of inquiry, rather then a narrowly defined regional economic 
analysis whose methodology is dependant on particular policy concerns. Optimally, a 
PC should first be studied in spatial isolation from the general economy, to shed light on 
actor and institutional interdependencies. It should then be analysed in its spatial context 
in relation to a larger (external) economic unit of which it is part, i.e. state or nation, so 
as to place it in its proper context as to how it is embedded into the local economy (vom 
Hofe and Chen, 2006; Wolfe and Gertler, 2007; Rosenfeld, 2000; Eisingerich et al, 2012).  
 
A PC's strengths are its existing resources and capabilities which form the basis for 
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developing competitive advantage. Its weaknesses are essentially the absence of certain 
characteristics that place it at a disadvantage relative to other systems, examples include 
patent protection strength/weaknesses, and the system's ability/inability to react to market 
changes/shocks. A PC's opportunities and threats are external issues which can impacts on 
a system's competitive position, examples include technological and/or market change, and 
changes in the marketplace or competitive position (Wolfe and Gertler, 2007; Rosenfeld, 
2000; Zhang and Haiyang, 2011).  
 
A SWOT analysis should also inform the development of a public/private dialogue 
process, and the development of supports to encourage pro-active private sector 
involvement in a PC system's development. A SWOT analysis provides policy makers 
with a better understanding of how a local economy is structured, and can assist in the 
formulation of direct 'accelerators' to re-equilibrate the identified system before 
initiating cluster specific initiatives. Examples of 'accelerators' include the development 
of key infrastructure elements, such as up-to-date telecommunications and NICTs, and 
suitable transport links (Ffowcs-Williams, 2000; Porter, 1998; Orsenigo, 2007) 
 
Additionally, it is crucial that supports are developed to encourage private sector 
involvement in a PC's development, particularly where private actor innovation and/or 
investments are restricted. Such supports should involve an incentive framework that 
encourages firms to see the value of such activities, and proactively supports them to enter 
into such activities in a self-funding market-based manner. In some cases, marketing 
strategies should also target the attraction of particular actor types into a system to address 
specific weaknesses, e.g. capital availability weaknesses (Anderson et al., 2004; Rosenfeld, 
1997; vom Hofe and Chen, 2006).  
 
The five EIFRs are discussed in the following sections, while sample SWOT questions 
relating to the individual EIFRs are presented in the following tables. 
 
EIFR 1: Knowledge infrastructure, resources and skills 
Information/knowledge plays a similar role in modern technology intensive sectors as 
energy/fuel played in the industrial revolution. As the line between basic and applied 
research becomes progressively more indistinct, modern industries increasingly rely on 
PREO-generated knowledge for marketable innovations and economic growth. This 
means the quality and character of a PC's PREO capabilities, resources, skills, and 
(sticky) knowledge sets are key elements in the synergy processes that influence a 
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system's development trajectory, due to the existence of local learning processes, 
technology transfers and spillover effects supported by geographic and cultural 
proximity (Wolfe and Gertler, 2007; Malecki, 1997; Anderson et al., 2004; Krafft et al., 
2011; Chen at al., 2011; Lundberg and Andresen, 2012).  
 
Cluster specific initiatives must seek to optimise a PC system's knowledge-base by 
addressing PREO infrastructural weaknesses/gaps, as technological infrastructure 
limitations restrict innovative activities by limiting research activities. This directly 
relates to the development of advanced and specialised factors that are necessary for 
enhancing a system's production capabilities, capacity, and accumulation of 
technological capabilities (Anderson et al., 2004; DTI, 1999d; MacPherson, 1998; 
Porter, 1998; Lundberg and Andresen, 2012).  
 
Aside from the importance of a PC's PREO-based research base in innovative and 
entrepreneurial developments, their education programs play central roles in 
determining the quality of a region’s skilled labour force. A suitably educated labour 
base is crucial, as a strong labour pool plays a key role in entrepreneurial and innovative 
spillovers (Anderson et al.2004; Prevezer and Swann, 1996; Asheim and Isaksen, 2002; 
Engel and Del-Palacio, 2011; Delerue and Lejeune, 2011).  
 
Initiatives must also focus on the development of suitably skilled labour through 
training courses tailor-made to the demands of the entire system. Ideally these should be 
formulated through public/private dialogue as worker skills and attitudes are invisible 
(tacit) factors in a PC system, in relation to economic diversity and competitiveness 
(Wolfe and Gertler, 2007; MacPherson, 1998; Engel and Del-Palacio, 2011; Lundberg 
and Andresen, 2012).  
 
Table 2.8: Sample Knowledge Infrastructure, Resources and Skills SWOT Questions 
Is a PC's existing knowledge base analytical and/or scientific in nature?  
What is the current state of a PC's research infrastructure?  
Are there important knowledge skill and infrastructure gaps? 
Are skills of required quality and diversity for all areas of the PC system?  
Is the whole value chain represented? 
Is the knowledge base expected to change in the next decade/decades?  
What infrastructural and skills-related issues may develop as the PC's system develops and evolves? 
Do PREOs and education providers have the resources and ability to respond to these changes? 
 
Additionally, efforts must be made to support a PC system's ability to retain skilled 
actors, in particular researchers, and deepen the system's skills base through actor 
immersion strategies, i.e. short-term placement programmes in other systems so as to 
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engender the development of more complex skill sets (this directly relates to EIFR 4) 
(Anderson et al., 2004; Koehler, 1996; Erden and von Krogh, 2011). 
 
EIFR 2: Entrepreneurial infrastructure, resources and skills 
High quality PREO assets (EIFR 1) cannot offset the lack of an entrepreneurial or 
innovative climate in a PC. As stated, vigorous entrepreneurial and innovative activity, and 
the active participation of entrepreneurs in the building of institutions, aided by forces of 
agglomeration, are fundamental elements which facilitate the formation and development 
of a cluster system (Porter, 1998; Romanelli and Feldman, 2007; Scott, 2007; Engel and 
Del-Palacio, 2011). 
 
A PC's innovative and entrepreneurial propensity is determined by its regional 
entrepreneurial infrastructure and supports, and the psychological and/or social 
characteristics of its actors. Entrepreneurship is an endogenous process, a learned set of 
guidelines that co-evolves with a region’s business activities and supports, creating a 
cluster specific culture. By creating new companies, entrepreneurs spark regional industrial 
transformations by indirectly building institutions that promote their sectoral needs, thus 
influencing path dependence and self-organisation (Feldman and Braunerhjelm, 2007; 
Wolfe and Gertler, 2007; Engel and Del-Palacio, 2011).  
 
Cluster specific policies must focus on the long-term development of a suitable local 
business environment, and on the inculcation of an entrepreneurial/innovative culture 
among system actors, to support entrepreneurial/innovative developments and 
experimentation. Essentially, a multi-faceted support system must be developed, shaped by 
patterns of public/private interaction and dialogue, which inter-link and co-evolve with a 
cluster's development so as to facilitate 'organic' system wide developments. Such a 
support system should focus on 'hard' and 'soft' resources and supports that upgrades the 
innovation capacity of firms, promotes rapid technological diffusion, and seeks to develop 
increased interactions between a system's actors (Compete, 2005; Anderson et al., 2004; 
Malecki, 1997; Lundberg and Andresen, 2012; Eisingerich et al, 2012).   
 
Public supports must be extensions, not replacements, of existing supports, and they must 
avoid reducing entrepreneurial and innovative pressures in a system. It is also essential that 
initiatives ultimately seek the development of privately organised supports which are 
entrepreneurial in nature, so as to respond optimally to a system's evolving nature and 
needs. This is also important due to their impact on the entrepreneurial character of new 
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firm developments and of the wider PC system (Feldman and Braunerhjelm, 2007; Scott, 
2007; Porter, 1998; Delerue and Lejeune, 2011). 
 
'Hard' system supports include infrastructures and resources that facilitate new, and 
optimise existing entrepreneurial and innovative developments. These include a suitable 
legal and regulatory framework and supports, in particular an optimised IP regime, and 
the availability of a complex range of financial supports and actors. A PC's legal/IP 
system and skills base must be of suitable quality and of sufficient depth of experience 
to encourage and protect systemic developments, as weaknesses can deter actors from 
entering commercial alliances due to the presence of excessive risk levels. Additionally, to 
develop and maintain entrepreneurial/innovative pressures, sectoral benchmarking should 
be adopted through the development or application of a suitable regulation system, e.g. the 
ISO 9001 quality management system (Anderson et al., 2004; Scott, 2007; Wolfe and 
Gertler, 2007; Maskell and Kebir, 2005; Engel and Del-Palacio, 2011).  
 
A PC with a limited track record of successful entrepreneurial developments will 
experience cumulative disadvantages in the number and type of investor actors and 
supports it will develop and/or attract, thus creating a negative feedback loop which 
undermines entrepreneurial developments. Where one funding source or investment actor 
type is present/dominant, it limits the type of actors which can access such funding as 
investor actors, in seeking to optimise their investment returns, have specific requirements 
and foci to their investment decisions (Romanelli and Feldman, 2007; Owen-Smith and 
Powell, 2007; Porter, 1998; Graf and Krüger, 2011). 
 
The public/private dialogue can animate the development of a wide range of new financial 
instruments and supports to facilitate different forms of innovative activities. These include 
seed and risk capital funding for new high-risk areas, and brokerage services between 
innovators and the banking sector, including business angels, so as to optimise the business 
models and the development trajectories of new firms. Public initiatives and supports 
should be introduced to facilitate the development of new entrepreneurial/innovative firms 
to build up perceptions of reliability and trust among regional partners in order to attract 
private investors into the system from other related sectors. Funding and investor variety 
provides entrepreneurs with viable alternatives and reduces the demand for/over-reliance 
on existing supports, including an over reliance on public supports (Maskell and Kebir, 
2005; Cooke, 2002; Zhang and Haiyang, 2011; Engel and Del-Palacio, 2011; Lundberg 
 44 
and Andresen, 2012). 
 
Competitive tendering processes should also be introduced in funding initiatives to drive 
the quality of a PC's entrepreneurial/innovative developments. A realistic 'standard', 
relevant to the system's state of development, should be adopted, but one which becomes 
ever higher as the system develops (Owen-Smith and Powell, 2007; Maskell and Kebir, 
2005).  
 
However, 'hard' support structure can only assist, and not create innovative/entrepreneurial 
developments. If the necessary competences and skills required to facilitate entrepreneurial 
developments do not exist, or are underdeveloped, actors will refrain from such 
developments due to prohibitive levels of perceived and/or actual risk. Entrepreneurship is 
an inherently localised phenomenon. Actors typically start companies based on prior 
experiences and interests. For example, they may seek to address an identifiable niche 
market existing firms may not acknowledge or find too small or risky to act on, and/or by 
using existing skill and knowledge sets to develop applications from licensed patents. As 
such, 'soft' PC system supports must form, advancing existing skills and introducing new 
skill sets to ultimately create an entrepreneurial culture (Casper, 2007; Orsenigo, 2007; 
Owen-Smith and Powell, 2007; Krafft et al., 2011; Eisingerich et al, 2012).  
 
In the context of EIFR 1, entrepreneur and researcher skill sets should overlap to optimise 
value chain developments. This relates to the need for PREOs to develop courses tailor-
made to the evolving demands of an entire system. Entrepreneurial/innovative skills can 
also be engendered through inter-firm/PREO placements, which also facilitate tacit 
knowledge exchanges. Such programmes are important as entrepreneurial developments 
are influenced by the pre-entry background of their founders, i.e. preceding tacit 
knowledge, experiences and contacts from their past working and/or educational activities 
(Feldman and Braunerhjelm, 2007; Scott, 2007; McKelvey, 1996; Erden and von Krogh, 
2011). 
 
Such skills-based initiatives, in alliance with a PC's 'hard' supports, feed the inter-related 
development of a PC's support ecosystem, and its entrepreneurial/innovative culture. In 
combination, they facilitate significant long-term cumulative benefits relating to a system's 
entrepreneurial orientation, which is determined and facilitated by a growing company 
base. Different forms of entrepreneurial developments can be characterised, as detailed 
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in Table 2.9. 
 
Table 2.9: Different forms of entrepreneurial developments 
Start-up firms: new, relatively inexperienced entrepreneurs seek to develop new commercial developments in a PC. Such firms emerge 
only when a suitable support framework emerges that lowers entrepreneurial 'entry barriers', through removing/reducing firm 
development risks, and which also encourage commercially minded actors to abandon their relative job security so as to establish and 
work within start-ups which have no guarantee of succeeding.   
Spin-out firms: new firms form through activity diversification from a related sector. The development of a support framework can 
'brand' a PC's innovative capabilities and capacities and attract non-local actors into a PC's system. This also strengthens a PC's 
capabilities by creating positive externalities, which further lowers entry barriers. 
Spin-off firms: new firms can emerge from within a PC system, e.g. actors seek to exploit commercially-viable PREO-based research, 
or create new ventures that address organisational problems/inertia in their 'parent' actor. Such developments will only occur where a 
suitable ecosystem is present. 
 
 
After (Compete, 2005; Casper, 2007; Dahl, Pedersen and Dalum, 2003; Eisingerich et al, 
2012).   
 
Spin-off firms are central elements in facilitating positive feedback in a PC's trigger 
event, as their innovations are likely to be path-breaking in nature, and they open new 
industrial sub-markets. Additionally, they are more integrated into a PC's internal 
structures because of the nature of their origin, i.e. their founder(s) have preceding PC-
specific research and/or entrepreneurial knowledge and experience. As they would 
derive their internal structures, routines and practices from existing system actors, they 
would be perceived as being more trustworthy by a PC's actors in comparison to spin-
out and start-up developments. This means they are able to access local entrepreneurial 
supports and skill sets, improving their probability of success (Dahl, Pedersen and 
Dalum, 2003; Segenberger and Pyke, 1997; Morgenroth and O'Malley, 2002; Engel and 
Del-Palacio, 2011; Delerue and Lejeune, 2011). 
 
Table 2.10: Sample Entrepreneurial Resource and Skill SWOT Questions 
What skill and service barriers exist that inhibit new entrepreneurial/innovative developments? 
How advanced and suitable is a PC's IP regime for its current activities?  
Are professional service firms specialised on the particular needs of the PC? 
Do PC actors have to access non-local professional service and skill sets? 
Are a PC's VCs mainly public or private in nature?  
How diverse are the types/sources of finance available to a PC?  
Does an observable entrepreneurial/innovative mindframe/culture exist? 
 
Overall, a PC's entrepreneurial support framework sustains and upgrades competitive 
advantage by facilitating new business model developments through providing the 
required flexibilities and opportunities to experiment. This framework can also facilitate 
the development of technological and/or organisational structures which engender 
different, yet complementary, business activities to a system's 'core' activities. This allows a 
PC to avoid systemic 'lock-in' developments (Carlsson, 2007; Wolfe and Gertler, 2007; 
European Commission, 2006; Graf and Krüger, 2011). 
 
EIFR 3: Networks 
Clusters are inherently interactive in nature and are characterised by extensive vertical 
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and horizontal networks. Geographic proximity has little influence beyond providing the 
appropriate contexts in which an industry can be supported and encouraged to grow, while 
transfers of knowledge through trust-based interactions/spillovers cannot develop to any 
level of complexity or depth solely through the use of NICTs. As such, inter-actor 
networks must form a central aspect of cluster specific policies (Rosenfeld, 1997; Forfás, 
2004; Porter, 1998; Carlson, 2007).    
 
An important aspect of competitive clusters is the ability of cluster actors to network 
extensively and to form networks selectively, as rapid exchanges of 
information/knowledge and externalities (spillovers) from such transfers are pre-
requisites to create the necessary synergies that result in a PC's trigger event. This 
relates to the interactive nature of Porter's diamond determinants (Porter, 1998; Europe 
Innova, 2008; Anderson et al., 2004; Krafft et al., 2011).  
 
Networks play a central role in the nature and character of the EIFRs, e.g. the 
development of spatially sticky PREO-based knowledge (EIFR 1) and its exploitation 
(EIFR 2) through filtered tacit knowledge. Additionally, networks are crucial for 
developing a cluster's internal logic, with respect to mimetic isomorphism and its impact 
on network density, and represent a value chain's 'synergy', i.e. the presence of an 
interactive industrial structure. This synergy cannot be created through top-down 
initiatives, but must develop through trust-based inter-actor networks. However, 
significant challenges exist in developing networks, as detailed in Table 2.11.  
 
Stimulating cooperative behaviour in locations lacking a pre-existing collaborative 
culture is complicated, as the fundamental element of trust in the formation and 
functioning of networks cannot be created solely through policy. However, networks 
can form through a mixture of induced and organic processes through a promotion 
programme which seeds the concept of inter-actor networks and supports their 
emergence. Multiple examples of such programmes exist internationally, yet the 
template upon which they are developed is the Danish Government’s Network 
Cooperation Programme (NCP), launched in 1989. The NCP was sponsored by the 
Danish Industry Ministry, and sought to improve the international competitiveness of 
Denmark's then non-networked SME dominated industrial base. The NCP drew 
inspiration from the 'third Italy' region in the Northeast of Italy, as detailed above 
(Forfás, 2004; Ffowcs-Williams, 2000; NESC, 1996; Engel and Del-Palacio, 2011).  
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Through a review of the NCP, and various derivative programmes, two key attributes 
can be identified. Firstly, network programmes focus on proactive human resource-
based promotion activities through a broker programme/service that identifies potential 
networks and encourages their development. Brokers, optimally, are actors with 
extensive local knowledge, e.g. a locally-based consultant or economic development 
agent. Local knowledge is crucial in bringing prospective firms together and 
establishing information exchange infrastructures, e.g. education and technology 
support programmes that facilitate interaction and learning synergies, provide advice on 
the potential benefits of cooperation, and initiate discussions on these benefits amongst 
firms (Ffowcs-Williams, 2000; Staber, 1996; Martin and Sunley, 2001).  
 
Table 2.11: Issues undermining network developments 
Pre-existing levels of cooperation between a PC's stakeholders may be insufficient to organically facilitate network 
development(s). 
A lack of awareness or understanding of the concept and benefits of inter-actor networks may exist among a PC's actors, e.g. 
networks can be misunderstood as being a quasi-social activity, i.e. ‘networking’, rather than an important business function, 
meaning actors would be reluctant to commit time and resources to a process that is not well understood, or whose results are not 
immediately obvious. 
The collaborative aspect of inter-actor networking, i.e. the sharing of resources and knowledge with other firms, particularly 
competitors, can seem an alien concept to actors that are traditionally protective and secretive. 
Actors may rely on a knowledge and information base drawn from their own contacts, meaning they are not in a position to 
identify the innovative opportunities networks can provide. 
Actors may foresee the benefits of inter-actor networks, yet may not have the resources and/or skills required to facilitate or co-
ordinate alliances, i.e. a 'collective action problem' can exist. 
After (NESC, 1996; Forfás, 2004; Ingley, 1999; Anderson et al., 2004; Kogut, 1988; 
Lundberg and Andresen, 2012; Krafft et al., 2011). 
 
A broker is also required for transparency, i.e. to engender a pragmatic and 
uncomplicated programme, as a multi-element programme would require too complex a 
management structure. Brokers must also facilitate the development of institutional 
mechanisms relating to formal representation, conflict resolution, and information 
exchange developments, which in combination, reinforce inter-actor trust and support 
informal information exchanges (Lagendijk and Charles, 1999; Anderson et al., 2004; 
Krafft et al., 2011).  
 
The second programme attribute is the provision of financial supports to encourage 
firms to embrace cooperation. It is important that a suitable support amount should be 
achieved which is not too generous or too restrictive, and which should diminish over 
the course of the programme to foster closer inter-actor alliances by avoiding 
overreliance on, or the exploitation of such funding (Ingley, 1999; Ffowcs-Williams, 
2000).  
 
In combination, the hands-on nature of the broker service, and the encouraging nature of 
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the financial supports address resistance to the programme, e.g. Danish business 
associations saw cooperation as undermining local entrepreneurship, this was addressed 
through the programme’s hands-on nature (Forfás, 2004; Ffowcs-Williams, 2000). 
 
Following a pilot project to test and optimally fine tune a programme to the specifics of 
the sector in question, it is run over two principle stages. The first stage involves 
brokers identifying potential 'networks', which are then 'artificially' induced. This stage 
involves a consultation phase, introducing both the programme's concept and that of the 
concept of networks, in alliance with the financial incentives. This approach aims to 
seed the concept through a learning by doing method, i.e. firms learn about networks 
through developing their own network dynamics, so as to gain an understanding of the 
abilities of networks to facilitate or constrain future actions and market opportunities. 
As such, firms can become more proactive in designing and managing potential future 
linkages (Gulati, 1998; Ffowcs-Williams, 2000; vom Hofe and Chen, 2006).  
 
The second stage involves creating a favourable institutional setting that encourages 
firms to explore new forms of business relationships. Essentially, through creating a 
framework for dialogue and cooperation, in the context of reciprocated investments of 
time, people and equipment, the second stage seeks to facilitate the evolution of the 
'artificially' induced first stage networks into natural, organically developed 'second 
generation' networks (Ffowcs-Williams, 2000; vom Hofe and Chen, 2006; Forfás, 
2004).  
 
Table 2.12: Sample Network SWOT Questions 
What is the structure of the PC's value chain? 
What is the interactive nature of its actors? 
Are horizontal (informal and inter-actor exchanges) and vertical (formal value chain buyer/supplier relationships) networks 
present? 
What is the dominant actor type? 
Can the PC be characterised as being a 'hub', or 'non-hub' location? 
 
Introducing a network perspective to cluster specific initiatives has important 
implications for their formulation and implementation. A PC's public and private actors 
must have a thorough and realistic understanding of the complex dynamics of network 
formation, the role of facilitation, and the duration and composition of formalised 
assistance in facilitating behavioural changes, as the trust- and reciprocity-based nature 
of networks takes time to develop. At minimum, using the NCP as a rough template, a 
network programme should cover a 3-to-4 year period in order to facilitate the required 
changes in firm behaviour patterns. These issues again highlight the importance of a 
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highly responsive and long-term cluster specific policy environment (Ingley, 1999; 
Forfás, 2004; Ffowcs-Williams, 2000; Malecki, 1997; Larson, 1993). 
 
Additionally, no agreement exists among various academic reviews of network 
programme case studies as to what constitutes a successful network programme. 
Depending on the measurement(s) used, dramatic variations in a programme's 
outcome(s) can be viewed. Indeed, the NCP's evaluation report, the Amphion Report 
(1996), found that the programme was a failure when it was judged in relation to the 
longevity of the artificially introduced networks, as the networks which survived 
developed between actors which had prior close associations and linkages, i.e. inter-
actor trust had already been established. However, when firm profitability, market share, 
and individual firm competitiveness were assessed, the programme was deemed a 
success. Essentially, the 'co-operation' effect, rapid consultation, interaction and rapid 
response go beyond what can be measured/accounted for through transmission costs. As 
such, prior to a programme being run, its 'targets' must be clearly identified, which can 
be determined through a SWOT analysis (see table 2.12) (Ffowcs-Williams, 2000). 
 
EIFR 4: Market information exchange resources 
Technical and structural differentiation among a PC's actors impacts on a system's 
internal synergy. The development of market information exchange resources, i.e. 
intermediary institutions and actors, including cross-cluster discussion forums (which 
may be themed, in relation to a PC's EIFRs), and intermediary technology transfer 
resources, such as science parks and incubators, can facilitate cross-system information 
dissemination, mimetic isomorphism, and spillover developments. As such, this EIFR is 
inherently related to, and indeed facilitates inter-actor network developments (Porter, 
1998, Anderson et al., 2004; Delerue and Lejeune, 2011; Forfás, 2004; Simon and 
Tellier, 2011).  
 
Cross-cluster discussion forums should draw from regional development organisations, 
government councils, e.g. innovation councils, trade associations, chambers of 
commerce, and a PC's supplier actors, as they are key conduits for transmitting 
information between a system's actors. Discussion forums are particularly important in 
relation to the collection and dissemination of information on a system's technology, 
skills, and management- and market-related developments. Such services are important 
as all actors cannot be fully up-to-date with or access all the relevant information on a 
system's developments, e.g. new technological and market segment developments, due 
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to their limited resources (Daskalakis and Kauffeld-Monz, 2007; Oughton et al., 2002; 
Delerue and Lejeune, 2011; Simon and Tellier, 2011) 
 
Discussion forums can also inform a PC's public/private dialogue process, and can 
expedite the development of a support ecosystem by identifying specific skills and 
competence weaknesses. Discussion forums can also impact on the visibility of a PC's 
'brand', regionally and internationally, through optimising a system's support ecosystem 
and entrepreneurial/innovative activities. This can facilitate the development of pro-
active initiatives to access and exploit non-local skills, competences and resources. 
Cross-PC/cluster discussion forums can identify common issues among different systems, 
cross-pollinate skills and competences to stimulate entrepreneurial and innovative 
developments, and encourage diversification that prevents systemic 'lock-in'. 
Additionally, short-term actor placements in more endowed PCs and/or fully developed 
systems can also seed non-local skills and competences in a system (Scott, 2007; Martin 
and Sunley, 2001; vom Hofe and Chen, 2006; Morris, 2011; Graf and Krüger, 2011). 
 
Discussion forums can also facilitate entrepreneurial/innovative developments through 
influencing the structures and development of intermediary technology transfer 
institutions. Two key types can be identified, science parks (detailed further in the 
following chapter) which act as sectoral research engines through having a specific 
sectoral focus, and incubators, which facilitate knowledge-based entrepreneurial 
developments. Both forms are key information exchange nodes between PREOs and 
industry actors as they typically locate in close vicinity of one, or several PREOs, and 
facilitate researcher/entrepreneur interactions through transfers of knowledge/information. 
As such, they allow PREO actors access up-to-date information on the requirements of 
commercial actors, allowing them to tailor their research programmes towards commercial 
areas, and they also allow commercial actors access the significant tacit knowledge 
reserves of PREO actors, and more optimally identify commerciable research, facilitating 
new entrepreneurial developments (Feldman and Braunerhjelm, 2007; Owen-Smith and 
Powell, 2007; Scott, 2007). 
 
Table 2.13: Sample Market Information Exchange SWOT Questions 
To what extent is the PC's system supported through defined, pro-active information services? 
Are all actors in a PC's value chain represented in these services? 
Are there common skills, competences and resource weakness? 
Have cross-PC/cluster skills and competence exchange initiatives developed? 
Are technology transfer intermediary institutions present in the system? 
What skills, competences and/or resources are present in these institutions? 
How inter-linked are they in relation to on-going PC developments? 
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Optimally, technology transfer actors should provide a range of hard and soft supports for 
all stages of commercial developments, i.e. by allowing entrepreneurs/innovators develop 
market-ready innovations and/or spin-off firm developments. Such supports could include 
office and laboratory space, equipment and materials, as well as project feasibility studies, 
market research services, and the provision of business management resources (this feeds 
into EIFR 2). Discussion forums can feed into the optimal development and 
implementation of these supports by constant up-dating and tailoring their development 
through information exchanges on a PC's development trends (Anderson et al., 2004; 
Forfás, 2004; Malecki, 1997; Engel and Del-Palacio, 2011). 
 
EIFR 5: Actor and institutional density, and skill, competence and resource depth 
A PC's trigger event is determined by its system being subject to a structured and self-
reinforcing process of growth and development. Such processes are facilitated by the 
formation of a diverse range of market and non-market actors and institutions, skills, 
and resources. This depth and density forms due to the EIFRs addressing systemic 
weaknesses by engendering an adaptive and responsive ecosystem in relation to a 
system's skills, resources, and institutional structures. This allows a PC to optimise its 
positive development trajectory, facilitating further EIFR-related developments, i.e. 
positive feedback inputs occur throughout the PC system, facilitating the development 
of the four determinants of competitive advantage (Porter, 1998; Keeble et al, 1999; 
Maskell and Kebir, 2005; Wolfe and Gertler, 2007; Krafft et al., 2011).   
 
Actor and institutional density is important in setting the overall context or framework 
in which clusters develop. It represents the stratification of a system's functions, i.e. the 
development of vertical and horizontal networks, facilitated by cross PC market 
information exchange resources. Skill and resource depth facilitates interactive 
synergies that a cluster system and its determinants require. These synergies, which 
include a PC's social structure, can be considered system-specific support structures that 
reinforce its competitive advantage, i.e. actor attitudes, practices, and connections 
become a key part of a region’s non-replicable asset base by influencing future actor 
behaviour through mimetic isomorphism (Maskell and Kebir, 2005; Wolfe and Gertler, 
2007; Gilding, 2008; Zhang and Haiyang, 2011; Howells and Edler, 2011) 
 
Where a PC fails to organically develop actor and institution density and depth, it 
experiences difficulties in developing agglomerated economies, and other critical mass 
opportunities. Failure to develop density can occur due to limitations in a PC's 
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population and/or market size, which can prevent user-producer interactions, restrict 
information flows, and prevent the formation of a sufficient base of related and 
interlinked firms. These issues restrict a system's ability to develop skill and resource 
depth, meaning it is unable to keep up with and/or exploit technological and innovative 
developments due to limited information exchanges (Malecki, 1997; Wolfe and Gertler, 
2007; Krafft et al., 2011; Howells and Edler, 2011). 
 
To address these issues, an 'anchor' actor strategy can be developed to facilitate positive 
externalities throughout the PC system, and to drive systemic depth and density by 
engendering coordinated networks of interconnected actors. There are three anchor firm 
strategy models.  
 
The first model is that of a PC's system organising around the organic development of a 
'star' actor, e.g. a trail blazing firm which experiences significant first mover advantage, 
or through chance/indirect developments, e.g. organisational problems/inertia in an 
existing actor resulting in new spin-off developments. Such developments may form due 
to serendipitous events, e.g. the chance development of a novel technology, direct policy 
interventions, e.g. investments in research facilities resulting in technological advances, 
and the development of a coordinating organisation/body which acts as a manager for 
the system's development. Such developments can boost a PC's system by signalling 
underexploited/latent systemic strengths and opportunities to the wider PC system, 
thereby encouraging actors to seek further innovative and entrepreneurial developments, 
thus facilitating significant positive feedback inputs (Dahl, Pedersen and Dalum, 2003; 
Kaiser, 2002; Porter, 1998).  
 
The second model is that of a PC's system organising around the facilities of TNCs, i.e. 
local TNC or FDI branch plants. Lazerman and Lorenzoni (1999) note that while 
clustering typically involves SMEs, TNCs can make important contributions to local 
economic development in many different ways. Where TNCs are embedded in a system, 
they can facilitate positive externalities, such as integrating scientific and management 
competences into the system, which can result in technological advances and new start-
up developments. To attract TNC interest, a PC must have globally recognised PREOs 
that focus on TNC-related research areas and/or firms engaged in relevant technological 
areas with IP suitable for R&D investment. By virtue of their size, TNCs can facilitate 
access to global markets, facilitate significant skills exchanges with non-local 
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PCs/clusters, and prevent/address regional insularity (Anderson et al., 2004; 
Birkinshaw, 2000; Enright, 2000; Porter, 1998; Lee, 2012; Eisingerich et al, 2012).  
 
Alternatively, TNC FDI activities can be introduced, in what Enright (2000) calls a 
'transplant' strategy, to address weaknesses in a PC's system. FDI developments can 
provide significant systemic inputs due to the construction of TNC facilities and 
supporting infrastructures, the provision of financial supports as part of their inward 
investments, the attraction of non-local service providers to a region, and can also provide 
local actors with access to alternative finance sources through collaborative partnerships 
(Anderson et al., 2004; Birkinshaw, 2000; Malecki, 1997; Howells and Edler, 2011; 
Eisingerich et al, 2012). 
 
The final model is an interdependent model, i.e. a mutually beneficial scenario where a 
PC and a TNC play interdependent roles in each other's development strategies. In this 
scenario, FDI can be positive where branch plants seek to become more innovative by 
forming collaborative alliances with a PC system to access its resources and 
competences. This can allow a PC’s actors to access non-local networks, resulting in the 
strategic development of new market networks and innovative capacity in the home 
market. Integrated TNC elements in a PC system advertises the system's ability to 
successfully develop products and processes, which improves its global profile/brand, 
which can lead to cumulative positive feedback processes emerging that drive a system's 
development trajectory (Europe Innova, 2008; Porter & Stern, 2001; Eisingerich et al, 
2012). 
 
In relation to the second and third models, Casper and Murray (2005) comment that the 
strength of a PC's ecosystem is important in how it adapts to and addresses the institutional 
characteristics of TNCs. TNCs will proactively work within an ecosystem that facilitates 
significant entrepreneurial and innovative developments, thus creating significant positive 
feedback inputs. Yet, TNCs can facilitate negative inputs in several ways. Their presence in 
a poorly developed PC can drain off important local skills and resources due to their more 
asset rich nature, relative to local PC actors. Additionally, TNCs have “little experience in 
memory of entrepreneurial activity” (Romanelli and Feldman, 2007: 109) due to their age, 
meaning they can undermine the formation of an entrepreneurial culture, while their size 
and vertically structured nature can inhibit the dissemination of information on 
entrepreneurial and innovative developments, undermining network and spillover 
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developments (Casper and Murray, 2005; Porter, 1998; Anderson et al., 2004; Biggerio, 
2002). 
 
Casper and Murray (2005) also comment there are several issues with FDI 'transplant' 
strategies. The degree of embeddedness of TNC FDI operations in a system depends on the 
level of autonomy they have from their parent operations, which is dependent on how 
technology intensive their activities are. Branch plant investments can be unstable due to 
their sensitivity to cost changes and to regulatory changes in the TNC's home nation. If a 
PC system relies on FDI activities, it may fail if such an actor leaves the system. 
Additionally, where FDI is introduced without a defined regional emphasis and/or logic, 
i.e. branch plants are placed in locations due to political pressures, not as aspects of a 
regional development strategy, it can result in the development of 'cathedrals in the desert', 
i.e. branch plants located in areas where they cannot link into the local economy due to 
limited actor numbers and activity levels (Porter, 1998; Brown, 2000; Graf and Krüger, 
2011; Eisingerich et al, 2012).   
 
Table 2.14: Sample Actor Thickness and Institutional Depth and Density SWOT Questions 
What is the scale of the PC in relation to its geographic, population and market size?  
Are aspects of the PC's scale expected to change? 
What is the scale, scope and character of a PC's ecosystem? 
What is the state and scale of a PC's firm base? 
How developed are a PC's business management competencies, including the presence of experienced non-executive directors in a 
cluster? 
What is the state and scale of dedicated service providers, professionals and technical actors? 
What is the scale, scope, character and degree of integration of TNC operations presence in a PC system? 
 
These issues mean that 'anchor' strategies must be developed through the public/private 
dialogue in order to evaluate their suitability to a PC system, and to optimise the degree of 
embeddedness of TNC operations (Porter, 2000; Anderson et al., 2004; Rosenfeld, 2002).  
 
2.4.6 Cluster informed policy themes 
Where a cluster emerges, subsequent policies will be cluster informed in nature. Such 
policies are less comprehensive than cluster specific initiatives due to the presence of an 
established support ecosystem that acts like a collective entrepreneur. No formal cluster 
mapping exercise is required or undertaken, as only specific system aspects are 
examined. As cluster informed policies are system specific and unique to a specific 
point in a cluster's development trajectory, general themes cannot be 
detailed/caricatured. However, in the context of the cluster emergence and development 
themes, clusters require sophisticated enabling actions and practices which concentrate 
of advancing the development of a cluster's entrepreneurial and innovative environment. 
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As such, where interventions are required, they will focus on systemic adjustments, 
responding to emerging needs/requirements to optimise a system's performance (Wolfe and 
Gertler, 2007; Anderson et al., 2004; Malecki, 1997). 
 
Cluster informed initiatives should also seek to optimise second generation firm 
developments, and to attract non-local actors into a cluster system so as to extend and 
consolidate its competitive advantage(s). There are two key non-local actor types whose 
presence indicates a system's maturity level, non-local TNCs and entrepreneurial 
support actors, in particular VCs. The presence of TNCs demonstrates the presence of 
suitable research activities and commercial developments, while non-local supports 
indicates the presence of a highly entrepreneurial environment. Their presence 
facilitates the further advancement of a highly advanced and complex entrepreneurial 
support ecosystem (Orsenigo, 2007; Feldman and Braunerhjelm, 2007; Anderson et al, 
2004; Graf and Krüger, 2011; Kolympirisa et al., 2011). 
 
2.5 CONCLUSION 
This chapter lays the theoretical foundation from which the remainder of the thesis is 
constructed. 
 
It demonstrates that the flexible forms of production associated with Post-Fordism are 
based on self-organised trust- and reciprocity-based inter-actor networks. Networks 
facilitate innovative development by addressing the bounded rationality of individual 
actors through the more optimal use and combination of various types of resources and 
exchanges of filtered knowledge. Such exchanges are optimised where close relationships 
have formed between actors that are located in close geographic proximity to each other 
(Zhang and Haiyang, 2011).  
 
The chapter demonstrates that geographic variations in regional endowments of firms, 
institutions, and social capital mean that non-reproducible regional specific organisational 
forms and targets emerge that link together to form a local knowledge community, or 
organisational field, which determines the innovative capabilities and development 
trajectory of sectoral actors (Engel and Del-Palacio, 2011; Graf and Krüger, 2011; Huggins 
et al., 2012).    
 
Where dense agglomerations and critical masses of actors, resources, infrastructures and 
networks emerge, industrial clusters may develop. Clusters represent more organised and 
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co-ordinated territorial systems which can be characterised as being intensely 
entrepreneurial and innovative in nature, and whose internal functions stratify 
organically, i.e. vertical and horizontal networks emerge through private actor 
developments (Krafft et al., 2011). 
 
The chapter demonstrates that the reasons why particular locations develop clusters, and 
others not, are reflected in the diverse and place specific elements of a nation, i.e. its 
resources and place specific historical traditions and cultures. Clusters are born and 
develop on the basis of case specific combinations of capabilities, incentives, and 
opportunities. Their development occurs when an area's favourable pre-conditions, e.g. 
naturally occurring factor conditions and/or seeds (directly or indirectly introduced 
positive elements), facilitate the emergence of a proto-cluster system in the context of a 
system specific trigger process that is determined by its development trajectory. Clusters 
emerge as a result of a trigger event, i.e. the development of critical masses of actors, 
entrepreneurship, resources and skills. Such events are system specific, and can occur 
through either spontaneous, planned or hybrid processes. Emerging clusters become 
self-reinforcing and self-sustaining through attracting key non-local actors into the 
emerging cluster system, and the development of second generation entrepreneurial 
developments. 
 
Where Governments seek to facilitate cluster emergence, they must seek to engage with 
existing competences and pre-conditions/seeds, and tailor policy initiatives to the 
particular circumstances of the sector in question. The chapter demonstrates that a 
system specific multi-faceted support ecosystem based around the inter-linked EIFRs 
should be developed through a continuous public/private dialogue process that 
introduces key infrastructures and supports to engender private actor entrepreneurial 
and innovative developments which facilitate a cluster's trigger event.  
 
Where clusters emerge, governance structures will be mainly private actor dominated, 
supported by public actor measures that seek to fine tune the regulatory environment 
within which a cluster system is based. Such measures seek to support the 
entrepreneurial environment of a cluster system, to optimise second generation firm 
developments and the attraction of key non-local actors. 
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CHAPTER 3: 
THE ORGANISATIONAL STRUCTURES OF THE 
INTERNATIONAL BIOTECHNOLOGY INDUSTRY 
 
3.1 INTRODUCTION 
This chapter details the organisational structure of the international biotechnology sector 
(bio-sector), and draws from the theoretical descriptions of inter-actor networks and 
industrial clusters presented in the previous chapter.  
 
The international bio-sector's structure is an example of the network absorption capacity 
of small high-tech Post-Fordist firms, in which small biotechnology firms (bio-firms) 
co-exist and interact with established Transnational Corporations (TNCs) and other 
sector actors in a variety of alliances/collaborations with different partners at different 
stages of the product development process (Giesecke, 2000; Harrison, 1997). 
 
Networks are not solely at the heart of the development of the international bio-sector, 
as the networks that characterise it emerged from distinct geographic roots. Many of the 
organisations that forged the bio-sector’s complex relationships are located in close 
geographic proximity to each other, meaning these networks are spatially concentrated 
in what are identified as industrial clusters (Visser and Boschma, 2002; Romanelli and 
Feldman, 2007; Feldman and Braunerhjelm, 2007). 
 
The first section draws from the theoretical description of industrial clusters, as 
presented in the previous chapter, and examines the development of biotechnology 
clusters and proto bio-clusters in the international bio-sector. This is derived through the 
analysis of key international bio-sectors. The second section draws from the theoretical 
descriptions of the motivations and characteristics of inter-actor networks, as presented 
in the previous chapter, to present typologies of the key sectoral actors and formal and 
informal inter-actor networks that are found throughout the complex, multi-stage, semi-
sequential biotechnology innovation/drug development process. This section also details 
regional differences in bio-sector network structures. The third section presents a bio-
cluster development policy template, based upon the entrepreneurial and innovative 
functional resource template presented in chapter 2, and observed patterns and themes 
in international bio-clusters. This identifies the main themes required to facilitate positive 
systemic feedback inputs and to optimally drive a proto bio-clusters' development 
trajectory in order to expedite a bio-cluster's emergence and sustainable development. 
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3.2 CLUSTERS IN THE INTERNATIONAL BIOTECHNOLOGY INDUSTRY 
Regional endowments of actors, their institutional and non-institutional characteristics, 
and how regional specific organisational forms developed, mean that hub and non-hub 
biotechnology sectors (bio-sectors) can be identified in the international sector 
(Malecki, 1997; Owen-Smith and Powell, 2007; Huggins et al., 2012).  
 
The 'hub' bio-sectors form dense geographic concentrations of actors, whose network 
structures are spatially concentrated in what are identified as industrial clusters, i.e. 
inter-actor networks “played an essential role in the development of stable regional 
clusters...[but clusters have] seeded the geographically dispersed structures that have 
come to characterize” (Owen-Smith and Powell, 2007: 63) the international bio-sector's 
hubs (Breschi et al., 2001; Giesecke, 2000; Prevezer and Swann, 1996; Anderson et al., 
2004).   
 
Few locations have developed biotechnology clusters (bio-clusters) internationally. 
Three US-based bio-clusters can be observed, i.e. San Francisco, Boston and San Diego, 
while only two non-US bio-clusters can be identified in Cambridge and Munich. 
Outside of these bio-clusters, 'non-hubs' are essentially little more than agglomerations 
of co-locating actors, principally biotechnology firms (bio-firms) and Public Research 
and Education Organisations (PREOs), grounded in regional ambitions to become 
significant players in the global sector. They exhibit and/or mimic structures and 
practices found within bio-clusters, yet fail to develop defining aspects, characteristics 
and features of bio-clusters due to place specific reasons, e.g. regional limitations in the 
numbers and types of institutions, resources and specialist suppliers. These locations 
can be termed proto bio-clusters (PBCs) (Wolfe and Gertler, 2007; Delerue and Lejeune, 
2011; Powell et al., 2002; Gertler and Levitte, 2005; Malecki, 1997; Graf and Krüger, 
2011). 
 
The following sections draw upon the cluster development trigger process and event 
themes presented in chapter 2, and detail the observable patterns in the different bio-
clusters and PBCs, drawing extensively from international case studies, so as to identify 
common features in the development and structures of the international bio-clusters, and 
common features in the development and structures of a selected number of PBC case 
studies, including common issues which undermine their development trajectories and 
trigger processes. 
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3.2.1 Bio-cluster development themes  
General similarities can be identified in the factors which facilitated the emergence of 
the observable bio-clusters systems, i.e. similar positive pre-conditions and seeds can be 
identified, while similarities can also be identified in their internal network structures. 
In part, these commonalities are due to Genentech's foundation in 1976 establishing 
both the international bio-firm development template, and the form/character of the bio-
sector's innovation process/value chain. 
 
Despite such similarities, the individual bio-clusters emerged due to case specific trigger 
processes which built upon and primed their case specific pre-conditions and seeds, 
engendering the formation of entrepreneurial and innovative support ecosystems 
tailored to the specific demands and requirements of their emerging cluster systems, and 
ultimately facilitated a system-specific trigger event through the development of a 
critical mass of entrepreneurial and innovative activity.  
 
3.2.1.1 General development themes of the US bio-clusters 
The US bio-sector emerged in the context of significant Federal- and State-level 
preconditions and seeds that directly and/or indirectly related to biotechnology. These 
preconditions/seeds developed due to direct and indirect impacts of the significant 
advanced and specialised Federal Cold War factor investments in the country's Public 
Research and Education Organisation (PREO) infrastructures and research programmes. 
These investments linked in with existing Federal structures and organisations, in 
particular the National Institutes of Health (NIH), the main US health and biomedical 
research agency which was established in 1930. As such, the US had developed a 
substantial PREO infrastructure with an advanced resource and research skills base, by the 
1970s (Marrs, 2001; Giesecke, 2000: Romanelli and Feldman, 2007; Erden and von 
Krogh, 2011) 
 
From the mid-1950s onwards, the Federal Government sought to exploit the significant 
commercial potential resulting from the Cold War PREO funding initiatives, and 
introduced advanced commercially orientated structures to the PREOs. Additionally, to 
engender a suitable commercialisation support environment, the Federal Government 
introduced the Federal Small Business Administration (1953) to assist the development 
of an innovative SME base, and the Small Business Investment Act (1958) to facilitate 
the proliferation of private speculative investors. The Small Business Investment Act 
linked in with the then emerging private US Venture Capital (VC) industry (Barry, 
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2007; Cooke, 2002).   
 
It is important to note that these support structures sought to facilitate developments in 
the wider economy, not just in one sector, and represented the coordination of Federal 
Government innovation and industrial policy threads/strands. This is an on-going 
process, as detailed further below (Casper, 2007; Owen-Smith and Powell, 2007).  
 
In combination, these developments initiated a long tradition of indirect Federal 
supports to facilitate and optimise SMEs/high-tech firm developments from PREO-
based research, and inculcated an entrepreneurial mindframe/culture among the US 
PREOs due to the substantial commercial rewards conveyed through successful 
commercial developments. Other significant preconditions/seeds that facilitated the US 
bio-sector's emergence included the established nature of the US pharmaceutical sector, 
the presence of a wealthy private actor-driven health-care system, which drove 
Transnational Corporation (TNC) R&D activities, and the New York-based NASDAQ 
stock market. This was established in 1971, and played a crucial role in the US bio-sector's 
subsequent development (Casper, 2007; Owen-Smith and Powell, 2007; Cooke, 2002). 
 
 The San Francisco bio-cluster's trigger process and trigger event themes 
The San Francisco bio-sector emerged following Genentech's foundation in 1976. The 
nature of Genentech's formation and development, detailed in chapter 1, 
characterised/symbolised the Bay Area's preconditions and seeds. These included:  
 
 the absence of 'traditional' disciplinary department structures in the area's PREOs. 
Their interdisciplinary and cross-functional organisational models were derived 
from those of the National Institutes of Health;  
 the presence of an advanced, commercially orientated PREO base, whose 
biotechnology-related research programmes were (and remain) focused on 
translating basic science into clinical applications due to the focus of the various 
Federal Government programmes on facilitating PREO-based commercial 
developments, and; 
 San Francisco's close proximity to the highly evolved and innovative high-tech 
support ecosystem of Silicon Valley (SV) (Owen-Smith and Powell, 2007; 
Feldman and Braunerhjelm, 2007; Delerue and Lejeune, 2011).  
 
SV impacted on the bio-sector's development trajectory in numerous ways. The area's 
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fledgling bio-firms tapped into SV's pre-existing structures, e.g. SV's advanced financial 
and business management development services and communications networks, and 
adopted SV's pre-existing business structures and cultures, including its high labour 
mobility structures and entrepreneurial mindframe. Essentially, SV's established 
entrepreneurial climate and evolving support structures acted as a model for the Bay Area 
bio-sector, which increased the Bay Area actors’ ability to access SV's resources through 
mimetic isomorphism (Powell et al. 2002; Prevezer and Swann, 1996; Europa, 2003; 
Delerue and Lejeune, 2011).  
 
These features linked into the defined entrepreneurial culture and open organisational 
structures bio-firms derived from the department organisations of their 'parent' PREOs. 
The PREOs had a preference for “informal, non-contractual ties in their regional networks 
[which] enabled financiers to shape innovation and organisational strategies” (Owen-Smith 
and Powell, 2007: 81). The open organisational structures facilitated rapid information 
diffusion, i.e. substantial spillovers occurred, and the system’s bio-firms formed overtly 
commercial approaches in the typical products they developed and in the alliances they 
formed (Powell et al. 2002; Prevezer and Swann, 1996; Feldman and Braunerhjelm, 2007).  
 
A key element in the structural development of the bio-sector was SV's experience in 
dealing with, and supporting the development of high-risk high-technology electronics and 
new information and communication technologies (NICT) firms, i.e. SV's VC firms 
understood the crucial nature of tacit and codified knowledge exchanges, through informal 
and formal inter-actor networks, in their development. Additionally, the VCs understood 
the level of hands-on financial and business support needed to successfully achieve their 
desired exit strategy. This innate knowledge significantly impacted on the development of 
the bio-sector's tripartite value chain, and facilitated the emergence of the San Francisco 
system's spatially agglomerated nature (Giesecke, 2000; Kenney and Patton, 2007; Chen at 
al., 2011; Erden and von Krogh, 2011).  
 
Genentech's meteoric development trajectory established its position as the system's 
anchor actor, and highlighted the significant commercial potential of biotechnology and the 
depth of the Bay Area's support ecosystem internationally. This resulted in a subsequent 
surge in bio-firm developments as a 'gold rush' mentality developed as investors rushed to 
replicate Genentech's successes. Essentially, a 'brand' effect emerged that cemented San 
Francisco's position at the vanguard of the international bio-sector's development. This 
 62 
facilitated a positive systemic development trajectory by encouraging commercially 
minded PREO academics to enter into commercial developments and/or to abandon their 
relative job security to work within a failure prone start-up bio-firm. Genentech's success 
also attracted in substantial non-local actor interest from less resource endowed areas, 
creating substantial spillovers and positive systemic feedback events (Compete, 2005; 
Casper, 2007; Engel and Del-Palacio, 2011; Graf and Krüger, 2011).  
 
The bio-sector's positive development trajectory was further amplified by the Federal 
Government optimising the Federal regulatory environment supporting the 
commercialisation of PREO-based research through introducing the Bayh-Dole and the 
Stevenson–Wydler Technology Innovation Acts in 1980 (European Commission Research, 
2007; InfoService Biotechnology, 2004). 
 
VCs quickly became the dominant actor in the bio-sector's network structure, as in seeking 
to replicate Genentech's successes, they sought to optimise their investment returns by 
avoiding the dilution of IP through multiple inter-actor alliances, i.e. limited inter-firm 
research and/or product development alliances formed between first generation bio-firms 
due to VCs seeking to engender alliances with TNCs. This development established the 
system's product commercialisation orientated character. However, due to the rapid 
proliferation of bio-firms, TNCs could be selective in entering such alliances. As the 
system's advanced support ecosystem supported entrepreneurial experimentation, the bio-
sector responded to this development through engendering second generation firm 
developments to allow the exploitation of increasingly niche market opportunities 
(Giesecke, 2000; Chen at al., 2011; Eisingerich et al, 2012).  
 
In the context of the Bay Area's significant preconditions/seeds, its rapid development 
trajectory, and its advanced support ecosystem, the bio-sector rapidly developed a mass of 
entrepreneurial and innovative activity and experienced a spontaneous trigger event in the 
early 1990s. A self-sustaining cluster system rapidly developed as its advanced nature 
acted as a national and international 'magnet' that attracted non-local actors, skills, 
competences and resources, particularly non-local TNCs and VCs from outside of SV. 
These inputs engendered substantial feedback inputs which created a self-sustaining cluster 
system (Graf and Krüger, 2011; Eisingerich et al, 2012).  
 
The bio-cluster is presently characterised by a dense complex inter-actor network structure, 
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due to its support ecosystem facilitating and driving niche market exploitation and 
enabling extensive career mobility between actor types, in combination with the deepening 
impact of mimetic isomorphism. The ecosystem continues to actively support 
entrepreneurial experimentation, which has allowed the cluster to avoid 'lock-in' 
developments, and which allowed the system to restructure itself in the context of the 
significant VC fluctuations caused by the Dot.com bubble in the 1990s (Owen-Smith and 
Powell, 2007; Graf and Krüger, 2011). 
 
 The Boston bio-cluster's trigger process and trigger event themes 
The Boston bio-sector's preconditions/seeds resembled those of San Francisco, i.e. there 
was an established and commercially orientated PREO base, including the 
Massachusetts Institute of Technology (MIT) and Harvard University, as well as a 
significant military research presence due to Cold War era Federal funding. A defined 
entrepreneurial climate had also formed as PREO derived commercial developments 
and advanced support structures had facilitated the development of a major electronics 
agglomeration by the mid-1970s (Judge, 1997).  
 
The bio-sector's trigger process emerged spontaneously following Genentech's 
emergence, yet its development trajectory took a different form than the Bay Area's 
trajectory due to the unique institutional characteristics of its actors.  
 
While SV's VCs facilitated and drove the San Francisco bio-sector's rapid development, 
VC involvement in the Boston bio-sector's development was relatively minor as few 
local VCs existed due to the area's proximity to New York. The bio-sector emerged and 
developed in the context of the intense commercial rivalry between MIT and Harvard, 
and the established entrepreneurial supports that had formed around its 
electronics/NICT agglomeration, i.e. PREOs were the network structure's dominant 
actor (Owen-Smith and Powell, 2007; Kenny and Patton, 2007; Graf and Krüger, 2011).   
 
In comparison to their San Francisco-based counterparts, Boston PREOs were (and 
remain) more focused on basic research activities, and were/are more conservatively 
and rigidly structured. These characteristics were reflected in the bio-sector's structure. 
PREOs transferred IP to spin-off bio-firms through formal licensing arrangements, 
which resulted in the bio-firms locating in close proximity to their 'parent' PREO(s). 
This facilitated the development of a dense PREO-orientated sectoral network structure 
(Owen-Smith and Powell, 2007; Kenny and Patton, 2007).  
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Several interlinked elements facilitated the bio-sector's positive development trajectory. 
The financial success of the bio-sector's first generation bio-firms engendered positive 
systemic inputs, e.g. the system's anchor actor, Genzyme, was established in 1981 and 
achieved a successful IPO in 1986. This created a more pronounced commercial mind-
set among the bio-sector's PREOs and drove commercial developments throughout the 
bio-sector which engendered a system 'brand'. This is demonstrated by the entry of the 
manufacturing facilities of Geneva-based Biogen, which was co-established by an MIT 
scientist, into Boston in 1983 (Owen-Smith and Powell, 2007; Feldman and 
Braunerhjelm, 2007).  
 
The bio-sector's development trajectory indirectly benefited from the decline of the 
area's electronics agglomeration during the 1980s, as the Boston area's minicomputer 
orientated electronics sector was supplanted by SV's microprocessor innovations, and 
also through alterations to the Federal Government's research procurement and military 
funding initiatives in the mid-1980s. Both events released researchers into the system, 
while the support structures surrounding the electronics agglomeration and the military 
research institutes (RIs) switched towards other high-tech sectors, including the local 
bio-sector, feeding into the system's support ecosystem (Watkins, 2004; Engel and Del-
Palacio, 2011).  
 
Boston's bio-cluster emerged in the mid-1990s due to a spontaneous trigger event 
caused by a critical mass of entrepreneurial and innovative activity. A self-sustaining 
bio-cluster system rapidly formed due to an influx of non-local VCs and TNCs, while 
the bio-sector's established entrepreneurial environment facilitated the development of 
second generation spin-off developments by the late 1990s. The system's evolving brand 
has attracted in significant national and international skills, competences and resources 
further driving its development trajectory (Owen-Smith and Powell, 2007; Graf and 
Krüger, 2011; Eisingerich et al, 2012). 
 
 The San Diego bio-cluster's trigger process and trigger event themes 
Despite the presence of similar preconditions/seeds to those found in the San Francisco 
bio-cluster, e.g. similar PREO structures and a similar proximity to SV, the San Diego 
bio-cluster emerged through a very different trigger process and trigger event.  
 
As with the Boston bio-sector, San Diego's bio-sector emerged following Genentech's 
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establishment. Despite the bio-sector's proximity to San Francisco, its trigger process 
was initially undermined by two inter-related systemic issues. Up until the mid-1980s, 
the area's PREO base was dominated by a significant US Army, Air Force and Navy 
presence which had developed at the beginning of the twentieth century, and then 
expanded through decades of Federal Cold War funding. As such, the area's PREOs and 
support structures had a less pronounced commercial orientation due to their focus on a 
closed dominant actor type (Romanelli and Feldman, 2007; Europa, 2003; Chiaroni, and 
Chiesa, 2006; Graf and Krüger, 2011; Eisingerich et al, 2012). 
 
By the mid-1980s, limited commercial developments had occurred due to an absence of 
VC involvement. Only 10 bio-firms had formed by 1986, mainly due to the magnetism 
of the San Francisco system's brand drawing potential resources away from the San 
Diego area. San Francisco's magnetism can be demonstrated by the fact that the 1980 
changes to the Federal regulations had virtually no direct/immediate impact on the San 
Diego system at the time. Additionally, and paradoxically, the limited level of 
commercial activity in the San Diego area undermined the development of a system 
brand (Romanelli and Feldman, 2007; Europa, 2003; Chiaroni, and Chiesa, 2006).  
 
The system's trigger process experienced two significant and serendipitous feedback 
inputs which dramatically altered its development trajectory in the mid-1980s. The gold 
rush mentality which developed after Genentech's IPO in 1980 resulted in the creation 
of many commercial ventures in efforts to engender Genentech-style results. In 1986, 
US TNC Eli Lilly bought Hybridtech, a spin-off bio-firm from the University of 
California, San Diego. As in San Francisco, San Diego's bio-firms adopted the open 
structures of the local PREOs. This created a clash of corporate management practices 
between the vertical Fordist structures of the TNC, and the horizontal structured Post-
Fordist bio-firm. This led to the majority of Hybridtech's management and research 
teams leaving the bio-firm (Timmerman, 2010; Chiaroni, and Chiesa, 2006).  
 
Indirectly, Hybridtech became the system's anchor actor and established its internal 
structure, as a mass of bio-firms were established through money generated from the 
Hybridtech merger. Indeed, the takeover's fallout ultimately resulted in the formations 
of nearly 50 first and second generation spin-off bio-firms, while several local VCs 
were formed by former Hybridtech employees (Chiaroni, and Chiesa, 2006; Casper, 
2007).  
 66 
This development coincided with the Federal Government's expenditure reductions in 
the mid-1980s impacting on military research expenditure, which indirectly and 
unintentionally shifted the focus/orientation of the region's military-orientated research 
and support structure towards the emerging bio-sector. Combined, these serendipitous 
developments created a surge in commercial activity, engendered a positive systemic 
development trajectory through facilitating significant systemic feedback inputs, and 
resulted in the rapid development of a critical mass of entrepreneurial and innovative 
activity which led to a hybrid trigger event in the mid-1990s (Casper, 2007).  
 
San Diego become a self-sustaining bio-cluster through establishing a complex support 
ecosystem, including significant local VC developments, that formed a distinct cluster 
brand which, despite its proximity to the San Francisco bio-cluster, has attracted national 
and international competences and resources into the system, including TNC R&D 
facilities. The extensive bio-firm base means a thick level of management and bio-firm 
development-related expertise has formed, facilitating and driving commercial 
developments throughout the system (San Diego Workforce Partnership Inc., 2000, 2002; 
Business Wire, 2004; Casper, 2007). 
 
3.2.1.2 General development themes of the European Union-based bio-clusters 
 The Cambridge bio-cluster's trigger process and trigger event themes 
The Cambridge bio-cluster emerged in the context of similar preconditions and seeds to 
those found in the US bio-clusters. Cambridge had an advanced PREO base which 
includes some of the oldest universities in the world, and which have been responsible 
for many of the technological breakthroughs that facilitated the bio-sector's emergence, 
including the discovery of the structure of DNA. Additionally, the Cambridge area had 
developed an electronics/NICTs agglomeration, termed 'Silicon Fen', while a number of 
pharmaceutical TNC branch plants were also located in the area (Breschi et al., 2001; 
Chiaroni and Chiesa, 2006; DTI, 1999).   
 
These developments had occurred due to proactive open market initiatives by the UK 
Government, starting in the late 1960s, to seed non-local skills and competences, e.g. 
encouraging foreign pharma-TNCs to establish UK operations, and to engender a more 
industrially proactive orientation in the area's PREOs through developing intermediary 
actors, such as the Cambridge Science Park, which opened in 1970, that sought to 
attract NICT companies into the area. These initiatives and supports facilitated the 
emergence of localised high-tech service infrastructures and an evolving public and 
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private commercialisation support environment (Simpson, 2002; Chiaroni and Chiesa, 
2006; DTI, 1999; Cooke, 2002; Graf and Krüger, 2011).  
 
The Cambridge bio-sector emerged in the late 1970s following Genentech's emergence, 
slotting into the area's evolving entrepreneurial supports. By the late 1980s, the bio-
sector had begun developing a mass of entrepreneurial/innovative activity, yet its trigger 
process was undermined by an absence of key sectoral actors, e.g. initial sectoral 
developments occurred in a near absence of VC coverage, which was partly caused by 
the absence of a successful anchor bio-firm. Furthermore, few defined or direct public 
development initiatives/supports existed. As such, limited feedback developments 
occurred to drive the bio-sector's development trajectory (DTI, 1999; Cooke, 2002).  
 
The Cambridge system experienced a hybrid trigger event during the mid-1990s 
through the introduction of a series of UK Government initiatives which developed in 
response to European Union-wide efforts in the early 1990s to address the increasing 
global dominance of the US bio-sector. These initiatives focused on supporting the 
commercialisation of PREO research and engendering PREO/firm networks through the 
development of major biotechnology-related RIs and intermediary actors, particularly 
incubator and science park developments, as well as the introduction of dedicated 
technical and business service providers. Rapid sectoral developments followed which 
built on the area's existing agglomerated strengths, meaning that Cambridge quickly 
developed into a self-sustaining bio-cluster system (Casper and Karamanos, 2002; 
Casper and Murray, 2005). 
 
The bio-cluster system rapidly developed an advanced support ecosystem which 
facilitated the bio-cluster's progress through a gradual contraction phase in the late 
1990s caused by limitations with VC funding due to the Dot.com bubble collapse. 
Additionally, a system brand has formed which has attracted in national and 
international skills, competences and resources, including bio-firms originating from 
non-local PREOs, as well as considerable pharma-TNC activity (Parc Cientific 
Barcelona, 2010).  
 
 The Munich bio-cluster's trigger process and trigger event themes 
The Munich bio-cluster also emerged in the context of significant preconditions and seeds, 
including some of the world’s oldest universities and RIs, a major pharmaceutical and 
chemical TNC sector, and extensive industrial manufacturing and electronics sectors 
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(Giesecke, 2000; Koehler, 1996).  
 
Munich's bio-sector emerged in the wake of Genentech in the late 1970s, yet its 
development trajectory was heavily restricted by deeply rooted systemic weaknesses until 
the mid-1990s. Germany's PREOs were vertically structured and disjointed in nature, i.e. 
distinct separations of activities existed between universities and RIs, and they also had a 
pronounced basic research orientation as legal restrictions prevented PREO actors 
engaging in commercial activities. This prevented a PREO-based entrepreneurial 
mindframe from forming. Commercial developments were inhibited and undermined by 
the country's vertically structured TNCs absorbing researchers and commercially viable 
PREO research, and also by the Munich area's limited support ecosystem. Sectoral 
developments were also restricted by the absence of defined or direct Federal and/or 
State (Land) sectoral supports to explicitly drive commercial biotechnology-related 
developments (Chiaroni and Chiesa, 2006; Koehler, 1996).  
 
Due to the high-risks involved, and the limited availability of support structures, 
particularly that of VC funding, Munich's first generation bio-firms adopted 
conservative platform technology activities/business models that were predominately 
based on US generated IP to exploit very narrowly defined niche market opportunities 
with German TNCs (Giesecke, 2000) 
 
However, as with the UK Government, in response to European Union-wide 
developments seeking to address the dominance of the US bio-sector in the early 1990s, 
the Federal German Government introduced the BioRegio bio-cluster development 
initiative in the mid-1990s, choosing Munich as one of the programme's locations. This 
comprehensive sectoral development programme directly resulted in the Munich 
system's planned trigger event, through facilitating the rapid formation of a mass of bio-
firms modelled on the 'Genentech template' by introducing intermediary actors, i.e. 
incubators and science parks, and public/private VC funds specifically focused on bio-
firm developments (Chiaroni and Chiesa, 2006; Casper and Murray, 2005). 
 
Despite the BioRegio programme's substantial supports, the Munich system has 
struggled to maintain a mass of commercial activity. This is due to the system's PREOs 
remaining vertically structured and disjointed, while the dominant actor type in the 
system's network structure are its TNCs. Additionally, the system's development 
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trajectory is being undermined by the new bio-firm developments being 
overwhelmingly platform technology-orientated in nature. An international mass of 
these bio-firms has formed, which is restricting opportunities for new bio-firm 
developments. Furthermore, an investment paradox has emerged, i.e. new bio-firms 
have experienced significant issues in accessing local VC funding, as the VCs are risk 
adverse due to the limited/restricted level of commercial developments (Chiaroni and 
Chiesa, 2006; DTI, 1999; Casper and Murray, 2005; Howells and Edler, 2011).  
 
These issues are reflected in the system's anchor actor being the BioRegio programme's 
local coordinating organisation, BioM. The bio-cluster's brand has developed 
predominantly due to its association with the BioRegio programme, rather than through its 
commercial activities. This means the system's 'magnetism' is essentially confined to 
Germany and neighbouring countries. So far the bio-cluster has only attracted significant 
non-local PREO-based skills, competences and resources (DTI, 1999; Casper and Murray, 
2005; Howells and Edler, 2011).  
 
3.2.2 PBC system development issues  
As stated, PBCs can be characterised as essentially being combinations of co-locating 
actors grounded in regional ambitions to become significant players in the global industry. 
As with bio-clusters, their trigger processes are case specific in nature. Yet, through 
analysing the development trajectories of a wide selection of international case studies, key 
themes of the main systemic and structural issues inhibiting and/or undermining their 
trigger processes can be identified, including issues relating to cluster specific policy 
initiatives. These themes are discussed in the following sections. 
 
3.2.2.1 Key PBC systemic and structural weakness 
As with bio-clusters, the development trajectories of PBC systems are strongly determined 
by the preconditions and seeds which form prior to their bio-sector's emergence. However, 
the existence of US, UK and German PBCs demonstrates that even where similar 
preconditions and seeds exist to those found in bio-clusters, they alone cannot facilitate a 
bio-cluster's emergence.  
 
PBC trigger processes emerged through proactive private actor developments in the 
context of general non-sector specific industrial supports, and/or due to the introduction of 
defined public initiatives seeking to engender bio-sectoral developments. Yet, regardless of 
how their trigger process emerged, systemic weaknesses prevent an optimal development 
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trajectory forming. Key weakness themes can be identified throughout their value chains, 
whose nature and character are inter-related, and which reflect the inter-linked nature of 
the biotechnology innovation process. 
 
PBCs typically have significant PREO infrastructures, yet an entrepreneurial development 
paradox may exist. Essentially, a PBC's PREOs may have a limited tradition of 
engendering innovative/entrepreneurial developments, which will inhibit the development 
of an entrepreneurial culture/mindframe and skills among PREO researchers and 
administrators. Such a scenario can develop for a variety of reasons, including the presence 
of established vertical structures among PREOs, the presence of established legal 
restrictions that prohibit academics from engaging in commercial developments, and/or the 
presence of poorly developed commercialisation support structures and systems, e.g. a 
country's IP and/or taxation regimes can inhibit entrepreneurial downstream developments 
due to perceptions of risk (Romanelli and Feldman, 2007; Giesecke, 2000).  
 
These issues can impact on sectoral developments in several ways:  
 
 significant public and/or private commercialisation supports will not develop due 
to a low PREO demand for such supports, which then feeds back into and further 
ingrains the limited PREO-based innovative/entrepreneurial developments;   
 the general absence of commercialisation supports and/or infrastructures typically 
results in the adoption of risk adverse bio-firm business models in the limited cases 
where such developments occur, i.e. platform technology activities, whose defined 
activities limit up- and downstream links in the sectoral value chain, thus 
undermining a system's network structure development, and;  
 limited PREO-based entrepreneurial developments will restrict/undermine 
downstream actor and sectoral developments, which paradoxically inhibit PREO-
derived entrepreneurial developments due to a lack of downstream demand for 
commercially viable research and limited spillover opportunities and/or 
developments (Romanelli and Feldman, 2007; Giesecke, 2000). 
 
Essentially, a conservative mindframe towards entrepreneurial developments becomes 
embedded throughout a bio-sector, limiting commercial activity and the development of a 
system 'brand'. This restricts a system's ability to attract in local and non-local labour, 
knowledge, resources. Indeed, limited sectoral activities can lead PBCs to loose key 
systemic competences and resources to more asset rich systems. Additionally, commercial 
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actors in a poorly developed bio-sector will seek alliances with actors in more asset rich 
locations in order to bypass indigenous systemic weaknesses. However, such strategies 
face significant issues as PBC actors come from systems with limited innovative images or 
reputations, and are competing with actors from more advanced/reputable systems for 
these resources (Powell et al., 2002; Gertler and Levitte, 2005; Zhang and Haiyang, 2011; 
Engel and Del-Palacio, 2011; Graf and Krüger, 2011; Eisingerich et al, 2012).  
 
Another issue that can inhibit a PBC's development trajectory is where its system's 
structure is dominated be a TNC. Their vertical organisational structures limit potential 
alliances with other sectoral actors due to their closed network orientation, while their 
age undermines the development of an entrepreneurial culture due to limited 
institutional memory of engaging in new entrepreneurial developments. Additionally, 
their substantial resources and facilities can also absorb PREO research and skills, 
undermining key systemic spillover and spin-off developments from PREOs. 
Furthermore, where TNC FDI operations are present in a system, they may only form 
limited alliances with sectoral actors due to their limited autonomy (Powell et al., 2002; 
Gertler and Levitte, 2005). 
 
3.3 ACTOR AND NETWORK TYPOLOGIES IN THE BIOTECHNOLOGY 
INDUSTRY 
3.3.1 Sectoral Actor Typologies 
In order to detail how biotechnology clusters emerge and operate, it is important to 
detail the main actor typologies of bio-sectors. These typologies are presented in Table 
3.1, which is derived from observable patterns in the international sector (principally the 
US sector). This table presents an augmented and up-dated version of typologies 
developed by Barley et al. (1992), reflecting the changing roles and inter-actor 
relationships caused by the international bio-sector's evolution (Owen-Smith and 
Powell, 2007; Romanelli and Feldman, 2007). 
 
It must be noted that all of the actor types detailed above are important in the 
functioning of a bio-sector's interactive value chain, by acting as either incubators or 
transfer mechanisms within the sector's innovation process, and are detailed separately 
for ease of presentation purposes only.  
 
3.3.2 Formal and informal network typologies in the bio-sector 
The following sections detail the main formal and informal network alliances found 
between the various actors in the international bio-sector's interactive sectoral value 
 72 
chain. Many of the relationships in the bio-sector are informal and undocumented, yet 
those presented here are derived from observable patterns in the key international bio-
sectors. These relationships can be considered as being generally applicable to the 
international bio-sector as a whole, yet they are reproduced in case specific manners 
(Barley et al., 1992; Romanelli and Feldman, 2007). 
 
3.3.2.1 Typology of formal inter-actor networks in the biotechnology industry 
Barley et al. (1992) identified ten key formal inter-actor relationships found in the 
international sector. These are presented in Table 3.2. 
 
3.3.2.2 The main inter-actor network types in bio-sector value chains 
The international bio-sector is an example of a complex, non-sequential network-based 
innovative high-tech Post-Fordist sector. The knowledge base from which 
biotechnology  innovations  draws is embedded in complex formal and informal 
networks between various actor types, including public research, government and 
industrial actors, while the development of biotechnology-derived products and 
processes involves many different formal and informal actor alliances, that have 
different spatial patterns, and which form at various stages in a product's and/or 
process's life-cycle (Morgan and Nauwelaers, 1999a; Owen-Smith and Powell, 2007). 
 
As a broad generalisation, the biotechnology innovation process can be characterised as 
a tripartite alliance chain formed around the coordinated efforts of key actor types, i.e. 
Public Research and Education Organisations (PREOs), bio-firms (the bio-sector's 
innovation process linchpin), and downstream commercial actors, e.g. pharmaceutical 
TNCs. These actors create a non-linear, continuously interactive structure in which a 
hierarchy cannot typically form. Their interactions, which are supported and facilitated 
by region-specific support structures, act as feedback loops that update and alter the 
innovation process, optimising the process for the benefit of all network members 
(Malecki, 1997; Morgan and Nauwelaers, 1999a; Owen-Smith and Powell, 2007). 
 
The following sections present a template of the bio-sector's networked structure, 
detailing the main formal and informal inter-actor networks found in the bio-sector's 
value chain, and also the evolution of formal downstream networks in the bio-sector. 
These relationships are derived from observable patterns in the US bio-sector, yet are 
replicated throughout the international bio-sector in case specific manners.  
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Table 3.1: The bio-sector actor typologies 
Public Research and Education Organisations (PREOs): Commercial biotechnology developments in the international bio-sector are predominantly 
based upon findings from the research programmes of PREOs, they also facilitate complex tacit and codified information exchanges, and crucial 
sectoral skills developments and transfers. There are three PREO actors:  
 Universities are the main source of the basic research from which commercial biotechnology activities are derived. Academic departments 
primarily focus on long-term speculative/exploratory basic research, which is important for volatile technology sectors, by being less subject to 
market pressures then commercial actors. Universities actively promote information transmission by adhering to “the [traditional] norms of the 
open information disclosure characteristic of public science” (Smith and Powell, 2004: 8) through lecturing, publications, and placements. They 
also provide undergraduate and research-orientated postgraduate education programmes. 
 Public Research Institutes (RIs): Typically established by university academics in association with government departments/agencies to develop 
themed research programmes based on their areas of expertise, RIs typically locate in close proximity to their 'parent' university/universities. The 
focus mainly on applied research; many commercial developments originate from RIs as governments seek, internationally, to engender such 
developments though facilitating formal alliances with commercial actors via defined commercialisation supports and infrastructures.  
 Research Hospitals (RH): RHs focus on specialised medical research, engaging in application-based diagnostic and therapeutic activities. RHs 
associated with a 'parent' university are typically located in close proximity. RHs are significant actors in the sector's innovation process by being 
the main source of clinical research trial samples, and are also involved in the clinical trials of new biotechnology-based therapeutics and 
diagnostics products, through joint research programmes with bio-firms and/or TNCs or via in-house laboratory research. RHs are among the 
main customers of biotechnology-derived pharmaceutical products and services. 
PREOs increasingly seek commercial developments from their activities, and have developed advanced commercialisation procedures to optimise 
research transfers to commercial concerns. These mechanisms include pronounced commercial elements in education programmes to 
inculcate/encourage commercial mind frames among researchers, industrial liaison offices (ILOs) seeking to identify viable research into link into 
firm-based research programmes, technology transfer offices (TTOs) proactively seeking to transfer IP to commercial actors (some US and UK 
TTOs are independent entities whose survival depends on successfully commercialisation), and the development of bio-incubators (located in close 
proximity to RIs) to optimise firm developments through training, development, financial support services. 
Biotechnology firms (Bio-firms): The bio-sector's innovation process, and key informal and formal networks, can be separated into two broad 
categories, upstream and downstream activities, relative to a firm’s position in the sector's value chain. PREO research can be conceived as the 
upstream end of the value chain. Firms seek to engender informal and formal relationships with PREOs to access and commercialise research. The 
clinical trials process and sale to the consumer can be conceived as the downstream end, i.e. predominately formal network-based interactions with 
TNCs and other firms. Bio-firms traditionally occupy the middle rung in the sector's innovation process, being the main transferring mechanism of 
PREO research to the market. They draw on heterogeneous communities of experts at various points in their development, and are established by 
PREO researcher to pursue research exhibiting clear commercial promise to develop commercial products and services in a wide variety of 
research areas (yet, overwhelming in pharmaceutical-orientated research). Their development is determined through formal alliances with investor 
actors, particularly Venture Capital firms, to finance their start-up and initial developments prior to forming alliances with downstream actors. A 
firm’s ability to access PREO-based knowledge and VC funding are the determinants of its research capabilities and its success in commercialising 
research through commercial actor alliances. 
Investors: The technical and financial resources required to develop biotechnology products are beyond the capabilities of most bio-firms as, in 
comparison to other high-tech intensive sectors, development costs in biotechnology are significantly higher, e.g. product development can take up 
to 20 years and cost up to US$1 billion. Different investor types play particular roles in the product development process:  
 Personal and Private funding sources: Due to their high risk nature, bio-firms often cannot access traditional finance sources, e.g. bank loans, 
meaning their set-up stages are often financed through personal and private funding, i.e. personal savings, private loans from friends/family, and 
non-business bank loans offset by the value of their intellectual property. 
 Public and Private Venture Capital firms: VCs have played central roles in the international bio-sector's development since its inception. 
Typically established by wealthy private investors or by governments seeking to develop indigenous sectors, they target relatively unproven 
businesses traditional investors (e.g. banks) avoid due to high-risks or excessive development costs. VCs are compensated through equity 
securities in a firm in return for an investment, and thus a portion of capital gains when the firm is traded on stock markets through an Initial 
Public Offering (IPO) or bought up/bought into by a TNC (the main exit strategies for VCs in bio-sectors). VCs provide managerial and 
technical expertise to optimise a bio-firm's business development (academic researchers normally receive minimal education/training in 
business-orientated subjects), and new management structures can be sought to deal with the complexities of negotiating downstream 
alliances/collaborations. Several issues with VC funds motivates bio-firms and VCs to seek exit strategies, including a mismatch between the 
typical length of a VC alliance (5 years) and the biotechnology product/process development cycle's duration (approximately 15 years), while 
VC funding oscillates due to the relative performance of global economies and other industries. 
Diversified Transnational Corporations (TNCs): TNC involvement in the international bio-sector predominantly focuses on pharmaceutical 
activities as the 'tradition' knowledge base they derived products from (organic chemistry) is reaching its technological development limits. 
Biotechnology draws from a different knowledge base (immunology and molecular biology) whose limits have yet to be clearly defined, and is 
easily adaptable to TNC requirements, meaning it is increasingly the basis of new pharmaceutical products/treatments. As the development costs 
and duration of new drugs is increasing due to stringent regulatory requirements, which impinge on TNCs recouping their development 
investments, and as effective patent-protection on traditional products is being impacted by generic products, TNCs are focusing on small volume 
niche market drugs, new versions of existing drugs, and have moved from mono-product to 'flexible' multi-product production. TNCs collaborate 
with bio-firms to optimise product development activities and fill their product development pipeline, which represent the main downstream 
relationships of the sector's innovation process. 
Government Departments and Agencies: Many industrialised nations have identified biotechnology as key to their future economic development. 
Governments are increasingly crucial in providing funding to drive sectoral developments. Such funding can be typified as being primarily PREO 
focused, through resource and capital investment programmes/initiatives in the research capabilities and infrastructures of PREOs. Governments 
are also placing increased commercial emphasis on PREO activities to drive sectoral developments, and have created dedicated public VCs funds 
to address speculative funding shortages in sectors. 
Additional actor types: 
 Supply firms facilitate research and production activities, service suppliers provide specialised systems and solutions to different issues arising in 
research. 
 Sub-national Biotechnology Centres are typically created by business associations to optimise a region’s network structure and density, and 
disseminate important region-specific information among sectoral actors. 
 Trade associations focus on specific sectors/sub-sectors, not particular locations, circulating sector-specific information and providing services to 
their members'. They can construct brands to improve a sector's profile, and act as lobbyists. 
 Private Research Institutes are usually founded by wealthy benefactors to fund research in areas that receive little commercial attention, but are 
judged to have social value.  
 Repositories (Gene Banks) are stores of genetic resources that seek to maintain genetic diversity by capturing a genetic picture at a particular 
point in time, and are important for future research projects, particularly genomic research. 
After (Burke et al, 2003; Owen-Smith and Powell, 2007; Prevezer and Tang, 2008; 
Gertler and Levitte, 2005; Powell and Brantley, 1992; Barley et al., 1992; Stuart et al., 
2007; Giesecke, 2000; Feldman and Braunerhjelm, 2007; Ernst & Young, 2007a; 
Ahrweiler et al., 2011; Lee, 2012; Eisingerich et al, 2012). 
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Table 3.2: Formal inter-actor network typologies in the biotechnology industry 
Research grants are awarded to facilitate research programme developments by allowing researchers build and develop their research capacity. 
They typically have defined durations with a fixed funding award, and with clear ownership designation of the generated IP between the grant 
provider and receiver. They do not involve the division of non-research activities, e.g. marketing rights. They are primarily awarded to PREOs by 
Governments, while bio-firms and TNCs can award them in exchange for right of first refusal for licensing a project’s results.  
Research agreements (product development not involved) differ from research grants by covering more applied research activities. They are 
typically commercially sourced, e.g. bio-firms or TNCs commission researcher to conduct a defined research programme. They involve finance, 
resource and skill transfers. IP ownership is strictly defined between the members.  
Research and Development (R&D) agreements are complex multi-actor agreements, where R&D activities are clearly defined among the 
participants (divisions of non-research activities, e.g. marketing activities, are not included). They agreements are important financial sources for 
bio-firms, due to their applied research focus, and involve formal and informal exchanges of resources, skills and codified information between 
agreement members. A bio-firm is the 'senior' partner, bearing most of the agreement risk/liability, while the 'junior' partner, e.g. a TNC, purchases 
a share of potential profit or loss, depending on the result(s) of a specific research programme. Initially, a 'junior' partner has minimal input in the 
research, yet as their relations and their underlying dependencies develop (i.e. relationships stratify as more defined roles and interactions develop), 
the 'junior' partner may demand increased input. Exclusive agreements can form resulting in the 'junior' partner buying into or outright purchasing 
the bio-firm, yet such developments are rare due to the complexity of the biotechnology innovation process. 
Product development agreements (research activities not involved) involve information, resource and financial exchanges relating to the clinical 
evaluation, marketing, and distribution of a biotechnology-derived product/process. In such an agreement, a bio-firm would retain the patent rights 
of a product it developed in collaboration with a previous upstream PREO partner, while the product development partner, e.g. a TNC, would fund 
aspects of the product’s development, acquire an exclusive licence to the product, and then pay the bio-firm product royalties on subsequent 
product sales. 
Joint ventures take on many forms, yet typically involve two or more actors collaborating on specific areas of a product's development process. 
Depending on an agreement's form, joint ventures can include joint research and/or development activity agreements, or take the form of two or 
more bio-firms creating new technologies and product lines through combining their resources and skills. In extreme cases, bio-firms may become 
contract laboratories for their joint venture partner(s).  
Licensing agreements grant exclusive IP rights to a third party through an agreed fee or royalty rate. They occur at both ends of the product 
development process. Upstream agreements can follow the completion of a PREO-based project which displays commercial potential. The 
principle investigating scientist(s) may enter an alliance with an existing commercial concern through conveying the exclusive or non-exclusive 
right to use a particular scientific discovery's IP. Downstream agreements occur between a bio-firm and a TNC to compete a product's clinical trials 
process. Such agreements are the most important formal downstream alliance type in the bio-sector by determining IP ownership. Manufacturing 
and marketing agreements can also develop through such agreements.  
Equity holdings/alliances take the form of alliances between bio-firms and VCs, or between bio-firms and TNCs. Typically they involve the partner 
actor becoming both a stakeholder and a shareholder in a bio-firm in exchange for financial investments. Alliances with VCs facilitate exchanges of 
business-related skills, while alliances with TNCs facilitate technological-related skills and resource exchanges. 
Manufacturing agreements form between bio-firms and TNCs, and are strategically and economically motivated. They can form at the end of an 
existing development alliance, and, by granting them access to the established distribution systems of TNCs, bio-firms can by-pass the need to set 
up manufacturing operations/facilities.  
Marketing agreements form after the successful completion of clinical trials. They grant an actor the marketing, supply and distribution rights to a 
product or technology, and can vary in their exclusiveness and expansiveness by being global agreements or territorially defined. They allow bio-
firms' access the extensive marketing operations of TNCs. 
Supply agreements develop where long-term relationships between actors, making a supply firm the primary supplier of a certain product or range 
of products to a customer. 
After (Powell and Brantley, 1992; Roche, 2000; Krafft et al., 2011; Giesecke, 2000; 
Barley et al, 1992; Malecki, 1997; Visser and Boschma, 2002; Chiaroni and Chiesa, 
2006; Prevezer and Swann, 1996; Bagchi-Sen at al., 2011). 
 
Again, it must be stated that all actors are important in the sectoral value chain, and that 
while the inter-actor networks are detailed below in separate sections, divided into the 
different elements of the sectoral value chain, they are separated solely for ease of 
presentation purposes. 
 
 PREO-based research networks 
The bio-sector's innovation process begins with PREO-based scientists engaging in 
collaborative and exploratory basic research programmes, i.e. scientific experiments 
targeting a particular biotechnology-related theme/topic. Typically, such activities 
involve scientists collaborating on research relating to the biology of a particular 
disease/condition, and the drug targets (i.e. the genes, enzymes, receptors or other 
proteins that trigger or block biochemical processes within a cell) which are the best 
candidates to medically treat the disease/condition in question. The biological role of 
these targets in disease initiation or progression is validated in a process that may take 
upwards of 15 years to complete, and entails establishing if a deoxyribonucleic acid 
(DNA), ribonucleic acid, or protein molecule directly participates in a disease process 
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and is therefore a suitable target to develop a new therapeutic compound (Lawrence 
Berkeley National Laboratory, 2000; Malecki, 1997; Stuart et al., 2007; Lia and Gengb, 
2012). 
 
This stage of the innovation process is predominantly characterised by informal 
strategic, exploratory, and exploitative networks that involve exchanges of mainly 
filtered tacit knowledge and information, as well as exchanges of codified scientific and 
technical competences and skills, and research-related equipment and resources among 
PREO-based actors. Collaborative research programmes form through extensive inter-
academic networks, developed and fostered by academics through their under- and post-
graduate and professional careers, through industrial and/or PREO work placements, 
and through signalling their research credentials to the wider research community 
through publications and conference presentations (Malecki, 1997; Owen-Smith and 
Powell, 2008; Krafft et al., 2011; Lia and Gengb, 2012).  
 
 
PREO research programmes can be characterised as being space specific 
agglomerations of tacit and codified scientific knowledge for two reasons. Firstly, the 
organisational structures and research capabilities of PREOs are dependent on their 
place specific research communities and infrastructures, which represent idiosyncratic 
local knowledge fields. Secondly, the information generated during a research 
programme's duration would be primarily held as researcher specific tacit knowledge, 
i.e. a research project would entail a specific methodological approach, background and 
training, and may originate from the findings of previous projects. This means that 
innovations are researcher-specific and do not transfer easily among different actors. 
The significance of the individual researcher in the innovation process is also 
compounded by the lack of overlap between the various areas of biotechnological 
research (Feldman, 1985; Prevezer and Swann, 1996; Breschi et al., 2001; Malecki, 
1997).  
 
Regional endowment of researchers, which are also place specific, determine the 
effectiveness of the filtering aspect of networks in localised learning processes, i.e. the 
manner in which local research is augmented by researchers accessing codified 
knowledge from non-local sources. By mixing local and global networks, researchers 
can complement a region's ‘‘local buzz’’, resulting in a more fertile innovation dynamic 
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through increasing idea diversity within a region’s knowledge base (Gertler and Levitte, 
2005; Graf and Krüger, 2011; Eisingerich et al, 2012; Huggins et al., 2012). 
 
 PREO networks with commercial actors 
PREOs actively promote information transmission and dissemination. As such, 
following the completion of a research programme, the generated tacit knowledge is 
ultimately codified through two principle avenues, which reflect a distinction in the 
commercial orientation of academics. Traditional research-orientated academic 
scientists predominantly focus on journal publications and/or conference presentations, 
while more overtly commercially minded entrepreneurial academic scientists will 
proactively seek commercial developments from viable IP generated from their research 
activities through seeking a patent development. The commercial orientation of 
academics, which is influenced by their previous career experiences, is regional specific 
and can be influenced by mimetic isomorphism (Casper and Murray, 2005; Murray, 
2004; Zucker et al., 1998, 2001; Lundberg and Andresen, 2012).  
 
Codification makes research findings available for licensing by commercial entities, e.g. 
bio-firms, or facilitates the creation of a start-up bio-firm (discussed further below) 
devoted to developing biotechnology-derived product and/or technique from 
commercially viable research. Licensing or start-up firm developments are the two main 
research commercialisation avenues in the international bio-sector (Lawrence Berkeley 
National Laboratory, 2000; Malecki, 1997; Visser and Boschma, 2002; Smith and 
Powell, 2004; Ahrweiler et al., 2011; Lundberg and Andresen, 2012).  
 
The most common formal alliances between PREOs and commercial actors are 
licensing arrangements, followed by relatively limited collaborative R&D agreements, 
research agreements (with no development elements), and relatively minor research 
grants. Formal codified PREO relations with commercial actors, i.e. bio-firms and 
TNCs, are motivated by strategic and economisation motives of accessing their 
financial resources and technological capabilities to commercialise research. 
Additionally PREOs gain insight into industrial trends, needs and requirements, as well 
as information on breakthrough downstream research developments, and possible 
avenues for extra funding. Entrepreneurial academics seek to reap the financial returns 
successful commercialisation infers, and advance their alliances with downstream actors 
(Balconi et al., 2004; Sorenson, 2003; NESC, 1996; Giesecke, 2000; Lundberg and 
Andresen, 2012).  
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 Upstream Bio-firm networks with PREOs 
Upstream alliances that bio-firms form with PREOs paradoxically represent the first 
downstream stage of the overall biotechnology innovation process, i.e. research findings 
enter the product development process. At this stage, PREOs represent the network 
structure's dominant actor type (Giesecke, 2000; Gertler and Levitte, 2005; Ozman, 
2006; Feldman, 2000; Graf and Krüger, 2011).  
 
As stated, bio-firms, internationally, are predominantly founded by entrepreneurial 
academics. As such, they often locate in close proximity to their 'parent' PREO. 
According to Malecki (1997), the process of entrepreneurship is geographically 
constrained as actors start new firms in areas related to their previous research activities 
and seek to continue the extensive formal and informal networks they previously 
enjoyed (Chiaroni and Chiesa, 2006; Morgan and Nauwelaers, 1999a; Ahrweiler et al., 
2011; Eisingerich et al, 2012).   
 
The relative geographic proximity and the degree of social inclusiveness of bio-firms to 
a PREO determines the degree to which informal relationships can be engendered, and 
facilitates access to commercially related and 'filtered' PREO-based tacit knowledge and 
sorted codified knowledge. Proximity also impacts on formal network formations. 
Through developing extensive explorative knowledge networks with PREO actors, bio-
firms can surmount the high costs of searching for commercially promising research. 
The earlier a technology is licensed, the greater the level of exclusivity that is gained, 
which is crucial in determining a bio-firm's future earnings (Kostiainen Sotarauta, 2002; 
Ozman, 2006; Ahrweiler et al., 2011; Malecki, 1997; Eisingerich et al, 2012). 
 
Overall, a bio-firm's ability to access, exploit and explore PREO knowledge sources 
determines its research capabilities, and directly influences its commercialisation 
activities. The filtering aspect of networks is increasingly important for bio-firms, 
internationally, as their research focus has intensified and become niche activity 
orientated. This development is due to the slowing pace and increasing costs of the 
biotechnology-derived drug development process, as detailed above. Additionally, bio-
firms that form relatively more license agreements with PREOs are more likely to craft 
revenue-generating strategic alliances with downstream partners, as they will have more 
to offer (Romanelli and Feldman, 2007; Schweitzer et al., 2005; Feldman, 1985; 
Prevezer and Swann, 1996; Lundberg and Andresen, 2012). 
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This trend has deepened the importance of short distances and close social relations 
between bio-firms and PREOs, so as to generate suitable trust and reciprocity levels to 
facilitate knowledge and resource transfers. Where close social relationships form, 
informal and formal alliances are optimised by reducing informal transaction costs and 
insecurities through minimising the distance over which interaction and communication 
are conducted. This enhances inter-actor task coordination, codified resource and 
knowledge transactions and engenders knowledge spillovers (Feldman, 2000; Balconi et 
al., 2004; Sorenson, 2003; NESC, 1996; Rowley et al., 2000; Uzzi, 1996).  
 
There are numerous non-contractual connections that bio-firms can engender with 
PREOs. These include a firm's founder(s) seeking to foster and deepen existing close 
personal contacts with academics, where a bio-firm is spun-out from PREO research, by 
maintaining academic appointments following its formation, the co-authorship of 
journal articles and conference presentations derived from collaborative research, 
through founders joining the scientific advisory boards of PREOs, through firms 
entering into/hosting study and work placements to facilitate competence and skill 
exchanges, and through collaborative training programmes (Chiaroni and Chiesa, 2006; 
DTI, 1999c; Morgan and Nauwelaers, 1999a; Erden and von Krogh, 2011). 
 
Aside from research-based networks, bio-firms also seek to develop close networks 
with PREOs as skilled human capital may be sourced from and/or developed through 
interaction with them. Additionally, transfers of organisational routines, through formal 
business competence exchanges, may occur during the initial set-up phase of a bio-
firm’s development, e.g. a bio-firm maturing in a PREO-based incubator may model its 
organisational routines and structures on those of its 'parent' PREO(s) (Owen-Smith and 
Powell, 2008).  
 
 Downstream Bio-firm networks with commercial actors 
Alliances between bio-firms and other commercial actors, e.g. other bio-firms and 
TNCs, represent the second downstream stage of the biotechnology innovation process, 
i.e. product development enters the clinical trials drug development process, detailed in 
Table 3.3 (Ernst and Young, 2000; Owen-Smith and Powell, 2007; Lee, 2012). 
 
At this point in the bio-sector's innovation process, commercial actors assume the 
dominant actor role in networks. Different dominant actors in a wider network structure 
play particular roles as a sector matures and innovation becomes less radical, as such 
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bio-firm networks become predominantly formal in nature due to the codified nature of 
commercialisation-related interactions, and also as such relationships can form with 
non-local actors, e.g. TNCs (Gertler and Levitte, 2005; Owen-Smith and Powell, 2004; 
Soh and Roberts, 2000; Kogut, 2000; Graf and Krüger, 2011; Lee, 2012). 
 
Table 3.3: The four phases of the clinical research trial process 
The first phase involves the investigation of the safety of a product, its biological effects, its effects on the human metabolism, kinetics (i.e. the 
rates of chemical reactions), and drug interactions in a small human population sample of between 20 to 30 individuals. This phase can take up to 
two years to complete. Five drug/product candidates will typically enter this phase, of which 80% will pass. 
The second phase investigates side-effect profiles, efficacy, and the dosage of a product on a large population sample of between 100 and 300 
individuals who have the disease/condition under investigation. This can take two years to successfully complete, and only 30% of the 
drugs/products which enter this phase will pass. 
The third phase investigates the reactions to long term use of a drug/product under investigation on a large sample of between 1,000 to 5,000 
individuals who have the disease/condition under investigation. This can take up to four years, 80% of the drugs/products which enter this phase 
will pass  
After the third phase, TNCs can then file an application with the relevant regulatory authority, e.g. the US Federal Drug Administration, to review 
and approve the product for sale. Only after approval is received can the producer commercially sell the product, although a further year of post-
marketing testing is required to guarantee its safety. This represents the fourth and final stage of the clinical trials process. 
After (Alliance Pharmaceuticals, 2002; Amgen, 2002; Élan Corporation, 2001; Ernst 
and Young, 2000).  
 
Bio-firms initially adopt the structures of their 'parent' PREO(s), yet they will mimic 
and adopt the observable structures of successful bio-firms which have formed 
downstream alliances with VCs and/or TNCs as they develop, i.e. mimetic isomorphism 
will occur. Bio-firms will seek to develop structural similarities with successful bio-
firms so as to facilitate similar downstream alliances through reducing perceptions of 
risk among potential collaborators (Owen-Smith and Powell, 2007; Slack and Hinings, 
1994; Chen at al., 2011; Delerue and Lejeune, 2011).   
 
The evolution of bio-firm networks from mainly open/informal to closed/formal forms 
is facilitated by formal (strategic, economising, exploitative and exploratory financial) 
resource and business knowledge/information networks between bio-firms and VCs. VC 
alliances facilitate the strategic development of firm-based commercially viable 
research, and result in the re-modelling of bio-firm management structures to optimise a 
VCs chosen exit strategy, as detailed above (Romanelli and Feldman, 2007; Schweitzer 
et al., 2005; Prevezer and Swann, 1996; Chen at al., 2011; Lundberg and Andresen, 
2012). 
 
Where VCs/bio-firms seek to enter formal alliances with a TNC, they wish to access the 
more advanced financial and technical resources of the TNC by forming market-
oriented strategic, exploitative and economising research and business orientated 
networks that facilitate scientific and technological competence and resource exchanges 
(e.g. the vast regulatory experience of TNCs), and the development of marketing, 
supply, manufacturing, sales, and distribution networks. In such alliances, a bio-firm 
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offers prospective TNC collaborators its scientific capabilities, i.e. its ability to evaluate 
external scientific knowledge, and its technical capabilities, i.e. its ability to utilise 
external knowledge. The formal nature of these alliances mean bio-firms achieve 
relationship asymmetry with TNCs, while TNCs access and control a bio-firm’s IP, and 
direct/influence the direction of its research programme(s) (Malecki, 1997; Ozman, 
2006; Powell and Brantley, 1992; Casper and Murray, 2005; Chen at al., 2011).  
 
Overall, bio-firms and TNCs create formal networks that enhance the sectoral 
innovation process by recombining new and old information in new ways. The nature of 
these alliances means their research teams establish close interactions, facilitating 
informal network developments as the level of trust and reciprocity develops/evolves. 
Both actors strategically seek to establish exploratory and exploitative information and 
resource networks to exchange skills, and tacit and codified scientific and business 
information/knowledge, as well as resource and procedural exchanges, so as to generate 
information spillovers (Visser and Boschma, 2002; Powell and Brantley, 1992; Lee, 
2012). 
 
Alliances between bio-firms and TNCs remain the international bio-sector's most 
optimal downstream alliance form, i.e. the 'Genentech template'. However, downstream 
alliances have stratified as the international bio-sector has matured.  
 
The first bio-firms in the mid/late 1970s focused on large, non-niche targets as they 
experienced first mover advantage and faced little sectoral competition. Genentech's 
successes sparked a 'gold rush' mentality among VCs and TNCs, leading to many bio-
firm developments internationally, which opened up non-US sectors. As such, TNCs 
and VCs could now be very selective in forming alliances, and could tailor research for 
themselves more optimally. Additionally, it became increasingly evident, as the 1980s 
progressed, that very few bio-firms could replicate/mimic Genentech's successes (Ernst 
and Young, 2001; Giesecke, 2000).  
 
These issues established the niche nature of bio-firm activities internationally. They 
resulted in the downstream end of the bio-sector's innovation process fracturing, in 
combination with TNCs reorganising their Fordist structures to mimic bio-firm 
structures. Yet, the relative size of bio-firms, and their operations, to TNCs shrank due 
to their increasingly narrow research focus, making inter-firm alliances much easier and 
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equitable than alliances with TNCs. This development was, and continues to be, 
facilitated by the establishment of new bio-firm forms which focus on specialist 
technological and research support services, not on commercialising research, i.e. 
platform technology firms, which provide specialist tools to other bio-firms in order to 
assist their drug discovery research, and product development firms, which conduct 
specific aspects of the clinical trials process for customer bio-firms (Giesecke, 2000; 
Ernst and Young, 2001; McMillan et al., 2000; Forfás, 1999).  
 
The networks which bio-firms develop with these service bio-firms resemble those 
found between bio-firms and TNCs, i.e. they are predominately formal in nature and 
feature codified exchanges of information and resources (McMillan et al., 2000; Forfás, 
1999).  
 
A related, though contrasting development is the emergence of second generation bio-
firms. These emerge where an established bio-firm identifies new product platform or 
product development opportunities through its R&D programme(s), yet resource 
restrictions may prevent it from addressing/investigating these opportunities. As such, 
the parent bio-firm may spin-out a new, second generation bio-firm to continue (for 
example) a new research programme, without stretching the existing bio-firm's finite 
resources (Powell and Brantley, 1992; Ernst and Young, 2001; McMillan et al., 2000; 
Giesecke, 2000). 
 
In this scenario, the 'parent' bio-firm becomes the dominant actor. Due to their origin, 
second generation bio-firms locate in close proximity to their 'parent' bio-firm so as to 
develop close informal and formal networks to facilitate exchanges of information, 
resources, personnel, and science and technological competencies. Additionally, they 
derive their research methodology, business ethos and management structure from their 
'parent' bio-firm. In the international bio-sector, more mature bio-firms in-source 
technology developed from their second generation counterparts, yet this is a relatively 
rare occurrence due to the bio-sector's slowing development pace (Giesecke, 2000; Gay 
and Dousset, 2005; Graf and Krüger, 2011; Eisingerich et al, 2012). 
 
Another alternative downstream strategy for bio-firms is where they re-invest earnings 
acquired through licensing agreements to either fund future research programmes, or to 
develop more advanced downstream capabilities, e.g. manufacturing or marketing 
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facilities, in order to allow the bio-firms to move down the product development 
process. These developments are motivated by the desire to retain more control over IP 
by restricting the level of interaction required with downstream partners, so as to retain 
a larger percentage of potential future financial returns. However, only a limited number 
of bio-firms have succeeded in developing such capabilities internationally (Cato 
Research, 2002; Scopa, 2000; Powell et al., 2005; Bagchi-Sen at al., 2011). 
 
The changing nature of formal downstream bio-firm alliances has impacted on TNCs. 
Yet, as stated above, the downstream alliance demands of TNCs have also altered. In 
response to this increasing mismatch with niche focused bio-firms, TNCs have 
restructured their existing research operations and/or established biotechnology research 
laboratories to mimic the horizontal, network-based organisational structures of bio-
firms. Several of the larger TNCs, e.g. GlaxoSmithKline, have also created virtually 
independent research operations that mimic the locational patterns of bio-firms, i.e. they 
locate in close proximity to PREOs in order to engender the same informal and formal 
networks found between PREOs and bio-firms (McMillan et al., 2000; Giesecke, 2000; 
Malecki, 1997).  
 
These changing structures have led TNCs to seek licensing agreements with sectoral 
actors engaged in early stage applied research activities, i.e. recently established bio-
firms, or directly with PREOs. This development has been facilitated by “...the 
availability of better prediction tools and more sophisticated methods for objective risk 
determination” (Ernst & Young, 2006a: 3), and is motivated by the limited number of 
bio-firms in the international bio-sector that are reaching the first stages of the clinical 
trials process. Coincidentally, start-up bio-firms are increasingly focusing on attracting 
TNC involvement, as they experience significant pre-clinical research funding issues 
due to on-going issues with 'traditional' sectoral investment sources, i.e. IPOs and VC 
funds, as detailed above (Ernst and Young, 2001; 2007a; McMillan et al., 2000; 
Giesecke, 2000; Powell and Brantley, 1992).  
 
Overall, these developments mean two inter-related innovation network forms can be 
identified in the downstream end of the sectoral value chain, particularly in main global 
bio-sectors: 
 
 'traditional' vertical innovation networks between PREOs, bio-firms and TNCs, 
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i.e. where bio-firms act as the main mechanism in transferring PREO-based 
research results/findings to the market place, and; 
 'horizontal' downstream-actor innovation networks involving bio-firms, second-
generation bio-firms, and bio-firm mimicking research entities of TNCs 
collaborating on network-based innovative activities (Malecki, 1997; Giesecke, 
2000; Ahrweiler et al., 2011).  
 
Horizontal downstream networks are focused on product developments, and are 
overwhelmingly formal in nature, as tacit and codified knowledge/information and 
resources are now predominantly held by commercial actors. This means that the 
relative importance of PREOs in downstream innovative developments decreases as a 
bio-sector matures, yet they remain crucial in generating the tacit and codified 
information/knowledge and skills that feed sectoral innovative developments (Gay and 
Dousset, 2005; Gertler and Levitte, 2006). 
 
3.3.2.3 Networking patterns in the PBCs 
The network structures and innovation processes of the global bio-clusters are the 
templates for the international bio-sector. They act like a collective entrepreneur, where 
sectoral actors form regional specific, dense concentrations/critical masses of complex 
and varied skills, resources, information and networks. These networks facilitate the 
rapid transfer and diffusion of information/knowledge and resources to engender sector-
wide innovative developments, and feed the development of self-supporting and 
generating regional agglomerations (Anderson et al., 2004; Feldman, 2001; Malecki, 
1997; Delerue and Lejeune, 2011). 
 
In comparison, in order to compensate for actor weaknesses/absences and 
network/value chain weaknesses, a common strategy for PBC actors is to develop 
distant collaborative network strategies with actors in more knowledge and resource 
rich locations, optimally bio-clusters. Essentially, these actors seek to develop 
alternative forms of proximity. For example, Powell et al. (2002) suggest there are four 
key global VC centres, i.e. Boston, New York, the San Francisco Bay Area and San 
Diego (coincidentally bio-clusters). Many PBC firms seek alliances with VCs in these 
global centres in order to circumnavigate investor actor weaknesses in their own bio-
sectors. Yet, they face significant issues in doing so due to the poor image/reputation of 
their bio-sectors caused by their limited innovative activities and developments (which 
paradoxically can be caused by their sectoral investor actor issues), and the intense 
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competition they face from more dynamic bio-sectors (Gilding, 2008; Casper, 2007; 
Zhang and Haiyang, 2011; Delerue and Lejeune, 2011).  
 
Additionally, alternative proximity strategies involve considerable financial, logistical, 
and managerial costs due to the absence of local proximity and the sometimes 
significant distances involved. These issues can dissuade hub actors from entering into 
such alliances, meaning that the less endowed hub regions experience cumulative 
disadvantages, and fall further behind relative to bio-clusters (Powell et al., 2002; 
Gertler and Levitte, 2005; Morris, 2011; Delerue and Lejeune, 2011). 
 
3.4 BIOTECHNOLOGY CLUSTER POLICY THEMES AND TEMPLATE 
3.4.1 Bio-cluster development policy themes  
The emergence and visible success of the international bio-clusters have encouraged 
different regional, National/Federal Governments and supra-national organisations to 
seek to engender similar developments in their own economies through different 
development strategies derived from observable patterns, processes and institutional 
arrangements in the established bio-clusters (Brown, 2000; Prevezer and Tang 2007; 
Avimelech and Teubal, 2007). 
 
The following sections detail the role of Government initiatives in the emergence of the 
bio-clusters, and the main issues relating to the cluster specific policy initiatives seeking to 
engender cluster emergence in the PBCs.  
 
3.4.1.1 The role of Government initiatives in the emergence of the international bio-
clusters 
Government initiatives have played case specific roles in directly or indirectly 
facilitating the emergence of the global bio-sector's bio-clusters.  
 
The US bio-clusters emerged in the context of substantial US Government investments 
in seeding general factor conditions and related and supporting industries, particularly 
the Cold War era funding initiatives which created the advanced and specialised 
infrastructures of the country's PREO base and the entrepreneurial support ecosystem 
which exploits the commercial promise these PREO investments engendered, so as to 
facilitate developments in the wider economy. These initiatives indirectly seeded a 
defined entrepreneurial/innovative culture which, in combination with the complex 
nature of the support structures, facilitated and drove the exploitation of the PREO-
based developments, and established a positive path dependence that optimised the US 
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bio-sector's development trajectory (Anderson et al., 2004; Bagchi-Sen at al., 2011).  
However, a key feature of the US bio-clusters is that a complex set of predominantly 
private actor driven, mutually reinforcing and aligned interests emerged in the context 
of indirect, though aligned, public interests and supports that fostered the development 
of the bio-clusters' value chains, and drove their trigger processes (Anderson et al., 
2004).  
 
The continuing indirect nature of the Federal initiatives exists due to the established 
absence of a specific Federal body to oversee sectoral developments. Yet, the Federal 
Government has continuously addressed issues restricting sectoral developments since 
the US bio-sector emergence, e.g. the Bayh-Dole Act (1980) addressed issues restricting 
the commercial exploitation of PREO research which emerged through the surge in US 
bio-sectoral activity that followed Genentech's emergence. Federal Government 
developments continue to focus on optimising the national entrepreneurial 
environment/ecosystem as a whole, and are not specifically focused on the US bio-
sector (Giesecke, 2000: Romanelli and Feldman, 2007).  
 
The absence of a sector-specific Federal industrial development programme has been a 
key factor in the development of tailored bio-cluster system governance structures and 
ecosystems. The development of these ecosystems continues to be driven by indirect 
State Government initiatives that focus on regulation and entrepreneurial ecosystem fine 
tuning. Essentially, State Governments have adopted cluster informed approaches that 
are tailored through public/private dialogue processes that include sectoral lobbying 
efforts and input from regional trade associations, which focus on system specific 
adjustments to respond to the evolving needs/requirements of a system. This approach 
seeks to induce continual, structured and self-reinforcing process of growth and 
development through on-going innovative and entrepreneurial activities (Giesecke, 2000: 
Romanelli and Feldman, 2007; Porter, 1998; Lundberg and Andresen, 2012).  
 
Examples of such measures include the introduction of specific skills and competence 
building exercises to improve a system's specialised factor and demand conditions, and the 
fine tuning of a bio-cluster's legal and regulatory environment, e.g. changes to tax regimes, 
to improve the strategies and structures of a system's bio-firms, and its related and 
supporting industries. The indirect nature of these initiatives means that no 
comprehensive State level/regional development strategies have been developed in the 
 86 
US, and that no specific typologies of cluster informed policies can be derived 
(Romanelli and Feldman, 2007; Feldman and Braunerhjelm, 2007; Wolfe and Gertler, 
2007). 
 
In relation to the EU bio-clusters, their pre-conditions and seeds developed in the 
context of different Government structures, i.e. the National and Local Government 
structures in the UK, and the different Federal and Land Governments in Germany. 
Additionally, both countries are members of the EU's supranational structure (Lewis et 
al., 2001).   
 
The UK's National Government had developed proactive efforts to engender advanced 
high-tech sectoral developments prior to Genentech's emergence. Local Government 
activities were primarily extensions of these initiatives. The National Government's 
initiatives engendered a national PREO-orientated entrepreneurial environment that 
facilitated the emergence of pharma-TNC and NICT/electronics agglomerations in the 
Cambridge area, i.e. positive path dependence elements (i.e. factor conditions, demand 
conditions, firm structure and strategy conditions, and related industries) were in place 
to facilitate and drive the bio-sector's positive development trajectory.  
 
In Germany, significant Federal and Land investments had facilitated the development 
of an advanced PREO base. Yet, despite Germany being the first country, 
internationally, to introduce a defined biotechnology specific PREO research funding 
programme in the early 1970s, it failed to establish a significant biotechnology-
orientated research base. This was due to the Federal Government's limited 
understanding of biotechnology resulting in the programmes formulation process being 
dominated by existing PREO researchers, meaning the programme failed to address the 
then emerging field of genetic engineering. Additionally, restrictions preventing 
academics entering into commercial developments, and the established vertical PREOs 
structures, undermined the development of an entrepreneurial mindframe and/or a 
tradition of collaborative alliances among academic and commercial actors (Giesecke, 
2000). 
 
The Cambridge and Munich bio-sectors emerged following Genentech's foundation, yet 
their development trajectories were undermined by system specific weaknesses, as 
detailed above. The UK Government introduced defined sectoral development 
 87 
initiatives in the early 1980s to address the lack of VC involvement in the bio-sector, 
which facilitated the development of an agglomeration of bio-firms. No public 
initiatives were introduced in the German bio-sector, meaning very limited sectoral 
developments occurred nationally.  
 
Both EU bio-clusters emerged due to the introduction of planned Government structures 
whose introduction was motivated by EU-driven efforts to address the increasing 
dominance of the US bio-sector. The UK government initially formulated cluster 
specific policies derived from observable patterns in the US bio-sector that engaged 
with the Cambridge bio-sector's existing actors and structures and facilitated the bio-
cluster's hybrid trigger event (Cooke, 2002; Department of Trade and Industry 1999; 
Casper and Karamanos, 2002).  
 
The Cambridge bio-sector's initiatives have become increasingly more tailored and 
attuned to the bio-sector's individual needs and requirements. Nationally, sectoral 
specific policies continue to be developed and implemented through dedicated agencies, 
including the Biotechnology and Biological Sciences Research Council, and through 
sectoral specific initiatives of the Department of Trade and Industry (Invest UK, 2001: 
Department for Environment, Food and Rural Affairs, 2007). 
 
The German Federal Government's BioRegio programme is responsible for the Munich 
bio-cluster's emergence, through introducing substantial commercial development 
infrastructures and supports, in particular dedicated VCs. The BioRegio programme was 
designed on observable patterns in the US bio-sector, yet formulated and tailored to the 
German bio-sector through a Federal consultation process that involved State 
Governments and key sectoral actors (Casper and Karamanos, 2002; Cooke, 2002).  
 
Unlike in the US, where the different governance structures inter-link to continuously 
seek to optimise the Federal ecosystem and address State specific issues through 
public/private cluster informed approaches, the different governance structures in the 
EU bio-clusters are disjointed and remain hierarchical/public actor dominated. These 
issues undermine their development trajectories: 
 
 in the Cambridge bio-cluster, the limited integration between the different 
governance levels is reflected in the presence of National regulatory issues 
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undermining the bio-cluster's entrepreneurial developments, including limited 
clarity in the UK's patenting regime, and issues relating to the country's taxation 
regime, and;  
 the Munich bio-cluster's on-going development is locally managed through the 
public/private structured BioM organisation, yet it is not integrated with existing 
Federal Governance structures, as reflected in the continuing systemic 
weaknesses caused by the hierarchical PREO structures (Casper and Karamanos, 
2002; Cooke, 2002).  
 
In comparison to their US counterparts, Casper and Murray (2005) characterise the EU 
bio-clusters as being more entrepreneurially conservative due to the more central role 
public initiatives play in their development, while their system structures are 
characterised by vertical structures, limited inter-actor networks and systemic spillover 
events. These issues undermine their development trajectories. As with the US bio-
clusters, the specific natures of their systems means that no specific cluster informed 
policy typologies can be derived (Casper and Karamanos, 2002). 
 
3.4.1.2 PBC cluster specific policy issue themes 
Many Governments have identified biotechnology as being strategically important for 
their country's future economic development. In many PBCs, as well as the Cambridge 
and Munich bio-clusters, cluster specific initiatives were initially developed through 
analyses of observable patterns in the established US bio-clusters. However, the German 
Government's BioRegio programme, itself derived from US sectoral observations, has 
become the template for the development of cluster specific initiatives since the turn of the 
century (Gilding, 2008; Wolfe and Gertler, 2007; Enright, 2000).     
 
PBC development initiatives can be characterised as being public actor dominated 
developments that are formulated with limited private actor involvement, and which are 
derived from snap shots taken of established bio-clusters. They seek to engender specific 
and rapid sectoral developments determined and based upon election cycles in order to 
justify the sometimes substantial investments made by these initiatives. Public supports 
ultimately seek to advance sectoral activities to a point where private actors organically 
enter a bio-sector, so as to engender a self-sustaining bio-sector system (Anderson et al., 
2004; Rochepeau, 2004; Venning and Yukawa, 2010). 
 
Such programmes are typically implemented over two main stages that focus on 
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addressing big issue topics, i.e. initially they seek to address PREO infrastructural and 
resource weaknesses in order to drive sectoral developments by generating commercially 
viable research, and subsequently they focus on facilitating transfers of this commercially 
viable research to new and existing commercial concerns by addressing limitations in 
sectoral commercialisation support infrastructures and resources, such as the absence of 
VC actors (Anderson et al., 2004; Venning and Yukawa, 2010).  
 
This focus on big issue topics can result in systemic development surges/expansions in 
relation to what existed prior to their introduction, yet their large target orientation can fail 
to surmount and/or fully address complex systemic bottlenecks/weaknesses, i.e. missing 
skill sets and/or resources, for a variety of reasons.  
 
Public initiatives can be characterised as being reactive in nature as public actors are 
directly removed from industrial development trends. This means that the essentially top 
down nature of PBC development initiatives can fail to address intricate and complex 
systemic weaknesses which can be embedded in the institutional characteristics of a PBC's 
actors, and/or exist due to their organisational structures, through imposing impracticable 
and/or unsuitable initiatives.  
 
As stated above, cluster specific initiatives typically focus on facilitating new commercial 
developments originating from PREO-based research through introducing early stage 
commercialisation supports. Yet, these supports fail to address existing private actor 
restrictions, including the conservative business models of existing bio-firms or the 
commercialisation support and investor actor funding limitations that downstream actors 
can face. This is due to such pre-existing downstream issues being viewed by public actors 
as being solely the domain of the private actors. Yet, the presence of innovation and 
entrepreneurial development paradoxes among established downstream actors will 
undermine sectoral developments.  
 
Furthermore, as cluster specific initiatives are typically formulated with limited private 
actor involvement, vested interests can dominate their formulation, thus undermining their 
suitability to fully address the specific issues present in a bio-sector (Anderson et al., 
2004). 
 
Additionally, the PBC case studies demonstrate that cluster specific initiatives mainly 
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focus on engendering defined niche focused platform bio-firm developments due to their 
relatively less risky and more predictable nature, in comparison to drug 
development/product orientated firms. This is in response to the expanding costs and 
duration of the drug development clinical trials process. This focus seeks to achieve rapid 
sectoral advances within a defined time period, yet while such a focus can indeed result in 
an initial surge of bio-firm developments, their limited nature propagates a risk adverse 
systemic 'environment' that restricts up- and downstream spillovers and sectoral 
developments (Anderson et al., 2004; Casper and Murray, 2005). 
 
As such, the envisaged level(s) of entrepreneurial developments fail(s) to emerge, meaning 
that time lags develop between the introduction of the initial supports and when public 
actors realise that deeper levels of intervention and longer time scales than previously 
initially envisaged are required. This is a common problem evident in most of the PBC 
case studies.  
 
The introduction of more advanced resources and initiatives usually involves more 
substantial input from private actors so as to formulate and introduce more system-specific, 
tailored, and intricate initiatives. However, the disjointed, stop-start nature of PBC 
development trajectories remains. The fractured build-up of sectoral supports results in 
more modest commercial development levels, relative to the private actor driven systems, 
as initiatives are insufficient to facilitate the optimal growth of PBCs in the medium to 
long-term as they remain tied to political election cycles. This is increasingly problematic 
as the economic, technical and development timelines and risks associated with the bio-
sector are increasing, i.e. target/goal driven approaches are increasingly unsuitable to 
optimally contain the evolving associated risks of biotechnological developments.  
 
Target-based initiatives can also distort markets through seeking the achievement of set 
targets regardless of their suitability to a bio-sector. An extreme example is the strong 
Government involvement in the Chinese bio-sector. Due to strictly defined targets and 
political/cultural factors, no bio-firm can fail. This has distorted the Chinese bio-sector's 
market by feeding systemic lock-in developments and undermined the development of the 
bio-sector's entrepreneurial ecosystem (Giesecke, 2000; Prevezer and Han Tang, 2007; 
Graf and Krüger, 2011).  
 
Furthermore, questions over the long-term sustainability of platform bio-firm orientated 
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development strategies are developing as a critical mass of such firms is forming 
internationally. This issue relates to Governments deriving their initiatives from similar 
'templates', i.e. the US bio-sector and the BioRegio programme, and it is further 
compounded by Governments seeking to engender sectoral developments in the context of 
the evolving and on-going development of established bio-clusters. Essentially, cluster 
specific initiatives are playing catch up with the bio-clusters, as well as trying to counteract 
the rising threats from cheaper and more specialised locations in the Far East and Southern 
Hemisphere that are offering lower production costs, strong science bases, and vast 
internal markets (Casper and Murray, 2005; Giesecke, 2000; Europe Innova, 2008). 
 
3.4.2 Cluster specific policy themes to facilitate bio-cluster developments 
The limited number of global bio-cluster developments directly associated with cluster 
specific initiatives, and the nature of the observable PBC's structural weaknesses, 
demonstrates that public actor initiatives cannot solely create bio-clusters. 
 
The German Government's BioRegio programme demonstrates that a comprehensive 
policy framework can establish national research agendas, introduce key infrastructures 
and institutions through specialist factor investments, and can also engender an 
entrepreneurial support ecosystem through micro-economic policy measures that optimise 
the development of existing and new system activities and engender the formation of inter-
actor networks. Yet, the BioRegio programme also demonstrates that such a framework 
cannot fully address a system's existing path dependence, i.e. established institutional 
characteristics, structural weaknesses, and/or a poor commercial culture/entrepreneurial 
environment which undermines entrepreneurial and innovative developments (Cooke, 
2002; Feldman and Francis, 2002; Delerue and Lejeune, 2011). 
 
The Cambridge bio-cluster case study demonstrates that cluster specific policies only 
succeed when they mesh with an existing system that forms in the context of substantial 
place-specific preconditions and seeds, and whose trigger process emerges over a period of 
decades through a system-specific development trajectory that involves a wide variety of 
complex and idiosyncratic interactions of competences, skills and resources held 
predominantly by private sectoral actors, in the context of a supportive ecosystem 
(Romanelli and Feldman, 2007; Wolfe and Gertler, 2007; Lee, 2012).  
 
These issues demonstrate that in order to fully address the evolving demands of a PBC 
system, cluster specific initiatives should be formulated and introduced through a long-
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term, responsive and adaptive policy framework which optimally builds upon strengths, 
and addresses weaknesses present in the four determinants of competitive advantage. 
Such a framework must be constructed through an open ended inclusive dialogue 
process that involves all the relevant public and private sectoral stakeholders, so as to 
tailor initiatives towards building on pre-existing competences and productive systems and 
to increase the ability and capacity of a system's actors to absorb innovation investments 
and resources. This issue has clear implications for the relationship between public actor 
technology/innovation and industrial policy strands (Porter, 1998; Asheim and Isaksen, 
2002; Oughton, Landabaso and Morgan, 2002) 
 
Such an inclusive dialogue process can be a challenge for highly-regulated/vertically 
structured Governments, yet it is required as a cluster system's skills, competences and 
resources must ultimately be private actor in nature. Additionally, the long-term 
inculcation of a coordinated systems-based entrepreneurial/innovative support ecosystem 
that suitably addresses all the demands and requirements of the bio-sector's characteristic 
interactive tripartite sectoral value chain cannot form solely through traditional 'top down' 
initiatives, as Governments are often directly removed from market forces and are at best 
reactive in nature (Anderson et al, 2004; Leydesdorff, Cooke and Olazaran, 2002; Porter, 
1998; Casper, 2007; Feldman and Braunerhjelm, 2007; Erden and von Krogh, 2011) 
 
Through using bio-cluster and PBC case studies, the policy recommendations detailed 
by DTI (1999) and Anderson et al. (2004), as well as the entrepreneurial and innovative 
functional resource (EIFR) requirements list presented in chapter 2, a template of cluster 
specific policy themes can be presented that both facilitate and drive entrepreneurial and 
innovative developments throughout a bio-sector's value chain (Casper, 2007; 
Romanelli and Feldman, 2007; Wolfe and Gertler, 2007). 
 
3.4.2.1 Knowledge infrastructure, resources and skills 
PREO generated scientific knowledge is the starting point of the bio-sector's value chain 
and innovation process. The technical capabilities and resources available to PREO 
scientists strongly determines a bio-sector's commerciable research activities by 
influencing start-up bio-firm and biotechnology-derived product and process 
developments. As such, a strong PREO science base is a key element in engendering the 
conditions which facilitate a bio-cluster's ultimate emergence (DTI, 1999d; 
MacPherson, 1998; Prevezer 1997).  
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Wolfe and Gertler (2007) comment that one of the soundest PBC policy programmes is 
the introduction of sustained investments in building the infrastructural base and 
education capabilities of a PBC's PREO actors, i.e. to develop a complex array of 
modern facilities and high-tech equipment resources so as to generate high-levels of 
basic research and industry-orientated applied research in a wide variety of 
biotechnology/biotechnology-related areas, and to develop a highly qualified skilled 
labour force. Such developments are required, as the quality and character of the 
research capabilities, skills, and (sticky) knowledge sets of a PBC's PREOs are key 
elements in the synergy processes that influence a system's development trajectory due 
to the existence of local learning processes, technology transfers and spill-over effects 
supported by geographic and cultural proximity (Malecki, 1997; Anderson et al., 2004; 
Casper, 2007; Anderson at al, 2004; Krafft et al., 2011; Engel and Del-Palacio, 2011).  
 
On its own, a strong science base will not facilitate a cluster's emergence, yet a weak 
science base will undermine innovative and entrepreneurial developments and a PBC's 
development trajectory. This issue directly relates to the development of advanced and 
specialised factors which are necessary to enhance a system's production capabilities, 
capacity, and accumulation of technological capabilities. In order to address hierarchical 
and disjointed organisational structures and limited cross actor interaction, initiatives 
must focus on developing cross institutional and inter-disciplinary infrastructural and 
administrative structures so as to facilitate inter-PREO actor knowledge exchanges and 
spillover events. Such infrastructures require the alignment/coordination of different 
technological platforms, which can result in more efficient use of resources, e.g. 
preventing unnecessary duplications of facilities and/or resources, and optimise the 
development of higher quality research and skills development programmes (Swann and 
Prevezer, 1996; Prevezer 1997; Cooke, 2002; Feldman and Braunerhjelm, 2007) 
 
PREO education programmes strongly determine a system’s ability to develop a 
suitably skilled labour force. This influences key network developments and inter-actor 
knowledge exchanges, key elements in the synergies which facilitate cluster emergence. 
A highly educated and skilled labour force feeds the growth of local enterprises and can 
ultimately attract non-local actors, and their skills, competences and resources, into a 
PBC as they seek to access a system's advanced PREOs. As such, PREOs must develop 
education courses that are tailor-made to address the various complex and evolving 
labour demands of a PBC's actors. This requires close and continuous collaboration 
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between PREOs and a system's actors in designing such programmes (Wolfe and 
Gertler, 2007; MacPherson, 1998; Anderson et al., 2004; Casper, 2002; Graf and 
Krüger, 2011; Eisingerich et al, 2012).  
 
Allied to skills development activities, initiatives should also focus on the retention of 
skills and competences in PREOs, particularly where a 'brain drain' occurs, so as to 
avoid undermining a system's development trajectory through skills flight to more asset 
rich bio-sectors. Initiatives should also be developed to attract local researchers back 
into a system from non-local research positions, as well attracting in non-local PREO 
actors to seed alternative skills, and competences. In order to foster and embed such 
developments, such initiatives require strategies to prevent potential 'belligerent' 
reactions from local researchers, as well as the presence of suitable PREO research 
infrastructures and resources, and a suitably advanced level of downstream actor 
activity (Anderson et al., 2004; Casper, 2002; Koehler, 1996; Engel and Del-Palacio, 
2011; Graf and Krüger, 2011; Eisingerich et al, 2012). 
 
3.4.2.2 Entrepreneurial infrastructure, resources and skills 
The engine of a PBC's trigger process, and the linchpin in its value chain, are the 
entrepreneurial and innovative activities and developments of a system's bio-firms. The 
presence of a growing bio-firm base is a crucial aspect in the successful development of 
a bio-sector as it creates several key cumulative benefits. Commercialisation advertises a 
system's innovative capacities and supports, encouraging increased system-based 
entrepreneurial developments, and can also attract non-local skilled labour, supports, and 
actors into the system (Compete, 2005; OECD, 2004; Porter, 1998; Romanelli and 
Feldman, 2007; Graf and Krüger, 2011). 
 
A system's entrepreneurial infrastructure and supports, and the psychological and/or social 
characteristics of its actors determines its innovative and entrepreneurial propensity. Such 
elements are optimised where a multi-faceted long-term support system, comprised of a 
complex range of 'hard' and 'soft' resources and infrastructural supports, develops through 
public/private interactions so as to support entrepreneurial/innovative developments and 
experimentation throughout a bio-sector's value chain (Compete, 2005; Anderson et al., 
2004; Owen-Smith and Powell, 2007; Malecki, 1997; Lundberg and Andresen, 2012).  
 
A PBC's entrepreneurial resources should seek to engender conditions which facilitate and 
drive the transmission of knowledge from PREOs to downstream actors, and provide the 
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flexibility and support for new entrepreneurial developments through reducing entry 
barriers. This includes developing supports that seek to prevent 'lock-in' events forming as 
technological and/or organisational structures evolve through facilitating entrepreneurial 
experimentation, i.e. the development of new business models. Bio-firm developments are 
themselves idiosyncratic entrepreneurial experiments as their forms, structures and 
activities are unique in nature and are determined by the system in which they form. 
Additionally, such supports should seek to encourage the adoption of biotechnology-
related processes among existing and related industrial sectors in order to facilitate new 
industrial applications in areas that complement the 'core' activities of a bio-sector (Wolfe 
and Gertler, 2007; Anderson et al., 2004; Europe Innova, 2008; Engel and Del-Palacio, 
2011; Lee, 2012). 
 
'Hard' entrepreneurial sectoral supports are detailed in Table 3.4. 
 
The commercial orientation of PREO actors is crucial in determining technology transfers 
to commercial concerns, through influencing the commercial orientation of research 
programmes and the nature and character of knowledge spillovers with commercial actors. 
These issues influence a PBC's development trajectory, as where an established 
entrepreneurial culture is not present among PREO actors, the perceived/actual risks 
associated with commercial developments will deter academics from seeking such 
developments. Additionally, the quality and range of the commercial-orientated routines 
that actors acquire during their PREO careers will strongly influence the commercial 
orientation and development trajectories of bio-firm developments (Klepper, 2001; 
Kostiainen and Sotarauta, 2002; Casper, 2002; Owen-Smith and Powell, 2004; Ozman, 
2006; Lundberg and Andresen, 2012). 
 
To address such issues, a series of value chain and entrepreneurial coaching/mentoring 
services should be developed, optimally in partnership with private actors. Such services 
could also be developed through introducing skilled non-local actors into PREOs so as to 
seed the relevant skills, e.g. through temporary placement programmes. At a minimum, 
commercialisation skills should be introduced as pronounced elements in established 
under- and post-graduate education programmes. Further options include the development 
of technology transfer and entrepreneurial coaching lectures, seminars and/or tutorial 
initiatives, and management training programmes to seed even basic entrepreneurial skills 
among new and existing PREO researchers and administrators (Feldman, 1985; Cooke, 
2002; Anderson et al., 2004; Engel and Del-Palacio, 2011; Graf and Krüger, 2011).   
 96 
Table 3.4: 'Hard' entrepreneurial sectoral supports 
Structural bridges between PREOs and downstream actors should be engendered to optimise knowledge exchanges and spillover developments, as the 
interface between PREO/commercial actors is a central element in a sector's value chain. As such, legal issues restricting PREO actors from commercial 
activities or entering commercial alliances or information exchanges with downstream actors should be addressed. 
A suitable IP regime to facilitate commercial developments through reducing perceptions of risk and uncertainty. For PREO actors, the nature of a 
IP regime can engender further commercial developments by influencing potential financial returns from successful commercial developments 
(through, for example, licensing agreements), and can advance their careers, depending on the internal promotion structures of PREOs. For bio-
firms, the commercial potential of their IP is often one of a limited number of tangible assets they possess prior to the successful development of 
their products/processes. The strength and quality of a bio-firm's IP will significantly impact on potential alliances with downstream actors, i.e. VCs 
and TNCs. 
Infrastructural supports can be introduced to encourage commercial developments, including the provision of suitable laboratory space to allow the optimal 
development of commercially viable research, and business development services/incubators. Such developments could be introduced and implemented as 
complementary elements, yet should include technical supply services that allow actors access modern high-tech instrumentation and premises through 
temporary leasing arrangements and flexible leasing arrangements. 
Structural and resources issues among the PREO technology transfer offices (TTOs) must be addressed to improve commercial transfers. Anderson et al. 
(2004) suggest the introduction of specific commercialisation structures to proactively drive PREO developments, including the restructuring of TTOs as 
independent commercial entities whose survival depends on proactively scouting for commercially viable research, and the incubation of potential 
commercial developments through innovation funding to motivate PREO actors to exploit commercially viable IP they develop. 
As biotechnology is capital intensive, private investor actor weaknesses/absences must be addressed. Such issues can create an investment paradox, 
i.e. conservative modelled firms cannot attract the interest of risk adverse investors as their inability to develop significant commercial 
developments dissuades investors from forming alliances with them. Public VCs/investment funds are often developed to address such issues, yet 
typically underperform due to the limited entrepreneurial mindframe/culture among actors and the conservative nature of public investors. As such, 
a wide range of public investment funds should be developed, optimally with private actors. These include a public credit system (to prevent 
struggling, though viable firms from bankruptcy), loan guarantees, and dedicated seed funds. These funds require realistic, not target/goal focused 
approaches, as the quality of commercial developments is important for a bio-sector's development trajectory, not the quantity. Funding should be allocated 
through a competitive tendering process (where appropriate) to ensure a high quality level is maintained. Proactive efforts should also be made to 
attract private investor actors through the development of public/private investment partnerships, potentially from related high-tech sectors to facilitate 
spillover developments. 
After (Cooke, 2002; Anderson et al., 2004; Casper, 2002; Kaiser, 2002; Engel and Del-
Palacio, 2011; Wolfe and Gertler, 2007). 
 
Such programmes could be extended and tailored to downstream actors, in particular pre-
existing bio-firms, in order to facilitate the development of their management and business 
structures. New and existing bio-firms require the presence of varied marketing and sales 
competencies, and specialist legal actors for complex licensing and co-operation 
negotiations. These supports could be developed through involvement from a panel of 
local and non-local experts from industry and academic positions. Such developments are 
important, as (for example) the quality of a bio-firm's technical and general business 
expertise strongly influences their ability to attract the attention of potential VC 
collaborators (Giesecke, 2000; Anderson et al., 2004; Casper, 2002; Eisingerich et al, 
2012). 
 
3.4.2.3 Inter-actor networks 
Inter-actor networks are central elements to the international bio-sector's innovation 
process and its intricate tripartite value chain, as the generation and communication of 
tacit and codified knowledge occurs through reciprocal, interactive, and strategic up- 
and down-stream alliances between sectoral actors (Barley et al., 1992; Romanelli and 
Feldman, 2007; Erden and von Krogh, 2011).  
 
The presence of extensive inter-actor networks is crucial for developing a bio-cluster's 
internal logic, and engendering the conditions which facilitate a system's trigger event, 
including spillover developments. Networks facilitate the distribution and dissemination of 
different forms of filtered information, and impact on a system's development trajectory in 
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numerous ways, including mimetic isomorphism. Additionally, networks are central 
elements in the nature and character of the EIFR ecosystem and play a key role in a PBC's 
public/private dialogue process (Owen-Smith and Powell, 2004; Ozman, 2006; Ahrweiler 
et al., 2011; Lundberg and Andresen, 2012). 
 
Yet, network developments can be problematic in bio-sectors where there is a lack of 
understanding of the concept of inter-actor networks and their associated benefits, or 
where collective action issues undermine their development, e.g. where an innovation 
paradox exists (Forfás, 2004; Anderson et al., 2004; Lundberg and Andresen, 2012). 
 
As such, network developments in a bio-sector should be sought through a programme that 
coordinates a mixture of induced and organic processes which seed the concept of 
networks amongst a bio-sector's actors by allowing them gain a theoretical and practical 
understanding of the capabilities of networks to facilitate or constrain future actions and 
market opportunities. Such a programme should involve a broker programme/service that 
identifies potential networks and encourages their 'artificial' development, thus facilitating 
interaction and learning synergies, in combination with the provision of financial supports 
to encourage actors to embrace cooperation. Ultimately, such a programme seeks to induce 
naturally/organically occurring private actor network developments, yet as this requires the 
development of inter-actor trust and reciprocity, central elements of inter-actor networks, 
such efforts require a long-term approach (Ffowcs-Williams, 2000; Martin and Sunley, 
2001; Casper, 2002).  
 
3.4.2.4 Market information exchange resources 
Cluster specific initiatives should be formulated and implemented through a 
public/private actor dialogue process. Yet, in order to address existing information gaps 
which could undermine such a process, it is important that cross-system exchanges of 
information occur through information exchange resources. Such resources should 
include intermediary institutions and actors, including cross-cluster discussion forums, 
and intermediary technology transfer resources, so as to optimise a PBC's internal 
synergy by engendering mimetic isomorphism and spillover developments facilitated 
by, and based on inter-actor networks (Anderson et al, 2004; Wolfe and Gertler, 2007, 
Owen-Smith and Powell, 2007; Zhang and Haiyang, 2011; Lundberg and Andresen, 
2012).   
 
Cross-cluster discussion forums should draw from a bio-sector's support actors, i.e. its 
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regional development organisations, trade associations, and supply actors. Such forums 
can facilitate the development of business and competitive intelligence supports and 
services to optimise a PBC's development trajectory by collecting and disseminating 
filtered and up-to-date information, including early movement signals, on a system's 
skills, markets, business and clinical development trends (Porter, 1998; Romanelli and 
Feldman, 2007; Zhang and Haiyang, 2011; Engel and Del-Palacio, 2011).  
 
For PREOs, these supports and services can allow the optimal development of 
commercially oriented research programmes, and can feed into the formation of an 
entrepreneurial mindframe. For new and existing bio-firms, such supports and services 
can engender a variety of benefits including the formation of related business activities 
in a PBC system, allowing firms to optimise their research activities, e.g. scientific 
advisory boards can emerge where experts provide scientific trajectory/development 
advice, and facilitate the development of new business models. Such developments will 
influence the nature of, and their ability to enter into alliances with investors and/or 
downstream actors (Anderson et al, 2004; Casper, 2002; Lundberg and Andresen, 2012). 
 
Such services and supports require the presence of a certain level of activity in a bio-
sector's value chain, including the presence of service and supply actors, a solid cluster 
management structure, and the presence of an established inter-actor network structure 
in order to regulate actor behaviour, due to the importance of confidentiality and privacy 
of company and research data (Anderson et al., 2004; Lia and Gengb, 2012). 
 
By establishing discussion forums, a system 'brand' may form or be introduced, which 
can impact on a PBC's regional and international visibility. A brand can feed into the 
development of cross-cluster cooperation initiatives to stimulate the circulation of non-
local information in order to boost a system's development trajectory, and prevent 
systemic 'lock-in' developments (Romanelli and Feldman, 2007; Owen-Smith and 
Powell, 2007; Engel and Del-Palacio, 2011; Graf and Krüger, 2011). 
 
A common manner in which bio-sectors seek to boost their international presence is the 
development of a biotechnology directory, a promotion/marketing tool to foster 
networks and knowledge exchanges nationally and internationally. Optimally, a 
directory should be established and run by a neutral organisation, e.g. a public agency, 
to address confidentiality issues. Such an organisation should be charged with 
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developing a detailed database to inform the directory, as well to establish international 
conferences (Anderson et al., 2004; Wolfe and Gertler, 2007). 
 
The establishment of a directory could link in with the creation of skill development 
programmes to address a bio-sector's existing skills and competences shortages, as well 
as international placement and recruitment programmes. Furthermore, a directory could 
link in with the establishment of consultation/advice boards that identify common issues 
among different systems, cross-pollinate skills so as to stimulate a system's 
entrepreneurial and innovative developments. Such developments would encourage 
economic diversification to prevent systemic 'lock-in', by addressing limitations in the 
diversity of a domestic knowledge base (France BIOTECH, 2001; Romanelli and 
Feldman, 2007; Owen-Smith and Powell, 2007; Engel and Del-Palacio, 2011; Graf and 
Krüger, 2011). 
 
Cluster specific initiatives should proactively seek the establishment of technology transfer 
intermediary institutions, i.e. science parks and incubators, to create geographically 
concentrated information exchange nodes between PREOs and downstream actors. Such 
institutions facilitate key value chain network and spillover developments through 
supporting the generation of market-focused IP and the emergence of PREO-based 
entrepreneurial developments. As such, they are key elements in the development 
trajectory of a PBC system (Wolfe and Gertler, 2007, Porter, 1998; Casper, 2002). 
 
While these intermediary actor types typically require public investments due to their 
high costs, public/private actor involvement is required in their design as, aside from the 
provision of office and laboratory space, equipment and materials, they must focus on 
providing a complex range of added value technological services, e.g. project feasibility 
studies, market research, business management, and legal services. The nature of their 
support infrastructures are crucial, i.e. they should be temporary in nature to support, 
not prop up commercial developments, and should evolve so as to reflect changing 
sectoral and firm development requirements (Anderson et al., 2004; Carlson, 2007; 
Lundberg and Andresen, 2012).  
 
Bio-incubators should be created as commercial entities whose survival depends on 
successful alliances and commercial developments so as to engender a pronounced 
commercial emphasis/orientation to their activities. In some cases, more extreme 
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incubator structures are created e.g. in the Munich bio-cluster, each bio-firm 
development is allocated a unique 'commercialising company', which is a specially 
tailored commercial entity that seeks to optimise a specific bio-firm's commercial 
development (Daskalakis and Kauffeld-Monz, 2007; Kogut, 1988).  
 
Science parks can be either themed or general in nature, yet they are centres of 
collaborative commercial research which bring together government, PREO and 
commercial actors so as to engender collaborative innovative activities and to facilitate 
entrepreneurial spin-off developments in cutting edge technologies, such as 
biotechnology. As such, they facilitate crucial transfers of PREO/commercial actor 
knowledge and information in the context of extensive, tailored research and 
commercialisation infrastructures, resources and skills (Anderson et al., 2004; Malecki, 
1997). 
 
While intermediary actors are associated with new commercial developments, several 
PBCs have introduced intermediary actors that also focus on facilitating and supporting 
the commercial exploitation of PREO-based IP in existing bio-firms. Existing bio-firms 
are targeted to address existing innovation paradoxes, typically through the provision of 
funding to issues that restrict their ability to develop more advanced innovative 
activities (Anderson et al, 2004).  
 
Intermediary actors feed into the skills development aspects of knowledge and 
entrepreneurial infrastructure, resources and skills. By developing common 
infrastructures, inter-actor PREO-based information exchanges can occur, allowing 
researchers from other areas to interact. Additionally, due to the close proximity to 
commercial actors, 'dual ladder' career paths can be developed to allow academics 
and/or commercial actors move between the different actors, i.e. flexible/permeable 
industry-academia interactions, to facilitate tacit knowledge exchanges and spillover 
developments. Furthermore, the development of incubators and science parks can feed 
into a PBC's branding, and assist in attracting in non-local skills, competences and 
resources to boost a system's development trajectory (Anderson et al., 2004; Malecki, 
1997; Graf and Krüger, 2011; Eisingerich et al, 2012). 
 
3.4.2.5 Actor and institutional density, and skill, competence and resource depth 
A PBC's development trajectory is optimised where a structured self-reinforcing process 
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of growth and development is facilitated and driven by the formation of a diverse range 
of market and non-market actors and institutions and associated competences and 
resources throughout the bio-sector's value chain.  
 
This depth and density is important in setting the overall context or framework in which 
cluster development takes place and forms, due to the other EIFRs engendering an 
adaptive and responsive ecosystem that facilitates and drives entrepreneurial and 
innovative developments and interactive synergies (Porter, 1998; Maskell and Kebir, 
2005; Wolfe and Gertler, 2007; Casper, 2002; Howells and Edler, 2011). 
 
Where such density and depth forms, due to the range of skills and resources and the level 
of entrepreneurial and innovative activities and opportunities present in a system, the local 
ecosystem can facilitate second generation bio-firm developments, while also attracting in 
non-local sources of labour, knowledge, resources and finance, particularly from non-
local private VCs and TNCs. Such developments facilitate significant positive systemic 
feedback inputs, including spillover developments (Malecki, 1997; Wolfe and Gertler, 
2007; Engel and Del-Palacio, 2011; Ahrweiler et al., 2011). 
 
Optimally, systemic depth and density should form organically. However, cluster 
specific policies are unlikely to facilitate such developments through initiatives alone, 
as evident in the Munich bio-cluster, yet efforts can be made to engender coordinated 
networks of interconnected actors, and facilitate systemic externalities through an 
'anchor' actor strategy. There are three anchor actor strategies, i.e. a system organised 
around the organic development of a 'star' actor, a system organised around the facilities 
of TNCs, and an interdependent model where a PBC and a TNC play interdependent 
roles (Anderson et al., 2004; Howells and Edler, 2011).  
 
Cluster specific initiatives can seek the development of a successful ‘role model’ bio-firm, 
i.e. a local bio-firm that successfully develops a commercialised biotechnology-derived 
product, to demonstrate the commercial potential and depth of a system's support 
structures to internal and external actors. Such a bio-firm can stimulate “...entrepreneurship 
among scientists in research centres...[encouraging commercial] exploitations of research 
results” (Chiaroni and Chiesa, 2006: 3) to develop commercial activities, thus further 
enhancing the entrepreneurial culture of a system (Prevezer and Swann, 1996; Scott, 2007; 
Kolympirisa et al., 2011).  
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In relation to the second strategy, despite TNCs being central elements in a bio-sector's 
value chain, the PBC case studies demonstrate that no such strategy, internationally, has 
been adopted. TNCs are typically viewed as being an element, not the central element, 
of cluster specific strategies, in part due to the limited influence governments have over 
them, yet also as TNCs undermine a system's development trajectory due to their size 
and scale where they are a system's dominant actor, e.g. the New York City PBC 
(Anderson et al., 2004; Baik, 1997; Doherty, 2001; Gilding, 2008; Graf and Krüger, 
2011; Lee, 2012).  
 
Essentially, the embeddedness of TNCs in a PBC's system is crucial in determining their 
impact on the system's development trajectory. As such, where TNC-related 
developments are sought, initiatives seek to embed organic systemic developments in 
parallel with/to encourage more complex TNC activities, i.e. an interdependent model. 
To attract significant TNC operations into a system, a PBC must have the combined 
presence of key PREOs, a global leadership in focused research areas with recognised 
health-care application(s), and also have effectively managed bio-firms with relevant 
leading-edge technologies and IP suitable for R&D investment, i.e. a sustained and 
innovative bio-sector needs to be present. Optimally, where a TNC enters a system, it 
will achieve a strategic alliance with a comparably sized innovating partner, i.e. an 
emerging/emerged bio-cluster system (Porter, 1998; Brown, 2000; Biggerio, 2002; 
Ahrweiler et al., 2011; Lee, 2012). 
 
3.5 CONCLUSION 
The international bio-sector is an example of a complex network-based innovative high-
tech sector. The value chain in leading bio-sectors is characterised by tripartite network 
alliances between PREOs, bio-firms (the value chain linchpin) and TNCs. The 
knowledge base from which biotechnology innovations draw upon is embedded in 
complex formal and informal networks between various actor types, including PREO, 
public and industry actors. The downstream end of the value chain is comprised of two 
inter-related, parallel vertical and horizontal aspects that involve different types of bio-
firms, i.e. drug discovery and service/platform technology firms, and TNCs.  
 
This complex network structure has been supported and facilitated by the development 
of extensive regional specific public and private sectoral supports. These include 
regional specific tiers of specialist supply firms, sub national biotechnology centres, and 
trade associations that are attuned to the demands of the region's actors. 
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Geographic variations in regional endowments of bio-firms, institutions, and social capital 
means there exist significant differences in how the bio-sector's innovation process is 
replicated internationally. Where dense agglomerations of actors, competences and 
resources form, bio-clusters can emerge, i.e. a mode of organisation of a productive system 
that contributes to the level of innovation and competitiveness of its constituent actors 
(Engel and Del-Palacio, 2011; Huggins et al., 2012).  
 
The emergence of bio-clusters, and the benefits associated with them have encouraged 
Governments internationally to seek to engender such developments where they have not 
emerged. However, bio-cluster systems are born and develop on the basis of case specific 
combinations of capabilities, incentives, and opportunities. The language used to describe 
the factors which determine bio-cluster development and emergence is vague/ambiguous, 
e.g. pre-conditions, path dependence/development trajectory, feedback and spillovers; 
meaning there is very little that is tangible, or strictly definable for policy measurements to 
be developed upon. Generalisations drawn from case studies are inadvisable due to the 
case specific nature of bio-cluster systems, however case studies play a particular role in 
identifying key parameters and relationships, and place policy 
recommendations/suggestions in their proper theoretical background.  
 
Bio-cluster specific policies should seek to develop the relevant pre-conditions and 
'seedings' that can ultimately facilitate and encourage a bio-cluster's emergence. Policy 
initiatives must include a strong science base, the foundation and the starting point of the 
bio-sector’s value chain, and the development of an entrepreneurial culture, a key 
requirement in the emergence of a critical mass of entrepreneurial activity. The 
development of inter-actor networks is vital due to the networked value chain, while the 
strength of a country’s bio-firm base and support 'eco system' are all key elements in a bio-
sector’s internal dynamics. 
 
As such, policy initiatives seeking to engender bio-cluster developments require a 
coordinated, supportive long-term systems-based approach, that is tailored to the 
evolving needs and circumstances (including chance/serendipitous events) of the bio-
sector in question through a public/private dialogue process, so as to create a suitable 
policy environment that facilitates the development of the various conditions that lead 
to bio-cluster emergence and development. Essentially, an evolutionary, systems-based 
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approach towards policy formulation and implementation is required. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 105 
CHAPTER 4: 
METHODOLOGY 
 
4.1 INTRODUCTION 
This chapter describes the methodology employed in compiling a detailed profile of the 
Irish biotechnology sector (bio-sector), and in identifying and analysing the network 
arrangements that exist in the indigenous bio-sector. The chapter is divided into four 
sections. The first section sets out the project’s research question. The second section 
details the methodology used in compiling a profile of the bio-sector’s actors. The third 
section describes the design and implementation of a questionnaire designed to obtain 
specific information on the networks that exist between the biotechnology firms (bio-
firms) and the other actors in the indigenous bio-sector. The final section outlines the 
approach taken in conducting interviews with key sectoral actors informed by the 
process of compiling the sectoral profile and through the completed questionnaires. 
 
4.2 THE RESEARCH QUESTION 
The empirical research in this thesis was guided by the following general research 
question:  
 
What networking arrangements exist among the actors in the Irish bio-sector, and what 
inter-actor networking strengths and weaknesses exist in the bio-sector that impact on 
its on-going development? 
 
Answering this question required the compilation of a detailed profile of the indigenous 
bio-sector, under four general key headings: 
 
 the Irish bio-sector's actors, 
 the bio-sector's inter-actor networks and interactions, 
 the functions, performances, and weaknesses of inter-actor sectoral networks 
and clusters in Ireland in relation to their international counterparts, and 
 existing Irish Government policies relating to the indigenous bio-sector. 
 
The manner in which this profile was compiled is discussed in the following sections. 
 
4.3 METHODOLOGY EMPLOYED IN CONSTRUCTING THE SECTORAL 
PROFILE  
4.3.1 Analysis of secondary documentation 
 
“There is a lack of data on the existence and extent of industry-industry networks in 
Ireland” (Forfás, 2004: 43). 
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The profile of the Irish bio-sector's actors was constructed using an augmented and 
updated version of the bio-sector actor typologies developed by Barley et al (1992), as 
presented in chapter 3 (Barley et al., 1992; Romanelli and Feldman, 2007). 
 
Literature relating to the indigenous bio-sector and its activities is in short supply. In 
terms of compiling a general profile of the bio-sector, InterTradeIreland’s Mapping the 
Bio-Island (2003) report was invaluable. This report detailed the activities, locations, 
and the scale of operations of bio-firms on the island of Ireland.  
 
Additional information on the bio-sector’s composition was derived from the 
BiotechnologyIreland.com website in 2004 and 2005. This website proved invaluable 
with respect to all aspects of the profile as it is the central hub of on-line information 
regarding biotechnology-related activity in Ireland, and includes a database of registered 
individuals and firms in all aspects/areas of Irish biotechnology and biotechnology-
related activity. The site is hosted by Enterprise Ireland (EI), and is home to Enterprise 
Ireland’s Biotechnology Directorate (EIBD), EI’s life science and food 
commercialisation group.  
 
The accuracy of the information contained in the InterTradeIreland report and the 
Biotechnology Ireland website was rigorously cross-checked against information from 
the websites of the individual bio-firms using the Google search engine. This procedure 
identified several inaccuracies in both of the main sources, and identified a small 
number of bio-firms not listed in either source. It was established that a small number of 
bio-firms had no web presence, or were not mentioned in material obtained from 
government agency literature/web sites. Contact with a senior academic in a National 
University of Ireland, Maynooth's (NUIM) Department of Biology with extensive 
national and international sectoral experience clarified the activities of these bio-firms. 
This academic’s advice was sought for clarification of subsequent ambiguities and 
inconsistencies that were encountered during this stage of the research. 
 
The next phase in creating the sectoral profile involved compiling an inventory of the 
biotechnology/biotechnology-related activities of Irish Public Research and Education 
Organisations (PREOs). Using the Google search engine, a detailed review of the 
activities of the relevant academic departments and their key researchers, along with 
their research interests, was carried out. In addition, an inventory of the relevant 
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biotechnology/biotechnology-related courses provided by these institutions was also 
compiled.  
 
This stage of the research also involved detailing the activities of the various research 
institutes (RIs) affiliated with the country’s academic departments, as well as other 
privately and publicly funded RIs. The bulk of this information came from EIBD, the 
BiotechnologyIreland website, and the review of the activities of University 
Departments. A report by the US-based New Economic Strategies group, The Global 
Reach of Biotechnology (2003), provided additional information on several of these RIs.  
 
Further information on a small number of RIs was obtained from a web search using 
Google. Due to the complex nature of the biotechnology/biotechnology-related 
activities in which these departments and RIs are engaged, several areas of ambiguity 
were again addressed through discussions with the senior academic. This stage of the 
profile also involved an investigation of the biotechnology-related activities of the main 
Irish hospitals, which was completed using web-based information.  
 
As part of the review of bio-firm- and university-based activities, details on the 
activities of the various Government departments and agencies which oversee 
biotechnology/biotechnology-related sectoral activity were also assembled. Literature 
from relevant Government departments and web-based sources, such as agency 
websites, and the aforementioned New Economic Strategies report were used to 
complete this section of the research. 
 
The next stage of the research involved identifying the various investors in the bio-
sector. Literature from EI and the IDA Ireland was used to identify biotechnology-
related investors, such as venture capital (VC) and seed capital funds, while a major 
web-based search uncovered other potential investors, mainly investment funds created 
by the main banking/financial institutions in the country. A series of discussions with a 
senior academic in the NUIM's Department of Economics with significant experience in 
international business identified further investor related areas, and clarified ambiguities 
that had developed. 
 
Following the completion of this stage of the review, a profile of the biotechnology-
related operations of diversified Transnational Corporations (TNCs) in Ireland, typically 
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involving pharmaceutical or biopharmaceutical activities, was constructed using 
information from the InterTradeIreland report, literature from IDA Ireland and EI, and 
relevant company websites. 
 
The final stage of the profile involved the compilation of an inventory of suppliers of 
goods and services to the indigenous bio-sector. This was compiled using the 
InterTradeIreland report, the Biotechnology Ireland website, and also through a rigorous 
search of web-based material derived from a detailed review of these sources.  
 
4.3.2 Questionnaire of bio-firms 
In the course of compiling the general profile of the indigenous bio-sector, it became 
apparent that the bio-sector loosely imitated the structure found in the US bio-sector, as 
detailed in chapter 3. However, while similar networks of interactions and 
collaborations can be identified, their size and scale are much smaller. However, the 
degree of complexity of the interactions and collaborations in the bio-sector, even at this 
early stage of the profile, was apparent. 
 
Originally, it was intended to flesh out the structure of the bio-sector via structured 
interviews with key personnel from the bio-sector’s various segments. However, 
following an analysis of the limited secondary material collected during the course of 
the research detailed above, it was felt that the complexity of networks in the bio-sector 
necessitated a more comprehensive information search.  
 
Accordingly, it was decided to conduct an initial postal questionnaire of all sectoral bio-
firms. The questionnaire aimed to investigate the exact details of the key formal 
networking arrangements that had developed among these bio-firms, and would then be 
followed by interviews with key individuals in these bio-firms that were identified 
through the review of secondary information sources and the questionnaire findings. 
 
A postal questionnaire, created using the procedure set out in Dillman (2000) as a guide, 
was issued to the 40 bio-firms identified during the sectoral review (the questionnaire, 
and a detailed description of the purpose of the questions, is presented in Appendix A). 
The questionnaire sought to elicit basic information about the bio-firms and to identify, 
in a systematic way, the formal and informal networks between the bio-firms and other 
sectoral actors. Specific bio-firm information was sought through the use of structured 
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questions, while respondents were also given the opportunity to voice their opinions on 
specific areas/topics and to elaborate their rationale/explanations where necessary. This 
information would also facilitate a more focused and informed subsequent interview 
process. 
 
The design of the questionnaire proved to be rather time-consuming, due mainly to 
difficulties in properly structuring and wording sections covering the types of 
collaborations/alliances formed in the bio-sector. These sections required specific 
information to be included in the questions (for example, a definition of what is an 
International Corporation) to remove any possible ambiguity so as to allow the 
respondents to accurately answer the questions.  
 
The draft questionnaire, when completed, was passed to the senior Department of 
Biology academic who assisted in the completion of the sectoral overview. As this 
individual was removed from direct involvement in the research project, a fresh 
perspective was brought to the questionnaire. On this individual’s advice, minor 
changes were incorporated into the questionnaire. 
 
In order to test the robustness of the questionnaire, a pilot version was issued to a select 
grouping of bio-firms identified in the sectoral review. Following a detailed analysis of 
their replies, no further changes to the questionnaire were deemed necessary.  
 
4.3.2.1 Questionnaire administration 
The next stage of the questionnaire process involved sending an introductory 'pre-note' 
to the remaining target bio-firms that were not part of the pilot questionnaire. This pre-
note, as specified by Dillman (2000), informed the recipients of the aims of the 
questionnaire, and asked for their assistance in completing it. A week later, the 
questionnaire and a detailed cover note, explaining in summarised detail the aim and 
objectives of both the questionnaire and the entire research project, were posted with an 
accompanying self-addressed envelope to the target firms (the questionnaire letters and 
correspondents with the target firms are presented in Appendix B).  
 
Following a two-week period, a lower number of responses than expected were 
received. 'Thank you' notes were issued to those bio-firms which had responded, and 
reminder notes issued to those who had not yet replied. The reminder notes emphasised 
the importance of the research and encouraged the respondents to complete and return 
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the questionnaire. The response to this stage of the questionnaire was very low.  
 
After a short period of time, replacement questionnaires were issued to the bio-firms 
which had not replied. A small number of bio-firms requested replacement 
questionnaires following the issuing of the reminder note. Once again the response rate 
proved lower than anticipated. In a small number of cases, contact details provided on 
bio-firm web sites proved to be out of date. Accordingly, new questionnaires were 
issued to these bio-firms once their details were updated.  
 
As stated, the questionnaires were issued to 40 bio-firms, of which 16 replied. It became 
apparent that, despite the successful results of the pilot questionnaire, a small amount of 
ambiguity existed in specific questions. For example, in Question Four, respondents 
were asked for the proportion of scientists/technologists employed, in several cases a 
figure was provided with no indication if this was the number of scientists/technologists 
in the bio-firm, or a percentage of the total employed by the bio-firm. However, issues 
of ambiguity were limited as not all of the respondents fully completed the 
questionnaire, which meant that an overall comparison between the answers provided 
for several questions was not possible. These issues were ultimately addressed through 
the in-depth interviews with the bio-firms. 
 
4.3.2.3 Questionnaire analysis 
As stated, 16 bio-firms replied to the questionnaire from the 40 which were issued. This 
was a much lower response level then anticipated, yet the completed questionnaires 
proved very useful in backing up the findings of the sectoral profile and in tentatively 
identifying sectoral trends.  
 
The completed questionnaire returns were analysed in two stages. Firstly, sequential 
lists of the individual answers as they appeared in the questionnaire were compiled in 
order to identify general patterns among the respondents. This analysis confirmed 
several findings of the sectoral profile, e.g. that the bio-firms were mainly small in sized 
(the overwhelming majority of the respondents employed less then 20 people), and that 
despite the majority of respondents employing very large number of scientists, very 
limited product developments had occurred. 
 
Secondly, a more focused analysis was conducted where the respondents were grouped 
according to their core activities, as identified in the sectoral overview, in order to 
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identify inter-sectoral trends or patterns (Table 4.1 details the numbers of respondents 
by their activities). This analysis also confirmed findings of the sectoral profile, e.g. 
formal linkages between the bio-firms and other actors in the bio-sector's value chain 
were very limited, and that the main area of sectoral activity was largely confined to 
diagnostic-/platform-related bio-firms. The questionnaires also proved very useful in 
identifying target bio-firms for the interview stage of the process.  
 
Table 4.1: Questionnaire respondents activity focus 
Pharma-Biologicals 2 
Pharma-Services 4 
Diagnostic 6 
Agri-food  3 
Bio-Environmental 1 
 
4.3.3 In-depth interviews  
4.3.3.1 Organisation of the interview process  
Using the completed sectoral profile and the completed questionnaire returns, a list of 
target actors for interview was compiled. Initially, this interview process was to focus 
on three different target groups:  
 
 key actors from the different PREOs, i.e. universities, RIs, hospital-based RIs, 
and the Institutes of Technology, 
 bio-firms, TNCs, and sectoral investors (e.g. VC firms), and 
 government agencies and the remaining sectoral actors. 
 
The rationale behind this segmentation of the research process was that it would allow 
for a more detailed analysis of the information generated about the specific target 
groups, which would then inform the formulation of the questions for the subsequent 
interview segments.  
 
Requests for interviews were emailed to the targeted actors. This email (presented in 
Appendix B) contained a brief summary of the aims of the entire project, and provided a 
brief description of the topics that would be discussed in the interview.  
 
The first target group involved key actors from Irish PREOs. As PREO-based research 
and PREO/bio-firm relations are the bedrock on which the biotechnology industry is 
founded, as detailed in chapter 3, it was important to document the experiences of the 
PREO actors in conducting research. Additionally, it was important to document their 
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experiences in forming linkages with bio-firms in Ireland, and (where relevant) abroad, 
in order to fully understand the initial stages of the biotechnology innovation process in 
Ireland.  
 
The bio-firm actors were predominantly selected following an analysis of the 
questionnaire returns, and also through a review of company literature and websites. 
Some additional target interviewees were identified during the course of the first set of 
interviews with PREO personnel. The target TNC, and speculative investor interviewees 
were also identified in the process of compiling the sectoral profile, and through the first 
set of interviews. 
 
The second part of the interview process proved to be very difficult to complete. 
Initially this stage was expected to be completed within a couple of months, but 
ultimately took over six months to complete due to a very low response rate among 
targeted actors, particularly among TNCs and speculative investors. Many efforts were 
made to contact TNC operations in Ireland, yet the response rate was extremely low, in 
part due to their branch plant nature. Several approaches had to be made to contact key 
TNCs, in particular Wyeth and Genzyme, before interview requests were granted. 
Following several unsuccessful attempts to contact speculative actors, the senior 
academic in the Department of Economics facilitated several contacts with investor 
actors.  
 
The third stage of the interview process with government agency actors aimed to 
develop an understanding of the bio-sector as viewed by these actors. Initially, this 
section was planned to be initiated only after the previous interview stage had been 
completed, so as to compare the experiences of the other sectoral actors to the aims and 
objectives of the state agencies, yet due to the delays caused by the poor response rates 
in the second stage of the interview process, the phased interview approach was 
ultimately abandoned. However, the initial decision to delay this final stage of the 
process proved to be successful, as clear differences were identified between the intent 
and opinions of the government agencies and other sector commentators.  
 
The remaining actor types identified in the course of the research were also included in 
this phase. As the number of suppliers of goods and services to the indigenous bio-
sector are limited, this part of the process proved relatively straightforward to complete.  
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4.3.3.2 The interview approach 
The interviews were conducted through a mixture of a structured open-ended approach 
and an interview guide approach, where specific topics were examined in each 
interview section. This mixture allowed for the recording of information on a fixed set 
of topics, thus facilitating comparison between interview returns, while also allowing 
for variations in actor responses/experiences, depending on case-specific circumstance 
and idiosyncratic information (Kitchin and Tate, 2000).  
 
The interview process sought to explore the informal networking arrangements of the 
various sectoral actors in the indigenous bio-sector, and also sought to seek further 
information on, and the clarification of, issues identified during the sectoral review and 
the firm questionnaire analysis. 
 
Those interviewed were also asked to identify key actors they felt would be able to 
expand/elaborate on certain comments they made. Due to the small size of the bio-
sector, many actors (particularly Government agency actors) had established significant 
sectoral contacts, or had experiences of working in different areas of the bio-sector. This 
'snow ball' process identified additional individuals and actors which/who had not been 
identified during the completion of the sectoral review. Several of the topics in question 
seemed to have a tenuous relationship to the purpose of the research project, yet when 
put in the context of the information gained during interviews, the links involved 
became more pronounced. This part of the interview process was vital in gaining extra 
insight into the functioning of the bio-sector.  
 
The interview stage of the research also drew attention to a range of additional literature 
and documentation relevant to the bio-sector which had not been accessed during the 
previous stages of the project. These related in particular to sectoral reports, funding 
sources, and programmes prepared and sponsored by the European Union and other 
Europe-wide bodies. This literature fed into, and facilitated a more informed interview 
process, and enabled a more accurate and detailed appraisal process, allowing the 
material gained from the interviews to be placed in its proper Irish and European 
contexts. 
 
4.3.3.3 Problems encountered 
The main issue experienced in this stage of the research was the sometimes quite 
significant time lag between a request for an interview being made and the prospective 
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interviewee agreeing to the request. In certain parts of the bio-sector, in particular in 
relation to TNCs and private speculative investors, very low response rates were 
received. These response rates were addressed somewhat by altering the wording of the 
interview request email sent to the selected individuals, i.e. by removing any mention of 
the degree being pursued.  
 
In a small minority of cases, individuals did not fully understand the geographic 
approach to the overall project, despite it having being detailed in the email request. 
This misunderstanding seems to have been due to a preconceived notion that only a 
student from a business/economics faculty would be interested in the subject area. In 
situations where this arose, a certain amount of time was spent addressing this 
misunderstanding/misconception.  
 
In relation to the request for the interviewees to identify prospective additional 
interview candidates, in most cases individuals were willing to suggest several 
individuals or provided contact details of future potential interviewees, yet in a limited 
number of cases this request was met with significant resistance, possibly due to 
confidentiality issues. However, as mentioned, due to the small size of the bio-sector, 
many actors (particularly Government agency actors) had established significant 
contacts throughout the bio-sector, which proved useful in addressing knowledge gaps 
in certain areas of sectoral activity. 
 
4.3.3.4 Interview analysis 
A total of 54 interviews were conducted with sectoral actors (a detailed break down of 
the respondent numbers and their activities is presented in Table 4.2). After the 
completion of each interview, a full transcription was completed. A detailed analysis of 
each transcript was then conducted using the NUD-IST (Non-numerical Unstructured 
Data Indexing Searching and Theorising) programme to compile a representative 
picture of the experiences of the individual actor, and to identify issues to be discussed 
further in subsequent interviews.  
 
This material, framed within the theoretical framework presented in chapters 2 and 3 
and the wide reaching literature review (as detailed above), was rigorously studied so as 
to generate the findings and policy recommendations presented in the remainder of the 
study. Following the completion of each interview stage, the transcriptions were divided 
and grouped into sequential lists of the general topics discussed during the different 
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stages. This identified general trends and patterns amongst the sectoral actors. 
Subsequently the transcripts were divided into groupings determined by areas of 
common sectoral activity, where such distinctions were applicable, in order to identify 
subsectoral patterns. After the completion of the entire interview stage of the research, a 
major review of the interview transcripts was completed so as to tease out issues 
relating to potential policy suggestions.  
 
Table 4.2: Interview respondents and activities  
PREO Administrators (including TTO and ILO actors) 7 
Biotechnology/biotechnology-related Department actors 9 
Research Institute actors 9 
Research Hospital actors 2 
Institute of Technology actors 1 
Pre-initiative bio-firms 8 
Post-initiative bio-firms 5 
TNC actors 3 
Investor/VC actors 3 
Government agency actors 3 
Trade Association actors 2 
Supply actors 2 
 
4.4 SUMMARY ACCOUNT OF INFORMATION FROM THE DIFFERENT 
RESEARCH STAGES 
This chapter has described the methodology involved in compiling a profile of the 
indigenous bio-sector and of its main actors, through using an updated version of the 
template of actor typologies developed by Barley et al (1992).  
 
The first stage of the research involved a review of secondary literature/documentation 
and an internet search with a view to detailing the actor typologies evident in the 
indigenous bio-sector. From this stage of the research, knowledge gaps in the full range 
of activities in the bio-sector were predominantly addressed. The review detailed 
patterns of sectoral activity and detailed the extent to which the various sectoral actors 
are interlinked through formal alliances.  
 
The second stage of the research involved a postal questionnaire of sectoral bio-firms 
that sought to detail the formal networking arrangements between the bio-firms and the 
actors in the bio-sector's value chain. There were 16 respondents from a total of 40 
posted questionnaires. The questionnaire returns demonstrated that the bio-firms were 
mainly small in size, engaged in limited activities mainly in diagnostic-/platform-related 
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areas, and that they had established very limited networks with actors in the bio-sector's 
value chain.  
 
The third and final stage of the research involved detailed structured interviews with 
key sectoral actors, the aim of which was to detail the opinions and experiences of the 
various actors on/of the bio-sector's current networking structure and its on-going 
development. This stage of the research investigated the informal and formal 
collaborations among the sector actors, and allowed the patterns of sectoral activity of 
bio-firms, and issues concerning these bio-firms, to be identified in detail.  
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CHAPTER 5: 
A REVIEW OF IRELAND'S ECONOMIC DEVELOPMENT SINCE 
1922 AND OF THE EVOLUTION OF THE IRISH GOVERNMENT'S 
BIOTECHNOLOGY-RELATED POLICIES 
 
5.1 INTRODUCTION 
This chapter places the following analyses of the Irish biotechnology sector (bio-sector) 
in their proper context in relation to Ireland's historical economic development and the 
development of policies related to the bio-sector. The manner in which policies relating 
to the development of the Irish economy were/are formulated and implemented 
depended/depends on the political environment of the time.  
 
This chapter is divided into three sections. The first section presents a general review of 
Ireland’s economic development from independence to the present day, and also of the 
general industrial policy development trends during the same period. This section 
highlights how the indigenous economy developed from being a relatively poor, 
agriculture-based economy towards becoming a highly modern, technology-based 
economy by the beginning of this century. Section two details the development polices 
relating to the indigenous bio-sector, particularly policy measures promoting indigenous 
Science, Technology & Innovation (STI) activities since the late 1950s, specific policies 
relating to the indigenous bio-sector, and government measures to promote the 
development of indigenous networks and clusters. The final section discusses how 
current industrial and STI policies, and the Governments approach towards developing 
networks and clusters, impacts on current policies in relation to the indigenous bio-
sector (a timeline of key events and publications relating to the development of public 
industrial and science, technology and innovation policies is presented in Figure 5.1).  
 
5.2 IRELAND’S ECONOMIC DEVELOPMENT SINCE THE 1920s 
The development of the Irish economy has occurred over a series of stages determined 
by the political and general economic landscape of the time. This section traces four 
broad stages in Ireland’s economic development: independence and the protectionist era 
(1922-1957), the open market transformation of the economy (1958-1992), the 'Celtic 
Tiger' economy (circa 1992-2007), and the post-Celtic Tiger era (post 2007). 
 
5.2.1 Independence and the Protectionist era 
In 1922, Ireland achieved political independence from the United Kingdom (UK). The 
island of Ireland was split into the twenty six counties that subsequently formed the 
Republic of Ireland, henceforth 'Ireland', and the six counties that make up Northern 
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Ireland.  
 
 
 
 
 
 
The country's economy at the time was predominantly centred on agriculture. The 1926 
Census of Population showed that 54% of the country's labour force was engaged in 
agricultural activities, while its industrial base was weak: the country's manufacturing 
sector comprised 10% of the labour force. The first Irish government, led by William 
Cosgrave from 1922 to 1932, overwhelmingly focused on the country's agricultural 
sector, and placed little emphasis on developing the country's industrial base 
Figure 5.1: Timeline of key events and publications relating to the development of public 
industrial and science, technology and innovation policies. 
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(Breathnach and Walsh, 1994; Ó Gráda, 1997).  
 
Underlying weaknesses in the country's industrial base could be traced to the 1800 Act 
of Union between the Kingdoms of Great Britain and Ireland. This effectively created a 
free trade zone by removing all trade barriers between the two countries. Aside from the 
Belfast region in the North East of the island, due to its successful linen industry, this 
caused de-industrialisation in the remainder of the country as it was poorly placed to 
compete with the highly mechanised industries that had developed in Great Britain 
during and after the Industrial Revolution (Girvin, 1983; Ó Gráda, 1997).  
 
Essentially, the island was an agricultural centred appendage to the UK economy. This 
situation remained after political independence, as Ireland remained part of the British 
Commonwealth until the late 1940s, i.e. the country remained in a free trade area and 
remained incapable of competing with British industry. The Cosgrave Government's 
conservative industrial policies advocated free trade, and few economic tariffs were 
introduced during its rule. Its policy focus on agriculture had very minimal effects on 
the economy's performance, while the country experienced high emigration rates 
(Breathnach and Walsh, 1994; Ó Gráda, 1997; Kennedy et al, 1994). 
 
In 1932, political party Fianna Fáil took power, remaining in power until 1948, thus 
strongly shaping Ireland’s economic direction in this period. Its policy focus was on 
achieving self-sufficiency in agriculture and industry through protectionist measures 
and import substitution. This was partly motivated by a balance of trade issue caused by 
the Great Depression, during which international demand for Irish agriculture products 
had declined significantly, yet it principally occurred due to a trade dispute with the UK 
which was subsequently termed 'The Anglo-Irish Trade War' (1932-1938) (Girvin, 1983; 
Government of Ireland, 2010).  
 
The Trade War began as the new Government refused to continue paying land annuities 
to the UK Government, i.e. repayments on government loans granted to Irish tenant 
farmers to purchase lands from their former landlords under the Irish Land Acts (1922) 
as part of the Anglo-Irish Treaty, also in 1922. The UK Government imposed a 20% 
tariff on Irish agricultural imports to the UK, which constituted 90% of all Irish exports, 
and the Irish Government imposed similar tariffs on UK imports into Ireland (Girvin, 
1983; Ó Gráda, 1997; Doyle, 1998). 
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This essentially led to the UK market collapsing for Irish farmers, which dramatically 
impacted on the agriculture-based economy. In an effort to minimise the Trade War's 
impact on the industrial sector, the government introduced an import-substitution policy 
to protect domestic firms through tariffs on imported products, and by encouraging the 
population to only buy Irish produced goods. To prevent foreign firms establishing Irish 
subsidiaries to avoid these tariffs, the Control of Manufacturers Act (1932) was 
introduced to ensure that the majority ownership of Irish companies was limited to Irish 
citizens. This resulted in 'Capital flight', as potential investors, and British owned firms 
left Ireland (Girvin, 1983; Ó Gráda, 1997; Doyle, 1998).  
 
The protectionist measures caused a brief surge in industrial-based employment and 
production, yet the limited sizes of both the Irish market and economy prevented long-
term growth. As a result, the Government established many state owned 
industrial/industrial-related concerns and assumed control of many private concerns, 
many of these nationalised, state or semi-state owned firms survived until the 
1980s/1990s (Abbot, 2001; McHugh, 1984).  
 
The Trade War ended due to political pressures in both the UK and Ireland, yet the 
Second World War prevented the Irish economy recovering, as general shortages, 
rationing and disrupted supply routes greatly restricted trade. Ireland benefited from 
trade with the UK during the World War, during which the Government's protectionist 
policies were relaxed (Doyle, 1998; Ó Gráda, 1997). 
 
Following the end of the war, Europe underwent a significant and sustained economic 
expansion period, which ended in the 1970s. Yet, Ireland isolated itself from these 
developments by fully reinstating and expanding its protectionist policies immediately 
after the war's end (Ó Gráda, 1997; McHugh, 1984). 
 
Between 1948 and 1957, several changes in Government occurred between Fianna Fail- 
and Fine Gael-led coalition Governments, in part due to the increasingly poor 
performance of the economy, including a significant balance of payment issue due to the 
limited indigenous industrial sector. By the beginning of the 1950s, after almost 20 
years of protectionist policies, indigenous manufacturing firms were characterised as 
being structurally poor. The great majority of firms were small in scale, were engaged in 
short production runs targeted predominantly for the limited domestic market. 
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Additionally there was a general lack of specialisation to their activities, while their 
products were characterised by low quality design and packaging due to their limited 
R&D and innovative abilities, which were compounded by poor marketing skills. 
Furthermore, firms “...appeared unwilling or unable to organise production to take 
advantage of export opportunities during the first post-war decade” (Girvin, 1983: 82).  
 
As a result of the limited industrial sector, substantial imports of industrial equipment 
and raw materials were required, without any compensating export growth occurring. 
This resulted in a sustained and significant balance of payments crisis which caused the 
economy to stagnate, and resulted in a huge increase in emigration: “Net emigration for 
1951-6 was 196,763, for 1956-61 it was 212,003. These rates were nearly three times 
the pre-war rates…” (Lyons, 1979: 625). It was becoming obvious that the protectionist 
policies were not conducive to long-term industrial growth (Lyons, 1979; Doyle, 1998; 
Kennedy, 2004). 
 
However, several key decisions were made during this period which had a considerable 
impact on subsequent economic developments:  
 
 Taoiseach John A. Costello (Fine Gael) declared Ireland a Republic in 1948, and 
the country left the Commonwealth the following year,  
 Ireland joined the Organisation for European Economic Co-Operation, the 
forerunner of the Organisation for Economic Co-operation and Development 
(OECD), in 1948,  
 the Industrial Development Authority (IDA) was established in 1949 to take 
responsibility of industrial development, and  
 An Córas Tráchtála, the Irish export board, was established in 1952 to aid and 
assist export-orientated firms (Doyle, 1998; McHugh, 1984; Drew and Foster, 
1994; EuroFound, 2009). 
 
5.2.2 Open Market Policies and Foreign Direct Investment 
In 1958, the Government, under Seán Lemass (Fianna Fáil), abandoned protectionism in 
favour of more outward-looking policies. According to McHugh (1984), this change in 
policy was motivated by the increasingly apparent limitations of protectionism, as well 
as the counterproductive nature of seeking to industrialise through protectionism.  
 
As stated, protectionist policies had isolated Ireland from the post-war European 
 122 
economic boom, which was being driven by the increased adoption of open market 
policies and the development of free trade areas internationally. For example, during the 
post-war period, the General Agreement on Tariffs and Trade (GATT) (1947), a 
worldwide agreement to reduce tariffs, and the European Coal and Steel Community 
(1951), the European Economic Community's (EEC) (1958) forerunner, were 
established (Collins, 1999; Doyle, 1998; McHugh, 1984). 
 
In order to create an Irish industrial export base, the Government introduced new 
policies to encourage industrial investment by Irish and foreign companies, through 
foreign direct investment (FDI), by promoting Ireland’s investment potential 
internationally and through introducing a range of incentives, including: 
 
 the relaxation of the Control of Manufacturers Act (1932) in 1958, and its 
ultimate repeal in 1964, 
 Export Sales Relief, initially introduced in 1956 as a temporary measure to 
reverse the balance of payments crisis, was expanded to remove corporation tax 
on profits derived from exports,  
 the IDA's activities were augmented to internationally advertise the availability 
of cheap labour, and  
 a range of financial incentives, including substantial capital grants of up to 60% 
and employment grants (Burke et al, 2003; Cogan and McDevitt, 2000; National 
Economic and Social Council, 1982; Lyons, 1979; National Economic and 
Social Council, 1982).  
 
These FDI-orientated policies had a substantial effect. During the 1960s, manufacturing 
employment levels and exports rose steadily, while the economy grew by an average of 
3% a year between 1959-64. However, the indigenous industrial base remained limited 
as it continued to predominantly focus on serving the Irish market (Clarke, 2006; 
Collins, 1999).  
 
The open market orientation of the economy was further deepened during the 1960s. 
Ireland joined the GATT in 1960, and signed the Anglo-Irish Free Trade Agreement 
with the UK in 1965. A key development during this period was the decision to seek 
membership of the EEC in 1961. Ireland eventually joined in 1973, meaning it became 
a cheap location for FDI firms seeking to service the national markets of the enlarged 
EEC (Clarke, 2006; Kennedy, 2004).  
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During this period, firms engaging in FDI in Ireland were mainly market-orientated, yet 
many were attracted by Ireland's low labour costs. At the time, Europe was experiencing 
a falling unemployment level which was driving up wage levels, thereby making Ireland 
relatively more attractive as an FDI location. As such, the FDI branch plants which 
subsequently located in Ireland can be characterised as having involved low skilled, low 
waged assembly line production to serve the UK and continental European markets, and 
formed very few local linkages with the economy. This branch plant phenomenon was 
facilitated by developments in new information and communication technologies 
(NICTs) and logistics that allowed a TNC's Headquarters to maintain direct control over 
their overseas operations. By the end of the 1960s, the “attraction of foreign investment 
now became the primary policy instrument in the contribution to industrial growth” 
(Girvin, 1983: 83). For example the IDA was reorganised and expanded in 1969, 
becoming a distinct semi-state body (National Economic and Social Council, 1982). 
 
The Irish economy began to run into problems during the 1970s due to a variety of 
factors. The global oil crisis in 1973 caused a significant economic shock, resulting in a 
protracted period of poor economic performance and inflation in most industrialised 
nations. Additionally, within Ireland there were frequent and protracted official and 
unofficial disputes “between employers and trade unions and between trade unions 
themselves” (The Labour Relations Commission, 2000) in key services such as 
commercial banks and public transport (Rupert, 2004; The Labour Relations 
Commission, 2000).  
 
During the 1970s, employment declined (between 1973 and 1976, manufacturing 
employment fell by over 5%), and inflation rates rose. The balance of payments 
experienced increased pressures due in part to declining agricultural exports, while the 
Public Sector Borrowing Requirement increased. In efforts to address these issues and 
the under-performing nature of the economy, the Government introduced various 
stimulus measures in the late 1970s. Yet, these failed to have much effect due mainly to 
the impact of the second oil crisis in 1979. Once again, the Irish economy stagnated 
(McHugh, 1984; Girvin, 1983; Kennedy, 2004; Rupert, 2004).     
 
In 1977, Fianna Fáil returned to Government, and adopted an economic strategy which 
caused significant economic difficulties during the 1980s. This strategy sought to arrest 
the high levels of unemployment by expanding the public sector, borrowing heavily to 
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do so, so as to facilitate a multiplier effect. Yet, interest rates soon increased due to the 
deepening global financial crisis caused by the oil crisis in 1979, while a 'buy Irish' 
campaign, introduced to neutralise the impact of the expenditure increase on the balance 
of payments, failed to have its desired impact. The unemployment rate declined, yet the 
majority of the newly created jobs were dependent either directly on government 
spending, or indirectly on deficit finance. This would quickly prove to be unsustainable 
(Honohan and Walsh, 2002). 
 
5.2.3 The development of 'jobless growth' and steps towards recovery 
The 1980s was a turbulent decade for Ireland. The major international recession caused 
by the second oil crisis strongly affected the country in the late 1970s/early 1980s. The 
country also experience considerable political turmoil (there were five general elections 
during the decade, two alone in 1982), while various economic policy decisions 
unintentionally added to the economic malaise. The late 1970s expansions in public 
spending ultimately caused the national debt to spiral out of control, from just over €10 
billion in 1980 to just over €30 billion in 1987, and resulted in tax rate increases as high 
as 60% as the various Governments struggled to rein in the worsening economy (Lee, 
1989; Doyle, 1998; National Treasury Management Agency, 2000; Honohan and Walsh, 
2002). 
FDI levels continued to fall, due partly to the high tax rates, as did manufacturing 
employment, while perversely the output of existing industrial firms increased. This 
development was termed 'jobless growth', i.e. firms increased productivity through 
adopting more automated production methods, not through expanding their workforce. 
It became apparent that the Government’s FDI orientated economic policy was 
increasingly being undermined (National Competitiveness Council, 1998; Girvin, 1983; 
Honohan and Walsh, 2002). 
 
The Government responded by commissioning a major external review of industrial 
policy in the form of a National Economic and Social Council (NESC) report in 1982, 
commonly referred to as the 'Telesis Report' after the American consultancy group 
which produced it. This report identified several issues that facilitated the emergence of 
'jobless growth'. It noted that Ireland’s economy was “becoming increasingly dependent 
on foreign-owned enterprises” (National Economic and Social Council, 1982: 149), and 
that little development had occurred in the technological or marketing standards of the 
indigenous industrial sector over the previous two decades. The report stated “no 
country had succeeded in achieving sustained economic growth except on the basis of 
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native industry, Telesis queried the Irish emphasis on foreign investment, and advocated 
greater commitment towards developing an indigenous industrial base” (Lee, 1989: 531; 
Cogan and McDevitt, 2000; National Economics and Social Council, 1982).  
 
FDI that entered Ireland during the 1970s was mainly in the high-tech sectors of 
electronics and pharmaceuticals/chemicals, yet their activities remained largely 
unskilled assembly and packaging work. “Foreign owned industrial operations in 
Ireland...do not embody the key competitive activities of the businesses in which they 
participate; [they] do not employ significant numbers of skilled workers...” (National 
Economics and Social Council, 1982: 151), as automation meant fewer people were 
required for the low skill activities.   
 
The Telesis report noted that FDI branch plants were not embedded into the Irish 
economy, stating “...it has to be acknowledged that policy to promote industrial linkages 
has not lived up to expectations. It is only a mild exaggeration to say that most of the 
newer foreign firms operate here as essentially an industrial enclave” (Industrial Policy 
Review Group, 1993: 31). Linkages to the economy were very limited as the plants 
made little use of Irish suppliers, and had no marketing or R&D facilities. The report 
noted little effort had been made to attract such aspects into Ireland to embed FDI, and 
that Ireland had to become more selective in the types of FDI it was attracting, by 
focusing on higher skilled activities and firms who would require extensive local sub-
suppliers (National Economic and Social Council, 1982; Cogan and McDevitt, 2000).  
Ireland was seen as a “...convenient manufacturing satellite for sales in the EEC. Over 
80% of the companies visited during our study came to Ireland primarily because it 
provided a tax shelter for penetrating the EEC” (National Economics and Social 
Council, 1982: 135). Ultimately, the foreign branch plants were profit generators, with 
the profits being repatriated back to the firms’ headquarters (The United Nations 
University, 1994).  
 
The report also noted indigenous firms were poorly developed and had “...not succeeded 
in developing competitive positions from new product ideas” (National Economic and 
Social Council, 1982: 127). The report characterised Irish business as being stunted due 
to decades of protectionism and limited political interest in developing indigenous 
industry. It also commented that “a native entrepreneurial cadre of the requisite quality 
had failed to emerge. Irish-owned industry could not compete internationally. It could 
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not even compete in the home market” (Lee, 1989: 536). The report called for a reduced 
dependence on FDI and an enhanced role for domestic industry, mainly through tackling 
the marketing and management defects which were a feature of the domestic sector 
(Industrial Policy Review Group, 1992). 
 
The Government responded to the Telesis report's findings and recommendations with 
the Industrial Policy White Paper in 1984. However, the Telesis report's main 
recommendations were largely ignored, as no major shift in focus occurred towards 
indigenous industry. The Government did introduce a Technology Acquisitions Grants 
Scheme and a National Linkage Programme to improve linkages between foreign 
branch plants and indigenous firms, yet both programmes met with limited success. The 
issues identified by the Telesis Report essentially remained (Cogan and McDevitt, 2000; 
Industrial Policy Review Group, 1992).  
 
The economic malaise continued through the decade, e.g. the National Debt as a 
percentage of Gross Domestic Product (GDP) had risen from almost 90% of GDP in 
1982 to almost 130% of GDP in 1986, while unemployment increased from 7.1 per cent 
in 1979 to almost 18 per cent in 1987. Drastic economic measures arrested the declining 
state of the country's finances by the mid 1980s, yet failed to lead to a noticeable 
recovery (O'Donnel and O'Reardon, 1996; Honohan and Walsh, 2002).  
 
In 1987, the Fianna Fail Government, with active support from the main opposition 
party, implemented an extensive series of economic reforms which facilitated a 
relatively modest recovery towards the end of the decade. These measures included tax 
cuts, a dramatic reduction in Government spending, and a temporary freeze on public 
sector recruitment in combination with cutbacks in public capital spending (National 
Treasury Management Agency, 2000; Honohan and Walsh, 2002). 
 
Several important developments occurred in the late 1980s which subsequently had 
significant impacts on the economy. In 1987, the first Social Partnership agreement, the 
'Programme for National Recovery' (1987-1990) was signed. This was a voluntary, 
socially oriented economic agreement between the Government, employers groups and 
Trade Unions that aimed to increase national competitiveness through strike and wage 
moderation, in return for tax reforms and action on unemployment. Also in 1987, the 
International Financial Services Centre (IFSC) was established in the Dublin’s 
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docklands. This offered a range of tax and other incentives to financial services firms 
that established operations within its defined zone (O'Donnel and O'Reardon, 1996; 
National Treasury Management Agency, 2000; Honohan and Walsh, 2002; Goodbody 
Economic Consultants, 2007; White, 2005). 
 
However, one of the most important developments for the economy occurred in 1989 
with the establishment of Intel's European manufacturing operations in Leixlip, County 
Kildare. This development changed the industrial base of Ireland’s economy by 
attracting more complex FDI investments in this field into Ireland through signalling 
“the availability of a well-educated workforce, attractive taxation and incentives, the 
availability of suitable land, good infrastructure services...[and] the quality of life in 
Ireland” (Keith Thompson, Intel vice president, quoted in Lillington, 2009; IDA Ireland, 
2010; Coleman, 2000). 
 
Additionally, the country benefited from the receipt of expanded EU structural grants 
after 1988. These grants, particularly those received under the European Regional 
Development Fund, had a substantial impact through allowing the government to 
complete infrastructure projects which had been deferred during the 1980s, without 
undermining the economy's initial recovery (Honohan and Walsh, 2002; Acheson, and 
Lambkin, 2009; European Commission, 2009). 
 
5.2.4 The 'Celtic Tiger' era 
Unlike the 1980s, the political climate during the 1990s was more stable. The main 
political focus was on continuing the economic recovery initiated in the late 1980s. 
During the early 1990s, several developments had a massive impact on the economy: 
 
 the National Treasury Management Agency (NTMA) was established by the 
Government in 1990 to manage the National Debt,    
 the national pay agreement continued with the Programme for Economic and 
Social Progress (1991-1994), and 
 the European single market came into effect in 1993, facilitating free movement 
of goods and services, labour and capital between EU member countries. This 
had a massive impact on Ireland's ability to attract FDI (Cassidy and O'Brien, 
2005; National Treasury Management Agency, 2000). 
 
In an attempt to optimise the future performance of the economy, the Government 
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sponsored another report to review the country's industrial policy, the Industrial Policy 
Review Group (1992), commonly referred to as 'the Culliton Report' after its chairman. 
This report reiterated many of the Telesis Report's findings, i.e. that while FDI had 
made enormous contributions to the Irish economy over several decades, “...the 
attraction of foreign investment is not a sufficient basis for developing a national 
advantage in advanced industries...Industrial growth through dependent branch plants of 
foreign firms can get us only so far” (Industrial Policy Review Group, 1992: 66). 
 
The report called for the country’s industrial policy focus to shift away from FDI, i.e. 
that future industrial development should be based on cultivating and developing 
indigenous industry, as there was a pressing need “...to have more firms that are Irish 
managed, have growth potential and are better integrated into the economy than the 
typical dependent branch plant of a foreign multinational” (Industrial Policy Review 
Group, 1992: 66). The report detailed a variety of key policy recommendations, 
including greater investment in R&D and a radical upgrading of the technological 
competence of indigenous industry (Breathnach, 2001; Cogan and McDevitt, 2000). 
 
The Government responded to many, but not all of the report’s recommendations under 
the 1993 Industrial Development Act. EOLAS and the IDA were dissolved and three 
agencies were established: 
 
 IDA Ireland: to focus solely on attracting FDI through selectively targeting 
sectors with long-term development potential and whose activities putatively 
would mean branch plants would have to develop linkages with the local 
economy,  
 Forbairt: EOLAS was subsumed into Forbairt, which focused exclusively on 
indigenous enterprise development, and  
 Forfás: which was created with responsibility for overall industrial policy 
formulation and to coordinate the work of Forbairt and the IDA Ireland (Burke 
at al, 2003; Breznitz, 2007; Government of Ireland, 1993a, 1993b).  
 
 
No serious efforts were made to move economic policy away from FDI, despite the 
Culliton report's findings. Yet, the Irish economy's subsequent transformation, due to the 
emergence of the Celtic Tiger economy in the early 1990s, effectively pushed 
indigenous sectoral development issues aside (van Egeraat and Breathnach, 2006).  
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During the Celtic Tiger economy (circa 1992~2007), Ireland was transformed into a 
post-industrial economy in a relatively short period of time. The country’s GDP almost 
doubled in real terms between 1992 and 2001, while average living standards rose 
dramatically, and per capita GNP moved from around sixty percent of the EU average in 
the late 1980s to almost one hundred percent by 2001 (Cronin, 2005; Breathnach,  1998; 
Honohan and Walsh, 2002).  
 
The exact causes for its emergence are debatable, yet one of the main forces behind the 
Celtic Tiger was a surge of inward investment that followed Intel's decision to locate its 
European manufacturing operations in the country in the late 1980s. This new FDI was 
attracted to Ireland due, in part, to the stability of the social partnership agreements, and 
decades of investment in higher education (in combination with a baby boom in the 
1970s) which resulted in a highly skilled and relatively cheap labour force. Additional 
factors included the continuing low rate of corporation tax, and Ireland's membership of 
the EU (Breathnach, 2001; Honohan and Walsh, 2002; van Egeraat and O'Byrne, 2010).  
 
These new investments were in modern ‘high-tech’ sectors, such as the electrical and 
optical equipment sector and the capital-intensive pharmaceuticals sector, that involved 
more high skilled activities and more sophisticated manufacturing production processes 
than the activities which had typified FDI since the early 1960s. As such, a significant 
shift in the composition of the manufacturing sector occurred, with a corresponding 
surge in manufacturing employment (Breathnach, 1998; Honohan and Walsh, 2002).   
 
Record job creation levels occurred in both foreign and indigenous companies. At a 
sectoral level, the services sector (particularly financial, business, health, and education 
services) accounted for the largest proportion of employment generated, while many 
'low-tech' low skilled manufacturing activities and jobs were replaced by high-skilled, 
high wage jobs, most notably in NICTs and Pharmaceuticals (Cronin, 2005; Goodbody 
Economic Consultants, 2007; Honohan and Walsh, 2002; van Egeraat and O'Byrne, 
2010).  
 
Even as the Celtic Tiger emerged, following the recommendations of the Culliton 
report, the Government commissioned a report by the Science, Technology and 
Innovation Advisory Council (STIAC) (established in 1994) to review the country's 
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Science, Technology and Innovation policy. The report, 'Making Knowledge Work for 
Us' (1995) (the report's findings are discussed further in the following section), 
highlighted the continuing lack of embeddedness of FDI branch plants, and the 
continuing small size, scale, and R&D levels of indigenous industry (Forfás, 1996; 
Acheson, and Lambkin, 2009).  
 
The government established a task force to implement the report's recommendations. 
This led to the country's first ever White Paper on Science, Technology and Innovation 
in 1996 (discussed further in the following section). The most important outcome of the 
White Paper was the Industrial Development Act (1998), which merged the Irish Trade 
Board (which marketed Irish goods and services nationally and internationally) and 
Forbairt to form Enterprise Ireland (EI), i.e. one main government agency was now, and 
remains, solely responsible for indigenous industrial development (Burke et al, 2003; 
OST 1996; Acheson, and Lambkin, 2009). 
 
As the 1990s progressed, the Celtic Tiger's impact on the economy deepened. Increased 
prosperity and low interest rates in the mid 1990s, resulting from the departure of 
Sterling from the European Exchange Rate Mechanism in 1992, led to significant 
private investments in the housing sector. Significant infrastructural development 
occurred through EU Structural Fund investments, e.g. the country's motorway network 
expanded significantly. In 1995, the Free Fees Initiative drastically reduced the costs of 
under-graduate third level education, furthering the country's skilled labour supply. 
Additionally, the National Pay Agreements continued with the Programme for 
Competitiveness and Work (1994-1996), and the Partnership 2000, for Inclusion, 
Employment and Competitiveness (1997-2000) (Honohan and Walsh, 2002; 
EuroFound, 2009; International Labour Organization, 2003). 
 
Yet, at the beginning of the new millennium “the [Irish] economy was displaying 
unmistakable signs of overheating” (Honohan and Walsh, 2002: 11). According to 
Cassidy and O'Brien (2005), the country's reliance on FDI had created significant 
weaknesses, as demonstrated through the substantial slow down in Ireland’s export 
growth after 2000 which was caused by several shocks to the Irish and global economy 
in 2001. The Irish economy's competitiveness was being undermined by its rising cost 
base, e.g. a steady increase in consumer prices, while a global downturn in the NICT 
sector had a severe impact on the Irish economy due to the country's high export 
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specialisation in the sector (Cassidy and O'Brien, 2005). 
 
While indigenous industry had expanded during the Celtic Tiger era, indigenous sectors 
remained in much weaker competitiveness positions, and continued to be characterised 
as being more traditional, labour-intensive, less research intensive and more embedded 
in the domestic economy than the high-technology FDI sectors. The structural 
weaknesses of indigenous industry were now spread “across numerous dimensions, 
suggesting that the [indigenous] sector would find it almost impossible to ramp up 
sufficiently rapidly to be able to replace foreign industry in the event of a sharp adverse 
shock to the latter” (Barry, 2006: 41). Essentially, the economy was now vulnerable to 
external shocks, such as “a significant downturn in the US economy” (Cassidy and 
O'Brien, 2005: 75).  
 
The early 2000s also saw a significant fall in manufacturing employment as more 
routine, labour-intensive activities relocated overseas, especially to China and Eastern 
Europe, e.g. clothing manufacturer Fruit of the Loom closed its Irish-based operations 
in 2004. Export growth recovered in 2004, due in part to the introduction of the Euro in 
2002, which further reduced inter-EU transaction costs and stimulated export growth, 
yet also due to a recovery in the global NICT sector. Additionally, several major new 
TNC investments occurred, e.g. Google opened its European HQ in Dublin in 2004. The 
economy’s growth continued due to a construction boom and a strong growth in 
services exports, yet not at the level of the mid-to-late 1990s (van Egeraat and 
Breathnach, 2006; Lavery, 2004; IDA Ireland, 2009).  
 
However, at this point serious competitiveness issues were apparent in the economy. 
Many senior economists, nationally and internationally, commented that while Ireland's 
economic growth was strong, e.g. government debt had been reduced dramatically and 
the unemployment rate was low (due to rising labour participation rates), the economic 
recovery was mainly being driven by the indigenous construction industry and 
significant increases in property values, e.g. national house prices increased by 270% 
between 1996 and 2006. Economic growth had become unbalanced due to the reliance 
on the construction industry. By 2006, almost 20% of Ireland's private sector workforce 
employment was dependent, directly or indirectly, on the property sector (Hennigan, 
2006; The Irish Times, 2003; Goodbody Economic Consultants, 2007). 
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Additional issues included “a sudden and substantial acceleration in the rate of 
consumer price inflation” (Cassidy and O'Brien, 2005: 85) following the Euro's 
introduction, and a steep rise in the total level of private sector debt due to investments 
in the property market. The Organisation for Economic Co-operation and Development 
(OECD) and senior Irish officials of the Central Bank and Financial Services Authority 
of Ireland noted that the Irish property market was overvalued by 15% in 2005. By 
April 2006, officials in the Irish Central Bank commented that the housing boom 
displayed significant signs of instability and posed a 'significant risk' to the economy 
(Murphy et al, 2008; Brennan, 2007; Lillington, 2009; Hennigan, 2006; The Irish 
Times, 2005; Goodbody Economic Consultants, 2007).  
 
Ireland, in particular the Greater Dublin Area (GDA), where the majority of the 
economic activity derived from the Celtic Tiger was focused, was increasingly 
expensive as a place to do business and to live, for a variety of reasons. Wage costs, 
particularly in the GDA, began to rise sharply. Two international surveys ranked Dublin 
within the top ten most expensive cities, globally, for office occupancy costs. The 
GDA's success also led to an unbalanced pattern of economic and spatial development 
at a national scale, as reflected in Ireland losing its Objective 1 status with the EU's 
structural funds. After 2000 the Country was divided into the Southern and Eastern 
areas (Objective 2) and the Border, Midland and West area (Objective 1) (Power, 2007; 
European Commission, 2000; van Egeraat and O'Byrne, 2010). 
 
Additional factors undermining Ireland's competitiveness included the increase in the 
corporation tax rate applied to manufacturing and certain internationally traded services 
from 10% to 12.5% in 2003 due to pressure from other EU members. Ireland faced 
increased competition from countries offering low taxes, cheap land prices, and 
educated workforces in efforts to attract FDI. Indeed, by the late 2000s, one of Intel's 
former Presidents commented that only one of the list of reasons why Intel had come to 
Ireland in 1989 still held, i.e. tax benefits (Lillington, 2009). The increased competition 
for FDI, and the decreasing national competitiveness was ultimately reflected in the 
decision of several large FDI firms to relocate Irish operations to such locations, e.g. the 
closure and relocation of Dell's Limerick-based manufacturing to Poland in 2009 
(Lillington, 2009; Mellor, 2009; Goodbody Economic Consultants, 2007; Honohan and 
Walsh, 2002). 
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By the beginning of 2008, it was apparent the Celtic Tiger era was ending. The country's 
property bubble began deflating in 2007, leading to a downturn in the construction 
dependant economy. This downturn was subsequently magnified by the impact of the 
global financial crisis, caused by massive liquidity issues (the 'credit crisis') in the US 
banking system that first appeared in 2007, and which subsequently sparked a global 
recession (Clark, 2008; Hennigan, 2006).  
 
5.2.5 The post 'Celtic Tiger' economy 
This global recession had a massive initial impact on the Irish economy. Unemployment 
as a percentage of the Labour force rose from 4.5% in 2007 to 13.2% in 2009. During 
the same period the general Government debt as a percentage of GDP rose from 24.8% 
to 57.7%. Contractions in GDP during the first half of 2008 indicated that the Irish 
economy had entered its first recession since the 1980s (Davy Research, 2009; Barret et 
al., 2009; FinFacts, 2009b).  
 
An emergency budget was introduced in July 2008 in an effort to halt the declining state 
of the public finances, which introduced drastic budget cuts. However, these measures 
proved unsatisfactory and a supplementary budget was introduced in April of 2009 to 
address a revenue shortfall caused by rapidly declining tax revenues of close to €4.5 
billion. Funding to many Government policies and initiatives was cut back or 
withdrawn in an effort to address the poor state of the economy (Doyle, 2009; Davy 
Research, 2009; Barret et al., 2009; FinFacts, 2009b). 
 
The Irish banking sector, which had become over-exposed to the Irish property market 
during the property bubble, came under severe pressure in the second half of 2008, as 
house and land prices continued to decline. The government was forced to nationalise 
the country's third largest bank, Anglo Irish Bank, and to recapitalise its top two banks, 
the AIB and the Bank of Ireland. In an attempt to address the worsening liquidity issues 
of the banks, the Government proposed a National Asset Management Agency (NAMA) 
in April 2009 to take over large property-related loans from the banks, to enable them to 
return to normal liquidity to assist in the economic recovery (Doyle, 2009; FinFacts, 
2009a). 
 
At present the Irish economy shows tentative signs of recovery, yet the long-term effects 
of the post-Celtic Tiger economic slump are difficult to predict. The ESRI (Fitzgerald et 
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al., 2008) predicted the current economic contraction of the Irish economy will level off 
around 2012-2014, with the economy expected to recover to near-2007 levels by 2020, 
yet it must be noted these predictions were formulated without considering the future 
impact of NAMA on the economy. The strong growth experienced during the Celtic 
Tiger is ultimately expected to give way to more sustainable increases over the next 
decade, with GDP and GNP growth averaging around 3 per cent between 2010 and 
2020 (Fitzgerald et al., 2008; Indecon International Economic Consultants, 2008; van 
Egeraat and O'Byrne, 2010).  
 
The ESRI also projects the trend of declining FDI in 'traditional' manufacturing 
activities to continue due to increasing international competition and the decline in 
Ireland's competitiveness for such activities. In relation to future employment trends, 
growth is likely to be heavily concentrated in the services sector, including the 
internationally traded and domestic services activities, with particularly strong growth 
in market services employment (Fitzgerald et al., 2008; Indecon International Economic 
Consultants, 2008; van Egeraat and O'Byrne, 2010). 
 
5.3 THE DEVELOPMENT OF GOVERNMENT POLICIES RELATING TO 
BIOTECHNOLOGY 
5.3.1 Measures to promote Science, Technology & Innovation, and the indigenous 
bio-sector 
From independence up until the late 1950s, the predominant focus of the various Irish 
Governments' Science, Technology and Innovation (STI) and industrial policies was 
towards the country's agricultural and food sectors. This contributed to, and 
compounded the negligible role innovative research played in indigenous industry; as 
detailed in the previous section, industry at the time was characterised as engaging in 
limited research activities, there had been little need to innovate due to decades of tariff 
protection (Acheson, and Lambkin, 2009; Teavey, 1995).  
 
The development of Irish STI policy began in earnest in the 1960s. In 1963, the 
Government and the OECD co-sponsored the 'Research and Technology Survey' to 
assess Irish scientific and technological research activities in order to inform the 
formulation of research-related and economic-orientated policy recommendations. The 
ensuing report, Science and Irish Economic Development (1966), highlighted Ireland’s 
need to actively develop science and technology in order to drive economic 
development. The Government responded to the report's main recommendation through 
establishing a National Research Council in 1967. The council's main responsibilities 
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were to advise the Government on policies related to industry and research, the 
development of a national research programme, and the establishment of the Regional 
Technical Colleges in 1968. The Council also provided a very limited number of annual 
research grants (Murphy, 1972; OECD, 1966; Acheson, and Lambkin, 2009).  
 
Cooper and Whelan (1973) noted that despite the changes to the Government's approach 
to research, the country's Public Research and Education Organisations (PREOs) 
research activities remained predominantly focused on agriculture, with little attention 
being paid towards industry. Additionally, due to their low level of research activities, 
indigenous firms could not benefit from these increased R&D activities, i.e. an 
innovation paradox existed, while the relatively more high-tech FDI firms had no 
interest in Irish R&D activities due to their branch-plant orientation (Cooper and 
Whelan, 1973; Teavey, 1995).   
 
These comments were repeated in the 1974 OECD review of the Irish government’s 
science policy, 'Review of national science policy: Ireland'. This review noted that the 
existing science policy lacked co-ordination, that R&D activities outside of state 
sponsored programmes remained minimal. It recommended the establishment of a 
Government agency to implement a coordinated science policy. In 1978, the 
Government responded by establishing the National Board for Science and Technology 
(NBST), which sought to place research policy at the centre of economic development, 
and established a limited grants scheme for the development of scientific and 
technological research (Government of Ireland, 1977; OECD, 1974; Yearley, 1995; 
Acheson, and Lambkin, 2009).  
 
Following the emergence of the biotechnology industry in the mid-1970s, governments 
in developed economies, and supra-national agencies, such as the European Economic 
Community (EEC), were quick to respond to the industry’s economic possibilities. The 
Irish Government noted biotechnology's potential importance for Ireland’s future 
economic development at the time, yet was relatively slow in developing policies to 
encourage/facilitate the development of indigenous capabilities in this area (Burke et al, 
2003; Kennedy et al., 1994).  
 
It must be noted that many of the Irish Government STI-related initiatives, and 
biotechnology-related initiatives which developed from the late 1970s onwards were 
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supported and/or motivated by a variety of EEC/European Union (EU) programmes, 
particularly through the different Framework Programmes (FPs). Since the first FP in 
1984 (the current, seventh, FP runs until 2013), the EU has viewed the life 
sciences/biotechnology as being one of the key technology areas of the 21
st
 century, 
particularly in relation to health care, agriculture, environmental protection, energy 
production and industrial processes. The importance of the FPs for Ireland's STI efforts 
increased during the 1980s, as public funding to STI-related agencies and policy 
initiatives suffered significant cuts as the various Governments tried to stabilise the 
declining economy, as detailed above (Pownall, 2000; Urwin, 2001; Cordis, 2006; 
Yearley, 1995). 
 
One of the first measures designed specifically to promote biotechnology in Ireland was 
established in 1983 by the NBST as part of an effort to compile a coordinated national 
STI programme. The Programme for Strategic Research provided grants for research in 
selected niche areas including biotechnology, NICTs and engineering. However, the 
programme’s impact was limited as its total grant funding amount was “considerably 
less than £1 million” (Yearley, 1995: 187) a year (Kennedy et al., 1994; Downey, 1979; 
Senker and Van Zwanenberg, 2000).  
 
Due to the rapid emergence and increasing impact of biotechnology internationally, the 
NBST and the IDA began investigating how establishing biotechnology-related 
expertise in Ireland could contribute to economic growth and productivity. In 1984, a 
model was devised for a National Biotechnology Initiative, which proposed the 
establishment of four centres based on three areas: 
  
 traditional processes, e.g. brewing and cheese making,  
 modern fermentation industries, e.g. enzymes and antibiotics, and  
 new industries resulting from biotechnology technologies, such as recombinant 
DNA (Burke et al, 2003; Kennedy et al., 1994; Office of the Houses of the 
Oireachtas, 2004). 
 
In 1987, partly motivated by the EU FPs, the government published the Science and 
Technology Act, shifting its science policy away from FDI towards promoting industrial 
development through the use of science and technology. The Act led to significant 
institutional reforms, including the creation of an Office of Science and Technology 
within the then Department of Industry and Commerce (presently the Department of 
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Enterprise, Trade and Innovation) and the formation of a unified agency, EOLAS, 
through the merger of the NBST and the Institute for Industrial Research and Standards 
(which had been responsible for setting and monitoring technical standards in industry). 
EOLAS was charged with developing a national programme in science and technology, 
and the development of closer linkages between PREOs and indigenous firms, so as to 
address the firms' limited innovative capacities. A key development, relating to STI 
policy, was the shift away from fixed asset investments and direct grants towards 
seeking to develop people, skills, and research capabilities (Burke et al, 2003; Cogan 
and McDevitt, 2000; Acheson, and Lambkin, 2009; National Economic and Social 
Council, 1993). 
 
The National Biotechnology Programme (NBP) was launched in 1987 as part of the 
Science and Technology Act, and introduced cooperative activities to commercialise 
PREO-based research through developing links between PREO researchers and the bio-
sector, and through the formation of start-up companies. The NBP's model differed from 
the proposed National Biotechnology Initiative in that five research institutes (RIs) were 
established in five different PREOs (as detailed in Appendix D). Each RI operated 
independently from the departmental structure of their host universities, and had its own 
specific research focus. In 1988, the NBP was renamed BioResearch Ireland (Burke et 
al, 2003; Cogan and McDevitt, 2000; The ELS Gazette, 2002). 
 
By the end of the 1980s, the level of Government funding available to the Irish 
scientific community remained limited, e.g. in 1990, “EOLAS's scientific program was 
intending to make around twenty awards averaging £15,000; little scientific apparatus 
could be purchased for such sums” (Yearley, 1995: 190). The majority of funding for 
scientists continued to come from the various EU initiatives under the FPs.  
 
As stated previously, the Government established the STIAC in 1994 following 
recommendations from the Culliton Report (1992) to formulate policy proposals on 
Science & Technology. The following year, STIAC published its report, 'Making 
Knowledge Work for Us' (1995), which highlighted the limited Governmental support 
for PREO-based basic and applied research activities. The Travers Task Force (chaired 
by John Travers, then Chief Executive of Forfás) was established to suggest ways to 
implement the report's recommendations. This led to basic research grants increasing 
from £1 million to £1.5 million (€1.27 million to €1.91 million, respectively), with an 
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extra £4 million (just over €5 million) being allocated to the country’s total science 
research budget. An STI awareness programme was also launched, and grants to fund 
Ph.D. and post-doctoral programmes in biotechnology/biotechnology-related subjects 
were increased (Burke et al, 2003; Forfás, 1995, 1996; Science and Technology 
Division, 1995; Acheson, and Lambkin, 2009).  
 
The Government responded to the STIAC report in 1996 with the country's first White 
Paper on Science, Technology and Innovation. This argued that indigenous industry 
needed to move away from traditional manufacturing activities towards a knowledge 
and know-how based economy, and recommended increasing their R&D and innovation 
abilities through the implementation of a coherent Science, Technology and Innovation 
(STI) policy, and the provision of greater resources for knowledge generation activities 
in the country's PREOs (Cogan and McDevitt, 2000; Cooke, 1996; Acheson, and 
Lambkin, 2009).  
 
The White Paper led to the creation of the Irish Council for Science, Technology and 
Innovation (ICSTI), the establishment of an interdepartmental committee, and a cabinet 
sub-committee on Science & Technology. Additionally, the Office of Science and 
Technology, within the Department of Enterprise, Trade and Employment, now 
formulated and developed all STI-related policies across all Government Departments 
(Burke et al, 2003; Acheson, and Lambkin, 2009).  
 
A significant surge in STI and biotechnology-related initiatives followed in the wake of 
the White Paper. An additional boost to Ireland’s scientific research capacity occurred 
when the Higher Education Authority (HEA), the statutory planning and development 
body for higher educational and research in Ireland, established the Programme for 
Research in Third Level Institutions (PRTLI) in 1998 to assist the “...development of 
[third level] institutional research capabilities through investments in infrastructure and 
in research programmes and support high-quality interdisciplinary and inter-institutional 
research” (Higher Education Authority, 2006: 11) (the HEA and PRTLI are detailed 
further in chapter 6) (Ryan, 2004; Higher Education Authority, 2005, 2006).  
 
Also following the White Paper's recommendations, the Government commissioned a 
Technology Foresight exercise in 1998. The subsequent Technology Foresight Report 
(1999) concluded that NICTs and biotechnology were “two pervasive and strategic 
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technologies underpinning many existing sectors in the economy and likely to underpin 
‘new’ industries in the future” (Acheson, and Lambkin, 2009: 8). The report 
recommended the establishment of a research fund to invest in niche technology areas, 
such as biotechnology, in order to enhance and ensure Ireland's future competitiveness, 
while it stated that investments in STI-related infrastructure were required to establish 
an internationally competitive PREO research base and stimulate the creation of PREO 
derived indigenous technology-based firms (Irish Council for Science Technology and 
Innovation, 1999; Acheson, and Lambkin, 2009). 
 
A major advancement in STI policy occurred with the launch of the National 
Development Plan (NDP) (2000-2006) in 1999, which allocated €2.5 billion specifically 
for research, technology & innovation activities through the Research, Technological 
Development and Innovation (RTDI) fund. This fund had several objectives: 
  
 to strengthen the research capacity of Irish PREOs and other research 
establishments relevant to the needs of the Irish economy,   
 to strengthen the capacity of Irish firms to assimilate the results of R&D into 
their products and processes, and  
 to provide support for sectoral research in agriculture, food, marine and the 
environment (National Development Plan, 2005a, 2005b: Forfás, 2003; Burk et 
al, 2003).  
 
As part of the NDP, following the Technology Foresight Report's recommendations, the 
government created `  (TFF) in 1999 to facilitate the development of PREO research in 
NICTs and biotechnology. The following year Science Foundation Ireland (SFI) was 
established as a sub-board of Forfás to administer and manage the TFF (Burke et al, 
2003; Department of Trade, Enterprise and Employment, 2000: 2001; ERCIM News, 
2000; Acheson, and Lambkin, 2009). 
 
These initiatives represented the first introduction of long-term, strategic approaches 
towards the development and funding of indigenous STI capacity in the State's history. 
By 2004, the R&D expenditure of the PREOs had reached almost €500 million, 
predominantly due to the PRTLI and the TFF (Forfás, 2005a, 2005b; Acheson and 
Lambkin, 2009).  
 
The Government subsequently committed to continuing and developing these initiatives 
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through the National Development Plan 2007-2013 (2007), which includes a provision 
for a €20 billion investment in Enterprise, Science and Innovation, with €8.2 billion 
being specifically allocated for scientific research. SFI has been charged with the 
responsibility of investing €1.4 billion, focused again equally on NICTs and 
biotechnology, while the PRTLI has been extended with €190m being provided for the 
programmes fourth cycle over the period 2007-2010 (Science Foundation Ireland, 2007; 
The Higher Education Authority, 2007a, b). 
 
These on-going programmes and initiatives have moved beyond primarily focusing on 
building infrastructure and developing a critical mass in PREOs towards developing 
optimal conditions conducive to the creation of commercial concerns from PREO-based 
research (Department of Trade, Enterprise and Employment, 2006; Government of 
Ireland, 2007). 
 
The Government announced a new Strategy for Science, Technology and Innovation 
(2006-2013) in 2006. This acknowledged that STI remained relatively underdeveloped 
in Ireland in relation to international standards, particularly in the transfer of PREO-
based research to the market place. The strategy aimed to facilitate the development of 
integrated science courses from primary level education to the fourth level, addressing 
research-related structural weaknesses in the country's PREOs (through the NDP), by 
developing the necessary soft and hard support structures to facilitate rapid technology 
transfers from PREOs, and also addressing the limited R&D capabilities and activities 
of indigenous firms (Acheson and Lambkin, 2009; Forfás, 2008).  
 
The strategy aims to develop industry-led research activities through the development of 
competence centres that translate firm-based research into commercialisable technology 
through collaborative research activities with PREO researchers. Jointly run by EI and 
the IDA Ireland, nine centres will ultimately be formed (none of which will be overtly 
related to the indigenous bio-sector) as collaborative translational research-based 
activities. A PREO/Small to Medium Enterprise (SME) collaborative initiative has 
recently been introduced by the Department of Enterprise, Trade and Innovation as part 
of the strategy, i.e. 'Innovation Vouchers' (Forfás, 2006, 2008; Acheson and Lambkin, 
2009; Department of Enterprise, Trade and Employment, 2008; Forfás, 2008).  
 
5.3.2 Government measures to promote indigenous networks and clusters 
One of the first mentions of networks in Irish Government literature occurred in the 
 141 
Industrial Policy White Paper in 1984. The Government subsequently introduced a 
Technology Acquisitions Grants Scheme and a National Linkage Programme to improve 
linkages between the FDI branch plants and indigenous firms. However, both 
programmes had limited success due to the limited research capabilities of indigenous 
firms and the outward focus of the FDI branch plants (as detailed previously) (Cogan 
and McDevitt, 2000; Industrial Policy Review Group, 1992).  
 
Due to the perilous state of the nation's economy during the 1980s, successive 
governments focused almost exclusively on addressing the dire state of the nation's 
finances at the expense of other policy areas. Topics such as networking were relegated 
to positions of low importance.  
 
Networks next appeared in the 'Culliton Report' in 1992. A key recommendation of the 
report was the promotion of industrial clusters of interlinked firms built around pre-
existing local strengths. Additionally, it proposed that the indigenous development 
agency (then EOLAS) should be organised on regional lines to be more conducive to 
cluster promotion. Yet, with the publication of the 1993 Industrial Development Act, the 
Government avoided committing to developing clusters, and opted to organise Forbairt 
(which subsumed EOLAS) on a sectoral basis for unstated reasons (Burke at al, 2003; 
Breathnach, 2001; Cogan and McDevitt, 2000). 
 
The Culliton Report’s clustering recommendations were subsequently supported by the 
publication of the NESC report 'A Strategy for Competitiveness, Growth and 
Employment' in 1993. This recommended the introduction of SME supports in areas 
such as innovation and management due to the increasing impact of Post-Fordism 
internationally, along with parallel co-operative structures to promote networks of 
related firms. However, the report also concluded that introducing such policies would 
prove problematic as they would require a level of vision and organisational capacity 
likely to be beyond the capabilities of the state sector (Breathnach, 2001; National 
Economic and Social Council, 1993).  
 
Following the publication of the STIAC report in 1996, the Government published the 
White Paper on Science, Technology and Innovation. This argued that Irish industry 
needed to move away from traditional manufacturing activities towards a knowledge- 
and know-how based economy. It recommended that the basic structural issue of Irish 
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firms, e.g. their small size and scale and low levels of R&D, be addressed through 
cultivating co-operating groups of companies through an Inter-Firm Cooperation 
Programme where firms would collaborate in key areas such as “...R&D, technology 
acquisition, process change and market development” (STIAC, 1995: 70), i.e. a 
network-based programme. The STIAC report recommended a brokerage service be 
implemented to facilitate network developments and information sharing among 
indigenous firms, similar to the Danish network programme detailed in chapter 2 
(Cogan and McDevitt, 2000; Cooke, 1996).  
 
The Government's response to the report’s proposals was generally positive. A steering 
group was set up in the Office for Science and Technology to investigate its findings. A 
consultancy report prepared in 1996 to analyse nine inter-firm networks between SMEs 
concluded that networks allowed firms to achieve greater economies of scale than when 
they were independently-operating entities. The report also found that where firms were 
located in close geographic proximity, the benefits of the networks were enhanced 
(Breathnach, 2001, Forfás, 1994; Engel and Del-Palacio, 2011).  
 
Also following the STIAC report, the NESC published two reports relating to networks 
and clustering. The first report, prepared by Philip Cooke (1996), looked at inter-firm 
networking in Europe, while the second (1997) was comprised of three studies in a 
research series that looked at clustering in three successful indigenous sectors (ADAPT, 
2002). 
 
Cooke’s report again highlighted the serious issues present in Ireland’s manufacturing 
sector, i.e. a strong FDI sector existed, yet one with few indigenous linkages, while 
indigenous firms remained predominantly small in size, had limited innovation 
capacities and had limited opportunities to learn from external sources, including 
PREOs. Cooke felt that the optimal way to develop indigenous firms was through 
establishing industrial clusters. He noted that in certain industrial areas in Europe, such 
as Baden-Württemburg in Germany and the Emilia-Romagna region in Northern Italy, a 
strong networking culture existed which heavily promoted innovation: “Industrial 
clusters are also a key feature of successful European economies…these are vertically 
and horizontally linked supply and subcontracting chains in interaction with public and 
private enterprise support services” (Cooke, 1996: vii).  
 
 143 
Cooke identified two main learning methods in his study, i.e. firm interaction (linkages 
and/or joint R&D initiatives) and learning from R&D conducted elsewhere, often 
conducted by a group of collaborating firms analysing and disseminating information on 
their competitors. Both methods involved inter-firm networking. Cooke recommended 
that co-operative structures should be established among Irish firms to achieve some of 
the economies of scale available to large firms: “…enterprise support for wider cluster 
formation should be provided to link...‘networks of networks’ around areas of major 
economic strength such as food, pharmaceuticals and electronics” (Cooke, 1996: vii). 
The proposals rationale was that government support in the areas of innovation and 
management would be less effective for individual firms unless this support was 
accompanied by measures promoting networks of related firms at sectoral and regional 
level (Breathnach, 2001). 
 
Cooke recommended institutionalising an interactive innovation culture through the 
establishment of a network programme derived from the Danish Network Cooperation 
Programme. This recommendation echoed the STIAC's network strategy proposal by 
seeking to assist the creation of inter-firm networks through a broker service. Cooke 
also proposed the subsequent establishment of a Cluster Support Programme to 
facilitate the development of clusters. 
 
Following the publication of Cooke’s report, Forbairt initiated a pilot network formation 
programme (1997-1998) among indigenous industry actors. Devised through advice 
received from Danish experts, the programme consisted of training a team of network 
facilitators/brokers, and the provision of financial assistance towards the set up costs of 
networks between the chosen actors. After a year, seventeen networks had been 
established focusing on research and product/process development cooperation 
(Breathnach, 2001; Forfás, 2004; Edquist and Hommen, 2008).  
 
The programme’s evaluation report concluded the networks had been beneficial to the 
participants, and that, due to the participant firm's inexperience in collaborating with 
competitors, the network facilitators’/brokers’ role, and patience, were vital for the 
programme's success. This meant that an effective framework for network promotion 
among indigenous firms had been established. The report proposed that a national 
programme for network promotion should be set up within Forbairt. However, no such 
programme was established. Subsequent network-related programmes introduced by 
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Forbairt/EI have been skills-based, e.g. Skillsnet (established in 1999) is a collaborative 
training programme involving collaborative networks between employers, unions and 
state agencies to improve workforce training particularly among SMEs (ADAPT, 2002; 
Breathnach, 2001; Edquist and Hommen, 2008; The Department of Enterprise, Trade 
and Employment, 2003). 
 
The three research papers that jointly formed the second NESC report (1997) were 
commissioned to establish the suitability of applying Porter’s cluster model to Irish 
industrial development. The authors initially struggled to find successful sectors to 
analyse, yet finally identified the music, dairy processing and software sectors after 
altering Porter’s criteria for defining competitiveness. The three mini-reports ultimately 
found that Porter's model was inappropriate in the Irish context, as it had little validity 
in a small, open economy like Ireland, and that it was better suited to large mature 
manufacturing economies like the US and Japan, and contended that 
augmentations/alterations to Porter's theory would be necessary. Indeed, Porter adjusted 
the geographic focus of his theory in a revised edition (1998) to include non-
internationally competitive regional industries, and identified significant benefits 
associated with closely approximated firms, e.g. competitive rivalry and the 
development of specialist pools of labour (Breathnach, 2001; Clancey et al. 1997; 
O’Connor, 1997; O’Gorman et al., 1997).  
 
In 1998, the Department of Enterprise, Trade, and Employment (presently the 
Department of Enterprise, Trade and Innovation) issued a policy statement, following 
the formation of EI, which drew on the NESC cluster reports and the proceedings of a 
NESC seminar entitled 'Sustaining Competitive Advantage'. The statement concluded 
that the industrial base in Ireland was not suitably advanced to support industrial 
clusters. However, the seminar proceedings presented alternative development strategies 
that highlighted networks as a means to facilitate cluster development (O'Donnel, 1997; 
O'Brein, 2004). 
 
In the following years, documents and statements released by EI and Forfás did not 
deviate from the established policy emphasis on promoting individual industry through 
individual firm development/cultivation, and they continued to pay lip service to the 
concepts of networks and clustering. This emphasis remained despite the publication of 
the National Competitiveness Council’s Annual Competitiveness Report in 1999 which 
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specifically called for the promotion of networks and clusters, stating that “SMEs can 
be competitive if they can realise collectively the advantages of economies of 
specialisation that they do not have individually because of their small size” (National 
Competitiveness Council, 1999: 157). Additionally, the ICSTI's Technology Foresight 
Report (1999) recommended the development of biotechnology clusters in Ireland, 
though no specific development proposals were identified (Irish Council for Science 
Technology and Innovation, 1999). 
 
However, over the last ten years the concepts of networks and clustering have seeped 
into the vocabulary of various Government Department and agencies, as evident in 
various publications issued since 2000. The Department of Enterprise, Trade and 
Employment’s 'Review of Industrial Performance and Policy' (2003) focused on 
developing Ireland’s economy through partnership structures focused on industrial 
niches. The proposed structures included features of networks and clusters. In seeking to 
optimise the expenditure from the NDP (2000-2006), the review called for close 
interactions, i.e. collaborative networks, between TNCs, indigenous companies, PREOs, 
VCs, regional and local authorities, and other actors. The review focused on developing 
niches in the software, biotechnology and digital media sectors, and highlighted the 
importance of SFI's CSET centres in fostering networks between PREOs and industry. 
Notably, the review criticised previous policies having worked against the formation of 
clusters in Ireland (The Department of Enterprise, Trade and Employment, 2003). 
 
The introduction of networking into the thinking of development agencies was further 
advanced with the publication of two policy reports in 2004. The first report, Innovation 
Networks, examined the functioning of inter-firm networks internationally and in 
Ireland. The report stated that the government “...should focus on inter-firm networks as 
a key building block for the development of the innovation capacity of Irish 
manufacturing and internationally traded services” (Forfás, 2004: 11) and that 
developing inter-firm networks is “an important precursor to the formulation of policies 
in relation to clusters” (Forfás, 2004: 11). 
 
The second report, 'Ahead of the Curve: Ireland's Place in the Global Economy', 
identified industrial networks as being key in the development of globally competitive 
indigenous niches. It recommended that an annual fund of €20 million be introduced to 
support business network developments. EI was charged with this proposal's 
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responsibility, yet EI's next strategy statement, covering the period 2005-2007, made 
only token references to networks and maintained the agency’s primary focus on the 
development of individual firms (Enterprise Strategy Group, 2004; Enterprise Ireland, 
2005; Edquist and Hommen, 2008). 
 
Network promotion was also highlighted in the Department of Enterprise, Trade and 
Employment’s 'Building Ireland’s Knowledge Economy' (2004), an action plan for 
developing R&D investment. The report specifically called for the introduction of a 
networking- and cluster-led approach under the guidance of EI and the IDA Ireland, 
through focusing on specific areas “…where Ireland can develop internationally 
recognised applied research competencies” (Department of Enterprise, Trade and 
Employment, 2004: 28). 
 
In response, EI initiated a pilot programme in 2005 to encourage research-based 
industry networks between companies on common topics in niche areas, including 
Biotechnology and NICTs. The programme demonstrated that while developing mutual 
research agendas among firms is challenging, the participant firms derived noticeable 
benefits, and that strong inter-company networks formed. In 2006, the DETE published 
'Strategy for Science, Technology and Innovation 2006-2013' which mainly focused on 
attracting and developing FDI, yet looked towards network developments as a means of 
optimising NDP investment returns in PREO R&D by improving the rate of technology 
transfer of research through industry-led networks. It also called for the promotion of 
inter-firm networks, based on EI's pilot programme, yet no action was taken 
(Department of Trade, Enterprise and Employment, 2006).  
 
The current National Development Plan (2007-2013) calls for the development of all-
Ireland business networks and clusters to facilitate greater levels of innovation between 
industry and PREOs, and for the optimisation of technology transfer of PREO research. 
Yet, Government policy remains focused on attracting and developing FDI. The plan 
also calls for the development of “…niches of business in which Ireland can carve out 
world market leadership” (Government of Ireland, 2007: 159). To date, no real action 
has occurred in relation to these proposals.  
 
In 2008, the DETE published 'Knowledge and Enterprise Clusters in Ireland', which 
acknowledges that networks and clusters were recommended many times since the 
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'Culliton Report', and comments that both concepts now form part of several on-going 
initiatives, including Skillnets, EI's network-related pilot programme, and 
InterTradeIreland's business networks. However, it also makes several statements which 
indicate that the concept of industrial clusters is not fully understood, including the 
statement that clusters have already formed in Ireland “in sectors such as ICT, 
bio/pharma and internationally traded services” (Department of Trade, Enterprise and 
Employment, 2008: 10). However groupings of firms are presented, by sectoral 
activities, in geographically concentrated locations as justification for such claims. No 
hard evidence of clustering is presented (Department of Trade, Enterprise and 
Employment, 2008a, 2008b).  
 
5.4 DISCUSSION 
5.4.1 Irish industrial and STI policies 
The previous descriptions of Ireland's industrial and STI policies demonstrates that no 
co-ordination exists between both policy strands, i.e. both strands exist parallel to each 
other, with no co-ordination and/or complementary supports being present. This 
scenario has existed since the state's inception, and continues despite the development 
of relatively more long-term and co-ordinated funding and development initiatives since 
the late 1990s.  
 
Since the adoption of open market policies in the late 1950s, the predominant focus of 
the state's industrial policies has been towards attracting FDI branch plants into the 
country, with limited policy emphasis on industrial sectoral development outside of 
agriculture. Successive reports from the 1960s onwards have characterised indigenous 
industrial firms as being small, strongly orientated around the small domestic market, 
and having a relatively low propensity towards innovative activities. These 
characteristics initially developed, in part, due to the protectionist policies which 
defined the country's economy until the late 1950s, and consolidated due to the minimal 
policy emphasis on indigenous firms, particularly relating to research-based activities, 
until the 1990s. Despite on-going efforts to address these issues, no culture of research 
or innovative activity exists among indigenous firms to cultivate (Cogan and McDevitt, 
2002).  
 
In relation to the country's science policy, limited emphasis was placed on PREO-based 
research activities outside of agricultural-related areas until the late 1990s. Investment 
levels in the country's PREOs have surged due to the various initiatives introduced 
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following the White Paper in 1996, yet they have had to address close to 70 years of 
under-investment in PREO infrastructure, equipment and skills-related areas (Cogan 
and McDevitt, 2002).  
 
Additionally, the established innovative limitations of indigenous industry, allied to the 
branch plant nature of FDI operations, despite the introduction of more 'high-skilled' 
FDI activities, means that the demand for indigenous PREO-based research has been 
minor until very recently. This fed into, and further compounded the limited abilities of 
the PREOs to conduct and devise industry-orientated research activities. 
 
Essentially, indigenous industry and PREOs have suffered decades of 'cumulative 
disadvantage' (NESC, 1993: 275) due to limited policy attention, the limited size of the 
Irish market, and their limited research and innovative capabilities. While efforts 
seeking to develop linkages between PREOs and indigenous industry have been 
introduced, no overarching policy structure exists to address the innovation paradox that 
presently exists, i.e. the limited abilities of PREOs to engage in, or diffuse 
commercially-orientated research activities, and the limited absorptive capacity, or 
ability of indigenous firms to engage in such activities. 
 
Additionally, the Government's industrial policies remain focused on FDI-related 
firms/sectors, particularly in seeking to attract more complex R&D-related FDI 
operation into the country. While more advanced FDI activities have been introduced, 
their linkages with the indigenous economy remain limited. Recent developments, e.g. 
the relocation of Dell's Limerick-based activities to Poland, have again exposed the 
vulnerability of this policy focus and approach.  
 
Barry (2006) commented that if “Ireland's ability to attract FDI were to deteriorate for 
any reason…(e.g., through a shift in US corporate strategy or a change in US tax laws), 
the country could be thrown back onto the resources of indigenous industry...[which] 
remain quite weak” (Barry, 2006: 54). In 2009, the US Government announced plans to 
remove 'deferral rules' that allow American firms defer reporting income generated in 
their non-US operations to the US Internal Revenue Service, and to claim tax credits for 
paying foreign taxes, i.e. tax exemptions or deductions on their US tax bill on, for 
example, investments on their non-US based factories. This development could have 
substantial impacts on existing FDI operations in Ireland, particularly if the changes to 
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the US tax system are extended (Staunton and Hancock, 2009; Fey, 2009). 
 
Additionally, recent decisions by different TNCs to restructure their global operations, 
in part due to the rising cost base of operating in Ireland, have had substantial impacts 
on the economy, e.g. Pfizer’s announcement that it would close three Irish-based 
manufacturing plants in 2010 (The Irish Times, 2010). 
 
5.4.2 Network- and Cluster-related policies 
Until recently, the concepts of networks and clusters did not feature in Irish industrial 
policy despite many reports since the early 1980s calling for their introduction. These 
concepts have entered the vernacular of Government agencies over the last 10 years. 
Yet, despite their increased prominence, no programme seeking the development of 
networks and/or clusters has been introduced due to an absence of commitment from the 
Government. 
 
There seems to be limited understanding of what both concepts are, judging by recent 
reports released by the Department of Enterprise, Trade and Employment. Networks are 
presented as a mix between business networks, i.e. quasi-social 'networking', and inter-
actor networks. In relation to clusters, no real evidence exists that the concept is fully 
understood, e.g. geographic proximity among some industry firms, with no regard for 
the nature of their interaction, is seen as being sufficient to declare such groupings as 
clusters. 
 
A major issue potentially hampering cluster-related policy formulation is that the 
regional aspect of clusters runs counter to the long established centralist structure of the 
Irish Government. From the state's inception until 2002, no clearly defined regional 
aspect to Irish Government structures, policies or programmes existed, while the 
government and its administration remains highly centralised around the GDA.  
 
One of the first calls to introduce regional aspects to Government policies was through 
the publication of a Government report, 'Regional Studies in Ireland' (1968), commonly 
referred to as the 'Buchanan report' after its author Colin Buchanan. This report sought 
to formulate economic development proposals with an explicit regional focus. It stated 
that Ireland's future economic development would concentrate around the GDA, and 
proposed that industrial development should concentrate in a limited number of 
development centres throughout the country in an effort to counterbalance the GDA's 
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magnetism. Less then a dozen locations were identified as being suitable for these 
centres, meaning the report's proposals received little public, and crucially, political 
support. Its findings were essentially shelved, and subsequent FDI activities were 
geographical dispersed, predominately in response to political concerns (Bradley, 2000; 
Dempsey, 2001). 
 
It wasn't until 2002 that a defined regional focus was introduced to Government policies 
with the publication of the National Spatial Strategy (NSS) (2002). The NSS was a 
long-term (20 year) strategic vision for Ireland’s future spatial development. It detailed 
an overreaching national framework for balanced regional development for the various 
policies, programmes and investments of the relevant government departments and 
agencies. However, it was unclear as to how elements of the strategy should be 
implemented (NSS, 2002).  
 
The NSS was formulated in response to the majority of the 'Celtic Tiger' related 
developments being focused and located in the GDA, as predicted by the Buchanan 
report. Due to Dublin’s position as Ireland’s capital city and centre of political activity, 
it has always been the country’s key economic centre. As stated above, Dublin’s 
importance to the Irish economy deepened during the 'Celtic Tiger' era, resulting in a 
significant imbalance between the GDA and the rest of the country (Brennan, 2007; 
Clark, 2008; Goodbody Economic Consultants, 2007). 
 
The NSS called for balanced regional development in a polycentric urban structure, i.e. 
that all regions should contribute to the optimal economic, social and environmental 
performance of the state as a whole. The strategy was structured and organised around 
the concepts of gateways, i.e. designated key urban centres whose critical masses of 
economic activity would drive the development of urban areas and their surrounding 
regions, and hubs, i.e. strategic regional centres that would invigorate their immediate 
surroundings and act as links between the gateways and rural areas. The gateway cities 
would act as the economic drivers of their regions, acting as a counter-balance to the 
GDA, and at the same time complementing it (Cooke, 2002: Department of Trade, 
Enterprise and Employment, 2003; NSS, 2002).  
 
The NSS emphasised the importance of regions in Ireland’s future economic 
development. Despite the increased influence and importance of globalisation to 
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economic development, regions increasingly play central roles in determining a 
country’s economic performance, i.e. high-value, high-innovation enterprises optimally 
develop in areas where there exist concentrations of enterprises, skills, infrastructure, 
and services, and PREOs with well-developed capabilities in their particular field. By 
developing gateways and hubs, the NSS aimed to increase the locations in Ireland that 
could offer a viable and attractive location for advanced high-technology enterprises 
(Cooke, 2002: Department of Trade, Enterprise and Employment, 2003). 
 
While the NSS contained no concrete proposals for developing industrial clusters, it did 
provide a rationale for concentrated spatial development upon which such policies could 
be developed, i.e. regional structured innovation/enterprise supports to facilitate the 
development of regional specific cores of knowledge and human capital, and varieties 
of networks that facilitate innovation and ultimately lead to cluster formation. 
Essentially, through developing and exploiting existing regional differentiations within a 
dedicated regional support framework, the NSS, as a very bare framework, presented a 
potentially useful model for an over reaching, network and cluster orientated 
development policy programme in an Irish context.  
 
However, funding for the Gateways Innovation Fund Programme, the NSS’s centre 
component, was deferred in 2008 as the Government sought to cut public spending 
following the post-Celtic Tiger economic slump. No indication of the funding being re-
established, or of the formulation of a replacement programme, has been made to date 
(Tansey, 2008).  
 
5.4.3 Biotechnology specific policies 
Following the emergence of the modern bio-sector in the mid 1970s, governments in 
many developed economies identified biotechnology as playing an important role in 
their future economic development.  
 
The Irish Government first identified biotechnology's importance for Ireland’s future 
development in the late 1970s, yet serious and sustained efforts to develop a significant 
indigenous bio-sector were not introduced until the late 1990s. These initiatives have 
focused on facilitating developments in the country's PREOs. To date, no defined or co-
ordinated policy programme has been developed that targets the entire bio-sector's 
development as a whole, i.e. biotechnology-related initiatives remain dispersed among 
different industrial and STI policies, no joining up of interrelated policy strands has 
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occurred.  
 
The bio-sector’s value chain is inherently network structured, while the international 
bio-sector's key hubs are industrial clusters. The absence of a defined network approach 
towards sectoral development, despite various Government reports identifying them as 
crucial features in the development of the international bio-sector, and the absence of 
defined regional aspect to current development initiatives are significant issues.  
 
Essentially, the uncoordinated industrial and STI policy strands, combined with the 
absence of network or cluster elements to these policies, demonstrates that the Irish 
Government's current policy approach towards developing the indigenous bio-sector is 
not suitably, or optimally focused towards the bio-sector's needs. 
 
Using the key points made in this discussion, the focus of the thesis now turns towards 
an analysis of the indigenous sector's network structure. 
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CHAPTER 6: 
ACTOR TYPOLOGIES IN IRELAND’S INDIGENOUS 
BIOTECHNOLOGY 
SECTOR 
 
6.1 INTRODUCTION 
This chapter applies the international biotechnology sector's (bio-sector) actor 
typologies to the Irish bio-sector, so as to identify the features, characteristics, and 
development trends of indigenous actors in relation to those found in the international 
bio-sector. The chapter is divided into two sections. Section one details the evolving 
nature and characteristics of the indigenous bio-sector's actors, in relation to the impacts 
of previous and on-going public sectoral development initiatives. Section two discusses 
the structure of the Irish bio-sector and how it compares to the actor typologies and 
sectoral structures in the key international bio-sectors, as detailed in chapter 3, in the 
contexts of the evolving characteristics of the actors themselves and the role of 
government initiatives in their development trajectories. The methodology employed in 
compiling these typologies was detailed in Chapter 4.  
 
6.2 ACTOR TYPES IN THE IRISH BIO-SECTOR  
The following actor typologies were derived from an augmented and up-dated version 
of typologies developed by Barley et al. (1992) and from observable patterns in the 
international bio-sector (as detailed in Table 6.1). It must be noted that all of the sectoral 
actor types are important in the sectoral value chain, acting as either incubators or 
transfer mechanisms within the bio-sector's innovation process. They are detailed 
separately below solely for ease of presentation.  
 
6.2.1 Public Research and Education Organisations 
Very limited Government investments occurred in the infrastructures, facilities, 
resources or skill sets of Ireland's PREOs over an almost 70 year period, prior to the mid 
1990s. This was due to the different Science, Technology and Innovation (STI) policies 
over this period predominantly focusing on supporting the country's agricultural and 
food sectors (as detailed in the previous chapter) (Acheson, and Lambkin, 2009; Burke 
et al, 2003).  
 
Irish Government STI policies began in earnest from the 1960s onwards, yet very 
limited research grants and/or infrastructural investments were introduced. Indeed, the 
majority of STI policy-related developments from the late 1970s onwards were 
supported and/or motivated by a variety of European Economic Community/European 
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Union programmes, particularly the different Framework Programmes. As such, 
entrenched institutional inertia co-existed with structural inflexibilities, i.e. the 
individual PREO actors types were clearly differentiated, and had relatively little 
resources to develop research facilities and/or programmes (Acheson, and Lambkin, 
2009; Cordis, 2006; Forfás, 2004).  
 
In the wake of the publication of the 1996 White Paper on Science, Technology and 
Innovation, the Irish Government identified biotechnology as being crucial for Ireland's 
future economic development. Since the late 1990s, sustained public investment 
programmes, particularly the Programme for Research in Third Level Institution 
(PRTLI) and the Technology Foresight Fund (TFF), have targeted the formation of an 
advanced PREO-based science base as a central element in the development of the 
indigenous bio-sector, and have facilitated substantial research infrastructure, resource, 
and skills-related developments.  
 
There are presently eight Universities (including the Royal College of Surgeons in 
Ireland), 14 Institutes of Technology (IoTs), 37 PREO-based research institutes (RIs) 
and 12 research hospitals (RHs). The largest concentration is in the Greater Dublin Area 
(the GDA), followed by Counties Cork and Galway (Figure 6.1).  
 
6.2.1.1 Universities 
The level of university-based research in the Irish bio-sector was restricted by the 
limited infrastructures, resources and skill sets which had developed due to the limited 
investments in the PREOs until the introduction of the on-going development 
programmes in the late 1990s. As detailed further in the following chapter, these issues 
undermined the commercial developments in the indigenous bio-sector.  
 
Since the late 1990s, the capabilities of Universities have advanced due to the on-going 
public investment programmes. However, it must be noted that such developments have 
been limited relative to those of the RIs, due to the pronounced RI focus of these 
programmes (detailed further in the following section).  
 
There are eight Irish universities (Figure 6.1), employing close to 500 academic staff in 
biotechnology-related subjects. Annually, around 500 students graduate from the 
universities'    biotechnology/biotechnology-related    undergraduate   and   postgraduate 
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Table 6.1: The bio-sector actor typologies 
Public Research and Education Organisations (PREOs): Commercial biotechnology developments in the international bio-sector are predominantly 
based upon findings from the research programmes of PREOs, they also facilitate complex tacit and codified information exchanges, and crucial 
sectoral skills developments and transfers. There are three PREO actors:  
 Universities are the main source of the basic research from which commercial biotechnology activities are derived. Academic departments 
primarily focus on long-term speculative/exploratory basic research, which is important for volatile technology sectors, by being less subject to 
market pressures then commercial actors. Universities actively promote information transmission by adhering to “the [traditional] norms of the 
open information disclosure characteristic of public science” (Smith and Powell, 2004: 8) through lecturing, publications, and placements. They 
also provide undergraduate and research-orientated postgraduate education programmes. 
 Public Research Institutes (RIs): Typically established by university academics in association with government departments/agencies to develop 
themed research programmes based on their areas of expertise, RIs typically locate in close proximity to their 'parent' university/universities. The 
focus mainly on applied research; many commercial developments originate from RIs as governments seek, internationally, to engender such 
developments though facilitating formal alliances with commercial actors via defined commercialisation supports and infrastructures.  
 Research Hospitals (RH): RHs focus on specialised medical research, engaging in application-based diagnostic and therapeutic activities. RHs 
associated with a 'parent' university are typically located in close proximity. RHs are significant actors in the sector's innovation process by being 
the main source of clinical research trial samples, and are also involved in the clinical trials of new biotechnology-based therapeutics and 
diagnostics products, through joint research programmes with bio-firms and/or TNCs or via in-house laboratory research. RHs are among the 
main customers of biotechnology-derived pharmaceutical products and services. 
PREOs increasingly seek commercial developments from their activities, and have developed advanced commercialisation procedures to optimise 
research transfers to commercial concerns. These mechanisms include pronounced commercial elements in education programmes to 
inculcate/encourage commercial mind frames among researchers, industrial liaison offices (ILOs) seeking to identify viable research into link into 
firm-based research programmes, technology transfer offices (TTOs) proactively seeking to transfer IP to commercial actors (some US and UK 
TTOs are independent entities whose survival depends on successfully commercialisation), and the development of bio-incubators (located in close 
proximity to RIs) to optimise firm developments through training, development, financial support services. 
Biotechnology firms (Bio-firms): The bio-sector's innovation process, and key informal and formal networks, can be separated into two broad 
categories, upstream and downstream activities, relative to a firm’s position in the sector's value chain. PREO research can be conceived as the 
upstream end of the value chain. Firms seek to engender informal and formal relationships with PREOs to access and commercialise research. The 
clinical trials process and sale to the consumer can be conceived as the downstream end, i.e. predominately formal network-based interactions with 
TNCs and other firms. Bio-firms traditionally occupy the middle rung in the sector's innovation process, being the main transferring mechanism of 
PREO research to the market. They draw on heterogeneous communities of experts at various points in their development, and are established by 
PREO researcher to pursue research exhibiting clear commercial promise to develop commercial products and services in a wide variety of 
research areas (yet, overwhelming in pharmaceutical-orientated research). Their development is determined through formal alliances with investor 
actors, particularly Venture Capital firms, to finance their start-up and initial developments prior to forming alliances with downstream actors. A 
firm’s ability to access PREO-based knowledge and VC funding are the determinants of its research capabilities and its success in commercialising 
research through commercial actor alliances. 
Investors: The technical and financial resources required to develop biotechnology products are beyond the capabilities of most bio-firms as, in 
comparison to other high-tech intensive sectors, development costs in biotechnology are significantly higher, e.g. product development can take up 
to 20 years and cost up to US$1 billion. Different investor types play particular roles in the product development process:  
 Personal and Private funding sources: Due to their high risk nature, bio-firms often cannot access traditional finance sources, e.g. bank loans, 
meaning their set-up stages are often financed through personal and private funding, i.e. personal savings, private loans from friends/family, and 
non-business bank loans offset by the value of their intellectual property. 
 Public and Private Venture Capital firms: VCs have played central roles in the international bio-sector's development since its inception. 
Typically established by wealthy private investors or by governments seeking to develop indigenous sectors, they target relatively unproven 
businesses traditional investors (e.g. banks) avoid due to high-risks or excessive development costs. VCs are compensated through equity 
securities in a firm in return for an investment, and thus a portion of capital gains when the firm is traded on stock markets through an Initial 
Public Offering (IPO) or bought up/bought into by a TNC (the main exit strategies for VCs in bio-sectors). VCs provide managerial and 
technical expertise to optimise a bio-firm's business development (academic researchers normally receive minimal education/training in 
business-orientated subjects), and new management structures can be sought to deal with the complexities of negotiating downstream 
alliances/collaborations. Several issues with VC funds motivates bio-firms and VCs to seek exit strategies, including a mismatch between the 
typical length of a VC alliance (5 years) and the biotechnology product/process development cycle's duration (approximately 15 years), while 
VC funding oscillates due to the relative performance of global economies and other industries. 
Diversified Transnational Corporations (TNCs): TNC involvement in the international bio-sector predominantly focuses on pharmaceutical 
activities as the 'tradition' knowledge base they derived products from (organic chemistry) is reaching its technological development limits. 
Biotechnology draws from a different knowledge base (immunology and molecular biology) whose limits have yet to be clearly defined, and is 
easily adaptable to TNC requirements, meaning it is increasingly the basis of new pharmaceutical products/treatments. As the development costs 
and duration of new drugs is increasing due to stringent regulatory requirements, which impinge on TNCs recouping their development 
investments, and as effective patent-protection on traditional products is being impacted by generic products, TNCs are focusing on small volume 
niche market drugs, new versions of existing drugs, and have moved from mono-product to 'flexible' multi-product production. TNCs collaborate 
with bio-firms to optimise product development activities and fill their product development pipeline, which represent the main downstream 
relationships of the sector's innovation process. 
Government Departments and Agencies: Many industrialised nations have identified biotechnology as key to their future economic development. 
Governments are increasingly crucial in providing funding to drive sectoral developments. Such funding can be typified as being primarily PREO 
focused, through resource and capital investment programmes/initiatives in the research capabilities and infrastructures of PREOs. Governments 
are also placing increased commercial emphasis on PREO activities to drive sectoral developments, and have created dedicated public VCs funds 
to address speculative funding shortages in sectors. 
Additional actor types: 
 Supply firms facilitate research and production activities, service suppliers provide specialised systems and solutions to different issues arising in 
research. 
 Sub-national Biotechnology Centres are typically created by business associations to optimise a region’s network structure and density, and 
disseminate important region-specific information among sectoral actors. 
 Trade associations focus on specific sectors/sub-sectors, not particular locations, circulating sector-specific information and providing services to 
their members'. They can construct brands to improve a sector's profile, and act as lobbyists. 
 Private Research Institutes are usually founded by wealthy benefactors to fund research in areas that receive little commercial attention, but are 
judged to have social value.  
 Repositories (Gene Banks) are stores of genetic resources that seek to maintain genetic diversity by capturing a genetic picture at a particular 
point in time, and are important for future research projects, particularly genomic research. 
After (Burke et al, 2003; Owen-Smith and Powell, 2007; Prevezer and Tang, 2008; 
Gertler and Levitte, 2005; Powell and Brantley, 1992; Barley et al., 1992; Stuart et al., 
2007; Giesecke, 2000; Feldman and Braunerhjelm, 2007; Ernst & Young, 2007a; 
Ahrweiler et al., 2011; Lee, 2012; Eisingerich et al, 2012). 
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courses. These courses cover a diverse range of biotechnology/biotechnology-related 
subjects including genetics, biology, biochemistry, micro-biology and molecular biology 
(see Appendix D for full details) (Forfás, 2001; Morrissey, 2011). 
 
Within the universities, Forfás (2003) noted specific areas of excellence in the following 
biotechnology-related areas:  
 
 biochemistry and molecular biology, 
 microbiology and chemistry, and 
 veterinary sciences, neurosciences, biotechnology and applied microbiology, and 
genetics (Forfás, 2003). 
 
6.2.1.2 Institutes of Technology 
The country’s IoTs were initially established as Regional Technical Colleges (RTCs) in 
1968, following the creation of the National Research Council in 1967, so as to “meet 
the technical training needs of [the] newly arrived multi-national manufacturing 
industries” (Acheson, and Lambkin, 2009: 3) attracted into Ireland through the adoption 
of open market policies in the late 1950s. Historically, the RTCs focused more on 
providing training courses in specific activities, e.g. laboratory technician training, 
rather than on research. 
 
In 1999, the RTCs were renamed IoTs, and their focus changed as government agencies 
sought to exploit their untapped scientific resources. Through PRTLI funding, their 
research activities have expanded, yet to a limited degree. To date, only two IT-based 
RIs have been developed in biotechnology-related areas (detailed in Appendix D) due to 
the development initiatives overwhelming focusing on the development of university-
based RIs (Higher Education Authority, 2004, 2007).   
 
6.2.1.3 Public Research Institutes 
A small number of (relatively) adequately funded and supported PREO-based RIs were 
formed during the 1980s, i.e. the five BioResearch Ireland RIs created in 1987 through 
the National Biotechnology Programme (NBP) (detailed in the previous chapter), and 
several Teagasc's RIs (discussed further below). The BioResearch Ireland RI's were 
initially intended to develop downstream links with the indigenous bio-sector by 
engendering the emergence of start-up bio-firms, yet they were ultimately established as 
independent entities from the departmental structures of their 'parent' universities, and 
subsequently failed to develop/feed into significant downstream developments, in part 
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due to the presence of a significant innovation paradox among the RIs and the wider 
bio-sector (Forfás, 2004).  
 
Following the introduction of the PRTLI and the TFF, 26 RIs have been established 
(Figure 6.2). Government agencies view these RIs as being key elements in the 
indigenous bio-sector's development, mirroring the characteristics of RIs in the 
international bio-sector. The RIs have been specifically created with inter-institutional 
structures, and proactively target the development of extensive networks/collaborations 
with downstream actors, as their long-term survival is dependent on generating money 
from successful commercial ventures, i.e. they are only fully funded for five years, with 
no default budget, after which they are expected to become self-sufficient entities by 
generating revenue streams via commercial alliances (Higher Education Authority, 
2006, 2007; Morrissey, 2011). 
 
6.2.1.4 Research Hospitals 
Until the late 1990s, hospital-based research was essentially an untapped resource in the 
indigenous bio-sector as these institutions received limited funding, and they conducted 
minimal research activities as a result. In the context of the indigenous bio-sector's 
limited commercial activities (detailed further below), Irish hospitals essentially had no 
involvement in commercial activities.  
 
Since the late 1990s, hospital-based research activities have increased with the 
development of several RHs and bio-incubators. There are currently 12 biotechnology-
related research and teaching hospitals (Figure 6.2) affiliated to Irish PREOs, eight in 
the GDA, and two each in Cork and Galway (discussed further in Appendix D). A key 
RH development was the establishment of the Dublin Molecular Medicine Centre 
(DMMC) in 2002, through PRTLI and the National Development Plan (NDP) (2000-
2006) funding, which links three Dublin-based universities and six RHs (Higher 
Education Authority, 2006; Dublin Molecular Medicine Centre, 2007a). 
 
6.2.1.5 The commercial orientation of Irish PREOs 
The commercial orientation of Irish PREOs, prior to the late 1990s, was poor due to a 
combination of factors, i.e. the limited nature of the commercialisation support 
procedures and infrastructures of all the PREOs, the limited commercial orientation of 
administrators and academics, and the limited emphasis on the commercialisation of 
PREO activities by Government actors. This scenario fed into, and was compounded by 
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the limited levels of downstream sectoral activity. 
 
Following the introduction of the on-going Government initiatives, significant 
improvements have occurred in the commercial orientation of the country's PREOs. 
These developments include the development of more advanced and proactive 
commercialisation procedures and infrastructures in their TTOs and ILO, while five 
innovation centres, i.e. incubators, have also been introduced: 
 
 the INVENT incubator located at DCU (opened in 2004); 
 the NovaUCD incubator located at UCD (opened in 2005);  
 the Trinity Bioincubator located at TCD’s Enterprise Centre (opened in 2004);  
 the NUIG Bioincubator (opened in 2004), and;  
 the Bio-incubation Centre located at UCC (opened in 2004) (Forfás, 2008; 
Enterprise Ireland, 2005a, 2005b, 2005c, 2005d, 2005e). 
 
These incubators replicate features of their counterparts in the international bio-sector, 
i.e. they provide laboratory space and financial and business supports in legal, 
marketing and management areas so as to facilitate the emergence of innovative 
commercial entities originating from PREO research. The incubators were established 
through funding and support from Enterprise Ireland (EI) and Enterprise Ireland's 
Biotechnology Directorate (EIBD), and have had substantial impacts on the 
commercialisation of PREO-based research, particularly through the recent RI 
developments (Forfás, 2008; Enterprise Ireland, 2005).  
 
Additionally, Science Foundation Ireland (SFI) established Centres for Science, 
Engineering & Technology (CSETs) in 2003. The CSETs assist the development of 
alliances between scientific and engineering PREO-based researchers and industrial 
actors, so as to develop new and existing Irish technology-based companies. Of the 
eight CSETS, four are engaged in biotechnology/biotechnology-related activities 
(Alimentary Pharmabiotic Centre, 2007: Forfás, 2004: The Irish Scientist, 2003: 
University College Cork, 2003: Science foundation Ireland, 2002, 2007). 
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The improved commercial supports and orientation of the PREOs has resulted in a 
relative surge in commercial activities, in particular a dramatic increase in the number 
of start-up bio-firms originating from RI-based research over the last 10 years. This is 
detailed further in the following section.  
 
6.2.2 Biotechnology firms 
A very small number of indigenous bio-firms were established prior to the development 
of the modern bio-sector in 1976 in areas that subsequently became biotechnology-
related sectors, e.g. pharmaceuticals and food processing. Following the development of 
commercial biotechnology technological applications, these firms began to adopt 
biotechnology processes/technologies and to develop biotechnology activities. 
Subsequently they abandoned their 'traditional' technological platform(s) completely in 
favour of biotechnological applications and procedures.  
 
In relation to 'traditional' bio-firms, there exist two distinct tiers in the indigenous bio-
sector, i.e. those formed before and after the introduction of the various sectoral 
development initiatives in the late 1990s which followed the publication of the White 
Paper on Science, Technology and Innovation in 1996 (in particular the Programme for 
Research in Third Level Institutions and the Technology Foresight Fund, as detailed in 
chapter 5). From here on, depending on when they were established, the indigenous 
firms are referred to as pre- and post-initiative bio-firms. Indeed, it must be noted that 
the pre- and post-initiative divides presented in this chapter, and in the remaining 
chapters, also refer to these time periods.  
 
In 2000, there were thirty Irish firms in the bio-sector. As with firms in the international 
bio-sector, they were predominantly established by commercially-minded PREO-based 
researchers that identified either a domestic market opportunity, e.g. the relative absence 
of diagnostic services, or a specific technology that had obvious commercial potential. 
However, as these pre-initiative bio-firms developed when the indigenous bio-sector 
was characterised by substantial structural weaknesses, they were very high-risk 
ventures for several reasons (Morrissey, 2011).  
 
In particular, the bio-firms emerged in the context of poor levels of 
entrepreneurial/commercialisation experience and supports among the PREOs (as 
detailed above), which resulted in many bio-firms buying their Intellectual Property (IP) 
from non-Irish PREOs. Additionally, due to the virtual absence of 'traditional' bio-sector 
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funding sources, i.e. a small and sceptical local VC community (detailed further below), 
these bio-firms relied mainly on private donations and substantial personal loans. In the 
very limited number of cases where bio-firms accessed speculative investor funding, 
they were with non-local investors, particularly US- and UK-based actors (BioResearch 
Ireland, 2001b).  
 
These issues resulted in the pre-initiative bio-firms adopting very conservative business 
models. Many bio-firms deliberately targeted slow growth rates and very narrowly 
defined niche areas, i.e. diagnostic-related activities, to side-step these issues, and 
offered services to commercial actors so as to finance their core R&D activities and 
maintain turnover. Overall, the operations of the majority of pre-initiative bio-firms 
were (and remain) limited in size and scope, while their narrowly defined activities 
meant they were not research focused/orientated. These issues resulted in a very limited 
number of pre-initiative bio-firms successfully developing products/processes in 
diagnostics and pharmaceutical biologicals areas (Malecki, 1997; Morrissey, 2011). 
 
In contrast, the post-initiative bio-firms can be characterised as 'Genentech template' 
start-up bio-firms, i.e. they emerged in the context of significant RI-based activities, and 
in the presence of advanced PREO-based commercialisation supports and dedicated 
biotechnology VC funds (discussed further below). However, due to their age and 
relative state of development, they are small in size and have yet to engender significant 
commercial activity. Additionally, they are engaged in therapeutic and platform 
technology-related activities, which means no firm-based drug development activities 
have occurred to date in the Irish bio-sector. 
 
There are presently 66 indigenous bio-firms engaged in biotechnology/biotechnology-
related activities. The largest concentrations of bio-firms are in the GDA (28 bio-firms), 
the Cork City region (13 bio-firms), and the Galway City region (7 bio-firms). The bio-
sector employs over 500 people directly, and the indigenous bio-firms generated over 
€430 million in turnover in 2003, yet the majority of this was accounted for by a very 
limited number of bio-firms (InterTradeIreland, 2003; Enterprise Ireland, 2005; IDA 
Ireland, 2007; Morrissey, 2011).  
 
Table 6.2 shows the sub-sectoral breakdown of their activities, and the number of bio-
firms involved in each activity in 2009. Irish bio-firm activities are overwhelmingly 
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pharmaceutically-orientated, yet the bio-sector's activities are quite varied, covering 
most areas of current biotechnology activity. There are a limited number of specialist 
supply firms in the bio-sector, e.g. platform technology and specialist research bio-
firms. This may appear to reflect trends of vertical integration found among bio-firms 
internationally, yet the nature of their linkages with other sectoral actors is restricted due 
to the bio-sector's limited size and activities. Their activities are very narrowly focused 
due to conservative business models, and in one case a supply bio-firm is essentially an 
'independent' subsidiary of a PREO (BioResearch Ireland, 2001; InterTradeIreland, 
2003).   
 
Table 6.2: Activity focus of the Irish bio-sector's bio-firms 
Bio-firm Type Bio-firm 
numbers 
Descriptions of bio-firm activities 
Pharmaceutical- 
biologics bio-firms 
23 Bio-firms which develop biotechnology-based vaccines and types of therapeutics.  
Pharmaceutical  
services bio-firms 
11 Bio-firms which provide services to the pharmaceutical-healthcare sector, including the provision of 
recombinant proteins and recombinant production services. 
Diagnostic bio-firms 17 Bio-firms which make measurement devices for diagnosing particular diseases or their resulting 
consequences. 
Agri-food bio-firms 9 Bio-firms that are engaged in the development of applications, including the production of biological 
materials, specialist products for human food or animal feed, and specialist cultures. 
Bio-environmental  
bio-firms 
6 Bio-firms which provide services focusing on the detection, prevention and/or clean-up of 
environmental damage. Their major products are based on microbial cultures.  
 
 
 
 
 
Based on InterTradeIreland (2003).  
 
The bio-sector's age structure reflects the limited/restricted nature of the pre-initiative 
bio-firms and the relative age and state of development of the post-initiative bio-firms. 
The majority of the bio-firms are less than twenty years old, which means very few 
have reached the product/process development stage. Indeed, almost all of the survey 
respondent bio-firms stated that around 80% of their workforces were engaged in 
research. The overall level of commercialisation activities in the Irish bio-sector, to date, 
has been minor (Burke et al, 2003; Ernst & Young, 2003; InterTradeIreland, 2003).  
 
6.2.3 Investors 
Until the introduction of the various development initiatives in the late 1990s, investor 
involvement in the indigenous bio-sector was limited due to its small size and restricted 
commercial activities, and the associated restrictions on development opportunity these 
issues caused. As such, investors were very sceptical of the bio-sector's commercial 
promise. Pre-initiative bio-firms relied heavily on private funding sources, as Irish VCs 
mainly focused on sectors with more obvious commercial potential, in particular ICT 
sector-related opportunities. It must be noted that no dedicated VC firm existed to 
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service the indigenous bio-sector until 2001 (Forfás, 2004). 
 
In alliance with the various on-going PREO-based funding programmes, several 
dedicated biotechnology VCs have been developed by public actors to address the 
relative absence of investor actors in the bio-sector and to drive commercial sectoral 
developments. These VCs have facilitated the surge of 'Genentech Template' post-
initiative bio-firms, as detailed above.  
 
The first dedicated VC, Seroba BioVentures, was established in 2001 under EI’s 
biotechnology strategy as an investment development firm. Its investment fund totalled 
€20 million, and sought to facilitate start-up bio-firm development from PREO-based 
research in the areas of therapeutics, medical devices and diagnostics, and new enabling 
technology platforms. Seroba was re-launched as Seroba Kernel in 2009, under EI’s 
Seed and Venture Capital Scheme 2007-2012 (discussed below) (Seroba BioVentures, 
2005; European Venture Capital Journal, 2009).  
 
Also in 2001, private investment company Growcorp was established by the 
Department of Enterprise, Trade and Employment (with funding provided through EI's 
Seed and Venture Capital Programme 2001-2006, discussed below), accountancy 
service firm PriceWaterhouseCoopers and private donations from the Irelandia 
Investment group to exclusively target the life science sector through its European 
Bioscience fund, which amounts to €25 million. Growcorp differs from Seroba Kernel 
by providing wet-lab space and specialist business services, including marketing and 
financial planning services/advice to its target bio-firms (Smyth, 2003; Enterprise 
Ireland, 2004). 
 
The number of VCs investing in the indigenous sector has subsequently increased due 
to successive EI co-ordinated Seed and Venture Capital Programmes in 2000-2006 and 
2007-2012. The 2000-2006 programme, created under the NDP 2000-2006, provided 
€98 million to 15 VC funds established under the previous EI VC programme (The EU 
Seed and Venture Capital Measure 1994-1999) to “...develop the venture capital market 
for [Small to Medium Enterprises] in Ireland” (Enterprise Ireland, 2005; 3). The follow-
on programme (2007-2012) is funded to a level of over €170 million, under the new 
NDP 2007-2013 (Finfacts Ireland, 2007; The Department of Enterprise, Trade, and 
Employment, 2006; Morrissey, 2011). 
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Among the biotechnology/biotechnology-related VC funds supported by EI are:  
 
 Enterprise Equity Venture Capital: established in 1987, it launched a €7million 
seed capital fund in 2003 for early stage technology companies, 
 Delta Partners: established in 1994 with a fund of over €60 million, it focuses on 
early stage companies in high-tech sectors including the bio-sector, 
 HotOrigin Fund I: established in 2001 with a fund totalling €2.3 million targeted 
towards Bioinformatics and new information and communication technologies 
(NICT) firms, 
 4th Level Ventures: established in 2004 with a fund of over €17 million, and 
 AIB Seed Capital Finance: established in 2007, and located on the UCD 
campus. The firm’s fund totals €30 million, half from EI, the remainder from 
AIB (Enterprise Ireland 2006, 2007). 
 
The net effect of the EI-sponsored programmes has been a substantial increase in VC 
involvement in the indigenous bio-sector, and the resultant development of the 
'Genentech Template' post-initiative bio-firms. However, the relative level of VC 
investments in the bio-sector, in comparison to other similarly sized and emerging bio-
sectors, “...has been on a very minor scale so far, and much of it has been focused on 
service companies in supporting roles such as clinical research services and clinical data 
management, rather than on [drug discovery] biotechnology start-ups” (Technology 
Ireland, 2004: 10).  
 
Additionally, the Irish VCs are overwhelmingly concentrated in the GDA. Despite their 
nationwide scope, over half of the VC investments in the indigenous bio-sector were 
made in the GDA by 2006. This has created discrepancies in how the bio-sector has 
developed regionally (Enterprise Ireland, 2005; Dodgson et al., 2008; Chen at al., 2011). 
 
6.2.4 Diversified Transnational Corporations 
TNCs first established operations in Ireland following the Government's decision to 
create an Irish industrial export base by attracting Foreign Direct Investments (FDI) 
after abandoning protectionist policies in the late 1950s. Since the early 1970s, the Irish-
based operations of pharmaceutical TNCs have been of great importance to the Irish 
Economy.  
 
Yet, TNC operations in Ireland until the mid 1990s were predominantly commercial-
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scale manufacturing-orientated branch plants that exported the vast majority of their 
output, and which developed very limited alliances with the indigenous economy. Their 
product and production processes would be fully developed in their home countries, 
after which process would be transferred to the commercial scale facilities in Ireland 
(van Egeraat, 2009; Girvin, 1983; Honohan and Walsh, 2002).  
 
Since the mid-1990s, Irish-based TNC operations have changed in form, in part due to 
proactive efforts by the relevant Government agencies to attract more high-tech skills 
intensive TNC activities into Ireland (discussed further below). These developments 
also reflect international trends in TNC operations: 
 
 TNCs have re-organised their production activities by focusing on smaller 
volume niche market drugs,  
 TNCs have also sought to improve the efficiency of their process R&D activities 
by moving away from mono-product production processes towards 'flexible' 
multi-product production processes which involve more process R&D activities,  
 TNCs have responded to the combined impacts of increasingly stringent 
regulatory requirements expanding the time and costs of new drug developments 
and the declining effective period of product patents, due to the emergence of 
generic pharmaceutical products, by adopting more biotechnology-based 
practices in their production plant activities to advance their product 
development processes (van Egeraat, 2009; Ernst & Young, 2007).  
 
As such, additional functions have been added to Irish TNC operations, notably process 
R&D activities in biopharmaceutical-related activities.  
 
The TNC sector in Ireland presently includes manufacturing operations of 13 of the 
world’s top 15 pharmaceutical firms, including Roche, GlaxoSmithKline and Wyeth. 
According to IDA Ireland, 120 overseas pharmaceutical and chemical companies were 
located in Ireland, employing over 20,000 people with combined exports totalling over 
$35 billion annually in 2006. This accounted for over 30% of total national exports, 
second in value to exports from the engineering/electronics sector (BioResearch Ireland, 
2000: Forfás, 2003: IDA Ireland, 2005, 2006; Morrissey, 2011).  
 
Recent R&D orientated developments in the operations of TNCs have resulted in 
Ireland emerging as a key location for biopharmaceutical active ingredient plants over 
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the last eight years. These developments include: 
 
 Pfizer established a €2 billion biopharmaceutical campus in Newbridge, County 
Kildare in 2003, creating the largest biotechnology plant in the world. The 
facility engages in drug development, process development and large scale 
production. Wyeth collaborates with a number of RIs, including the Irish Centre 
for Applied Neurotherapeutics, and the National Institute for Cellular 
Biotechnology,   
 Schering-Plough has established research facilities in Cork and Wicklow. The 
Cork biotechnology plant engages in R&D on process development activities, 
including phase II and III clinical trials of new products. The Wicklow R&D 
operation is involved in process development and analytical methods in the 
development of drugs in Phase II & III clinical trials, and also manufactures 
clinical trial quantities of new drugs in a pilot production plant,   
 Eli Lilly’s biopharmaceuticals manufacturing facility in County Cork,  
 Bristol-Myers Squibb invested €9.6 million in 2005 to establish collaborative 
biopharmaceutical research facilities located at Dublin City University and the 
National University of Ireland, Galway,   
 Genzyme invested over €6 million in 2001 to expand process R&D activity in its 
Waterford plant, and 
 Boston Scientific established a Galway-based R&D operation in the mid 1990s 
which is engaged in the product and process development of stents used in 
cardiovascular and cancer treatments (Business Ireland, 2005; IDA Ireland, 
2007, 2006; NorDubCo, 2009). 
 
Pharmaceutical TNC plants are concentrated mainly in the GDA and County Cork. The 
GDA has the largest concentration, with 18 pharmaceutical TNC operations. The Cork 
region has the second biggest concentration of TNC operations, and the largest single 
concentration of pharmaceutical TNC activity (26 plants) in Ireland. The third largest 
concentration, County Galway, has the largest concentration of TNC medical devices 
facilities (14) in Ireland (IDA Ireland, 2007; InterTradeIreland, 2003; Van Egeraat, 
2006). 
 
6.2.5 Irish Government departments and agencies 
The Irish Government first identified biotechnology's strategic importance for Ireland’s 
future development in the late 1970s. Yet, in the context of relatively limited STI 
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initiative developments from the late 1960s onwards, the first public measures to 
promote biotechnology were formed in the early 1980s, e.g. the National Board for 
Science and Technology's Programme for Strategic Research (1983) which provided 
very limited grants for research in selected niche areas, including biotechnology. The 
first programme to focus specifically on biotechnology was the National Biotechnology 
Programme (1987), which resulted in the formation of BioResearch Ireland's RIs 
(Kennedy et al., 1994; Downey, 1979; Senker and Van Zwanenberg, 2000; Morrissey, 
2011).  
 
In the wake of the country's first White Paper on Science, Technology and Innovation in 
1996, a significant surge in STI and biotechnology-related initiatives occurred. This 
surge included the development of a variety of Government agency initiatives (detailed 
further in the following sections), from the late 1990s onwards, which have sought to 
replicate and develop similar structures as found in the international bio-sector.  
 
Initially, these programmes, i.e. the PRTLI and TFF, focused on addressing the 
preceding decades of underinvestment in the infrastructures, resources, and skills of the 
country's PREOs, and the cumulative disadvantages these issues had created, through 
focusing on developing RIs to facilitate developments throughout the entire bio-sector. 
Yet, the on-going initiatives have increasingly moved beyond this initial PREO focus 
towards seeking to develop the conditions that are conducive to creating commercial 
concerns from PREO-based research, i.e. commercialisation support infrastructures and 
investor actors. As detailed above, this has resulted in a surge of 'Genentech template' 
bio-firms (Acheson, and Lambkin, 2009; Department of Trade, Enterprise and 
Employment, 2006; Government of Ireland, 2007) 
 
As with the international bio-sector, various Government department and agencies 
oversee specific aspects of biotechnology development in Ireland. The roles and 
activities of these department and agencies are detailed in the following sections (Burke 
et al, 2003; Forfás, 2004).  
 
It must be noted that the Irish government and its administration are highly centralised 
around the GDA, a scenario which has essentially existed since the state's inception, i.e. 
no clearly defined regional aspects to Irish Government structures, policies or 
programmes currently exist.   
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6.2.5.1 The Department of Enterprise, Trade and Innovation  
The Department of Enterprise, Trade and Innovation (formerly the Department of 
Enterprise, Trade and Employment) governs a number of key state agencies, i.e. Forfás, 
EI, SFI and the IDA Ireland, which implement and realise the department’s policies on 
enterprise, employment promotion, trade development, and the regulation of businesses 
(The Department of Enterprise, Trade and Employment, 2003).  
 
6.2.5.1.1 Forfás 
Established in 1994, Forfás is the national policy and advisory board for enterprise, 
trade, science, technology and innovation, and both co-ordinates the activities of, and 
delegates specific powers to, IDA Ireland and EI. Its functions include the provision of 
analysis, advice and support to the Minister for Enterprise, Trade and Innovation on 
issues relating to the development of industry, enterprise, technology and innovation. It 
is also charged with the promotion of scientific research and innovation in association 
with SFI and the Advisory Council for Science, Technology and Innovation (detailed 
further below), and is responsible for the publication of Government reports in the areas 
of scientific research, technological development and innovation (Forfás, 1996; 
Government of Ireland, 2003; Irish Council for Science Technology and Innovation, 
1998; New Economy Strategy, 2003).  
 
6.2.5.1.2 Science Foundation Ireland 
SFI was established in 2000 as a sub-board of Forfás through the NDP 2000-2006, with 
subsequent funding being provided through the NDP 2007-2013. SFI seeks to create a 
critical mass of world-class research through a competitive research grant scheme, and 
to facilitate existing Irish enterprises to develop innovation programmes based on 
indigenous research (Burke et al, 2003; New Economy Strategy, 2003; The ELS 
Gazette, 2002). 
  
Through the TFF, which represented “...the single biggest investment in research and 
development in the history of the state” (Department of Trade, Enterprise and 
Employment, 2001) at its inception, SFI seeks to facilitate PREO-based research 
developments through attracting internationally renowned researchers into Irish PREOs, 
as well as developing highly qualified and skilled researchers within Irish PREOs. The 
TFF ultimately aims to form a critical mass in two key research areas, i.e. biology and 
biotechnology, and information and communications technology. The fund’s target areas 
within biotechnology are:  
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 molecular and cellular biosciences,  
 bioinformatics & computing,  
 functional genomics and proteomics,  
 integrative biology, and  
 novel enabling technologies from other disciplines (Department of Trade, 
Enterprise and Employment, 2000; Forfás, 2003; Science Foundation Ireland, 
2003).  
 
SFI also seeks to attract new overseas high-technology firms into Ireland so as to foster 
new indigenous high-tech start-ups, while simultaneously strengthening the capabilities 
of existing foreign and Irish-owned firms through the advanced opportunities derived 
from the increased PREO-based activities and capabilities (Technology Ireland, 2004; 
Government of Ireland, 2003).  
 
6.2.5.1.3 The Industrial Development Agency Ireland 
The Industrial Development Agency Ireland (the IDA) was established in 1949 to take 
responsibility of Ireland's industrial development. Its functions have changed over the 
decades, reflecting the evolving nature of Ireland's industrial policy. Since 1993, it has 
been responsible for securing new overseas investment from high-tech, manufacturing 
and international services sectors (such as the electronics, pharmaceuticals and 
healthcare, and international financial services sectors), and encouraging the expansion 
of existing Irish-based FDI enterprises and operations. The IDA seeks to attract 
international projects which can operate competitively and profitably from within 
Ireland, and to embed TNC R&D operations through engendering research networks 
with PREO and commercial actors. In 2008, it was directly responsible for the creation 
of over 8,000 new jobs, while IDA assisted companies employed over 136,000 people 
in permanent employment, and spent over €16 billion in the Irish economy (IDA 
Ireland, 2003, 2004; The ELS Gazette, 2002; Department of Trade, Enterprise and 
Employment, 2009; New Economy Strategy, 2003).  
 
The IDA offers several incentives to TNCs to locate stand-alone R&D operations in 
Ireland, to add R&D activities to their existing operations, or to expand their existing 
R&D activities. These incentives include: 
 
 The R&D Capability Grant Scheme, to assist TNCs expand or establish new 
R&D operations. Among the scheme’s incentives are capital cost contributions 
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towards establishing R&D units, 
 A multi-faceted R&D funding programme that offers TNCs feasibility studies on 
planned R&D programmes, training to increase basic skill levels of staff and 
management, and a pilot R&D project to identify potential strengths and 
weaknesses so as to enhance their R&D activities, 
 The Research Technology & Innovation scheme, to encourage TNCs to develop 
existing Irish-based R&D activities, or form new R&D projects. The initiatives 
funding is capped at €650,000, which can be applied to either product or process 
development activities, and 
 The Innovation Partnership Initiative, which is run in collaboration with EI. This 
provides financial assistance to develop collaborative research projects with 
Irish PREOs, including IoTs (Enterprise Ireland, 2006; IDA Ireland, 2007).  
 
The IDA also offers R&D supports to drive research developments across industrial 
sectors:  
 
 R&D Tax Credits: introduced in 2004, these aim to encourage firms to undertake 
additional and/or new R&D activities, and to engender research alliances with 
PREOs by requiring recipient firms to outsource up to 5% of total R&D 
expenditure to an EU-based university. This is facilitated by allowing firms 
avoid paying tax on earnings from IP where the underlying R&D was conducted 
in Ireland. The credits apply to research related overheads, plant/machinery, 
wages and buildings, and   
 Stamp Duty on IP: in order to attract IP to Ireland, no stamp duty tax is charged 
on IP transfers into the country, including any patent, trademark, copyright, 
registered design, or invention transfers (IDA Ireland, 2007).  
 
6.2.5.1.4 Enterprise Ireland 
Enterprise Ireland (EI) was established in 1996, and is responsible for the development 
of indigenous industry. Its key functions include the provision of a wide range of 
business supports and funding to indigenous firms so as to establish a competitive 
position in the global marketplace and to embed FDI operations in the Irish economy. 
Several of EI’s business supports focus specifically on biotechnology, including the 
hosting of the BiotechnologyIreland website (Burke et al, 2003; The ELS Gazette, 2002; 
Treacy, 1998).  
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EI seeks to orientate the indigenous bio-sector towards a more commercial direction 
through its biotechnology strategy. The strategy aims to facilitate and nurture 
'Genentech Template' style start-up bio-firm developments through developing 
indigenous private sector seed and VC funds, and seeks to encourage foreign 
entrepreneurs and early stage companies with sufficient development potential to locate 
in Ireland (New Economy Strategy, 2003).  
 
EI has also developed several schemes and incentives to address weaknesses in the 
management and protection of indigenously generated IP. These developments mirror 
entrepreneurial supports present in the leading international bio-sectors. Two codes of 
practice relating to the management of IP generated through PREO-based research 
activities have been developed, i.e. the IP Fund for the Higher Education Sector, and the 
IP Assistance Scheme.  
 
The IP fund seeks to address the exorbitant costs and complexities associated with 
licensing which can undermine PREO-based licensing developments. Patent filing can 
cost €7,000 for the first year, following which a patent co-operation treaty (PCT) must 
be sought, costing another €7,000. A PCT lasts for 18 months and applies to 120 
countries, yet if an academic wishes to maintain the patent (for example, where an 
academic hasn’t yet licensed the product/process, or a collaborating company refuses to 
take on the patenting costs), applications must be made in individual countries, at which 
point costs approach €50,000. EI’s patenting fund will only finance this process if a 
technology displays sufficient commercial potential to justify the investment (The 
Department of Enterprise, Trade and Employment, 2008; World Intellectual Property 
Organization, 2007). 
 
The IP Assistance Scheme, established in 1998, provides information and advice on the 
protection, development and commercialisation of IP. The receipt of funding for the 
legal protection of IP depends on the strength of a patent application, which must 
include detailed marketing and manufacturing plans (Forfás, 2004; The World 
Intellectual Property Organization, 2007).  
 
EI also hosts an Innovation Partnership initiative scheme to support joint industry-
PREO research through providing financial, business advice and structural supports to 
the relevant actors. The scheme seeks to open new business possibilities for Irish 
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researchers. Additionally, EI has introduced a commercialisation fund to support the 
commercialisation of PREO-based research that displays clear commercial potential in 
the areas of Life Sciences/Biotechnology, Informatics, and Industrial Technologies. This 
fund focuses on start-up developments, yet also seeks the development of technologies 
“...that can be licensed to an in-house company or to an existing Irish company. 
Otherwise, [EI looks] at licensing to an international or multinational company” 
(Technology Ireland, 2004: 29). To optimise licensing efforts, the fund includes a proof-
of-concept grant that allows PREO researchers to develop a product prototype from 
commercially viable research over a three year period so as to gain a better response 
from firms (Enterprise Ireland, 2007, 2005; Forfás, 2004). 
 
6.2.5.1.5 Enterprise Ireland’s Bioresearch Directorate  
EI took control of BioResearch Ireland in 2003 as part of its biotechnology strategy, 
creating the EIBD. Under the stewardship of EIBD, the original research orientation of 
BioResearch Ireland's RIs has been augmented to include a more pronounced 
commercial emphasis to their activities. This reflects the aim of EI's biotechnology 
strategy, i.e. to increase the commercialisation of PREO research through technology 
transfers and the development of campus-based initiatives related to RI’s research 
activities (BiotechnologyIreland, 2005; Burke et al, 2003).  
 
6.2.5.1.6 The Advisory Council for Science, Technology and Innovation 
The Advisory Council for Science, Technology and Innovation (ACSTI) was 
established in May 2005, replacing The Irish Council for Science, Technology and 
Innovation. ACSTI is an independent government advisory council, supported by 
Forfás, that answers directly to the Minister for Enterprise, Trade and Innovation. It 
provides advice to the Minister on policy-related issues relating to STI through 
compiling detailed reports (Burke et al, 2003; The Advisory Council for Science, 
Technology and Innovation, 2006).  
 
 
6.2.5.2 The Department of Education and Skills  
The Department of Education and Skills supervises the country’s PREOs, directly 
influencing their under-graduate and post-graduate educational biotechnology 
programmes. The department aims to develop and promote education programmes 
relevant to the social, cultural and economic needs of the country (The Department of 
Education and Science, 2007). 
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6.2.5.2.1 The Higher Education Authority and the Programme for Research in Third 
Level Institutions 
The Higher Education Authority (HEA) is the statutory planning and developmental 
body for higher education and research in Ireland. It is the funding authority for the 
PREOs and a number of designated higher education institutions, such as the Royal 
College of Surgeons, Ireland. As such, it is the main source of funding for third and 
fourth level education in biotechnology and related disciplines in Ireland. In addition, 
the HEA administers the Programme for Research in Third Level Institution (PRTLI), 
which was established in 1998 to fund science and technology research in these 
education institutions (Government of Ireland, 2003; Higher Education Authority, 
2005).  
 
The PRTLI targets the development of the research capabilities of the country’s PREOs 
through infrastructural and programme investments designed to support inter-
disciplinary and inter-institutional research. The PRTLI has been central in the 
indigenous bio-sector’s on-going developments, funding the establishment of 28 
biotechnology/biotechnology-related PREO-based RIs since its introduction. Under 
cycle 4 of the PRTLI (2007-2011), announced in January 2007, an additional €190 
million will be invested in research (Forfás, 2004; HEA, 2006, 2007b). 
 
6.2.5.3 The Department of Agriculture and Food  
The Department of Agriculture and Food monitors and controls aspects of food safety 
and animal and plant health, and regulates the agriculture and food industries through 
the implementation of national and EU legislation. The Department also supervises 
several state bodies engaged in research, training, market development and promotion in 
the agriculture and food sectors (The Department of Agriculture and Food, 2006). 
 
6.2.5.3.1 Teagasc 
Teagasc, the Irish agriculture and food development authority, was established in 1988 
through the merger of two Government agencies, An Foras Talúntais (formerly 
responsible for agricultural research) and An Chomhairle Oiliúna Talmhaíochta 
(formerly responsible for agricultural education and advisory services). Teagasc is a 
semi-state agency that is responsible for R&D, training and advisory services in the 
agri-food sector. It runs nine dedicated RI’s throughout Ireland, five of which (Figure 
6.2) are engaged in biotechnology-related research activities (Teagasc, 2005, 2006).   
 
6.2.5.4 The Department of the Environment, Heritage and Local Government  
The Department of Environment, Heritage and Local Government has a very wide 
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remit. It is responsible for the promotion of sustainable development, the protection of 
the country's environment and heritage, infrastructure provision, regional development 
and local government. It is also responsible for the administration of governmental 
policy on Genetically Modified Organisms (GMOs) through the Environmental 
Protection Agency (EPA) (The Department of the Environment, Heritage and Local 
Government, 2006).  
 
6.2.5.4.1 The Environmental Protection Agency 
The EPA was established in 1993 with the remit of protecting the Irish environment. It 
supervises the government’s GMO regulations, which are regulated under two EU 
Directives, i.e. directive 90/219/EEC, on the use of GMOs in Europe, and directive 
2001/18/EC, on the introduction of GMOs into the Irish environment. The EPA also 
maintains a publicly accessible database on GMO users in Ireland.  
 
The EPA provides research funding for biotechnology-related projects, including 
projects which evaluate the effects and impacts of GMOs on Ireland’s biodiversity. 
Additional EPA sponsored programmes include the advanced technologies for 
environmental protection programme, and the Science, Technology, Research & 
Innovation for the Environment programme. These seek to utilise nanotechnology and 
biotechnology in developing new solutions to environmental problems (The Department 
of the Environment, Heritage and Local Government, 2006; The Environmental 
Protection Agency, 2004, 2007a, 2007b).  
 
6.2.5.5 The Department of Health and Children  
The Department of Health and Children is responsible for the strategic planning and 
implementation of policies related to the Irish health system, in conjunction with the 
Health Service Executive (HSE). The Department formulates policy through an 
evidence-based approach, overseeing the activities of the Health Research Board (HRB) 
and RH research laboratories (as detailed above) (The Department of Health and 
Children, 2007, 2008). 
 
The HSE was established in 2005 to manage the delivery of the healthcare and personal 
social service in Ireland. It replaced the previous regional Health Boards and Authorities 
by merging their activities into a single national entity. The Minister for Health and 
Children has overall responsibility for the HSE in Government (Health Service 
Executive, 2009).  
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The HRB was established in 1986 to improve health through research-based initiatives. 
The HRB supports a wide variety of medical research on medical and health-related 
activities, including child health, drug misuse, and mental health issues. The findings 
from these programmes assist Government policy formulation (The Health Research 
Board, 2006a, 2006b).  
 
The HRB supports various biotechnology-related research facilities and programmes, 
including biomedical research fellowships and the development of clinical trial 
facilities, in collaboration with the Dublin Molecular Medicine Centre (DMMC), based 
in several Dublin-based RHs under the Dublin Centre for Clinical Research banner 
(Dublin Molecular Medicine Centre, 2006). 
 
6.2.6 Additional actor types 
6.2.6.1 Suppliers of Goods and Services 
Due to the limited nature of the Irish bio-sector's activities, prior to the introduction of 
the on-going Government initiatives in the late 1990s, supply actor developments were 
limited. This meant that the main markets for Irish supply actors were in European 
markets, in particular the United Kingdom bio-sector.  
 
Despite the on-going sectoral initiatives, the number of specialist supply firms in the 
bio-sector remains limited due to the continuing low levels of sectoral commercial and 
research activities. Indeed, many sectoral service requirements, such as specialist 
business development services and patenting information, are predominantly provided 
by government agencies, such as EI. This means that a significant proportion of supply 
firm business remains with non-Irish contacts (BiotechnologyIreland, 2007; Cato 
Research, 2007). 
 
It must be noted that the review of sectoral actors found that the majority of the bio-
sector's supply firms are located in the GDA.  
 
6.2.6.2 Sub-national Biotechnology Centres 
No biotechnology centres exist in the Irish bio-sector. Existing research may display a 
regional focus, e.g. the RIs under the stewardship of EIBD, yet this is due to the 
locations of their host universities, not because of specific or premeditated policy 
decisions on locating research groupings in, or at county level centres. Sub-national 
government is poorly developed as the Irish government's structure and administration 
is highly centralised around the GDA, i.e. regional-level government structures are non-
 177 
existent, while county and city councils have a very limited range of functions and 
powers.  
 
6.2.6.3 Trade Associations 
There are several trade associations in the Irish bio-sector, yet these are solely post-
initiative developments. 
 
6.2.6.3.1 InterTradeIreland 
InterTradeIreland is one of six North/South implementation bodies established in 2000 
under the control of the North/South Ministerial Council created as part of the Belfast 
Agreement in 1998. It seeks to engender business development networks, co-ordinate 
trade, and facilitate information exchanges between the two administrations on the 
island of Ireland. This body has published many cross-border sectoral reports, including 
Mapping the Bio-island (2003) (as detailed in chapter 4) (Irish Venture Capital 
Association, 2003). 
 
InterTradeIreland has proactively supported cross-border initiatives to encourage the 
development of the bio-sectors on the entire island, and has launched research and 
network-based partnerships to develop business networks between various actors in 
Ireland and the UK. These include:  
 
 Fusion: a technology transfer programme to establish PREO/business 
collaborations, 
 INNOVA: a collaborative R&D programme that funds research collaborations 
between PREOs and private companies, particularly Small to Medium 
Enterprises,  
 Expertiseireland.com: an on-line research commercialisation networking portal 
which acts as a research database that allows researchers advertise their 
commercially orientated research activities to interested firms, and 
 BioMedIreland: a networking organisation that facilitates knowledge-based 
network developments between health technology and biotechnology 
researchers. It was formed by InterTradeIreland, the Irish Medical Devices 
Association, BioBusiness Northern Ireland and the Irish BioIndustry Association 
(InterTradeIreland, 2006; Government of Ireland, 2003; InterTradeIreland, 
2006). 
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6.2.6.3.2 The Irish BioIndustry Association 
The Irish BioIndustry Association (IBIA) was established in Dublin by the Irish 
Businesses and Employers Confederation (IBEC) in 1998 to promote the development 
of the indigenous bio-sector, particularly in areas influencing the commercialisation of 
research. The IBIA engages in a wide range of activities, including government 
lobbying to create a more supportive regulatory environment and optimise government 
support for the bio-sector’s development. The IBIA actively promotes the development 
of the PREO educational and research infrastructures, and seeks to increase the level of 
networking and R&D collaborations between its members and PREOs through working 
groups and private actor centred information dissemination services (The Irish 
BioIndustry Association, 2007; The Irish Scientist, 1999; Technology Ireland, 2004). 
 
6.2.6.3.3 Bioconnect Ireland 
Bioconnect Ireland is a voluntary organisation that was established in 2001 by bio-
sector actors returning to Ireland from various overseas locations in response to the 
significant issues they experienced in accessing information on the various sectoral 
activities which had developed in their absence. As such, an informal networking forum 
was established where sectoral actors could meet to discuss current activities and issues. 
Due to its success, similar organisations have been established internationally 
(discussed below) (Enterprise Ireland, 2007; National Institute for Bioprocessing 
Research and Training, 2007).  
 
6.2.6.3.4 Biolink USA-Ireland  
Biolink USA-Ireland was formed in 2003 to facilitate linkage developments between 
expatriate US-based and Irish sectoral actors. The organisation has chapters (regional 
focal points) in 10 US biotechnology centres, including Boston, Chicago, New Jersey, 
New York, North Carolina, Philadelphia, San Diego, San Francisco, Texas, and 
Washington DC (Biolink USA-Ireland, 2005; BiotechnologyIreland, 2005a). 
 
6.2.6.3.5 Biolink Canada-Ireland 
Biolink Canada-Ireland was created in 2006 in collaboration with EI in response to the 
success of Biolink USA-Ireland, to facilitate the development of linkages between 
actors in academia, commercial enterprises, and government agencies located in Ireland 
and Canada, for the benefit of both bio-sectors (Biolink Canada-Ireland, 2006; 
Enterprise Ireland, 2007b).  
 
6.2.6.3.6 TechLink UK-Ireland 
TechLink UK-Ireland was established in 2003 to establish networks among expatriate 
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Irish professionals working in the UK in the areas of biotechnology, nanotechnology, 
pharmaceuticals, academia and services (BiotechnologyIreland, 2005b; TechLink UK-
Ireland, 2007). 
 
6.2.6.4 Private Research Institutes 
There are presently no private Irish biotechnology orientated RIs in the Irish bio-sector, 
while very limited non-Irish private RI activities have occurred. For example, the 
Wellcome Trust has invested in several RI- and RH-based developments since the late 
1990s, such as Dublin City University's Vascular Health Research Centre and 
University College Dublin's Conway Institute of Biomolecular and Biomedical 
Research (Department of Enterprise, Trade and Employment, 2006; DCU, 2005). 
 
6.2.6.5 Repositories (Gene Banks)  
No repository/gene bank developments have occurred in Ireland. An all-Ireland gene 
bank, GeneLibrary Ireland, was jointly proposed in 2003 by the HRB and the Northern 
Ireland Research and Development Office so as to develop a research resource that 
would be used in combination with the Human Genome project. The library is still in 
the planning phase, and is intended to consist of a bank of anonymous DNA samples 
drawn from a cross-sectional sample population, linked to clinical and demographic 
data (Health Research Board, 2005, 2009). 
 
6.3 DISCUSSION  
All actor types are important as incubators or transfer mechanisms within the bio-
sector's complex Post-Fordist sectoral value chain. The bio-sector’s innovation process 
can be characterised as a complex inter-linked innovation system which involves 
PREO-based actors seeking to develop and exploit commercially viable research 
findings, bio-firms (through VC/investor actor assistance) transferring PREO derived 
research results/findings to the market place through applied research programmes, and 
TNCs, which seek to facilitate such commercial developments so as to fill their product 
development pipelines.  
 
These activities are supported and facilitated by various Government department and 
agency initiatives and policies which seek to engender commercially viable PREO 
research activities and downstream transfers, so as to optimise bio-firm developments 
through commercial development supports, resources and infrastructures, and create a 
positive and supportive policy environment. Additionally, the bio-sector's innovation 
process is supported and facilitated by the activities of dedicated specialist goods and 
 180 
service suppliers, trade associations, and sub-national biotechnology centres (Boje, 
2001; Harrison, 1997; Owen-Smith and Powell, 2007; Barley et al., 1992; Malecki, 
1997). 
 
The development of the Irish bio-sector has occurred over two distinct epochs, i.e. the 
pre- and post-initiative eras, which have had considerable impacts on the structures and 
activities of the bio-sector's actors. 
 
The indigenous bio-sector first emerged in the early 1980s following the introduction of 
the first government sponsored biotechnology programmes, including the NBP. Yet in 
the context of the preceding long-term absence of investments in the research 
capabilities, infrastructures and resources of the country's PREOs, and the virtual 
absence of dedicated commercialisation support infrastructures to support indigenous 
industrial developments in the wider economy, the pre-initiative bio-sector's 
development trajectory, activities, capabilities and resources were very limited.  
 
The restricted nature of the pre-initiative PREOs meant little commercially viable 
research developed. In combination with the virtual absence of commercial supports, 
particularly the substantial investor actor limitations, a very small number of pre-
initiative bio-firm developments occurred, mainly in platform related areas derived 
predominantly from non-Irish IP sources. Paradoxically, the limited sectoral activity 
undermined the development of sectoral support actors, whose restricted nature 
undermined potential sectoral developments by reinforcing the conservative (platform) 
nature of existing bio-firms, which fed into the limited level of PREO-based innovative 
activity (Morrissey, 2011).  
 
The poor innovative nature of the pre-initiative bio-firms links into national trends in 
the Irish industrial base during this period. From independence up until the late 1950s, 
the Governments' STI and industrial policies focused on the country's agricultural and 
food sectors, which contributed to and compounded the negligible role innovative 
research had in indigenous industry. Yet Irish industry at that time had little need or 
motivation to innovate due to decades of tariff protection, while limited market 
size/demands meant they were mainly small in scale, and engaged in short production 
runs of low quality designed products. Despite relatively modest increases in PREO-
based research occurring from the late 1960s onwards, indigenous firms could not 
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benefit from these developments due to their low research activities and capabilities, i.e. 
an innovation paradox existed (Cooper and Whelan, 1973; Teavey, 1995; Morrissey, 
2011). 
 
Despite changes to the Government's industry policy from the late 1950s onwards, i.e. 
the adoption of open market policies to proactively seek FDI, and Ireland joining the 
European Economic Community (the forerunner to the European Union) in 1973, little 
emphasis was placed on facilitating changes to the nature and character of the 
indigenous industrial base up until the mid 1990s. This was despite several Government 
sponsored reports from the early 1980s onwards calling for such measures to be 
introduced (Acheson, and Lambkin, 2009; Teavey, 1995). 
 
TNC FDI operations which located in Ireland following the adoption of the open market 
policies were typically engaged in low skilled, low wage assembly line production to 
serve the UK and continental European markets. They formed, at their most basic level 
of operations, very few linkages with the Irish economy. In relation to the Irish-based 
pharmaceutical TNC operations established during this period, their branch plant nature 
meant they conducted little research activities, which further undermined potential 
PREO- and firm-based innovative developments in the indigenous bio-sector (Cogan 
and McDevitt, 2000; National Economics and Social Council, 1982). 
 
Overall, these issues reflected a lack of coordination between the Government's STI and 
industrial policy strands, i.e. industrial policies did not seek to engender commercial 
developments which linked into PREO research, while indigenous spin-off or start-up 
developments were undermined by a poorly developed and constructed policy 
environment which failed to drive and/or facilitate indigenous entrepreneurial and/or 
innovative developments, thus establishing the innovative paradox in the indigenous 
industrial base (Morrissey, 2011). 
 
An additional policy-related issue which undermined the bio-sector's optimal 
development was the established policy emphasis of promoting individual industrial 
sectors through individual firm development/cultivation, i.e. there was an absence of 
defined regional aspects to Irish Government structures, policies or programmes from 
the state's inception until 2002.  
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Observable regional differences existed in how the indigenous bio-sector developed, 
due to different regional endowments of sectoral actors. Three main pre-initiative 
sectoral concentrations had emerged by the late 1990s, as detailed in Table 6.3.  
 
Table 6.3: Regional endowments of pre-initiative sectoral actors 
The Greater Dublin Area  
(the GDA) 
 - Bio-firms: 16. 
 - PREOs: 26 (five universities, three IoTs and 18 RIs, 
   including three BioResearch Ireland RIs). 
 - Largest concentration of TNC activities. 
The Cork City area  - Bio-firms: 8. 
 - PREOs: 4 (one university, one IT, and 2 RIs). 
 - Second  largest  concentration of TNC operations, largest 
    pharmaceutical TNC activity concentration. 
The Galway City area  - Bio-firms: 5. 
 - PREOs: 4 (one university, one IT, and 2 RIs). 
 - Largest concentration of TNC medical devices facilities.  
Based on (InterTradeIreland, 2003; Enterprise Ireland, 2005; IDA Ireland, 2007; van 
Egeraat and O'Byrne, 2010). 
 
Due to its greater actor endowment, the GDA attracted a larger share of the pre-
initiative resources and funds allocated under the restricted Government initiatives. This 
meant that the GDA enjoyed cumulative advantages in comparison to other areas of the 
sector, in particular the Cork and Galway city areas. Regional imbalances, in terms of 
development trajectories, resource and actor allocations, undermined the development 
of these regions, as skills and resources migrated to the relatively more asset rich GDA. 
Regional differences became entrenched, which undermined sectoral developments 
nationally. 
 
The introduction of on-going public actor initiatives seeking to develop the indigenous 
bio-sector, introduced since the late 1990s, have led to rapid and significant sectoral 
developments, relative to conditions and activities of the pre-initiative bio-sector. Their 
initial focus on developing the research capabilities of the country’s PREOs has created 
significant infrastructures, specifically the new RI developments, resources and skills 
which have advanced the range and depth of their research activities.  
 
The subsequent introduction of dedicated commercialisation supports and 
infrastructures, particularly the development of dedicated public VC funds to address 
the bio-sector's chronic investor actor weaknesses, have facilitated the emergence of 
post-initiative start-up bio-firms, which mirror the international bio-sector's 'Genentech 
template'.  
 
However the ultimate impact of these initiatives on the bio-sector has been limited for a 
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variety of reasons:  
 
 the initiatives have had to address the substantial long-term cumulative 
weaknesses in the PREOs and commercialisation supports by introducing and 
developing missing infrastructures, resources and skills,   
 significant commercial results have yet to materialise in the bio-sector due to the 
on-going compromised nature of the pre-initiative bio-firms, i.e. the 
development initiatives have essentially by-passed these bio-firms, and as the 
post-initiative bio-firms have yet to produce significant levels of commercial 
products and/or processes,   
 the bio-sector's activities are predominately driven and facilitated by/through 
public actor activities, i.e. limited private actor developments have occurred, 
which restricts its commercial orientation, 
 the nature and character of entrepreneurial and innovative developments are 
being restricted by the narrow range of commercialisation supports, i.e. the 
general absence of alternative investor actors outside of public funded VCs,  
 downstream commercial avenues for indigenous actors’ remain limited, 
particularly in relation to TNCs. Despite on-going international structural 
development trends among TNCs being reflected in Irish-based TNC operations, 
their activities remain predominantly manufacturing orientated/branch plant in 
nature, and   
 the limited level of downstream sectoral activity also means that limited goods 
and service supplier development have occurred.  
 
Essentially, the Irish bio-sector's development has been disjointed and it continues to 
experience 'cumulative disadvantages' due to the lack of coordination between the 
Government's STI and Industry policy strands. This is reflected in on-going trends in 
the wider Irish industrial base. Outside of the biotechnology and NICT sectors, little 
policy emphasis has been placed on facilitating or driving indigenous industrial 
developments, i.e. industrial policies still focus on attracting TNC FDI, or in addressing 
the on-going research and innovative limitations of Irish firms. These issues mean that 
an innovation paradox remains in the indigenous industrial base.  
 
Additionally, no defined regional aspects emerged in Irish Government structures, 
policies or programmes until 2002, when the National Spatial Strategy (NSS) was 
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introduced. The NSS was a long-term strategic vision for Ireland’s future spatial 
development that indistinctly detailed an overreaching national framework for balanced 
regional development for the various policies and programmes of the relevant 
government departments and agencies. However, the funding for the central component 
of the NSS has been deferred since 2008 (The Stationery Office, 2002).  
 
Despite the NSS creating a national framework for balanced regional development, no 
regional elements were/have been introduced to the on-going sectoral development 
initiatives. As such, no effort has been made to address the deepening regional 
differences in how the indigenous bio-sector has developed. Table 6.4 presents a 
comparison of pre- and post-initiative regional endowments of sectoral actors (no 
significant changes of TNC endowments have occurred beyond those detailed in section 
6.2.4).  
 
Table 6.4:  Comparison of pre- and post-initiative regional endowments of sectoral actors 
 Pre-initiative actor endowments Post-initiative actor endowments 
The GDA  - Bio-firms: 16. 
 - PREOs: 26 (five universities, 
    three IoTs and 18 RIs). 
  
 - Bio-firms: 28.  
 - PREOs: 34 (five universities, 
   three IoTs and 26 RIs),  
 - The overwhelming majority of 
    the country’s VC firms.  
The Cork City area  - Bio-firms: 8. 
 - PREOs: 4 (one university, one 
   IT, and 2 RIs). 
 - Bio-firms: 13. 
 - PREOs: 9 (one university, one 
    IT, and 7 RIs). 
The Galway City area  - Bio-firms: 5. 
 - PREOs: 4 (one university, one 
   IT, and 2 RIs). 
 - Bio-firms: 7. 
 - PREOs: 7 (one university, one 
    IT, and five RIs). 
 
Based on (Enterprise Ireland, 2005; IDA Ireland, 2007; van Egeraat and O'Byrne, 
2010). 
 
Due to the absence of regional development elements to Government policies, the bio-
sector's activities remain heavily focused on the GDA and the Cork and Galway city 
areas due to their larger actor and activity concentrations. Smaller centres have emerged 
in other areas of the country located around PREOs, i.e. IoTs, yet have few bio-firms 
and/or no TNC operations located in close proximity to them meaning their activities 
are limited in scale and scope. Essentially, despite increases in the activities of all 
PREOs, and in sectoral activities nationally, the Government's uniform policy approach 
to the sector's development continues to entrench existing regional differences, i.e. skills 
and resources continue to migrate to the more asset rich GDA, undermining sectoral 
developments nationally (Chen at al., 2011). 
 
Overall, the review of the Irish bio-sector's actors shows that, when compared with the 
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international bio-sector's template, there are nine identifiable actor types in the 
indigenous bio-sector. Ireland currently has no county level biotechnology centres, 
private RIs, or genetic repositories/gene banks. Sectoral activity is mainly concentrated 
in the 'upstream' end of the sector's evolving value chain, and is spatially concentrated 
in three main urban locations, in particular the GDA. 
 
The following chapter analyses the informal and formal networks found between the 
actors detailed in this chapter. 
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CHAPTER 7: 
FORMAL AND INFORMAL INTER-ACTOR NETWORKS IN THE 
INDIGENOUS BIOTECHNOLOGY SECTOR 
 
7.1 INTRODUCTION 
Two epochs can be identified in the indigenous biotechnology sector's (bio-sector) 
development, relative to the introduction of the on-going government development 
initiatives in the late 1990s. The pre-initiative sector was characterised by limited 
sectoral actor numbers, limited sectoral activities, and a general absence of sectoral 
development supports. In contrast, the bio-sector has undergone substantial 
developments due to the on-going public initiatives having primarily focused on 
engendering and exploiting PREO-based commercial developments in order to drive the 
bio-sector's activities.  
 
This chapter analyses the formal and informal inter-actor networking arrangements 
found in the bio-sector's value chain during both epochs. This analysis is based on the 
findings generated from the biotechnology firm (bio-firm) surveys and sectoral actor 
interviews, and the review of the indigenous sector actor types. These networking 
arrangements are compared and discussed in relation to the bio-sector networking 
template in order to present an overview of the indigenous bio-sector's network 
structure and development. Additionally, this chapter draws from chapter 5, so as to 
place the development of the bio-sector's networks in their proper policy and economic 
development contexts. 
 
The chapter is divided into two sections. Section one compares the formal and informal 
networking arrangements of the Irish bio-sector's actors as found in both the pre- and 
post-initiative bio-sectors to the international bio-sector's network typologies. Section 
two presents a discussion on the indigenous bio-sector's network structure, and analyses 
the development and evolving nature of the bio-sector's network arrangements and their 
regional characteristics. 
 
7.2 INTER-ACTOR NETWORKS IN THE INDIGENOUS BIO-SECTOR 
Regional differences in sectoral actor endowments, and the institutional and non-
institutional characteristics of these actors, mean that significant differences exist in 
how bio-sector value chains are constructed, i.e. regional specific organisational forms 
impact on how inter-actor networks form, function, and develop.  
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The innovation process in the hub bio-sectors can be characterised as a tripartite value 
chain formed around the coordinated efforts of three principal actors, i.e. Public 
Research and Education Organisations (PREOs), bio-firms, and pharmaceutical 
Transnational Corporations (TNCs). These actors create a complex non-linear, 
continuously networked interactive structure. Bio-firms are the linchpin in the bio-
sector's innovation process as they occupy the middle rung in the industry’s value chain. 
Two broad activity categories, relative to a bio-firm’s position in the innovation process, 
can be characterised:  
 
 upstream sectoral activities, i.e. research-based activities, which are 
predominantly orientated around the activities of PREOs, and  
 downstream sectoral activities, i.e. the developmental stages of the clinical trials 
process, traditionally the domain of TNCs, and the final sale to the consumer 
(Malecki, 1997; Owen-Smith and Powell, 2007; Stuart et al., 2007; Giesecke, 
2000).  
 
7.2.1 PREO-based research networks 
The bio-sector's innovation process begins with PREO-based scientists engaging in 
collaborative and exploratory basic research programmes. These collaborations are 
characterised by informal, strategic, exploratory, and exploitative networks that involve 
exchanges of filtered tacit and codified scientific and technical competences, skills, and 
research-related equipment and resources. Such networks develop through the under-
graduate and post-graduate and professional careers of academics, as well as through 
industrial and/or PREO work placements, publications, and conference presentations 
(Malecki, 1997; Owen-Smith and Powell, 2008; Prevezer and Swann, 1996; Lia and 
Gengb, 2012).  
 
The organisational structures and research capabilities of PREOs depend on their place 
specific research communities and infrastructures. These represent idiosyncratic and 
localised knowledge fields of researcher specific tacit knowledge, which determine the 
effectiveness of the filtering aspect of networks, and also how academics interact with, 
and assume non-local skills and knowledge (Owen-Smith and Powell, 2008; Gertler and 
Levitte, 2005; Prevezer and Swann, 1996; Engel and Del-Palacio, 2011; Lee, 2012).  
 
The level of PREO-based research activity in the pre-initiative Irish bio-sector was 
constrained by decades of public actor under-investment in PREO infrastructures, 
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facilities, equipment and skills. Of the four PREO actor types:  
 
 the biotechnology/biotechnology-related university departments were, relatively, 
the most developed of the PREO actors;  
 a very limited number of research institutes (RIs) were formed during the 1980s, 
in particular BioResearch Ireland RIs;  
 hospital-based research was virtually non-existent due to the near absence of 
research facilities, and; 
 IT-based research was essentially non-existent due to their historic focus on the 
application of technology rather than its development.   
 
Very limited cross-institutional networks developed due to the presence of extensive 
structural inflexibilities, i.e. the PREO actors were clearly differentiated, and limited 
intra- or inter-institutional collaboration occurred due to institutional inertia. 
Respondents commented that where alliances did form, they were mainly intra-
departmental in nature, as cross-institutional network developments were undermined 
by the lack of common research infrastructures, i.e. academics accessed different 
technologies, and/or had different but incompatible experiences of similar/related 
technologies. One university-based academic commented:   
 
“...within my Department, we could collaborate a bit where we could. But when you 
talk about linking up with researchers in other universities, we simply couldn't. Even 
where obvious projects could have been developed, we just couldn't do it. The gaps in 
what we had, what we could do, on both sides, the logistics of it all was just too great” 
(University respondent 4, interview). 
 
In combination, these issues heavily restricted the levels of scientific tacit and codified 
knowledge academics could generate.  
 
Due to the limited research capabilities and activities of the PREOs, many academics 
established alliances with non-Irish researchers, predominantly US- and UK-based 
academic and commercial actor-based researchers, i.e. they sought to develop 
alternative forms of proximity in order to access more substantial resources and 
information sources. One University-based academic commented that:  
 
“getting in contact with [bio-]firms was tough, very often they would get in touch with 
us. But most of these developments [with university- and/or commercial actor-based 
researchers] came mainly through old contacts we had with former students or 
colleagues that had left for jobs in other countries” (University respondent, interview).  
 
However, the nature of these developments was constricted by the limited activities and 
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capabilities of the Irish researchers. A university-based respondent commented that 
while Irish academics “could sometimes access better equipment, and sometimes 
slightly larger funds [through these alliances] than we'd normally be able to get...[the 
alliances were restricted] by what we could offer at the time. Which wasn't all that 
much” (University respondent 2, interview). Furthermore, the high management costs of 
these alliances meant such alliances were predominantly formal in nature, which 
undermined spillover developments.  
 
Significant and sustained developments have occurred in the PREOs since the late 
1990s due to on-going development initiatives. PREO interview correspondents stated 
that the Programme for Research in Third Level Institution (PRTLI) and Science 
Foundation Ireland's (SFI) Technology Foresight Fund (TFF) programmes, specifically, 
have addressed many serious infrastructural, facility, personnel, and equipment issues 
which had previously restricted PREO-based research activities. Overall, “a research 
community has been built from the ground up [due to these initiatives], this is taking 
time to bed in” (Academic respondent 5, interview). 
 
The PRTLI investments have introduced common infrastructures between the different 
institutions, a crucial development, as “you have to have some sort of common 
technology platforms, an interface between the different scientists, to allow inter-
institutional collab[oration]s” (RI respondent 5, interview). As such, the level of 
internally generated tacit and codified research knowledge has surged, which has 
facilitated significant increases in intra- and inter-institutional exchanges of personnel, 
competences and resources through strategic, economic, exploratory and exploitative 
networks, and has also advanced collaborative alliances with non-Irish academics.  
 
Many interview respondents commented that the most important of the various PREO-
based developments has been the establishment of the new RIs through the PRTLI. One 
University respondent commented:  
 
“The research centres have transformed the research landscape. It's day and night stuff 
really, with regards to what was there and what we have now. Real money has been 
pumped into developing them...you now have access to new equipment, skills, 
resources at a level we could only have dreamed about in the past” (University 
respondent 7, interview).  
 
The RIs have been established in close proximity to their 'parent' universities, and have 
been specifically established as inter-departmental and/or inter-university institutions, 
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i.e. their structures have pronounced collaborative elements, and they also have a 
defined commercial orientation. A public development agency respondent summed up 
the attraction of RIs for the government:  
 
“...the Government quite likes the idea of this joining together of minds, and they view 
these centres as a very cost effective way of spending money. You are asking people to 
set up some infrastructure that would be shared across different institutions” 
(Government agency respondent 2, interview). 
 
Indeed, relative to the pre-initiative RIs, these new institutes have facilitated more 
extensive research collaborations and intra- and inter-department, and inter-institutional 
network developments between the RIs and their 'parent' universities. However, the 
overall development of collaborative alliances between the RIs is ultimately restricted 
by their different and specific research foci, i.e. extensive collaborative preliminary 
laboratory work does occur between certain RIs, it is limited to instances where 
research areas overlap. Limited information exchanges and personnel transfers have 
also occurred for the same reason.  
 
Additionally, due to the RI centred focus of the on-going development initiatives, 
Hospital- and IT-based research activities remain limited. In part, this is due to their 
relatively more entrenched infrastructural and skills weaknesses having taken longer to 
address. However, many interview respondents highlighted the establishment of the 
Dublin Molecular Medicine Centre (DMMC) as being a crucial development in the Irish 
bio-sector. The centre's cross-institutional structure has facilitated significant informal, 
tacit information exchanges through the sharing of key personnel among its members, 
including research nurses and several post-doctorate researchers.  
 
Overall, the post-initiative PREO actor and network developments have produced 
positive externalities and have facilitated limited spillover developments. The PRTLI's 
funding means that academics now have access to up-to-date equipment, which has 
allowed them to internalise more research and reduce their dependence on non-Irish 
RIs. This has mitigated certain issues, particularly timetable issues, and means 
academics can commit to a wider range of research topics through optimising their 
activities. Several respondents noted that access to modern, up-to-date equipment is 
vital in order to gain international recognition:  
 
“...in order to get papers published...you have to have used certain techniques. This 
means there is a certain element of keeping up with the Joneses in order to keep a 
presence, in order to bring in funding. This is a serious point, as you can’t get your work 
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recognised [internationally] if you are stuck using old practices or procedures. If you’re 
not seen as being up to date, you simply can’t progress” (RI respondent 4, interview). 
 
This has impacted on the non-local linkages formed by Irish researchers. Indigenous 
researchers are increasingly able to 'advertise' their activities internationally and develop 
networks with non-Irish researchers. These developments are allowing Irish academics 
to access international knowledge networks, and deepen and more optimally exploit the 
various pre-initiative linkages they developed with non-local academics.  
 
In alliance with the cross-institutional nature of the RIs, the increased level of research 
activity resulting from the infrastructural developments has also driven network density: 
  
“The most obvious example I know of sharing of infrastructure and of know-how is a 
cohort of [Irish] researchers in an area that was new to us. We didn’t see that one 
developing, but they have been absolutely critical in developing the [existing] programme 
between the different players [in the RI], as well as the new activities” (RI respondent 8, 
interview). 
 
The size and scale of the PRTLI and SFI, relative to pre-initiative investments, have 
also created a PREO-centred 'brand', which has engendered a series of cumulative 
benefits. This 'brand' has advertised the improved resources and capabilities of Irish 
academics internationally, facilitated improved access to international knowledge 
networks, and has allowed Irish academics to deepen and more optimally exploit the 
various pre-initiative linkages they had developed with non-Irish academics.  
 
Additionally, supporting and facilitating these developments has been the attraction of 
high skilled, internationally renowned 'star' researchers into Ireland through SFI’s TFF. 
One academic respondent commented that the TFF:  
 
“...has really worked. The type of academic it has attracted is high quality...these guys, 
the first wave if you like, have spread the word back in their home countries, about 
what’s happening here, about our activities and what we can do. That's opened a lot of 
doors for us. Really, it [the TFF] has built on its success in lots of different ways” 
(PREO respondent 3, interview). 
 
Regional endowment of researchers determines the effectiveness of the filtering aspect 
of networks in localised learning processes, i.e. how the local research 'buzz' is 
augmented by researchers accessing codified knowledge from non-local sources. 
Significant non-Irish research expertise have been imported into Irish PREOs, which 
has both facilitated improved access to international knowledge sources and networks, 
and has increased the depth and variety of scientific competences of the local mix, thus 
facilitating more robust information filtering networks (Gertler and Levitte, 2005; Graf 
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and Krüger, 2011; Eisingerich et al, 2012). 
 
7.2.2 PREO networks with commercial actors (Bio-firms and TNCs) 
PREOs proactively promote the transmission and dissemination of information by 
adhering to “the norms of the open information disclosure characteristic of public 
science” (Smith and Powell, 2004: 8) through lecturing, publications, academic and 
industrial placements, and conference presentations (McMillan et al., 2000).  
 
Yet, the manner in which a research programme's findings are ultimately codified, i.e. 
through a publication or a license development, reflects the commercial orientation of a 
programme's academics. Traditional research-orientated academic scientists focus on 
producing journal publications and/or conference presentations, while commercially 
minded entrepreneurial academic scientists seek to engender formal commercial 
developments, i.e. a patent development or start-up bio-firm development, where 
commercially viable Intellectual Property (IP) is generated (Casper and Murray, 2005; 
Malecki, 1997).  
 
Additional formal commercial alliances which form between PREOs and commercial 
actors, i.e. bio-firms and TNCs, include relatively limited collaborative R&D 
agreements, research agreements (with no development elements), and relatively minor 
research grants. For the academics, these relations are motivated by strategic and 
economisation motives of accessing the financial resources and technological 
capabilities of the commercial actors, so as to commercialise research, while they also 
allow academics to gain insight into emerging industrial trends, needs and requirements 
(Casper and Murray, 2005; Smith and Powell, 2004; Giesecke, 2000; Lundberg and 
Andresen, 2012). 
 
Due to the decades of public under-investment in the infrastructures, resources and 
skills of the various Irish PREOs (as detailed above), their research capabilities and 
activities were heavily restricted, which limited the level of information PREO 
researchers could produce and disseminate. PREO respondents stated that where pre-
initiative codified outputs emerged, they overwhelmingly took the form of academic 
publications for a variety of interlinked reasons. 
 
Academic publications were the central elements in the pre-initiative promotion 
procedures of the PREOs, i.e. licensing developments were not included in such 
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procedures, meaning few researchers proactively sought their development. A RI-based 
interview respondent noted “a lot of researchers did work that just sat on a shelf...all 
they had to do is go a bit further to commercialise something, but there was no 
motivation” (RI respondent 3, interview).  
 
The commercial orientation of all pre-initiative PREO actors, “from the administration 
right through to the researchers...[was very poor, as] historically, Universities weren't 
bothered in commercial collaborations” (RI respondent 3, interview). This scenario 
developed due to the virtual absence of commercial elements in the limited public actor 
PREO development initiatives, i.e. pre-initiative public funding was predominately 
block funding in nature and was allocated without any specific or explicit 
commercialisation requirements.  
 
As such, no commercialisation pressure or motivation existed or developed among 
PREO actors. This resulted in the development of an entrenched approach towards 
commercialisation among academics and administrators. A university respondent 
commented 
 
“…academic involvement with industry was seen as not being desirable, the notion [among 
academics] was [that] the researchers were pure and should avoid industry. There was an 
element of ‘this person is from industry, they don’t know anything about science, [that] 
they are just purely money driven`” (University respondent 7, interview). 
 
A university respondent commented that “one administrator [in the mid 1990s] said to 
me `Don't bother [collaborating with commercial actors], you'll never get your money 
off them`” (RI respondent 5, interview). Another university respondent commented that 
“the main issue used be with the university's administration....very often they scored 
own goals by making the firms [i.e. commercial actors] go away...[because of a] lack of 
interest, or unreasonable views” (University respondent 6, interview). 
 
In combination with the PREOs' limited research capabilities, these issues strongly 
inhibited formal alliance developments with the bio-sector's commercial actors, i.e. few 
patent developments or start-up bio-firms emerged or originated from the pre-initiative 
PREOs. Yet, such developments were further restricted by the limited financial 
resources and technological capabilities of the sector's bio-firms, TNCs and investor 
actors, as detailed in the following section. This meant that PREO actors had limited 
opportunities and capabilities to gain insight into industrial trends in the indigenous bio-
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sector, its needs and/or requirements.  
 
Where downstream commercial alliances developed, they primarily formed with non-
Irish downstream actors as PREO researchers sought to by-pass the indigenous bio-
sector's shortcomings. These collaborations were overwhelmingly formal in nature due 
to the limitations of the PREOs, i.e. they predominantly took the form of defined 
research investigations into the specific behavioural aspects of products/processes. In 
some cases the non-Irish collaborator would conduct parallel in-house investigations 
and use the PREO-based research simply to compare and validate their findings. Several 
academics commented that such alliances typically arose from non-Irish actors 
establishing contacts through accessing journal publications, conference presentations, 
and/or through contacts with former graduates or colleagues who had taken up 
employment in the non-Irish sectors. 
 
The various issues and limitations of the PREOs also meant that researchers were 
generally unable and/or unwilling to participate in the various European Union (EU) 
programmes which sought to facilitate EU-wide PREO alliances with commercial 
actors (Appendix C), in particular as these programmes required PREO applicants to 
have pre-existing collaborations with industry-based actors. Additionally, the 
bureaucracy levels of these programmes were excessively prohibitive, while their 
prescribed timescales were generally unsuitable for academic researchers. 
 
The capabilities and resources of Irish PREOs have advanced due to the on-going 
Government development initiatives. These initiatives have facilitated increased 
information transmission and dissemination through 'traditional' avenues, e.g. journal 
publications, yet they have also facilitated crucial patent developments and engendered 
more advanced formal alliances between PREOs and commercial actors, particularly 
research and/or development agreements, and joint ventures.  
 
The main factor driving these developments is the defined commercial emphasis of the 
on-going initiatives. This has strongly impacted on and changed the commercial 
orientation of the PREOs and their administrators and academics. A university 
commercialisation respondent stated that “there has been a huge change in their 
approach [i.e. the commercialisation approach of the public agencies], but what has also 
been crucial has been the overall money that's now available” through the various 
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initiatives (University commercialisation respondent 1, interview).  
 
Agency actors are increasingly proactive in facilitating commercialisation developments 
among PREOs, while a key development, highlighted by several interview respondents, 
has been the augmentation of the types of funding available to PREO actors. One 
university respondent, with extensive industry experience, commented that the switch 
from block grants towards competitive funding sources has contributed towards the 
increased commercial orientation among PREOs as “the academics have to compete for 
funding, before they really didn't. This means they are now also beginning to see 
commercial rewards as an alternative source of funding” (University respondent 1, 
interview). 
 
The post-initiative bio-firm developments have also augmented the entrepreneurial 
character and environment of the indigenous bio-sector. Their establishment 
demonstrates to commercially minded PREO actors that successful commercial 
developments are possible through the current support structures, potentially “open[ing] 
up an entrepreneurial spirit that is clearly missing [in PREOs]” (Investment respondent 
1, interview). 
 
Additionally, the attraction of non-Irish researchers through the TFF has been crucial in 
augmenting the commercial orientation of Irish academics and in engendering a more 
pronounced entrepreneurial mind frame due to their more pronounced commercial 
nature. As detailed above, these academics have added to the local 'buzz', and have 
created a more fertile innovation dynamic through increasing idea diversity within 
Ireland's knowledge base. A TTO respondent commented:  
 
“By attracting these [non-Irish] researchers, you've now got a huge range of background 
and approaches. So I see it as success breeding success...if I see a guy arriving at work 
driving a fancy car that he bought as he successfully commercialised something, I'll say 
'I can do that too.' So this is driving things along...it’s the returns for licensing that will 
drive the developments, the monetary rewards...” (TTO respondent 5, interview). 
 
This comment was echoed by a development agency respondent:  
 
“We are beginning to see a kind of competition; ‘Well that guy is earning so much from 
a patent that he has licensed to BASF or to Pfizer, and I’d like some of that too.’ This 
kind of competition...we are seeing an increase in patenting, which is a primary 
indicator of people moving towards commercialisation. It’s still early days, but certainly 
much more promising” (Development agency respondent 2, interview). 
 
A VC respondent commented that these developments have engendered a noticeable 
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change in the commercial orientation of academics since the late 1990s:  
 
“it is less typical to find...[a new academic] who has gone from undergraduate, to post-
graduate, to post-doc[torate], and into to full time academic work without experiencing 
anything else. Most of the new lecturers...I've noticed that I meet more with a business 
edge to them, more than I would have, definitely” (VC respondent 2, interview). 
 
Supporting and complementing these efforts to engender a more pronounced 
commercial mind set amongst Irish PREO actors, in relation to the commercial 
orientation of their research and the formation of downstream developments, has been 
the development of infrastructures and resource supports that seek to both encourage 
and facilitate entrepreneurial developments. These include: 
 
 the augmentation of PREO promotion procedures to include licensing 
developments. This has resulted in the “publish or be damned [attitude] being 
replaced by [a] publish, and you loose IP mindframe” (PREO respondent 4, 
interview),  
 the addition of defined commercialisation elements to the employment contracts 
of post-initiative academics, 
 the upgrading and expansion of the capabilities, resources and activities of the 
different Technology Transfer and Industrial Liaison Offices (TTOs and ILOs),  
 the introduction of intermediary actors to facilitate PREO/downstream alliances, 
such as Enterprise Ireland's (EI) bio-incubators, and SFI’s Centres for Science, 
Engineering & Technology, and  
 the introduction of dedicated commercial supports, including VCs and the 
various commercialisation-orientated funds of EI, to drive commercial 
developments from PREOs.  
 
However, while these developments have resulted in more advanced commercial 
alliances and developments between PREO actors and downstream actors, e.g. the 
emergence of the post-initiative bio-firms, and have fed into and further enhanced the 
commercial orientation of PREOs, the overall level of “commercialisation know-how 
amongst Irish academics is not an integral/intrinsic part their of their knowledge set” 
(Forfás, 2004: 103). This comment was echoed by several interview respondents; an 
investment respondent commented that “the business side [of PREOs] hasn’t grown as 
fast as the science aspect...technically they are up there, but commercial management in 
 197 
Universities is still very poor” (Investment respondent 1, interview). A university-based 
respondent commented that “...what is important is having people who can interact with 
companies and who have a very clear commercial focus...having the people who can go 
out then and sell the concept, sell the products. They simply aren't there” (University 
respondent 4, interview).  
 
Additionally, commercial developments are restricted by the limited number of 
indigenous downstream outlets for PREO research. One academic respondent 
commented that “[government] funding has only focused on idea generation...while the 
universities have developed, there really isn't an industry in Ireland” (Academic 
respondent 6, interview).   
 
Pre-initiative bio-firms remain engaged in activities that limit possible alliances, while 
the post-initiative bio-firms are in the relatively early stages of their development and 
have yet to reach a point where further alliances can form (these issues are discussed 
further in the following section). Additionally, many academics, particularly those 
engaged in diagnostic-based activities, state that severe difficulties remain in their 
ability to form alliances with Irish-based TNC operations. Despite the development of 
more research-orientated activities in their operations, the TNC operations remain 
essentially branch plant in nature due to their on-going limited autonomy:  
 
“TNCs in Ireland still have no real research activities, they have no research ethos that I 
can link into…their research programmes are basically all laid out for them, with 
specified goals and targets. None of their [research] programmes developed from their 
own activities, they are just imported from the research centres in the US, or 
Switzerland” (PREO respondent 8, interview).  
 
Even with the increased level of PREO and post-initiative bio-firm activities, “there 
remains limited appeal for TNCs in Irish research activities...we're trying to develop 
links, but there isn't much here at the moment that we'd want to, or can link into” (TNC 
respondent 1, interview).  
 
The improved international image of the PREOs engendered through the PRTLI and 
TFF (as detailed above) has facilitated an increased though still limited number of 
alliances with non-Irish downstream actors. These alliances remain predominantly 
formal in nature, i.e. defined resource and knowledge transactions, and most commonly 
take the form of:  
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 commercial research grants, i.e. commercial actor sponsored post-graduate 
research projects, particularly research masters degrees due to their short time 
frames. A PREO correspondent commented that the “simple research based 
grants can be quick...[they are usually] funded for 3 years, though we do get 
involved in smaller programmes that can take around one to one and a half years 
to complete” (PREO respondent 3, interview). This respondent also stated that 
the commercial actors are effectively getting high quality research for very small 
sums of money through such grants; 
 research (no development) agreements with commercial actors. These 
agreements involve investigations of the behavioural aspects of firm-developed 
products/processes, and take the form of strictly defined collaborative 
agreements which end once the programme reaches its testing phase. After this 
phase ends, the commercial actor assumes control of the succeeding 
development stages; 
 'joint venture' developments between academics and commercial actors. Unlike 
joint ventures found in the international bio-sector, such ventures have strictly 
defined parameters, where the development aspect of these arrangements occur 
solely in the non-Irish-based product/process development facilities of the 
partner TNC, and; 
 licensing agreements between academics and non-indigenous bio-firm and TNC 
operations. So far, such developments have been extremely limited in number.  
 
7.2.3 Upstream bio-firm networks with PREOs 
Bio-firm/PREO alliances represent the first downstream stage of the biotechnology 
innovation process, i.e. research enters the product development process. At this point 
of the bio-sector's innovation process, PREOs represent the network structure's 
dominant actor type for a variety of reasons. Internationally, bio-firms are 
predominantly founded by entrepreneurial academics, and locate in close proximity to 
their 'parent' PREO. Close proximity and social inclusiveness with PREOs determines a 
bio-firm's research capabilities by influencing the formation and maintenance of close 
social relationships which facilitate access to 'filtered' tacit and codified commercially 
viable knowledge. These features are increasingly important due to the niche orientated 
nature of bio-firms internationally. Additionally, formal business competence exchanges 
facilitate transfers of organisational routines during the initial stages of a bio-firm’s 
development, while bio-firms also seek to access skilled human capital from PREOs 
(Owen-Smith and Powell, 2008; Powell and Brantley, 1992; Romanelli and Feldman, 
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2007; Malecki, 1997; Graf and Krüger, 2011; Eisingerich et al, 2012). 
 
Pre-initiative upstream networks between Irish bio-firms and PREOs were very limited 
for a variety of reasons, including:  
 
 the poor commercial orientation and support structures of the PREOs, as 
detailed above;  
 the presence of employment regulation rigidities among the PREOs which 
prevented personnel exchanges between bio-firms and PREO actors, and;  
 the conservative nature of the pre-initiative bio-firms, i.e. their diagnostic 
activity focus.  
 
As such, Irish PREOs did not form the core origin points of the overwhelming majority 
of the pre-initiative bio-firms, as these bio-firms by-passed the limited availability of 
commercially viable indigenous research through forming licensing agreements with 
non-Irish PREOs. A pre-initiative bio-firm respondent commented:  
 
“…we're a diagnostic firm with no Irish [PREO] links...If we were based in the US then 
we'd have collaborated more with university researchers…when the company started, 
there was very little here [in Ireland] we were interested in linking into. In fact, there 
was very little we could link into” (Bio-firm respondent 5, interview).    
 
Where collaborations formed between the pre-initiative bio-firms and indigenous 
PREOs, restrictive contract-based research collaborations developed. These were 
typically short-term bio-firm sponsored postgraduate research projects with very 
narrowly defined targets, i.e. minimal informal and/or formal resource and knowledge 
transactions formed, which inhibited spillover developments.  
 
Despite the on-going post-initiative sectoral developments, these relationship 
characteristics still define the pre-initiative bio-firms, as they have essentially been by-
passed by the various initiatives. This issue is detailed further in the following chapter. 
 
In relation to the post-initiative bio-firm developments, over 30 post-initiative 
'Genentech template' bio-firms having been created over the last ten years from research 
originating from the new RIs. These post-initiative bio-firms mimic the organisational 
and locational trends of bio-firms in the international bio-sector by locating in close 
proximity to their 'parent' PREOs. These developments have seeded important strengths 
in the bio-sector.  
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Due to the nature of their origin, and their ability to access and exploit the increasing 
PREO-based activities and the more advanced indigenous and international skills and 
knowledge sets which have been retained and/or emerged in the country's PREOs, more 
advanced informal tacit/embodied knowledge exchanges have developed with PREO 
actors, relative to the pre-initiative exchanges. This means that key upstream 
relationships found in international hub bio-sectors have developed, i.e. Irish PREOs are 
the key actors in the upstream end of the post-initiative bio-firms' innovation processes 
(Enterprise Ireland, 2007; Krafft et al., 2011).  
 
However, the overall level of alliances between the post-initiative bio-firms and Irish 
PREOs remain limited due to their relative age and size, yet they are expected to 
advance as the bio-sector's development progresses. The on-going limitations in the 
commercialisation experience and orientation of PREO actors, as detailed above, means 
that limited exchanges of resources continue to occur. Additionally, on-going 
employment regulation rigidities continue to restrict personnel exchanges among 
PREOs and bio-firms, particularly by preventing bio-firm founders from maintaining 
academic appointments following a bio-firm’s formation. 
 
7.2.4 Downstream Bio-firm networks with commercial actors 
The downstream network arrangements of the Irish bio-sector’s pre-initiative bio-firms 
were strongly shaped by the sectoral actors’ weaknesses at either end of the bio-sector’s 
innovation process. The restricted innovative activities of the PREOs meant pre-
initiative bio-firms adopted conservative business models in areas where little research 
activity occurred, and/or in which collaboration was essentially superfluous to 
requirements, e.g. diagnostics- or specialist supply-based activities. 
 
Additionally, their conservative nature developed in response to the general absence of 
the 'traditional' commercial supports, infrastructure and services found in hub bio-
sectors, particularly dedicated VCs. A very limited number of pre-initiative bio-firms 
received VC investments, and only when they approached the later stage of their 
development, i.e. when prospective investment returns were more clearly defined. A 
bio-firm respondent in one such bio-firm commented that this approach “was wrong, 
completely against the supposed purpose of a VC” (Bio-firm respondent 7, interview).  
 
Due to these issues, bio-firm respondents commented that they actively sought non-Irish 
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VC funding. However, they had very limited success in establishing such alliances as 
“...there really wasn’t any track record of success in Irish investment in life sciences, 
potential investors were quite nervous about getting into the [Irish] sector” (University 
respondent 3, interview).  
 
Furthermore, the possible downstream alliances bio-firms could develop were limited 
due to the manufacturing-orientated nature of the TNC branch plants, while inter-firm 
networks were heavily restricted by the lack of overlap between their activities due to 
their conservative niche nature.  
 
Where pre-initiative bio-firms established downstream alliances, they primarily 
developed with non-Irish actors, i.e. the bio-firms sought to access skill-sets and 
resources that were unavailable indigenously. However, a very limited number of 
indigenous downstream relationships did develop, predominantly through pre-existing 
contacts firm-based actors had previously established while working in other areas of 
the bio-sector.  
 
Despite such origins, these were restricted formal alliances due both to the nature of 
their activities, and also due to the sectoral context in which they emerged. Additionally, 
a very limited number of inter-firm equity alliances (buy-outs) occurred when relatively 
larger diagnostic bio-firms acquired the IP of smaller bio-firms so as to expand their 
product range. No downstream joint-research, R&D, development alliances developed, 
while manufacturing and marketing alliances were virtually non existent.  
 
In the post-initiative bio-sector, formal post-initiative downstream networks remain 
predominately with non-Irish actors, though this is slowly changing as sectoral activities 
gradually develop.  
 
Inter-actor downstream networks in the post-initiative bio-sector remain limited for a 
variety of reasons. The continuing limited nature of the bio-sector's actors, in terms of 
numbers, variety and activity restricts their development, e.g. bio-firm activities still do 
not overlap to an extent that facilitates inter-firm collaboration(s), while the pre-
initiative bio-firms remain small and conservative in nature. Despite the post-initiative 
bio-firms having a defined commercial orientation due to the manner of their origin, 
commercial linkages in the bio-sector have yet to noticeably advance due to the time lag 
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between their foundation, i.e. most of the post-initiative bio-firms are around 5 years 
old, and when they are expected to produce commercial products, i.e. the majority of 
these bio-firms have yet to reach the point where they can enter into networks with 
other commercial actors.  
 
Commercial developments are also being restricted by the presence of various issues 
relating to investor actor coverage and involvement in the Irish bio-sector. The bio-
sector's investor coverage is essentially limited to the post-initiative public VCs, i.e. 
there is too limited a range of investor actor types, such as seed investors, in the 
indigenous sector. This limits the type of commercial developments that can occur in the 
indigenous sector, as:  
 
“not everything [i.e. commercial development] will suit a VC firm. Because there really 
are no other kinds of investors, projects with real promise will be overlooked...that 
means everyone is trying to fight for the same funds. That won't work, you are too 
limited with what you can go for, and in what they will look out for” (University 
respondent 1, interview). 
 
However, many interview respondents commented that the level of indigenous VC 
funding, as a whole, is “not enough to develop a drug in Ireland” (Bio-firm respondent 
5, interview), and is barely sufficient to support the first stages of a clinical trials 
research processes. Several respondents, including a VC actor, noted that even if an 
indigenous research programme reached the second stage of clinical trials, none of the 
indigenous VC firms have sufficient funding levels to completely finance such trials.  
 
Additionally, VC coverage in Ireland is overwhelmingly concentrated in the GDA. This 
is a significant sectoral issue, as internationally VC funding is spatially concentrated 
due to its reliance on informal networks. VCs characteristically only 'expand' their 
coverage to non-local areas when a bio-sector matures and delivers visible commercial 
promise. The limited commercial activity in the Irish bio-sector means that the GDA 
focus will continue for some time, and will paradoxically undermine non-GDA 
commercial developments as GDA-based developments advance. 
 
Several interview respondents stated that they had sought funding from non-Irish 
investors in order to by-pass these issues. One bio-firm respondent commented that he 
had “spoken to a number of VCs outside Ireland...[we] met with a VC representative in 
the States who represented about 20 different VC companies in the New York area” 
(Bio-firm respondent 6, interview). However, this respondent noted that this strategy is 
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problematic as the Irish bio-sector remains perceived as having a “...really poor [track] 
record. The investors still feel too unsure about the possibilities of successfully 
developing a company here” (Bio-firm respondent 8, interview).  
 
In relation to downstream alliances between Irish sectoral actors and TNCs, they 
continue to be limited by the on-going manufacturing-orientated nature of many of the 
TNC operations in Ireland. This situation remains despite the increased number of 
research-orientated TNC operations which have been set up in the country through the 
on-going efforts of the IDA Ireland, and the development of key intermediary actors 
between TNCs and PREOs, i.e. the Centres for Science, Engineering & Technology.  
 
In part, this is due to the new TNC operations being essentially R&D branch plants that 
have little autonomy over the research programmes they conduct. Their nature 
undermines the development of alliances with sectoral actors. Additionally, their 
research activities are characterised as being close to the end of the applied research 
phase/at the beginning of the product development process, which means they are 
engaged in activities that are too advanced for linkages with PREO actors to develop. 
 
However, due to their more pronounced research focus, a limited number of TNCs have 
begun to explore opportunities of linking up with PREO-based research programmes. 
Yet, as one TNC respondent stated, “a lot of work and restructuring has to occur [in the 
Irish PREOs] before it begins to happen” (TNC respondent 2, interview).  
 
This echoes comments made by another TNC respondent, i.e. that there is still too little 
sectoral activity 'across the board' for TNCs to develop significant alliances with 
sectoral actors. Essentially, the limited track record of the indigenous bio-sector in 
developing biotechnology-derived products/processes, and the absence of a sectoral 
'star' bio-firm development, means that TNCs from hub bio-sectors remain unconvinced 
about the commercial potential of the bio-sector.  
 
Additionally, the costs of establishing and maintaining long distance alliances with such 
an unproven bio-sector are perceived as being prohibitively high. One investment actor 
noted that TNCs will “...only start getting interested [in indigenous] firms when they get 
near the clinical trial stage, but...many products can’t be brought up to the point where 
[TNCs]...would get interested because the firms don’t have the resources or finance to 
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do so” (Investment respondent 1, interview).  
 
In a proactive response to the limited scope of the bio-sector, a limited number of post-
initiative bio-firms have augmented their 'traditional' activities. Several bio-firms have 
provided consultancy services to commercial actors from related indigenous sectors that 
they have either identified and/or been approached by, and which are interested in 
adopting biotechnology-related processes and/or entering the bio-sector. Such services 
seek to inform these actors about the unique demands, activities and opportunities 
available through biotechnology, and which are present in the indigenous bio-sector. 
Additionally, several bio-firms have begun hosting training and lecturing programmes 
on biotechnology in order to address particular knowledge gaps they have identified in 
certain areas of the bio-sector and related sectors.  
 
These supplementary activities constitute a form of indirect network development in the 
bio-sector. A bio-firm respondent noted “...there have been some changes in the types of 
contracts we have taken, and with the types of clients or customers we’ve had” (Bio-
firm respondent 1, interview) as a direct result of these activities. These developments 
have engendered limited spillover developments, through combining different sources 
of knowledge and resources.  
 
7.2.5 Sectoral support actor networks 
The main international bio-sectors develop extensive regional-specific public and 
private sectoral support structures, which include private investment actors and 
specialist supply firms. These support actors facilitate and drive sectoral developments 
through engendering close alliances with the main actors in the sectoral value chains.  
 
As stated above, the pre-initiative bio-sector's support structures were extremely limited 
due to its limited innovative activities. This, paradoxically, fed into the limited nature of 
the sectoral support structures: 
 
 private VC actor involvement in the bio-sector (as detailed above) was limited 
by, and fed into the conservative nature and limited research activities of the bio-
firms,   
 indigenous supply firm activities were restricted by, and fed into this limited 
activity level, and  
 no sectoral trade associations or sub-national biotechnology centres existed.  
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Due to these support limitations, sectoral actors proactively sought alliances with non-
Irish supply firms. Yet, paradoxically, the limited level of sectoral activities meant that 
the main customer markets of the pre-initiative supply firms were in other EU countries, 
particularly the UK. These issues inhibited crucial knowledge, resource and skill 
transfers, which undermined sectoral innovative developments.  
 
Significant issues remain in the range of professional supports that indigenous actors 
can presently access in the bio-sector. The on-going post-initiative sectoral 
developments have largely been facilitated and driven by the introduction of dedicated 
public sectoral supports, in particular the dedicated public VCs and the advanced PREO 
commercialisation support, e.g. the bio-incubators introduced by EI. Yet, very limited 
private specialist supports have formed in response to these developments to address the 
more advanced needs of the bio-sector.  
 
Additionally, the public supports are conservative in nature due to their public nature, 
their relative age, and also as the Irish bio-sector's ultimate commercial potential has yet 
to be established. Furthermore, they overwhelmingly focus on the post-initiative bio-
firms. 
  
Overall, the limited numbers of suppliers means that sectoral actors continue to develop 
extensive linkages with non-Irish supply firms out of necessity. As such, the 
accumulation of specialist cores of knowledge in the bio-sector remain restricted, i.e. 
the support services are not specialised on the particular needs of the bio-sector's actors, 
meaning Irish actors have to rely on relatively more generic goods and services from 
non-Irish sources. This further limits inter-actor interaction and spillovers in the 
indigenous bio-sector.  
 
Furthermore, the number of indigenous private supply firms remains limited due to the 
continuing limitations in the activities of the indigenous bio-firms. One supply firm 
respondent stated that Ireland is “...still a fairly small market, relatively speaking. 
Overall, there is always room for more” (Supply firm respondent 2, interview). Supply 
firm respondents commented that their main customer markets remain in other EU 
countries, which also means that bio-firm and PREO actors continue to have extensive 
supply networks with supply firms in other EU countries.  
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In relation to sectoral trade associations, several associations have emerged since the 
late 1990s, e.g. the Irish BioIndustry Association. These developments have facilitated 
significant flows of tacit knowledge among sectoral actors. However, their overall 
impact has been limited by the overall state of the bio-sector's activities. Additionally, 
several respondents identified the lack of coordination among the different association 
actors as undermining collaborative developments. Furthermore, no clear regional 
focus, co-ordination or interaction exists among them, which is limiting and fragmenting 
important inter-actor business and competitive intelligence exchanges.  
 
Overall, these support actor issues mean that crucial knowledge, resource and skill 
transfers remain limited, which continue to restrict sectoral innovative developments.  
 
7.3 DISCUSSION ON THE IRISH BIO-SECTOR'S NETWORK STRUCTURE 
There are two broad identifiable forms in how the bio-sector's innovation process is 
replicated internationally, i.e. hub and non-hub bio-sectors.  
 
The network structures and innovation processes of global hub bio-sectors act like a 
collective entrepreneur, where actors form dense concentrations, i.e. critical masses, of 
regional specific skills, resources, information and networks, which facilitate the rapid 
transfer and diffusion of information/knowledge and resources, and engender sector-
wide innovative developments and self-supporting and generating regional 
agglomerations (Anderson et al., 2004).  
 
Hub bio-sectors are defined by the two inter-related downstream sectoral network 
forms, i.e. vertical and horizontal downstream networks, extensive region-specific 
public and private support structures, including public and private investment actors and 
specialist supply firms, a sectoral 'brand' that advances actor networks and sectoral 
support structures through facilitating extensive external alliances, and significant 
labour pool diversity, which facilitates significant knowledge spillovers and drives 
sectoral network density (Anderson et al., 2004; Feldman, 2001; Malecki, 1997; 
Delerue and Lejeune, 2011).  
 
Outside of the global hubs, bio-sectors are essentially little more than combinations of 
co-locating actors, principally bio-firms and PREOs, grounded in regional ambitions to 
become significant bio-sectors. Their network structures are poorly developed, 
characterised by limited innovation levels caused by region specific limitations in actor 
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numbers, resources, skills and specialist suppliers. To compensate, a common strategy 
for non-hub actors is the development of distant collaborative network strategies with 
more knowledge and resource rich bio-sectors, so as to access resources, skills, and 
competences missing in their indigenous bio-sectors. Yet, such strategies face 
significant issues as the poor innovative image/reputation of a bio-sector will dissuade 
non-local actors from entering into such alliances, while non-hub actors face intense 
competition for these resources from more dynamic bio-sectors. Where such strategies 
fail to materialise, less endowed hub bio-sectors experience cumulative disadvantages, 
and fall further behind relative to the hub bio-sectors (Powell et al., 2002; Gertler and 
Levitte, 2005; Malecki, 1997; Casper, 2007; Morris, 2011). 
 
The pre-initiative bio-sector's network structure was compromised by a general absence 
of sectoral actors and activity. The bio-sector's innovation process was heavily 
compromised by the poor development of the different PREO actors, due to decades of 
public underinvestment. Their restricted research activities and characters were reflected 
in the limited and conservative nature of the bio-sector's bio-firms, which were 
compounded by the general absence of sectoral supports, particularly VCs. Commercial 
activities were also compromised by the relative absence, or lack of participation of key 
downstream actors in the bio-sector, in particular TNCs.  
 
Overall, the pre-initiative bio-sector's network structure can be characterised as having 
been non-hub in nature, i.e. groupings of conservatively structured actors which 
engendered limited spillovers due to their poor networking arrangements with 
indigenous actors, and whose main networks were with non-Irish actors as they sought 
to by-pass the chronic shortcomings of the indigenous bio-sector. The lack of sectoral 
innovative activity meant no sectoral branding occurred, which undermined these 
alternative proximity strategies. In combination, these various issues undermined the 
bio-sector's development trajectory.  
 
Due to the PREO centric focus of the on-going public development initiatives, more 
significant network activities have formed in the upstream end of the bio-sector, yet a 
critical mass of sectoral actors, activities and networks has not formed.  
 
PREO-based networks resemble networking patterns found in the hub bio-sectors, due 
to the advanced research activities of the post-initiative RIs and their close proximity to 
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their 'parent' university facilitating significant spillover developments. Additionally, 
transfers of this increased research activity into commercial concerns, i.e. the post-
initiative 'Genentech Template' bio-firms, has occurred through the introduction of 
Government-sponsored commercialisation supports, i.e. PREO-based innovation centres 
(incubators) and dedicated VCs. As such, more extensive intra-PREO and PREO/bio-
firm networks have developed, facilitating key transfers of filtered tacit and codified 
knowledge and resources.  
 
Yet, significant systemic weaknesses remain in the bio-sector's network structure. The 
ability of pre-initiative bio-firms to form collaborative networks remains constricted by 
the presence of an established innovation paradox. Additionally, a time lag has 
developed between the emergence of the post-initiative bio-firms and their ability to 
enter significant downstream collaborative alliances. These issues are amplified by the 
on-going limited level of supply firm developments, and the continuing minimal 
involvement of Irish-based TNC operations in the bio-sector. 
 
In combination, these issues mean that a sectoral 'brand' has not emerged, which 
continues to limit the bio-sector's ability to attract in key non-local actors and skills 
(these issues are discussed further in the following chapter). Overall, the Irish bio-
sector's network structure remains non-hub in nature. 
 
A key issue undermining network developments in the bio-sector is the established, 
long-term absence of network elements in previous and on-going Government industrial 
policies, despite successive Government sponsored publications since the 1980s having 
called for their introduction (Forfás, 2004; Edquist and Hommen, 2008).  
 
This scenario also remains despite networks being noted by Government agencies as 
being key elements in the bio-sector's development. A government agency respondent 
commented that the right “leadership needs to be in place. While the interest is there 
[among government actors], they haven't figured out how to do it” (Government agency 
respondent 2, interview). 
 
Government agencies are seeking to develop inter-actor collaborations, yet not as part 
of a defined collaborative networking programme. Agencies are using funding to 
essentially force actors to collaborate, predominantly to facilitate more optimal and 
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efficient uses of personnel and resources. Respondents with experience of EU-funding-
induced collaborative initiatives, upon which these efforts are based, commented that 
such collaborations typically end once a project ends due to their contractual nature, i.e. 
the collaborations are not trust-based networks. Where trust is absent, actors will 
sacrifice potential gains derived through co-operation by pursuing self-interests due to 
the perception of risk (Forfás, 2004: Government of Ireland, 2007).   
 
This issue feeds into the absence of regional development elements in the on-going 
initiatives, as detailed in chapter 6. As with actor endowments, regional differences exist 
in how the Irish bio-sector's network structure has developed. Three main 
concentrations can be identified in the indigenous bio-sector, i.e. the Greater Dublin 
Area (the GDA), and the Cork City and Galway City regions. The GDA has the largest 
and most developed network structure in the bio-sector due to its larger actor and 
activity concentration. Essentially, the GDA's more complex endowments of 
infrastructures, skills and resources have facilitated more advanced spillover 
developments, and has advanced at a greater rate relative to the Cork and Galway City 
regions, while also continuing to draw away skills and resources from these regions 
(DETE, 2003: InterTradeIreland, 2003; Chen at al., 2011). 
 
Overall, the Irish bio-sector's network structure is poorly developed due to significant 
on-going sectoral actor weaknesses, and the absence of a suitable policy environment 
which addresses the interactive, inter-linked and inter-dependent elements which 
characterise and typify the international bio-sector's innovation process. 
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CHAPTER 8: 
POLICY PROPOSALS FOR THE DEVELOPMENT OF THE 
INDIGENOUS BIOTECHNOLOGY SECTOR 
 
8.1 INTRODUCTION 
This chapter presents a set of policy recommendations relating to the future 
development of the indigenous biotechnology sector (bio-sector). The chapter is divided 
into three sections. The first section presents a general review of various strengths 
which have developed in the indigenous bio-sector, on which future sectoral 
development initiatives may build, as well as the various weaknesses which may/will 
undermine on-going and future sectoral development efforts. These areas are analysed 
in relation to the Irish bio-sector's value chain, its actors and their activities, and are also 
analysed in the context of observable development trends in the international bio-sector. 
The second section proposes a comprehensive policy framework which seeks to 
coordinate the indigenous bio-sector's development in a systems-based manner so as to 
engender the conditions which will optimise entrepreneurial and innovative activities 
across the entire bio-sector. This framework is derived from the entrepreneurial and 
innovative functional resource themes presented in chapter 3. The final section 
concludes the chapter. 
 
8.2 A REVIEW OF THE INDIGENOUS BIO-SECTOR'S GENERAL 
STRENGTHS AND WEAKNESSES 
8.2.1 General sectoral strengths 
The indigenous bio-sector has undergone significant and substantial developments through 
the on-going Government initiatives that have been introduced since the late 1990s. 
Significant sectoral strengths have been seeded, particularly as a result of the Programme 
for Research in Third Level Institutions (PRTLI) and Science Foundation Ireland's (SFI) 
Technology Foresight Fund (TFF).  
 
Their size and long-term nature have seeded important strengths in the PREOs, 
specifically through facilitating the development of actor and institutional density 
through the formation of a world class science base. This is creating “strong foundations 
that the industry can now be built on” (Investment respondent 1, interview).  
 
The PRTLI has facilitated key infrastructural, resource, and skills developments that 
have resulted in significant advances to the capabilities and activities of the PREOs and 
their actors. A crucial PRTLI-related sectoral development has been the introduction of 
the commercially orientated post-initiative research institutes (RIs). Their defined 
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collaborative orientation has been important in engendering key spillover developments 
within the PREOs, as well as feeding into and driving downstream sectoral 
developments (discussed further below).  
 
Parallel to the PRTLI, the TFF has allowed the PREOs to retain skilled indigenous 
researchers, and also to attract high skilled internationally renowned 'star' researchers 
into Ireland. The TFF has also created a limited 'brand' effect which has attracted in 
non-Irish researchers, facilitating crucial spillover developments and skill transfers, and 
advertised the PREO-based developments and their improved and increased skills, 
activities and facilities to the international research community and to the wider 
international bio-sector in general.  
 
The increased PREO research activity these developments have engendered has been 
complemented by the introduction of more substantial commercialisation support 
structures and resources in the PREOs. The capabilities and resources of the PREO's 
Technology Transfer (TTO) and Industrial Liaison (ILO) offices have been upgraded 
and expanded, while important new intermediary actors between PREOs and 
downstream actors have been developed, e.g. the incubators introduced by Enterprise 
Ireland (EI). These supports have been complemented by the introduction of different 
commercialisation-orientated funds by EI, which particularly focus on optimising 
commercial developments originating from the new RIs. 
 
Supporting and complementing these supports have been proactive efforts to engender a 
commercial mind set amongst PREO actors, in relation to the commercial orientation of 
their research and the formation of downstream commercial developments. These 
efforts are being driven through the augmentation of the PREO promotion procedures to 
include patenting and licensing activities, and the addition of defined commercialisation 
elements to the employment contracts of 'new' post-initiative academics. Additionally, 
the TFF has contributed to the engenderment of a more pronounced entrepreneurial 
mind-frame through allowing PREOs to draw in industry-based researchers when 
sourcing potential employees.  
 
These PREO-based developments have been complemented by public actor efforts to 
engender an environment in the wider bio-sector that supports commercial downstream 
developments. These efforts have created significant strengths, relative to the pre-
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initiative bio-sector, and include:  
 
 the crucial emergence of post-initiative bio-firm developments, and; 
 the introduction of dedicated VCs. 
 
The composition of the downstream end of the bio-sector's value chain has grown in 
complexity through post-initiative 'Genentech Template' bio-firm developments. They 
have emerged due to the introduction of dedicated commercial supports, particularly the 
introduction of dedicated VCs, which seek to exploit the increased levels of PREO-
based research. These developments have augmented the bio-sector's entrepreneurial 
character and have also advanced its international reputation.  
 
The emergence of the post-initiative bio-firms has created limited, though important 
positive sectoral feedback events. Through the nature of their origin, i.e. the exploitation 
of indigenous PREO-derived IP, they have demonstrated the bio-sector's latent 
commercial potential to commercially minded sectoral actors, in particular academics, 
and have advertised the depth and quality of the bio-sector's commercialisation 
supports, thus encouraging increased commercial developments from within the 
PREOs.  
 
Additionally, the introduction of dedicated VCs is a crucial development in optimising 
the bio-sector's development trajectory, specifically through facilitating the post-
initiative bio-firm developments, and also through advertising the more complex 
commercialisation supports which exist in the bio-sector to commercially minded 
researchers, and to international actors.  
 
8.2.2 General sectoral weaknesses 
Despite the impacts of the on-going initiatives, a significant range of interlinked sectoral 
issues/weaknesses exist that are obstructing and undermining the optimal development 
trajectory of the bio-sector.  
 
8.2.2.1 PREO-based weaknesses 
The majority of the sectoral developments engendered by the on-going initiatives have 
been heavily concentrated in and around the country’s PREOs. However, the continuing 
legacy of decades of underinvestment in the country's PREOs prior to the late 1990s and 
the resultant limitations in the availability of equipment and skills means that significant 
weaknesses remain in the structures and activities of the PREOs. These include:  
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 the relative absence of funding for basic research programmes; 
 key skills weaknesses; 
 on-going structural weaknesses; 
 the on-going weak commercial orientation of administrators, academics and 
students; 
 on-going weaknesses among sectoral commercial support and intermediary 
actors, and; 
 the continuing limited commercial 'marketing' by PREOs. 
 
8.2.2.1.1 Basic research funding weaknesses 
The on-going funding programmes have focused overwhelmingly on applied research. 
This focus can be explained by the distinct commercialisation drive/impetus attached to 
the initiatives, the importance of a strong science base for sectoral developments, and 
the finite resources available to the Government. Indeed, several respondents 
acknowledge that the funding bodies wish to maximise their returns for the money 
invested, as “you can spend years on a basic research topic, and it can happen that soon 
it becomes outmoded, or someone does something that makes that research 
irrelevant...The pace is too fast for purely speculative research” (PREO respondent 2, 
interview). 
 
However, respondents commented that this applied research focus is too limited and 
short-sighted, and will become a significant long-term weakness, as “you need basic 
research to feed into applied activities...they are both as important as the other” (PREO 
respondent 1, interview). This comment reflects statements expressed in several 
government publications. The Science, Technology and Innovation Advisory Council 
report (1995) commented that a balance had to be reached between applied and basic 
research, while the Department of Trade, Enterprise and Employment (2006) noted that 
“...attempts to build a system of applied research without a base of excellence in the 
underpinning sciences [i.e. basic research] are not sustainable” (Department of Trade, 
Enterprise and Employment, 2006: 22).  
 
Additionally, despite several definitions of basic and applied research activities being 
presented in Government publications, through the Government agency respondent 
interviews, it is apparent that a certain level of confusion exists as to the distinction 
between both forms of research, e.g. a government agency respondent commented 
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“…basic research is commercial [i.e. applied] research” (Government agency 
respondent 2, interview).  
 
8.2.2.1.2 Key skills weaknesses 
Three main PREO-based skills weaknesses presently exist, as identified by sectoral 
respondents.   
 
Firstly, the numbers of new students entering third level science courses are declining 
due to the low take up of science subjects at secondary level education. This has the 
potential to develop into a major competitive disadvantage for Ireland, by restricting the 
skills supply to the indigenous bio-sector. It must be noted that this issue is outside of 
the remit of this project (Forfás, 2003, 2007; van Egeraat and O'Byrne, 2010). 
 
Secondly, prior to the introduction of the on-going initiatives, a graduate 'brain drain' 
from the PREOs existed, i.e. many graduates left Ireland due to the limited sectoral 
employment opportunities. While the introduction of the development initiatives, and 
the resultant increase in PREO activities, significantly reversed this trend, the PREO-
based developments have exposed the absence of a structured career path in Irish RIs 
for researchers wishing to focus exclusively on research.  
 
As such, highly trained actors are leaving research positions to advance their careers. A 
RI respondent commented that:  
 
“...being a professional researcher who is focused one hundred percent on research is 
not possible...for someone in their late twenties to continue in research it is very 
difficult. There are very few permanent research posts, or pensionable positions. Things 
are too temporary for someone to settle down in...so people get out of research and 
move into companies, or into lecturing...those that leave have to be replaced, and it 
basically restarts the system” (RI respondent 5, interview). 
 
This issue has major implications for the bio-sector's ability to develop and retain a 
specialised labour pool. While this issue has been acknowledged by the Government, no 
developments to address this issue have yet occurred (Forfás, 2008).  
 
Several PREO-based respondents commented that this scenario will intensify, as the 
Government's on-going skills development drive, which has also sought to increase the 
supply of PhD graduates to the bio-sector, is not part of a coordinated programme. 
Essentially, these skills developments are being targeted in isolation, while little effort is 
also being taken to address the lack of science uptake in secondary schools, as well as 
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existing downstream sector weaknesses. 
 
Finally, several PREO respondents commented that the absence of national and/or 
international academic or industrial placements for Irish academics is a critical issue 
undermining the development of key skill sets, and the diffusion of tacit and codified 
research information, commercial knowledge and spillover developments throughout 
the bio-sector.  
 
Perversely, industrial placements are key elements in undergraduate biotechnology 
courses, and greatly influence the commercial orientation of students by allowing them 
to place their academic learning into practice in an industry setting in order to acquire 
significant levels of tacit knowledge and exposes them to the demands, requirements 
and pressures of a commercial environment. One RI-based respondent with 
undergraduate placement experience in both the US and Irish bio-sectors commented 
that the placements demonstrated: 
 
“...that biotech isn’t just research...I worked in a lab[oratory] in America and saw the 
research side. I was working in a diagnostics lab in Dublin where I saw the production side 
of things up close, so I learnt it’s not all research based” (RI respondent 6, interview).  
 
The absence of placements therefore restricts the level of industrial experience and 
know-how academics have, which inhibits their ability in dealing with, and entering 
into, commercial activities. Respondents noted that this issue initially developed due to 
the limited resources available to both PREO and downstream actors in the pre-
initiative bio-sector, as well as due to the presence of structural rigidities, i.e. pre-
initiative employment contract rigidities and administrative structures dissuaded actors 
from entering into placements. Despite the on-going PREO infrastructural 
developments, no defined programmes have formed and/or been introduced, while the 
structural rigidities remain. Additionally, respondents commented that the increased 
funding levels available to academics have unintentionally discouraged researchers 
from seeking such placements, or from seeking 'work' sabbaticals.  
 
8.2.2.1.3 Cross disciplinary structural weaknesses 
The post-initiative RIs represent the first development of cross disciplinary institutional 
structures in the country's PREOs. However, their ultimate effectiveness as bridging 
mechanisms will be determined by how they address existing/on-going academic norms 
and values in the different 'parent' departments, schools, and universities.  
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Established 'mismatches' between the discipline-specific structures and cultures of the 
different RI actors are impacting on their forms and functioning, i.e. discipline-specific 
values, cultures, reward structures, budget and management systems mean intangible 
'walls' have formed among the different elements of the RIs. 
 
Additionally, despite significant developments having occurred in the country's IoTs and 
research hospitals (RHs), many respondents commented they essentially remain outside 
of the on-going sectoral developments and activities. Indeed, the research elements of 
the country's hospitals are only integrated into RI activities in the Greater Dublin Area 
(GDA) through the Dublin Molecular Medicine Centre. This issue was identified by 
many respondents as restricting potential networking and commercialisation 
opportunities across the bio-sector.  
 
8.2.2.1.4 The weak commercial orientation of administrators, academics and students 
The commercial orientation of academics and administrators in the pre-initiative bio-
sector was poor. Despite the more pronounced and defined commercial emphasis that 
the on-going initiatives are seeking to embed in the PREOs, respondents commented 
that the commercialisation skills among PREO administrations remain very limited, and 
continue to undermine commercial developments from PREOs. Several respondents 
commented there is a clear need for “…more trained people [in administration 
positions], as a lot of the [current] people don’t have real formal training” (Investment 
respondent 1, interview).  
 
Essentially, the long term absence of a defined commercial focus to PREO-based 
activities means no commercialisation culture exists for on-going initiatives to build 
upon, i.e. a time lag has developed between the introduction of the post-initiative 
supports and their ability to address these issues.  
 
This is proving difficult to address due to the presence of a distinguishable 'age gap', as 
identified by many respondents, between commercially-orientated academics and those 
who are not. This issue exists due to the presence of different employment contracts 
types and when these contracts were signed. Pre-initiative PREO promotion procedures 
placed no weight on licensing or commercial developments, only on publishing. While 
these procedures have now been amended to include patenting in promotion evaluation 
processes, this is a relatively recent development.  
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Despite the introduction of the more advanced PREO commercialisation procedures and 
supports, the limited commercial know-how among the pre-initiative PREO academics 
remains. A number of senior academic respondents commented that their desire to 
initiate commercial activities is restricted by their limited commercialisation/business 
acumen. One such respondent commented that “if something did come out of some 
research, I wouldn’t know where to start...I haven’t done a patent, and I’m not sure what 
is involved. There are set avenues you take and all that, but I’m not too sure about 
them” (University respondent 3, interview).  
 
Indeed, a TTO respondent commented that this 'age' divide has impacted on commercial 
developments:  
 
“We've had stuff slip through our fingers, stupidly so. One guy published something that 
should definitely have been patented...he hadn't been to any of the commercial courses 
we'd run. I told him all he had to do was wait about two weeks for the patenting 
paperwork to be filed and then he could publish it all...but he didn't know anything 
about what I spoke to him about...we've really had to fight sometimes to get people up-
to-date on these things” (TTO respondent 1, interview).  
 
An investor respondent noted the importance of commercial know-how:  
 
“If [as an academic] I walked up to you and said that I want you to put €50 million into 
a company I’m creating, but I’ve never run a business before. I’ve never sold one, never 
taken one from basic stage to something where someone is willing to buy it. If I came to 
you like that, you’re not going to give me €50, let alone €50 million. You’ll only give it 
to people with experience. I mean, how else can you justify it?” (Investor respondent 1, 
interview). 
 
Aside from inhibiting commercial developments, this limited commercialisation 
acumen also feeds into the commercialisation culture in which current students develop 
and emerge from, i.e. the poor commercial orientation and skills of senior academics 
will impact on the commercial orientation of the bio-sector's future researchers and 
industry employees, which will then feedback into future sectoral developments. 
 
Indeed, the commercialisation elements in current PREO under- and post-graduate 
education programmes are minor. Undergraduate degree courses predominantly focus 
on educating students in the technical aspects of biotechnology/life sciences to prepare 
them for industry-based technical jobs following their graduation, while post-graduate 
studies overwhelmingly focus on research activities. As such, students enter their 
professional careers with very limited experience and knowledge on developing 
commercially orientated research activities, patents, and/or licensing agreements. 
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A bio-firm respondent commented that, optimally: 
 
 “[industry actors would] like to see a module dedicated to the business world and 
commercialisation, a bit like the MIT [the Massachusetts Institute of Technology] model 
where everyone coming out with a masters or a Ph.D. knows what they are doing with 
regards their IP, and can talk the talk...but this doesn't exist” (Bio-firm respondent 8, 
interview).  
 
Several respondents commented that this skills issue is a major stumbling block to the 
long-term development of commercial concerns in the indigenous bio-sector, as 
commercial expertise plays a key role in the development of commercially viable 
research, and in commercial developments.  
 
8.2.2.1.5 PREO commercial support and intermediary actor weaknesses 
Despite noticeable developments having occurred in the ILOs and TTOs of the PREOs 
due to the on-going initiatives, many respondents commented that significant issues 
remain.  
 
Wide discrepancies exist amongst the commercialisation policies and supports of the 
individual PREOs, i.e. similar, though different agreement forms and requirements 
exist, which several respondents typified as being poorly designed. These issues create a 
level of uncertainty that undermines collaborative, inter-actor and inter-institutional 
alliances. 
 
An investment respondent commented that “the business side [of the PREOs] hasn’t 
grown as fast as the science aspect...technically they are up there, but commercial 
management in Universities is still very poor” (Investment respondent 2, interview), i.e. 
the drive to commercialise PREO-based research has not been matched by a 
corresponding increase in commercialisation supports. Indeed, a TTO respondent 
commented that the existing commercialisation supports “are just hitting the bare 
minimum level really...they are not aiming high enough, and it's all too piecemeal too” 
(Technology transfer respondent 3, interview).  
 
A key issue is the absence of a uniform Intellectual Property (IP) policy among the 
PREOs, despite the implementation of up-to-date patent and IP policies and the drafting 
of an PREO IP code of practice by SFI and EI (along with other agencies) in 2005. An 
investment respondent, with extensive experience of the US bio-sector, commented that 
“...there is virtually no experience in this area [IP] in Ireland at present.” This is 
“turning people away, all because of the risk levels they perceive” (Investment 
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respondent 1, interview), which contributes to an international perception of Ireland 
having weak IP policies.  
 
Additionally, the bio-sector's intermediary actors are essentially restricted to EI's 
incubators (innovation centres). An investment respondent commented that these 
incubators “are full, but they aren't real incubators...if you compare [them to] what’s 
available in other countries” (Investment respondent 2, interview), due to the relatively 
limited nature of their facilities and the limited provision of business and management 
development services and supports. This respondent also commented that the incubators 
“...were filled on a first come, first serve basis. No quality checks took place. So there 
are projects in these places that will never succeed...and that means viable projects are 
left out” (Investment respondent 2, interview).   
 
Another key issue, as identified by many respondents, relates to Enterprise Ireland’s 
Biotechnology Directorate (EIBD). EIBD has no direct on-campus activities at two 
universities, the National University of Ireland, Maynooth (NUIM) and the University 
of Limerick (UL), nor at any of the country's Institutes of Technology (IoTs) or RHs. 
This scenario exists despite many of these PREOs being engaged in 
biotechnology/biotechnology-related research programmes and, in relation to NUIM, 
UL, and Athlone IT, having on-campus biotechnology/biotechnology-related RIs. This 
issue has impacted on the commercial-orientated research activities in these PREOs, 
and also on their ability to develop commercial alliances.  
 
This scenario originated with the establishment of EIBD's predecessor, BioResearch 
Ireland, in 1987. BioResearch Ireland's five RIs were established in the country's 
existing five university locations, yet UL and NUIM were established, respectively, in 
1992 and 1997. Following EIBD's establishment in 2003, the pre-existing facilities and 
arrangements were continued, only their commercial focus was augmented.  
 
One investor respondent commented:  
 
“BioResearch Ireland should have been organised around a central point rather than being 
spread throughout the universities and ignoring Maynooth and Limerick. It has to have hurt 
those universities...if someone wants to spin-out a company in either place, where do they 
go?” (Investment firm respondent 1, interview).  
 
A university administration actor respondent from one of these universities commented: 
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“We’ve argued with [EIBD] for support, but for a long time the response has been to use 
the person in XX [a nearby EIBD-supported university]. But there is a conflict of interest 
there. If [an EIBD representative in a nearby EIBD-supported university] has two projects, 
one from their own academics and one from us, the XX [based] project will get precedence. 
The EIBD people are…fully aware of the awkward situation, but there is a conflict of 
interest. If someone worked here for a day or two a week, at least they would be here and 
we could talk to them. But EI have said the only way to get someone on campus is to have 
significant activity. So it’s a chicken and egg scenario, and it does cause problems in trying 
to get stuff out to interest potential collaborators” (University respondent 2, interview). 
 
A TTO respondent in one of the two Universities commented that the absence of EIBD 
had impacted on the level of commercial developments that had originated from his 
university: “...up to 2000, the entire university had one patent...when it came to our first 
patent, we had no structures in place” (TTO respondent 1, interview). Various 
respondents in these PREOs commented they had essentially adapted to the on campus 
absence of EIBD, yet they still view this scenario as being a significant weakness 
undermining potential commercialisation developments, i.e. “...the physical presence of 
EIBD is required” (TTO respondent 4, interview).  
 
8.2.2.1.6 Limited commercial 'marketing' by PREOs 
PREOs in the leading international bio-sectors proactively mine for commercially 
viable research, in the context of extensive commercialisation procedures and supports, 
and also seek suitable commercial actors with which to engender such developments. In 
contrast, the TTOs and ILOs of Irish PREOs are characterised by commercial actor 
respondents as being “full of traditionalists who won't actively mine for information” 
(Bio-firm respondent 6, interview).  
 
A PREO-based respondent commented that, in relation to the commercialisation 
pressures deliberately engendered by the on-going initiatives, it was vital that the 
PREOs had “people who can interact with companies and who have a very clear 
commercial focus...who can go out then and sell the concept, sell the products...[but] 
they simply aren't there” (University respondent 6, interview). An investment 
respondent commented that the PREOs “are not putting in enough human resources to 
do all that’s required, finding the research, preparing it, and then go out on the streets, 
so to speak, to sell it” (Investment respondent 1, interview).  
 
Several bio-firm actors, who had previously sought to develop alliances with Irish 
academics, commented on their continuing frustration at the significant restrictions and 
difficulties they face in accessing information on the completed and on-going 
commercially viable research programmes/projects of the PREOs. The PREO have their 
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own research database on the projects being conducted by their full-time academic and 
postgraduate researchers, yet they are not uniform in content or presentation, while 
commercial respondents commented that the information they contain is either too 
academically orientated, or not specific/detailed enough to be useful for their non-
academic queries.  
 
These issues are impacting on possible commercial alliances. A bio-firm actor 
commented that his firm often finds interesting research by accident: “...many times we 
have stumbled on research that would be carried out in hospitals, or in Universities, that 
would certainly be valuable to us” (Bio-firm respondent 4, interview), while another 
bio-firm respondent stated that “we [are] getting most of our information from the US” 
(Bio-firm respondent 9, interview) directly as a result of this issue. 
 
8.2.2.2 Bio-firm weaknesses 
The bio-sector's pre-initiative bio-firms are engaged in diagnostic-based activities that 
were mainly derived from non-Irish IP. As such, they engage in limited research 
activities, and have established very limited linkages with other sectoral actors. 
Additionally, despite the on-going sectoral development initiatives having facilitated the 
development of more advanced 'Genentech template' bio-firm developments, the 
development agencies have focused on engendering diagnostic and therapeutic bio-firm 
developments.  
 
As a result of their business models, both pre- and post-initiative bio-firms are 
characterised by relatively low investments in research, indeed an investment paradox 
can be observed among the pre-initiative bio-firms. This means that significant inter-
actor exchanges of formal information/knowledge and of science/technology 
competences between bio-firms and PREOs, and downstream actors are not occurring.  
 
Overall, the limited entrepreneurial character of the bio-sector's bio-firms is one of the 
most serious issues influencing its development trajectory. Yet, additional issues can be 
identified in the character of the indigenous bio-firms, these include:  
 
 the majority of the bio-sector's pre- and post-initiative bio-firms are engaged in 
pharmaceutical-based activities, i.e. therapeutics and diagnostics. Yet, a mass of 
bio-firms in such areas is forming in the international bio-sector. This means that 
the Irish bio-sector is essentially seeking to compete in an already crowded 
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market place,  
 there is a lack of advanced bio-firm activities, in particular drug development 
activities, in the bio-sector. This is a key weakness, as the bio-sector is open to 
possible 'lock-in' developments if shock/chance events occur in the international 
bio-sector. Additionally, this issue restricts the bio-sector's ability to attract more 
complex actor and skill types, e.g. advanced TNC research operations, which 
will inhibit future spillover developments,  
 the lack of commercial activity means there is a real threat that the advanced 
level of PREO-generated IP may ultimately result in what one academic 
respondent termed 'IP flight' to bio-sectors with more advances capabilities and 
activities, due to the restricted commercial avenues that presently exist in the 
bio-sector, and  
 the limited range of sectoral activities and the relative absence of successful 
product commercialisation mean the indigenous bio-sector has a very limited 
international image, outside of the PREO-based developments, which 
undermines the ability of commercial actors to enter into alliances with actors in 
the hub bio-sectors. 
 
8.2.2.3 Entrepreneurial development skills and investor actor weaknesses 
The indigenous bio-sector has a significant lack of entrepreneurial experience and 
know-how. An investment respondent stated:  
 
“[the bio-sector] requires people who have made it as entrepreneurs and who have been 
successful, and entrepreneurs who have not been successful, who have failed, in order 
to get that level of awareness...we don’t have the history of this type of thing here, we 
don't have that depth of experience to draw from” (Investment firm respondent 2, 
interview).  
 
This issue is one of the biggest tasks/challenges facing the bio-sector's development. It 
is crucial that bio-firms optimally develop their business side to an internationally 
competitive level, as accessing indigenous funding sources will become increasingly 
competitive as more commercial entities develop, while suitably developed business 
elements are fundamental requirements in accessing non-Irish funding sources. An 
investment respondent stated that “...a great idea is nothing but a great idea without the 
right experience and skills to develop the idea into a firm. This is when an entirely 
different skill set is required...and these skills are missing in Ireland” (Investment 
respondent 1, interview).  
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Several respondents noted that the bio-sector's demand for these skills greatly 
outstripped their supply, as evident after Élan’s restructuring in 2003; Élan halved its 
global work force in 2002, releasing many highly skilled personnel, many of whom had 
extensive management skills. This resulted in a massive bidding war among prospective 
sectoral employers, as bio-firms sought to access their skills sets (Technology Ireland, 
2005). 
 
Additionally the indigenous bio-sector's investor coverage is essentially limited to 
public sponsored VC funding, i.e. a very limited range of investor actor types exist. This 
limits the type of commercial developments that can occur in the indigenous sector, as 
different investor actor types have different risk profiles. Many sectoral respondents 
commented that the limited variety and public nature of investor actors is feeding into 
and reinforcing the post-initiative development focus on diagnostic and therapeutic 
firms.  
 
Several academic and bio-firm respondents stated that, in seeking to by-pass the lack of 
investor variety, they had sought investment funding from non-Irish sources. Yet, the 
limited track record of commercial developments in the bio-sector means such investors 
remain unconvinced about the bio-sector's commercial potential.  
 
Furthermore, possible exit strategies for investor actors are limited in the indigenous 
bio-sector, i.e. alliances with TNCs and stock market floatations are undermined by the 
relative absence of TNC involvement in the bio-sector, while market floatations are also 
very limited. Investor respondents commented that the Irish stock market is limited in 
size and is risk averse due to the unproven nature of the bio-sector, while alternative 
stock market options are limited, i.e. US stock markets are ever more circumspect about 
the commercial potential of bio-firms due to the continuing consolidation and the 
maturation of sectoral activities, while European stock markets which do accept bio-
firms, such as the London-based FTSE, and the Frankfurt Stock Exchange, were 
characterised by sectoral investment actors as only being uninterested in investing in 
EU-based bio-firms when US VC interest is present. 
 
Essentially, an investment paradox exists, i.e. the limited commercial developments and 
exit strategy options in the Irish bio-sector deter potential investors from entering an 
'unproven' bio-sector, while limited investor coverage, due to the perceived risks and 
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costs in developing commercial developments, restricts commercial developments.  
 
8.2.2.4 TNC-related weaknesses 
The IDA Ireland's efforts to embed/seed TNC R&D biotechnology-orientated operations 
into Ireland have had limited, yet important success, i.e. TNCs, such as Genzyme and 
Wyeth, have located R&D operations in Ireland. Their involvement in sectoral 
activities, however, is very limited as they are essentially R&D 'branch plants' that have 
little autonomy over their research programmes. Furthermore, their activities are 
characterised as being close to the end of the applied research phase/at the beginning of 
the product development process, which means their activities are too advanced to 
develop linkages with PREOs. 
 
Despite the adoption of more biotechnology-related activities in the Irish TNC 
operations, which reflects an international trend among TNCs, a TNC respondent stated 
that sectoral activity remains too limited 'across the board' for significant TNC alliances 
to develop with sectoral actors.  
 
An investment correspondent noted that, even with the increased level of PREO-based 
research activities, “the equipment base in Irish PREOs...isn't up to the pace of the 
TNCs” (Investment respondent 2, interview), which, allied to the limited research 
autonomy of the Irish-based TNC operations, means that few research-based alliances 
have developed.  
 
Additionally, PREOs are not optimally addressing the skills requirements of the TNCs. 
An analysis of the skills requirements of GDA-based TNCs by van Egeraat and O'Byrne 
(2010) highlighted a number of national issues, particularly the presence of a mismatch 
between TNC skills requirements and the relevant PREO courses. This is a developing 
and deepening issue, which particularly relates to the increased adoption of 
biotechnology-related practices in the TNCs (Forfás, 2003).  
 
In relation to indigenous bio-firms, pre-initiative bio-firms have little to attract major 
TNC interest, while the post-initiative firms have developed very limited TNC alliances 
due to their current state of development. An investment actor noted that TNCs will:  
 
“...only start getting interested [in indigenous bio-]firms when they get near the clinical trial 
stage, but...many products can’t be brought up to this point...because the [bio-] firms don’t 
have the resources or finance to do so” (Investment respondent 1, interview).  
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This means that indigenous bio-firms are effectively caught in a TNC-related 
development paradox, i.e. to attract TNC attention they must first develop substantial 
R&D programmes, yet they require TNC involvement to develop such programmes.   
 
Ireland's ability to attract in more advanced TNC activities is also being undermined by 
the country having become an expensive location for businesses as a result of the 'Celtic 
Tiger' economy. Wage costs, particularly in the GDA, have risen, while a range of non-
pay costs, including energy, telecommunications, insurance, and waste management 
costs, have also increased significantly to impact on Ireland's competitiveness, relative 
to other EU countries. These issues were significant contributory factors by the 
decisions of Dell and Pfizer to close/re-size their Irish operations (Cassidy and O'Brien, 
2005; van Egeraat and O'Byrne, 2010). 
 
TNCs are sensitive to regional differences in labour costs, indeed respondents 
commented that the more traditional and cost-sensitive segments of the Irish 
Pharmaceutical sector are facing increasing competition from low cost R&D locations, 
i.e. India and China. Respondents commented that issues relating to the strength and 
quality of IP protection in these countries are currently discouraging TNCs from re-
locating to these countries, but that “...it's really only a matter of time before they sort 
out their IP problems and these [Irish-based TNC] elements move” (TNC respondent 3, 
interview). 
 
Ireland's ability to retain and attract FDI activities also faces serious infrastructure-
related threats relating to the supply of adequate and affordable water and wastewater 
services, crucial requirements for TNC production processes due to their requirements 
for access to large quantities of fresh water, and suitable wastewater facilities (van 
Egeraat and O'Byrne, 2010; Forfás, 2008).  
 
Serious issues exist, or are forecast to develop in relation to these services, nationally. In 
relation to the main TNC locations, i.e. the GDA, and the Cork and Galway City 
regions, Forfás (2008) noted that Dublin/the GDA is expected to experience water 
supply and waste water treatment shortages by 2013. On-going and planned 
infrastructural developments are ultimately expected to be insufficient to fully cater for 
future increases in demand by enterprise in the region. Galway will face a water supply 
shortage by 2013, no future developments are planned, while Cork is also expected to 
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begin reaching its full water and waste water infrastructural capacity by 2018 (Forfás, 
2008; Dublin City Council 2009a, 2009b; van Egeraat and O'Byrne, 2010). 
 
Additionally, Ireland has a limited wastewater infrastructure. Dublin City’s wastewater 
infrastructure focuses solely on the Ringsend Wastewater Treatment Works. Even with 
the completion of a planned upgrade, maximum capacity will be exceeded by 2014. 
Galway is already experiencing serious waste water treatment issues, while Cork is 
expected to exceed its waste water treatment capacity by 2013. No future developments 
are planned for either city (Forfás, 2008; Dublin City Council 2009a, 2009b; van 
Egeraat and O'Byrne, 2010). 
 
In relation to contaminant waste disposal facilities, a key requirement for bulk 
manufacturing TNC operations, the Cork region is adequately provided for, yet no 
contaminant waste incinerator exists in the GDA. The vast majority of contaminated 
material produced by GDA-based TNCs is exported to the UK for disposal, which 
increases operation costs considerably. No dedicated industrial waste incinerator 
developments in the GDA or in Galway are currently planned (van Egeraat and 
O'Byrne, 2010). 
 
8.3 SECTORAL DEVELOPMENT POLICY PROPOSALS 
The analysis of the various strengths and weaknesses present in the indigenous bio-
sector demonstrates that while the on-going public initiatives have facilitated important 
sectoral advancements, they have not counteracted the bio-sector's existing path 
dependence and development trajectory.  
 
This issue reflects the Irish Government's limited understanding of the bio-sector's 
complex structure. Essentially, the government has approached the bio-sector's 
development as if its value chain was a traditional linear structure, i.e. the PREO-
centred developments are viewed as automatically/organically driving downstream 
developments, such as attracting in more complex TNC activities and private 
speculative investor actors.  
 
Many sectoral interview respondents commented that there is no guarantee these 
elements will automatically appear, as sectoral activity levels are too limited for such 
developments to emerge 'organically' for the foreseeable future. This is demonstrated by 
the failure of the post-initiative commercial developments to offset the relative absence 
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of an entrepreneurial climate among sectoral actors.  
 
Essentially, the scale and depth of the inter-related weaknesses are proving difficult for 
the on-going initiatives to fully address, as their current form cannot address various 
features of the pre-initiative bio-sector which remain deeply engrained in the characters 
of the bio-sector's actors and their structures/infrastructures, e.g. the limited information 
spillover developments that occur in key areas of the bio-sector's value chain due to 
previous sectoral limitations undermining the development of an interactive 
environment. This means that entrepreneurial and innovative developments throughout 
the bio-sector's value chain are restricted, as the on-going weaknesses create and 
reinforce negative feedback inputs which undermine the bio-sector's development 
trajectory. 
 
The limited entrepreneurial and innovative developments occur due to the absence of a 
defined or co-ordinated policy programme that targets the entire bio-sector's 
development as a whole, as well as on-going issues with policies that impact on the 
wider industrial base. These include: 
   
 the lack of co-ordination between the Government's industrial and STI policy 
strands, i.e. both strands exist parallel to each other, with no co-ordination and/or 
complementary supports being present;  
 the reactive and top-down nature of Government initiatives, i.e. their formulation 
does not pre-empt development trends and/or issues which could emerge due to 
their introduction, and;  
 the absence of the concepts of networks and clusters as defined aspects of 
current industrial policy despite many reports since the early 1980s calling for 
their introduction, and their entry into the vernacular of Government agencies 
over the last 10 years.  
 
Furthermore, the continuing focus and dependence of the Irish economy on foreign 
direct investment (FDI) and the limited research and innovative activities of the 
country's indigenous industrial-base means that an innovation paradox remains among 
Irish PREOs and indigenous industrial firms, i.e. the limited abilities of PREOs to 
engage in or diffuse commercially-orientated research activities, and the limited 
absorptive capacity or ability of indigenous firms to engage in such activities.  
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As such, an advanced commercialisation mindframe and support infrastructure in the 
wider industrial base does not exist, which means that innovative developments in the 
indigenous bio-sector are essentially an anomaly. This issue also inhibits potential cross 
sectoral developments, and feeds into and compounds the poor entrepreneurial 
environment found in the bio-sector.  
 
Overall, these issues demonstrate that a comprehensive coordinated, long-term and 
adaptive systems-based policy framework which transcends business and election 
cycles is required to replace the current piecemeal policy approach, and to optimally 
address the complex, inter-related and wide range issues which are present in the bio-
sector. Such a framework must seek to build upon and advance the bio-sector's existing 
strengths, in a systematic manner, so as to facilitate inter-actor synergies and spillovers that 
engender a more advanced and pronounced entrepreneurial and innovative environment. 
 
Essentially, policy developments must focus on engendering positive externalities in 
order to drive and optimise the bio-sector's path dependence and development 
trajectory. Positive externalities are required to build upon existing systemic strengths 
and address existing systemic weaknesses through positive feedback inputs. Different 
supports play different roles in the technological and regional dynamics of a system, yet 
they are mutually determined in a complex web of circular cumulative causation which 
continuously alters through place/system specific feedback.  
 
Key determinants of the bio-sector's positive development trajectory will be 
entrepreneurship and innovation, i.e. the development of new firms, products and 
processes, which will create positive feedback inputs that reinforces a bio-sector's 
evolution by addressing issues such as lock-in and technological discontinuities. Such 
developments are facilitated and determined by the presence of an entrepreneurial support 
'ecosystem' that both facilitates and encourages innovative developments. The factors 
which characterise an ecosystem are fundamentally linked.  
 
The development of a comprehensive, coordinated, long-term and adaptive systems-based 
policy framework will require closer collaboration between the Department of Enterprise, 
Trade and Innovation (DETI) and the Department of Education and Skills (DES), in order 
to coordinate the Government's innovation and industrial policy strands, and to integrate 
the activities of all Government agency actors which currently impact on the indigenous 
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bio-sector.  
 
Yet, the optimal formulation and implementation of such a complex framework should 
occur through consensus building among all relevant public and private sectoral 
stakeholders, including local authorities, chambers of commerce, business associations 
and enterprise boards.  
 
In the context of the bio-sector's current state of development, and the established nature of 
the Irish Government's structures and policies, a public/private dialogue process would 
initially require substantial public actor leadership, under the auspices and guidance of 
Forfás and EI, so as to introduce the suitable interactive dialogue structures that would 
evolve with sectoral developments and would ultimately engender a collaborative, private 
actor driven entrepreneurial environment.  
 
The participation of the bio-sector's key public and private actors is crucial in facilitating 
the emergence of a rapidly adaptive policy environment that allows the bio-sector to 
quickly and suitably respond to possible/potential future developments in the 
international bio-sector. Examples of such developments include:  
 
 the potential opportunities that the on-going stratification of the downstream end of 
the  international bio-sector's innovation process may present in the context of the 
increasingly niche activity focus of bio-firms and the increasing adoption of 
biotechnological practices by TNCs internationally, and;  
 the potential of Genomics to revolutionise all aspects of the bio-sector and 
expand the reach and impact of biotechnology into areas never previously 
thought possible by replacing/undermining existing industrial paradigms.  
 
Additionally, a defined regional emphasis must also be developed to tailor initiatives to 
optimise the idiosyncratic development trajectories of the main geographic 
concentrations of the bio-sector's activity, i.e. the Greater Dublin Area, the Galway City 
area, and the Cork City area. This would require an increased degree of co-ordination 
between the regional branches of development agencies and local authorities must also 
develop, so as to create a 'collective' vision for regional industrial and economic 
development.  
 
However, developing a regionally focused public/private dialogue process will be a 
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challenge as few established public/private actor dialogue systems presently exist. 
National consultation procedures with non-Government actors, such as academic 
researchers and business actors, are limited to the on-going national wage agreements, 
consultation processes in the development of foresight papers, and private actor 
lobbying. Additionally, no defined autonomous regional Government structures 
currently exist.  
 
As such, the development agencies, local authorities, chambers of commerce, business 
associations and enterprise boards should prepare a joint statement that states the intent of 
sectoral development initiatives.   
 
The following 'hard' and 'soft' policy suggestions are derived from the findings of 
chapters 5, 6 and 7, and are presented in the context of the entrepreneurial and 
innovative support 'ecosystem' framework template presented in chapter 3. In essence, 
these suggestions represent complementary aspects of an interactive, multi-faceted, 
systems-based support ecosystem that seeks to build on underlying strengths of the 
indigenous bio-system, and to engender the conditions that facilitate and drive 
entrepreneurial and innovative developments among all areas of the bio-sector's networked 
structured, nonlinear value chain, to create a self-sustaining system that optimises its 
development trajectory.  
 
8.3.1 Knowledge base infrastructure, resources and skills 
The quality and character of the research capabilities, resources, skills, and (sticky) 
knowledge sets of a bio-sector's PREOs are fundamental elements in engendering the 
synergy-based processes that will drive its trajectory. These elements ultimately 
determine a bio-sector's commerciable research activities, and its bio-firm and 
biotechnology-derived product and process developments.   
 
The majority of the bio-sector's strengths have been seeded in the country's PREOs. The 
following policy suggestions seek to build upon the substantial infrastructural and skills 
developments introduced by the on-going initiatives, and to address existing issues 
identified above in section 8.3. These include:  
 
 the clear division of activities between PREO actors, i.e. the various university 
departments, and their associated research institutes (RIs) are effectively 
'separate' entities, while the Institutes of Technology (ITs) and the Hospital RIs 
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are essentially removed from on-going developments;  
 the limited commercial orientation of academics and administrators due to the 
presence of a restricted entrepreneurial culture, and;  
 the uncertainty of the long-term ability of PREOs to retain key skills, due to the 
absence of researcher career paths. 
 
In order to achieve a critical mass of research activities, inter-institutional collaboration 
among all the PREO actors needs to emerge. This requires public initiatives to address 
the existing infrastructural and resource issues among PREO actors that restrict inter-
actor alliances and tacit knowledge exchanges. Public investments, through the PRTLI, 
must also seek to improve and expand the research capabilities of the IoTs and Hospital 
RIs, so as to integrate them into the commercial research-related activities of the bio-
sector. This is particularly pertinent due to the pharmaceutical orientation of the bio-
sector.  
 
Essentially, more holistic structures should be sought in the PREOs, to remove existing 
structural and institutional divisions, i.e. a more integrated, intra- and inter-departmental 
'spectrum' like structure should be developed which introduces integrated departmental 
and institutional structures and supports, and compliments the different research and 
teaching activities of the PREOs. Such structures would facilitate the more efficient 
development and use of PREO infrastructures, resources and skills by improving the 
inter-institutional mobility of researchers and technicians.  
 
However, introducing more integrated intra-PREO structures would require a significant 
restructuring of the existing structures and facilities of the country's PREOs, while it 
would also be important that such developments should retain the diversity of the 
different PREO institution types. As such, the design and implementation of conjoined 
administrative structures and infrastructures could occur over a long-term, phased 
process developed through a consultation process with all the relevant actors and 
supported through public actor regulatory alterations and funding supports (Forfás, 
2004). 
 
Furthermore, the current policy focus on facilitating increased applied research activities 
among PREO actors must be expanded to include basic research activities. Basic 
research advances the scientific/technological knowledge base of PREOs and is a key 
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requirement for the long-term development of a complex and varied 'world class' 
research base and downstream sectoral developments, as it also plays a central role in 
the development of a highly skilled workforce, thus directly contributing to new 
technological and entrepreneurial developments. As private actors avoid basic research 
activities due to their exploratory, less definable nature and higher risk profile, public 
funding is therefore crucial.  
 
In relation to the on-going skills development activities of the PREOs, it is vital that 
suitable under- and post-graduate educational courses in all biotechnology-related 
subjects are introduced. Such courses should be developed within a comprehensive 
skills development programme, which should feed into secondary level education 
course developments (this area is outside of the remit of this study), so as to respond to 
and meet the existing and future skills demands of all downstream sectoral actors, 
including bio-firms and TNCs. This suggestion echoes the Government's Strategy for 
Science, Technology and Innovation (2006-2013). 
 
Optimally, such a skills development programme should be informed by the 
public/private consultation processes in order to optimally tailor them towards the 
demands and needs of the bio-sector's actors, and should link in with the information 
disseminating structures and placement programmes proposed in section 8.3.4, as well 
as efforts to engender a pronounced sectoral entrepreneurial culture. 
 
A key requirement for the bio-sector's development trajectory is the ability of its PREOs 
to retain and develop a skilled labour pool. A key issue undermining such a development 
is the absence of a defined career path in the RIs. This issue must be addressed to ensure 
the optimal development of the PREOs and the bio-sector. Addressing this issue will 
require the long-term development of suitable structures, which could potentially be 
developed through the introduction of integrated PREO structures, as suggested above. 
Such structures should include a rigorous internationally competitive selection process, 
including competitive research fellowships, to ensure that a high quality level is 
developed and maintained (Forfás, 2008; Delerue and Lejeune, 2011).  
 
Additionally, the TFF's focus should be expanded to attract skilled Irish researchers back 
into indigenous PREOs so as to facilitate increased spillover developments, and feed the 
development of a national network promotion programme. This would be dependent on 
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an increased level of sectoral activity, as well as the presence of a defined researcher 
career path. Additionally, integration strategies should be developed to complement the 
TFF so as to better integrate such academics entering existing PREO structures, as well 
as to address potentially belligerent reactions from existing academics (Anderson et al., 
2004). 
 
The infrastructural recommendations presented in this section are directed towards the 
HEA, with respect to the agencies and funding programmes under its aegis, and the 
Departments of Education and Finance. The suggested skills recommendations are 
directed towards the relevant bodies under the aegis of the DES.  
 
8.3.2 Entrepreneurial infrastructures, resources and skills 
The on-going sectoral development initiatives have increasingly focused on facilitating 
commercial developments from the increased activities of the PREOs. These efforts, in 
combination with the introduction of commercialisation supports, have facilitated the 
emergence of post-initiative bio-firm developments, which has augmented the 
commercial orientation of the bio-sector.  
 
However, the overall level of entrepreneurship in the bio-sector remains restricted due 
to:  
 
 the general absence of an entrepreneurial mindframe among PREO academics 
and administrators;  
 the still limited nature of the recently introduced commercialisation supports;  
 the limited availability of business development actors/skills;  
 the restricted nature of the post-initiative bio-firm developments, and;  
 the established innovation paradox among the pre-initiative bio-firms caused by 
the very limited nature of the pre-initiative sector. 
 
The engenderment of vigorous entrepreneurial and innovative sectoral activity will 
ultimately be determined by the development of a sectoral entrepreneurial support 
infrastructure and the psychological and/or social characteristics of its actors; 
entrepreneurship is an endogenous process, a learned set of guidelines that co-evolves with 
a region’s business activities and supports, creating a system specific culture (Compete, 
2005; Anderson et al., 2004; Owen-Smith and Powell, 2007; Engel and Del-Palacio, 2011).  
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A more complex, integrated and proactive commercialisation support infrastructure 
must be developed to both facilitate and drive entrepreneurial developments throughout 
the bio-sector, particularly among PREO academics and administrators and the pre- and 
post-initiative bio-firms. It is important that such an infrastructure focuses on quality, not 
quantity, and that it avoids the development of protectionist elements that reduce 
entrepreneurial and innovative pressures in the bio-sector, e.g. the introduction of 
direct/indirect subsidies. Such an infrastructure must also support entrepreneurial 
experimentation in order to facilitate the emergence of a more complex and varied bio-
sector. These developments must also be extensions, not replacements, of existing supports 
and should actively seek the ultimate development of a range of privately organised 
supports, e.g. private VC (Owen-Smith and Powell, 2007; Engel and Del-Palacio, 2011). 
 
The following suggestions essentially build upon and expand current PREO structures 
and capabilities to develop a comprehensive support structure. Many of the following 
suggestions are directed towards EI. 
 
Significant issues and differences exist in the depth and range of the commercialisation 
capabilities and resources of the PREOs' TTOs and ILOs. Additionally no uniform IP or 
licensing regimes exist among the PREOs, while database format differences and the 
limited advertising of PREO research activities are inhibiting the development of 
downstream alliances. Furthermore, Enterprise Ireland's Bioresearch Directorate (EIBD) 
has no direct on-campus activities at the National University of Ireland, Maynooth 
(NUIM), and the University of Limerick (UL), while no direct supports have been 
developed at the IoTs or the relevant Hospital RIs.  
 
In order to address these issues, EIBD should be remodelled to form a more 
comprehensive, integrated national commercialisation structure, i.e. on-site facilities 
should be established at all existing (and future) PREO actors so as to engender a more 
defined and pronounced commercialisation orientation to their activities.  
 
Parallel to the proposed programmes in section 8.3.1 that support the development of 
basic and applied research programmes and the integrated PREO structures, EIBD 
should introduce advanced commercialisation procedures and supports, including 
uniform IP and licensing regimes, that integrate with the existing structures, so as 
identify and optimally support the exploitation of commercially viable research. Their 
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long-term aim should be the seeding of relevant skills and competences among PREO 
administrators, ILOs, TTOs, academics and students, in alliances with the relevant hard 
commercialisation supports (detailed below), in order to facilitate and drive commercial 
developments with the wider sectoral system. 
 
A possible alternative to establishing on-site EIBD facilities, in the context of the 
limited PREO-based commercial activity and the lack of uniformity to their 
commercialisation procedures, is the development of a central entrepreneurial support 
structure that all PREOs can access. Such a structure, which would fall under the 
supervision of EI (EI already hosts the BiotechnologyIreland website), would 
complement and build upon existing support structures through providing up-to-date 
and standardised IP, licensing and legal supports.  
Regional elements to such a service could eventually be established, as, in the context 
of the bio-sector's on-going development trajectory, the requirements of the individual 
PREOs would become increasingly idiosyncratic. Such a service could be also 
expanded to address the limited level of service and supply firms present in the bio-
sector.  
 
Furthermore, a centralised database, detailing standardised and up-to-date information 
on PREO-based research programmes, could also be developed so as to improve the 
ability of commercial actors to access detailed information on on-going and completed 
PREO research programmes.  
 
In relation to the bio-sector's bio-firms, various initiatives must be introduced to 
coordinate and advance the assortment of entrepreneurial infrastructures and resources 
which currently exist.  
 
The limited investment levels of indigenous bio-firms in research is one of the most 
serious issues influencing the bio-sector’s ongoing development, particularly through 
restricting the formation of substantial up- and downstream inter-actor 
alliances/networks. The sectoral development initiatives must focus on boosting the bio-
sector's entrepreneurial 'pressure', as despite the new RIs having generated many long-
term benefits, their public nature means they will fail to develop the local actor 
synergies associated with commercial/private entities.  
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Existing bio-firm development supports and initiatives are overwhelmingly focused on 
the post-initiative bio-firms. This focus must shift to address the poor relative state of 
development and activities of the pre-initiative bio-firms in order to deepen the depth 
and activity variety of the indigenous bio-sector, this proposal relates to section 8.3.5.  
 
Several respondents commented that an opportunity exists for the Government to 
provide funding to allow the pre-initiative bio-firms develop research programmes. Yet, 
such funding could potentially distort the market place through becoming an indirect 
subsidy. As such, such supports should be modelled on EI's existing R&D funds, which 
seek to enable small to medium enterprises (SMEs) develop their innovation capability 
and absorptive capacity, so as to allow SMEs develop their research activities/capacity 
and business structures to a level where collaborations with other actors becomes 
feasible.  
 
This approach would require a long-term focus and the introduction of suitable business 
development and technical supports that would address the conservative business 
models and limited innovative competences and resources that characterise the pre-
initiative bio-firms. Optimally, such aspects should be addressed through establishing 
tailored development consultancy services that allow the bio-firms access optimised 
research and commercial resources and skill sets, so as to increase their absorption 
capacity in such areas.  
 
Parallel to such developments, a TFF style programme or consultancy service should be 
developed to address the key areas speculative investors focus on, i.e. the capabilities of 
the pre-initiative bio-firms' marketing and management teams and the quality and 
strength of their technology and finances, so as to improve their chances of forming 
alliances with sectoral investor actors (Department of Enterprise, Trade and 
Employment, 2008). 
 
A key factor impinging on the bio-sector's development is the limited availability and 
restricted nature of sectoral investor actors. The public VC developments, introduced since 
2001, were necessary to address the virtual absence of investor actor involvement in the 
pre-initiative sector, yet the lack of alternatives to these VCs has fed into the narrow focus 
of post-initiative commercial developments.  
 
 237 
Essentially, the variety of available investor actor funding must expand. Bio-firms require 
different funds and investor skills at different stages of their development, i.e. there is a 
need for seed capital investors, and risk capital investors for new high-risk areas. 
Additionally, brokerage services, including business angels, are also required to optimise 
interactions between innovators and investors by building up reputation, trust, and 
perceptions of reliability among regional partners.  
 
As the level of commercial activity in the bio-sector is too limited to facilitate such 
developments through private actor actions alone, they should be introduced through 
public sponsored measures which seek to advance firm-based developments to a degree 
where private investment actors emerge and/or enter the sector organically. As attracting 
private and/or non-Irish investors into the bio-sector ultimately depends on the successful 
post-initiative firm developments, this will be a long-term development target. It is vitally 
important that the bio-sector's investment actors and supports ultimately become private 
actor dominated so as to address its currently limited entrepreneurial nature/character, 
while the current public actor domination will become unfeasible as the bio-sector evolves. 
 
In relation to 'soft' entrepreneurial supports, a key issue undermining sectoral 
entrepreneurial activities is a general absence of entrepreneurial and/or commercial 
skills throughout the bio-sector. Different options exist in how to address these issues.  
 
Tailored education and training development programmes should be introduced to seed 
entrepreneurial skills across all areas of the bio-sector, so as to engender an 
entrepreneurial mindframe. Such programmes will require a long-term focus in order to 
fully address the ingrained/established nature of old and out-dated skill sets present in 
many sectoral actors. While new skills can be introduced through tailored programmes, 
ultimately a suitable entrepreneurial mindframe can only be engendered, and 
transmitted to future generations, through seeding the relevant competences, in 
combination with the long-term accumulation of acquired experiences and tacit 
knowledge exchanges, which accumulate over time through sectoral activities, this issue 
relates to sections 8.3.3 and 8.3.4. 
 
In particular, such programmes should seek to address the existing 'divide' between 
academics and commercial actors. The level of commercialisation 
experience/knowledge among PREO academics and administrators is a key issue 
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inhibiting the bio-sector's optimal development. Furthermore, the commercialisation 
elements of education programmes in the PREOs are relatively minor, at best 
comprising small portions of the overall course content in under- and post-graduate 
courses. This means future academic and bio-firm actors enter their professional careers 
with minimal commercial experience and knowledge.  
 
Addressing these issues will require a major recasting of the traditional ethos of Irish 
PREOs and their administrative structures, so as to create the relevant attitudes, skills 
and procedures. These developments must also occur parallel to the introduction of 
suitable resources and funding supports so as to optimally support commercialisation 
efforts. 
 
Seeding PREO commercialisation skills should optimally occur through an evolving 
skills development initiative that seeks to engender the relevant competences and skills 
from the start of an academic's education and career, i.e. at the under-graduate level, and 
deepen them as students/academics work their way through the PREO system. Through 
introducing more advanced and structured commercialisation elements to education 
programmes, which optimally should include industrial placements (detailed further 
below), the commercial orientation of students would become more pronounced through 
making them more aware of the commercial possibilities in their future careers.  
 
In relation to academics, comprehensive educational programmes should be introduced 
to educate academics on the commercialisation procedures of the PREOs, the roles of 
the relevant government agencies, and available funding sources. It must be noted that 
various commercialisation programmes have been developed by the quality promotion 
and professional development offices of the different PREOs, and are run in conjunction 
with their commercialisation offices. However, these programmes have been developed 
and implemented largely without government agency involvement/consultation, i.e. 
they do not form part of a coordinated commercialisation skills development drive, and 
no uniformity exists among them. Overall, they have had limited success, as reflected in 
the limited commercial developments generated by PREO actors, particularly in the 
context of the on-going commercialisation support developments. 
 
Commercialisation education programmes for academics could be developed and 
implemented through a public/private mentor programme that identifies suitable 
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academic candidates and tailors programmes to optimise their skills development by 
covering all areas relevant to commercialisation processes. These developments could 
also link into, and complement the more pronounced commercialisation focus of the 
'new' non-local academics, i.e. those attracted to Ireland through SFI's TFF, and actors 
returning to academia from industry positions, thus engendering spillover 
developments. 
 
A key element of such efforts must be the development of industrial placement 
programmes for academics, and also PREO-based placements for industrial actors. 
Placements are essentially untapped elements in the bio-sector with regards to exposing 
academics to the practises and demands of commercial actors, and in facilitating more 
complex downstream networks and spillover developments.  
 
However, the lack of established structures among both PREOs and bio-firms to 
facilitate such placements and to deal with the associated administrative and resource 
issues must be addressed. Such structures could be developed in association with the 
introduction of non-local skills and resources. In relation to bio-firm placements, they 
should be implemented as part of the on-going government initiatives, e.g. they should 
be introduced as required elements in publicly funded spin-out bio-firm developments, 
and in any future funding initiatives targeted towards developing PREO/bio-firm 
alliances. However, the success of such a programme would be dependant on the overall 
level of research conducted by indigenous bio-firms increasing.  
 
The level of commercialisation and entrepreneurial skills present among indigenous 
bio-firms, even in the context of the on-going initiatives, remains limited. To a large 
degree this is due to the general absence of an established entrepreneurial mindframe in 
Ireland, as stated in the Culliton Report (1992), due to the relative absence of an 
innovative indigenous industrial base. This has inhibited the development of a culture 
which accepts even minor acceptance of trial and error through entrepreneurial 
experimentation, and is compounded by the absence of inter-actor networks.   
 
Additionally, entrepreneurial experimentation in the bio-sector, and among SMEs in the 
wider economy, is undermined by the limited availability of skilled business 
development and management actors. This impacts on the ability of both pre- and post-
initiative bio-firms to access speculative investor finance. Yet, the limited innovation 
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activities of the bio-firms further restricts their ability to access business management 
skills, i.e. a negative feedback loop exists.  
 
Optimally, such missing commercial and entrepreneurial skills and competences should 
be identified and addressed through coordinated long-term skills development 
programmes derived through a public/private actor dialogue process, e.g. through 
exploiting the connections established by the BioConnect organisations and sectoral 
placement programmes. This would require seeding the relevant competences and the 
presence of suitable and evolving entrepreneurial supports, in order to engender the 
conditions which facilitate the organic build up and development of a particular/unique 
set of competences in the wider economy, specifically through entrepreneurial 
experimentation in innovative developments over an extended period of time.  
 
The infrastructural suggestions presented in this section are presented to the 
Departments of Finance, the DETI, and EI. These management skill proposals are 
directed to the DETI. 
 
8.3.3 An inter-actor network development programme 
The international bio-sector is characterised by its inter-actor network structure; the 
sector's value chain is inherently network-based, and is rooted in tacit and codified 
knowledge spillovers, particularly in relation to ‘sticky’ knowledge exchanges 
embedded in localised social interactions. Networks are crucial elements in developing a 
bio-sector's internal logic, through facilitating and encouraging spillovers and 
entrepreneurial developments. 
 
The indigenous bio-sector's network structure is disjointed, limited, and, in the case of 
many actors, networks exist predominantly with non-Irish actors. In part, this scenario is 
due to the limited numbers of sectoral actors and the resultant limitations in sectoral 
activities, yet it is also due to inter-actor networks not being intrinsic elements of 
current Irish industrial policy measures (Enterprise Strategy Group, 2004).  
 
An effective methodology for such an Irish-based networking programme, developed 
upon the Danish Government’s Network Cooperation Programme, has already been 
developed in an Irish setting. Forbairt ran a Pilot Programme on Inter-Firm Co-
operation Networks between 1996 and 1997, and successfully established inter-actor 
network developments. Yet, despite the programme's evaluation report recommending 
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that a full-scale national programme be developed, no further action was subsequently 
taken.  
 
This programme should now be reanimated, up-dated and tailored through the 
public/private actor dialogue process to the demands and needs of the indigenous bio-
sector, and also to strengthen collaborative alliances where they exist. Due to the central 
role of trust in how networks develop and function, and in the context of the current 
state of the bio-sector's network 'structure', such a network development programme 
would require a long-term approach.  
 
Yet, there is a clear need for a deeper understanding of the concept of inter-actor networks 
among development agencies. To address this issue, a programme development advisor 
could be used to re-introduce, and educate public actors on the concept and the associated 
benefits of inter-actor networks, through providing key insight into linkages and 
interdependencies between actors in supply chains in order to seed the concept and to 
better inform policy formation.  
 
Overall, a network development programme would assist in engendering a more 
innovative bio-sector through addressing the poor levels of inter-actor collaborations. It 
would also facilitate significant sectoral feedback events, particularly the circulation of 
filtered PREO and firm-based knowledge of research activities, management practises, 
and would also feed into and optimise the public/private dialogue process.  
 
This policy suggestion is directed towards EI, the DETI, and the DES.  
 
8.3.4 Market information exchange resources 
The current level of inter-actor information exchanges in the bio-sector is limited due to 
the lack of established interactive and collaborative infrastructures or dialogue 
processes which facilitate cross-system information dissemination. In part, this is due to 
the absence of established public/private actor dialogue systems and defined centralist 
Government structures in the wider economy. These issues limit sectoral synergies and 
spillover developments, and undermine the bio-sector's development trajectory. For 
such an information dependent sector as biotechnology, this limitation must be 
addressed through the development of cross-system discussion forums and information 
disseminating systems. 
 
 242 
Such developments would require the establishment of infrastructures and resources to 
allow the gathering, filtering and dissemination of information. Such structures should 
link in with the proposed PREO and entrepreneurial services and infrastructures and inter-
actor network development approach. Business and competitive intelligence services 
require extensive business know-how and local contacts to suitably service the bio-sector's 
needs, while the sectoral strength and confidence derived from self-regulation through 
inter-actor networks are also required for such an interactive service to work optimally 
(Anderson et al., 2004; Malecki, 1997; Engel and Del-Palacio, 2011).  
 
The initial development of such a support/service would require public actor leadership 
in the context of the bio-sector's current state of development, while a limited level of 
indigenous bio-firms means substantial downstream contacts cannot be developed. 
Currently, such a service falls somewhere between the actions/roles of the IDA Ireland and 
EI, yet should also involve the Irish BioIndustry Association, BioConnect Ireland and its 
off shoots, and InterTradeIreland in a coordinated system that builds upon and advances 
existing national, cross boarder and international networks to facilitate resource and 
skills exchanges. 
 
The development of cross-system discussion forums could also link in with the 
proposed public/private dialogue process. As it often takes several years until policy 
effects can be fully detected, in order to allow all sectoral stakeholders to have a broad 
view of all topics relating to the bio-sector, it is important to consider the 
implementation of continuous benchmarking, technology assessment and technology 
foresight exercise processes to inform the formulation and implementation of tailored 
sectoral development initiatives (Engel and Del-Palacio, 2011).  
 
Additionally, such forums could facilitate the introduction of sectoral skills 
development programmes, in particular the introduction of non-local research and 
entrepreneurial skills developments. The skills base in the bio-sector must be subject to 
an on-going development processes to address the evolving needs of the bio-sector's 
actors, and to allow sectoral actors access up-to-date, relevant and different forms of 
skills and knowledge.  
 
The development of international dissemination systems, i.e. placement programmes in 
more asset rich bio-sectors, and the formation of advice councils which draw from more 
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advanced and/or emerging systems, would allow sectoral actors to plug existing skills 
gaps, as identified through the public/private dialogue process, access new/emerging skills 
sets, and seed alternative skills and knowledge sets in the bio-sector. In the long-term, 
such programmes could potentially facilitate the attraction of non-local actors into the 
bio-sector and the development of a sectoral brand, however these developments would 
require a significant increase in the overall level of current sectoral activities. 
 
Allied to these developments, it is crucial that PREO-based incubators and research 
parks are also developed to create key information exchange nodes between PREOs and 
industry actors. These developments must feed into the development of more advanced 
commercialisation supports and commercialisation skills programmes.  
 
A very limited number of incubator developments (innovation centres) exist. Yet, 
incubators should optimally be developed at all PREO actors, including the IoTs and 
hospital RIs, and should link in with the EIBD-related developments proposed above. 
The business development skills of the existing (and future) incubators must also be 
expanded and re-enforced to provide a suitable commercialisation environment that 
facilitates and encourages researchers to develop commerciable IP and/or establish 
commercial alliances.  
 
It is crucial that more advanced assessment procedures be introduced to ensure that the 
programmes which enter the incubators are of a suitable quality, so as to optimise 
commercial developments. A project's potential, and its specific criteria/needs must also 
be evaluated annually to optimise its development/realisation, and to remove 
underperforming firms/ideas. Such developments could be engendered through the 
cross sectoral discussion forums proposed above, i.e. through using a panel of visiting 
external experts to analyse and select a stronger selection of projects, optimise incubator 
programmes. 
 
In relation to potential research parks developments, they should be introduced in the 
context of the various suggestions presented in the previous sections, and located at key 
PREOs, not at 'Green Field' sites, so as to facilitate increased localised commercial 
developments and knowledge spillovers among sectoral actors. However, their 
development would require that the level of sectoral activities, and the 
commercialisation skills, resources, capabilities and orientations of all sectoral actors 
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advance significantly beyond their current levels. 
 
The suggestions presented in this section are directed towards the DETI, in respect of 
the agencies under its aegis  
 
8.3.5 Actor and institutional density, and skill, competence and resource depth 
A limited mass of entrepreneurial and innovative activity has formed in the indigenous 
bio-sector due to the existing weaknesses in the sector's PREOs, the limited level of 
downstream sectoral developments, and the absence of key market and non-market 
actors, institutions, and skills, competences and resources. As such, the bio-sector 
presently experiences difficulties in developing agglomerated economies, labour pools, 
skills, supply firms and other opportunities critical mass engender due to these systemic 
limitations.  
 
To address these issues, and coordinate the bio-sector's development initiatives and 
development trajectory, an 'anchor' actor strategy could be developed to proactively 
engender a more pronounced private actor orientation to the bio-sector's activities, as its 
dominant actor is currently the National Government.  
 
There are three anchor actor models:  
 
 the organic development of a 'star' actor (e.g. a star bio-firm development);  
 the organisation of systemic developments around the facilities of local TNC 
operations, and;  
 an interdependent model where a mutually beneficial alliance develops between 
a system's actors and TNC operations.  
 
Optimally, the development of a 'star', or anchor bio-firm would create an 
entrepreneurial role model in the bio-sector that could initiate an increased level of 
PREO spin-off developments by inculcating an entrepreneurial attitude/climate and 
driving the development of an entrepreneurial support system. Such an actor does not 
presently exist in the sector, or has yet to emerge. 
 
However, anchor actor developments could be sought in alternative, niche areas in 
associated sectors indirectly related to the indigenous bio-sector, i.e. by facilitating 
PREO links with biotechnology-related small to medium sized enterprises (SMEs). It 
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must be noted that SMEs are identified here as separate entities to bio-firms, i.e. they 
were not formed solely to pursue the commercial development of basic or applied 
biotechnology research, but were formed by entrepreneurs that identified niche 
opportunities in sectors indirectly related to, and not centred upon biotechnology. 
 
Forfás (1999) noted that a variety of established biotechnology-related sectors exist in 
the economy, i.e. the agriculture, marine, forestry, chemicals, food and drink, and 
environmental management sectors. While limited biotechnology-related research 
occurs in these areas, e.g. agriculture-related research activities are predominantly 
confined to Teagasc's RIs (Appendix E), they mean that significant latent potential 
exists in developing a more complex and varied indigenous bio-sector (Morrissey, 2011; 
Marine Biotechnology Ireland, 2011).  
 
This proposal relates to the international bio-sector focusing mainly on pharmaceutical-
based research and activities, specifically cancer- and drug/therapy-related areas. The 
Irish bio-sector has also developed a strong pharmaceutical orientated science base in 
the PREOs, while the majority of bio-firm activity is also related to pharmaceuticals. 
Essentially, the Irish bio-sector is focusing on competing in an already crowded/highly 
competitive market place. 
 
This focus is not addressing or exploiting the massive range of opportunities and 
possibilities which biotechnology offers, or which Post-Fordism offers. Commercial 
applications of modern biotechnology have been most successful in specialist niche 
markets where economically competitive alternatives do not exist. Potentially, SME-
based developments in biotechnology-related sectors represent a significant and 
essentially untapped and unexploited opportunity for Ireland to secure different forms of 
competitive advantage, as corresponding and underlying PREO-based research 
activities occur in a variety of alternative sectoral areas, e.g. marine, aquatic, and 
agriculture (Morrissey, 2011; Marine Biotechnology Ireland, 2011).  
 
Such developments could expand the number of potential downstream alliances 
available to PREO actors, particularly for the more application based IoTs, and could 
lead to the development of a more research-orientated SME sector in areas related to 
biotechnology, which itself could feed into the development of a more diverse/multi-
faceted bio-sector (STIAC, 1995; National Economic and Social Council, 1997).  
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The Irish industrial base is characterised as being engaged in very limited R&D 
activities, which restricts opportunities to develop research-based alliances with PREOs. 
Yet, a model for facilitating innovative SME developments, through alliances with 
PREOs, exists in the form of the Atlantic University Alliance (AUA). The AUA was 
established in 1999, through funding received from the National Development Plan 
2000-2006, the EU, and its host universities, the University College Cork, UL and the 
National University of Ireland, Galway. The AUA proactively seeks to cultivate a more 
research-orientated SME sector through advertising relevant research programmes, and 
facilitate research-based collaborations with their partner PREOs. The AUA also allows 
interested/suitable SMEs to access PREO-based research findings and specialist 
academic advice so as to address technological issues they face. The AUA's 
commercialisation structure complements and supports existing structures in the 'parent' 
universities, i.e. the three universities work together, yet are independent of each other.  
The AUA could be used as a template for the development of regional organisations to 
develop a more research-orientated SME sector in areas related to biotechnology, and to 
engender the concept of indigenous firms conducting R&D. This would require such a 
structure being developed nationally, and the introduction of a complex series of 
initiatives and supports similar to those proposed for the bio-sector in section 8.3.2 to 
address the limited innovative capacities of SMEs, and allow them develop the 
necessary capabilities and resources to absorb and apply research and new knowledge to 
their activities. Such developments would follow recommendations made by various 
Government publications relating to the development of networks and information 
sharing among indigenous firms. 
 
SME-based developments could also be driven by alterations to existing Government 
regulations and procurement policies in order to create innovative pressures that drive 
biotechnology derived product developments. For example, the Environmental 
Protection Agency's Science, Technology, Research & Innovation for the Environment 
programme could be used to develop biotechnology-derived solutions to environmental 
issues, rather than just basic products or services (Forfás, 2006). 
 
In relation to a TNC-centred anchor strategy, several issues make such a strategy 
essentially unsuitable for the indigenous bio-sector. An increased number of research-
orientated TNC operations have been introduced into the country due to the proactive 
encouragement and support from the IDA Ireland. The current operational structures 
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and activity focus of the Irish-based TNC branch plants limit opportunities for 
significant sectoral alliances, while the limited state of the bio-sector's development 
would mean a TNC anchor strategy would essentially swamp the bio-sector's 
development trajectory, as their more advanced activities and resources would siphon 
off skills, resources and competences. 
 
However, it is important that efforts to attract more R&D intensive TNC operations into 
the country continue, so as to facilitate more complex alliances with sectoral actors. 
Optimally, this would occur organically through sectoral activities attracting such 
developments into the country, yet current development trends indicate such 
development will not occur immediately. More complex TNC operations could be 
attracted through a series of inter-related policy measures, that link into the suggested 
initiatives presented above, as four distinct opportunities, which are concentrated 
around the country's PREOs, exist in the indigenous bio-sector.   
 
Firstly, advanced drug incubator facilities are increasingly crucial to TNC as their 
research activities become more sophisticated. Drug incubators are specialised 
biopharmaceutical drug development laboratories where TNCs establish a drug master 
file, essentially a development template/blueprint that establishes result reproducibility 
and which informs the clinical trials process and later scale up processes. Such a file is 
vitally important in licence developments, and the demand for these facilities is greater 
then the global supply.  
 
Academic respondents noted that by investing in such facilities, which are relatively 
cheap, Ireland could tap into a significant lucrative market. Suitable royalty-style 
agreements could generate considerable financial return for PREOs, as the value of such 
a small-to-medium scale production run is very high for TNCs. This strategy could 
attract more complex TNC R&D operations into Ireland, by advertising the depth and 
quality of Irish researcher skills, and PREO facilities and research activities, yet at a 
minimum would result in TNCs establishing more complex activities in the country.  
 
Secondly, as part of their diversification strategies, TNCs are increasingly seeking to 
acquire IP from, or enter into licensing agreements with RIs. Academic respondents 
commented that this development presents Ireland with an opportunity to develop RIs 
specifically tailored towards TNC's research activities, so as to engender more complex 
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and engrained TNC research activities. Due to their defined TNC focus, such RIs would 
be separate to, yet compliment the structures of the current Centres for Science, 
Engineering & Technology. Such developments would be attractive to TNCs as they are 
increasingly seeking to address the rising costs of the clinical trials process. By 
developing alliances with such RIs, they would be able to conduct relevant research 
without the associated levels of capital investments. To a degree, this suggestion 
replicates the ready built factories offered by the IDA Ireland to entice FDI into Ireland.  
   
Thirdly, PREO-based research parks could be developed which could link into the 
proposed commercial development services and supports and placement programmes 
for academics and students, so as to facilitate skills developments and engender 
spillovers. Such developments have occurred in the international bio-sector, e.g. 
Singapore's bio-sector, and would essentially mimic the IDA Ireland’s existing TNC 
enticement strategy of providing pre-building factory space, yet in a more complex and 
advanced manner.  
 
Finally, an opportunity exists for the bio-sector's public and private stakeholders, 
including the PREOs and downstream sectoral actors, to jointly formulate and 
implement tailored PREO education curricula that optimally address the bio-sector's 
various skill demands. This public/private stakeholder aspect is important to address 
information gaps in the development of such courses. TNCs could be allowed to inform 
the formulation of PREO education courses in order to address existing skilled labour 
shortages they are experiencing in several key areas of their operations. As international 
trends indicate that biotechnology will become increasingly important for TNCs, 
tailoring courses to the evolving demands and needs of TNCs would position the bio-
sector to optimally address and adapt these trends. 
 
The suggestions presented in this section are directed towards the agencies under the 
aegis of the DETI, the Department of Agriculture and Food, the Department of the 
Environment, Heritage and Local Government, and the Department of Finance, as well 
as City and Council Enterprise Boards. 
 
8.5 CONCLUSION 
Despite the various developments engendered by the on-going sectoral initiatives, the 
initiatives have failed to fully address the restricted innovative resource and skill 
capacities present in the bio-sector, particularly among PREO actors and pre-initiative 
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bio-firms, as well as the virtual absence of key value chain actors, e.g. TNCs.  
 
In the context of the sectoral template and the regional systemic concentrations evident 
in the international bio-sector, as presented in chapter 3, these issues demonstrate that a 
more complex overarching policy framework, constructed through a public/private 
dialogue process, is required to engender a regionally tailored systems-based 
entrepreneurial and innovative support ecosystem which facilitates and drives 
entrepreneurial and innovative activities throughout the bio-sector's value chain.  
 
The development of a suitable knowledge base, including the promotion of high-level 
basic and applied research, and skilled human resources must continue as a key policy 
focus. The country's PREOs should be remodelled to have a more overtly/defined 
commercial emphasis through introducing skills development services which seek to 
engender an entrepreneurial mindframe, so as to optimise the commercialisation of 
viable research. Such developments should feed into the development of improved 
commercialisation and entrepreneurial supports for downstream sectoral actors, 
particularly so as to optimise the development of existing and new bio-firms.  
 
Additionally, a defined network development programme must be introduced, in 
alliance with structural supports, to facilitate increased inter-actor knowledge exchanges 
throughout the entire bio-sector, to optimise sectoral spillover developments, and the 
identification and exploitation of commercial opportunities in the bio-sector. Such 
developments should link into PREO-based structural and commercialisation-based 
resource developments in order to feed into new and on-going commercial 
developments.  
 
The indigenous bio-sector's development trajectory could be orientated around an 
anchor actor strategy. Different options exist, yet optimally the bio-sector's development 
should be driven by indigenous commercial developments. Such an actor strategy may 
originate from the indigenous bio-sector, yet the wide reaching nature of the science of 
biotechnology means several sectors in the indigenous economy, in areas where 
potential biotechnology-derived applications may apply and/or be derived, could 
emerge as alternative anchor actors, thus facilitating the development of a more diverse 
and complex indigenous bio-sector. 
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CHAPTER 9:  
A COMPARATIVE ANALYSIS BETWEEN THE IRISH AND 
INTERNATIONAL BIOTECHNOLOGY SECTORS 
 
9.1 INTRODUCTION 
This chapter is divided into two sections. The first section analyses sectoral actor, 
network, cluster/agglomeration and policy typologies in the international and Irish 
biotechnology sectors (bio-sectors). In particular, this section applies our understanding 
of these four elements, as derived from the Irish bio-sector analysis chapters, to the 
international bio-sector. This informs the second and final section, which presents a 
discussion on what this analysis demonstrates in relation to non-hub bio-sectors. This 
discussion seeks to highlight the importance of non-hub sector studies in advancing our 
understanding of the international bio-sector, specifically with regards to how sectoral 
development initiatives are formulated, structured and implemented in these bio-sectors. 
 
9.2 ANALYSIS OF THE INTERNATIONAL CASE STUDIES AND THE IRISH 
BIO-SECTOR 
Five hub biotechnology sectors/biotechnology clusters can be identified in the 
international biotechnology sector (bio-sector), three in the United States (San 
Francisco, Boston, and San Diego), and two in the European Union (Cambridge and 
Munich). These hub sectors/biotechnology clusters (bio-clusters) are the most studied 
sites in the international bio-sector; indeed the templates of sectoral actors, networks, 
bio-clusters and sectoral development initiatives presented in chapter 3, i.e. the 
foundations upon which the review of the Irish bio-sector was constructed, were derived 
from these bio-sectors.  
 
In comparison to these hub bio-sectors, investigative studies on the actors, networks, 
regional agglomeration tendencies, and/or policy initiative forms of the remaining bio-
sectors, i.e. the non-hub/Proto bio-cluster (PBC) sectors, are less intensive or 
comprehensive. In part, this is due to academic research focusing on the hub sectors in 
efforts to derive solutions to identified issues/weaknesses in non-hubs.  
 
This means that little academic work has been done on how non-hub sectors can 
contribute to our understanding of the hubs, and the international bio-sector as a whole. 
Analysing non-hub sectors advances our understanding of the workings of bio-sectors 
by informing a more comprehensive understanding of how actors, networks, 
agglomerations/clusters and policy interact/function internationally in the context of 
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different pre-conditions, sectoral characteristics, and regulatory environments. 
 
9.2.1 An analysis of the actor typologies of the international case studies and the Irish 
bio-sector 
All sectoral actor types are crucial to a bio-sector's performance and activities, by acting 
as either an incubator or transfer mechanism within the complex and interactive Post-
Fordist sectoral value chain, as presented in Table 9.1. Superficial analyses of hub bio-
sectors can highlight specific actor types as being more important than others in sectoral 
innovation processes, yet such analyses ignore/miss many crucial relationships and 
inter-dependencies (Owen-Smith and Powell, 2007; Romanelli and Feldman, 2007). 
 
Table 9.1: The main contributions of the international bio-sector's actor analysis to the Irish bio-sector 
Commercial developments, internationally, are predominantly based upon the research programmes of Public Research and Education 
Organisations (PREOs). Their long-term speculative/exploratory basic research programmes and information transmission and information 
disclosure characteristics are important for volatile technology fields/sectors, e.g. biotechnology. The quality of their infrastructures and skills are 
vital in determining the depth and range of their research and skills development programmes. 
Bio-firms traditionally occupy the middle rung in the sectoral innovation process, and are the main transferring mechanism of PREO-based 
research findings to the market place. Predominantly established by commercially minded PREO actors to pursue research that exhibiting clear 
commercial promise, they emerge in the context of significant commercial supports and competences that seek to optimise their development 
trajectories.  
Bio-firm developments are dependent on formal alliances with different investor actors, particularly Venture Capital (VC) investors. VCs target 
high-risk businesses that traditional business investors avoid, and are key facilitators in firm developments by providing crucial managerial and 
technical expertise to optimise their start-up and initial developments so as to enter formal alliances with downstream actors, e.g. Transnational 
Corporations (TNCs). 
TNCs are traditionally the last element in sector value chains, which includes the clinical trial process, and are increasingly adopting biotechnology 
in their operations as biotechnology research is easily adaptable to their technological requirements.  
Government actors play critical roles in sectoral developments and activities through determining the depth/quality of hard and soft infrastructures, 
skills and competences of sectoral actors. This reflects the wide technological base and range of activities of biotechnology, which means that the 
direct and indirect involvement of Government departments and agencies in a bio-sector covers a wide remit.  
Supply actors facilitate research and production activities throughout a bio-sector. Goods suppliers provide equipment, chemicals and biologicals 
bio-firms require for research activities, while service firms provide a wide range of advanced and specialised systems and solutions to issues that 
arise in different fields of biotechnology research. Sub-national centres disseminate region-specific information among sectoral actors, while trade 
associations circulate information and provide services relating to their members' core activities. Such actors can facilitate the development of 
sectoral brands which attract non-local skills and resources into a sector, facilitating positive externalities which deepen the hub nature of these bio-
sectors. 
Bio-firms in the hub sectors are increasingly focused on niche areas on inter-firm alliances. This has been facilitated by the emergence of specialist 
service provider firms which focus on specialist technological and research support services, i.e. platform technology firms (which provide 
specialist tools) and product development firms (which conduct specific aspects of the clinical trials process). In response, TNCs have restructured 
their operations to mimic the organisational structures of bio-firms and focus on smaller volume niche market drugs. These developments have 
fragmented the downstream end of the value chain of hub sectors, highlighting their actor, resource, and skills depth and variety and exposing the 
shortcomings and weaknesses of the non-hubs. 
(Smith and Powell, 2004; Barley et al, 1992; Breschi et al., 1999; Prevezer and Tang, 
2007; Avnimelech and Teubal, 2007; Gertler and Levitte, 2005; Stuart et al., 2007; 
Giesecke, 2000; Malecki, 1997; Forfás, 1999; Lia and Gengb, 2012). 
 
Where a country's PREOs experience long-term absences of public actor investments, 
their research-related capabilities and activities will be restricted and undermined due to 
the presence of significant infrastructural, resource, skills and competence weaknesses. 
Such issues will be emphasised where structural rigidities and established institutional 
conservatism are present. Where such elements exist in the context of a general absence 
of commercial orientation among PREOs, they will undermine and strongly limit 
activities and commercial developments throughout a bio-sector's value chain, and will 
particularly undermine bio-firm-related developments and activities. 
 
Substantial PREO-based infrastructural and skills developments can be engendered 
through the introduction of public actor initiatives which seek to address preceding 
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weaknesses and to ultimately drive sectoral activity levels by facilitating more advanced 
commercial developments. Yet, while introducing more advanced infrastructures and 
skill sets will result in noticeable advances, these developments will only create a 
development surge, i.e. the developments will be substantial in relation to the previously 
limited conditions and activities, yet they will not fully address the established path 
dependence of PREO actors.  
 
Due to the restricted activities and capabilities of a bio-sector's PREOs, limited transfers 
to commercial concerns will occur. In such a scenario, where bio-firms do emerge, it 
will be common for bio-firms to source their Intellectual Property (IP) from non-local 
sources so as to bypass the weaknesses of the indigenous PREOs.  
 
Such bio-firms will be characterised as being conservative in nature, i.e. the 
type/character of their activities will typically be in diagnostic- and platform-related 
activities. This conservatism will impact on the overall level of commercial activity of a 
bio-sector, and will contribute to the development of a sectoral innovation paradox, i.e. 
actors in poorly endowed regions do not/cannot engage in significant innovative 
activities as they typically under invest in Research and Development (R&D), which 
means they cannot/do not engage in significant R&D activities (Asheim and Isaksen, 
2002; Anderson et al, 2004; Giesecke, 2000; Morris, 2011).  
 
These conservative characteristics will be amplified if such bio-firms develop in the 
context of a virtual absence of commercial development supports, particularly an 
absence of investor actors, and their associated skills and competences. Such issues will 
further engrain and entrench a conservative mindframe among a bio-sector's actors, and 
will mean that bio-firms will seek alliances with investors in non-local sectors, 
specifically hub bio-sectors. Yet, due to the limited sectoral track record in 
entrepreneurial and innovative developments, and the costs associated with the 
management of such alliances over long distances, non-local investors are less inclined 
to enter into such alliances. This scenario will result in an investment paradox emerging, 
i.e. bio-firms cannot attract significant investor interest due to their limited 
developments, which exist due to their inability to develop significant commercial 
developments (Leydesdorff at al., 2002; Casper, 2002; Kaiser, 2002).  
 
These paradoxes and the entrenched institutional and activity conservatism and 
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limitations will inhibit and constrict entrepreneurial and innovative activities throughout 
a sectoral value chain, i.e. extensive cumulative disadvantages will be experienced. As 
such, the bio-sector will fall further behind in relation to more resource endowed bio-
sectors (Morris, 2011). 
 
Where public actors seek to drive entrepreneurial developments in a bio-sector by 
introducing advanced commercialisation supports and infrastructures, in order to exploit 
the increased commercial potential derived from preceding PREO-centred initiatives, 
they will engender a surge in bio-firm developments. Essentially, more substantial bio-
firm developments will emerge in the context of the preceding development levels, and 
will advance the commercial orientation of a bio-sector, yet the new bio-firm 
developments will hit significant structural weaknesses caused by the preceding 
conservative and limited sectoral activity levels of the bio-sector. Additionally, those 
bio-firms which emerged prior to the introduction of sectoral development initiatives 
will typically be excluded from the development initiatives, meaning their conservative 
natures and associated paradoxes will remain. This results in the formation of a 
disjointed bio-sector, which undermines and compromises the bio-sector's development 
trajectory. 
 
Furthermore, public commercialisation supports can also undermine the bio-sector's 
development trajectory. Due to their public nature, investor actors will adopt a 
conservative nature as they seek to establish themselves in an unproven bio-sector, and 
also seek to successfully deliver noticeable returns for their substantial public 
investments. As such, conservative business models and activities will be sought, e.g. 
platform-related activities. This activity orientation feeds into and engrains the 
conservative nature of the bio-sector, and restricts entrepreneurial developments, rather 
than assisting them. Additionally, such supports will focus only on post-initiative bio-
firms, thus contributing to the disjointed nature of the bio-sector. 
 
Where the bio-sector's innovative development levels are restricted by PREO and bio-
firm limitations, TNC involvement will be minimal as the limited collaborative 
opportunities will be available to them. This scenario is amplified where TNCs are 
predominately branch plant in nature, i.e. they have limited autonomy in their activities.  
 
Even where a bio-sector undergoes a surge in sectoral activity as a direct result of public 
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actor development initiatives, TNC involvement will remain minimal as entrenched 
sectoral weaknesses mean activity levels will not advance rapidly to such a level where 
collaborations are possible. This scenario will remain even where increasing numbers of 
research operations are introduced by the TNCs into their branch plant operations, in a 
reflection of the increasing adoption of biotechnology practices in their operations, 
internationally.  
Limited sectoral activities will undermine the development of sectoral support actors. 
As such, the main markets for the supply actors which do emerge in the context of 
limited indigenous sectoral activities will be in non-local bio-sectors, as they seek to 
bypass indigenous sectoral weaknesses. This will reinforce the adoption of conservative 
structures, and encourage the development of alliances with non-local suppliers among 
sectoral actors. Sectoral surges which result due to sectoral development initiatives will 
not change or address this situation due to the entrenched weaknesses of the existing 
pre-initiative bio-firms and the limited developments engendered by the post-initiative 
bio-firms.  
 
The characteristics and activities of sectoral actors reflect the policy environment in 
which they emerge and develop. Where such an environment is shaped by long-term 
protectionist policies, and a subsequent pronounced focus on Foreign Direct Investment 
(FDI) driven industrial and economic developments at the expense of defined and 
pronounced indigenous industrial development initiatives, a country's indigenous 
industrial base will be strongly compromised by the limited entrepreneurial and/or 
innovative developments such policy approaches will engender. Indeed, these 
approaches will facilitate the emergence of an innovation paradox in the wider industrial 
base. This scenario will be amplified where there is long-term uncoordination between 
public industrial and STI policy streams. Furthermore, where policy formulation and 
implementation occurs through a top down process that has virtually no regional 
elements, differences in regional development trajectories will become established and 
engrained due to different regional endowments of sectoral actors and activity levels, 
which can cause imbalanced regional development and thus undermine the development 
of a national bio-sector.  
 
Where a Government identifies biotechnology as being a key strategic target in securing 
the future development of its economy, development initiatives are typically formulated 
and derived from 'snapshots' of the hub bio-sectors, i.e. they focus superficially on 
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elements of the substantial infrastructures, skills, and resources which characterise the 
hub bio-sectors, in efforts to mimic their depth and range of sectoral activities. Due to 
the manner in which they are formulated, the ultimate impact of snapshot-derived 
initiatives will be limited as they will not/cannot address the substantial and long-term 
cumulative weaknesses found among a bio-sector's actors and value chain. Indeed, such 
an approach can even contribute and entrench sectoral weaknesses.  
 
Snapshot public initiatives will be unintentionally introduced in an uncoordinated 
staged manner, due to the manner in which they are formulated. Typically, the public 
initiatives will initially focus on developing the infrastructures and capabilities of the 
country’s PREOs. These elements are viewed as automatically facilitating the 
emergence of substantial commercial developments, and are seen as being sufficient to 
achieve this aim. Yet, while such initiatives can lead to rapid developments, relative to 
the conditions and activity levels which existed prior to their introduction, it will 
subsequently become apparent that further initiative developments are required to 
address various competence issues and structural bottlenecks that inhibit commercial 
developments, e.g. the general absence of entrepreneurial skills, competences and 
supports among sectoral actors.  
 
Commercialisation development supports will subsequently be introduced, particularly 
dedicated VCs funds so as to facilitate commercial developments. Yet, due to their 
public nature, they will fail to address engrained weaknesses which undermine 
commercial developments, and they can also entrench entrepreneurial conservatism 
through seeking and supporting conservative business models in efforts to optimise their 
investment returns. Additionally, these initiatives will not seek to, or be able to address 
the limited involvement of TNCs and supply actors.  
 
9.2.2 An analysis of the network typologies of the international case studies and the 
Irish bio-sector 
The international bio-sector's value chain is a complex, non-sequential network-based 
Post-Fordist structure. The knowledge base from which biotechnology innovations 
draws is embedded in formal and informal networks between various actor types, 
including public and industrial researchers, while the development of biotechnology-
derived products and processes involves many different formal and informal actor 
alliances at various stages of a product's and/or process's development.  Informal and 
formal networks are important for all aspects of sectoral activities, as detailed in Table 
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9.2. Informal networks are crucial in innovative developments, while formal networks 
are important for crucial transfers of codified knowledge and play central roles in 
commercial developments. Inter-actor networks are optimised where close relationships 
and spatial proximity exist between actors.  
 
Table 9.2: The main contributions of the analysis of the international bio-sector's network structure to the Irish bio-
sector 
The sectoral innovation process can be characterised as a tripartite alliance chain formed around the coordinated efforts of PREOs, bio-firms, and 
TNCs, who create a non-linear, continuously interactive structure in which a hierarchy cannot typically form. Their interactions act as feedback 
loops that update and alter innovation processes for the benefit of all network members. Sectoral network structures are place specific, reflecting 
actor activities, historical factors (accumulations of infrastructures, resources, skills, and competences), and evolving policy environments. 
Academic scientists engage in collaborative basic research programmes that involve filtered tacit knowledge and information exchanges, and 
codified scientific and technical competence exchanges. Their programmes can be characterised as space specific agglomerations of scientific 
knowledge, where regional endowment of researchers and resources determine the effectiveness of networks in localised learning processes. 
Codification of PREO research occurs through journal publications and patent development/licensing agreements with commercial actors. Yet, a 
pronounced entrepreneurial orientation among academics may lead to the creation of bio-firms so as to exploit commercially viable research. 
Entrepreneurship is an inherently localised phenomenon, determined by place specific developments of skills, competences and experiences, and 
the presence of entrepreneurial-related policy actions. 
Alliances between bio-firms and PREOs represent the first downstream stage of the biotechnology innovation process. Bio-firms seek to locate 
close to their 'parent' PREO(s) to maintain/engender knowledge exchanges and skill transfers through informal and formal networks. Relative 
geographic proximity and social inclusiveness determines how they maintain/engender relationships with academics so as to access their 'filtered' 
tacit and codified knowledge. Such alliances determine a firm's research capabilities, and influence its commercialisation activities. Bio-firms can 
also derive their organisational structures and internal practices from their parent PREO(s).  
Alliances between bio-firms and other commercial actors, particularly TNCs, represent the second stage of the biotechnology innovation process. 
This represents the downstream end of the sectoral value chain, inter-actor networks become predominantly formal in nature (TNC/bio-firm 
alliances are facilitated through formal strategic networks with investor actors, particularly VCs). TNCs seek alliances to exploit the IP of bio-
firms, offering the firms their extensive resources and infrastructures, while the firms offer their advanced research activities and capabilities.  
Suppliers play facilitator roles in sectoral activities, forming close formal and informal networks with sectoral actors. These relationships are 
increasingly important as sectoral technologies and processes are increasingly niche orientated. Indeed, exclusive supply alliances can form, driving 
sectoral network structure depth and density. Sub-national and trade associations are key information disseminating services, and can facilitate 
sectoral brand development that attracts in non-local actors and boosts sectoral depth and density.   
Governments indirectly and directly facilitate sectoral network developments in many ways. The dominant organisational practices and routines of 
actors can be indirectly influenced by Government actor actions (e.g. the structures of PREOs influence the structures adopted by bio-firms). The 
development of intermediary actors, e.g. incubators and science parks, can facilitate network developments between PREOs and commercial actors. 
Governments can also develop or guide network promotion programmes. 
Hub sector network structures are increasingly complex due to the niche orientation of bio-firms and the downstream value chain fragmentation, 
i.e. the niche research/activity focus of bio-firms means inter-firm alliances are more equitable than alliances with TNCs, while TNCs have 
restructured their research operations to mimic the organisational structures of bio-firms and established virtually independent research operations 
that mimic bio-firm locational patterns to engender alliances with PREOs.  
Dense agglomerations of bio-sectoral activity develop in the hub sectors as non-local actors seek to locate in these sectors so as to develop alliances 
with the advanced activities of their PREOs and bio-firms. These developments will drive and engrain the development trajectory of these hub bio-
sectors, which means they will experience cumulative advantages. These developments demonstrate inter-actor networks are increasingly crucial in 
the internal activities and logic of sectoral actors and activities, and emphasises the impact network structure weaknesses in non-hubs have on their 
entrepreneurial and innovative activities. 
(Morgan and Nauwelaers, 1999a; Owen-Smith and Powell, 2007; Erden and von Krogh, 
2011; Gertler and Levitte, 2005; Gilding, 2008; Giesecke, 2000). 
 
Non-hub bio-sectors are essentially little more than combinations of co-locating actors, 
principally bio-firms and PREOs, grounded in regional ambitions to become significant 
players in the global bio-sector. Their network structures are poorly developed due to 
the presence of extensive structural inflexibilities, e.g. limited innovation levels caused 
by regional specific limitations in the resources, skills and competences of their actors, 
and the presence of various paradoxes, including innovation and investment paradoxes, 
which undermine and inhibit sectoral activities and developments. As such, their value 
chains are fragmented, and their sectoral activities are compromised.  
 
Where a bio-sector's PREOs are poorly developed, limited transfers will occur among 
academic researchers, which will undermine innovative developments, or to commercial 
actors, specifically bio-firms. The absence of alliances with commercial actors will 
become engrained due to the absence of an entrepreneurial mindframe, resources and 
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competences among academics and administrators. To compensate, a common strategy 
for non-hub bio-firms is to develop distant collaborative network strategies with actors 
located in more knowledge and resource rich bio-sectors. This issue is demonstrated by 
the prevalence of the pre-initiative bio-firms sourcing their IP from non-local sources.  
 
The limited and conservative nature of bio-firms is compounded where there is a 
general absence of sectoral supports, particularly VCs. Due to such weaknesses, bio-
firms will adopt conservative business models and activities. As such, these actors face 
significant issues in establishing alliances with non-local actors due to the poor 
image/reputation of the indigenous bio-sectors and the intense competition they face 
from more dynamic bio-sectors. This scenario will also undermine sectoral network 
development opportunities as they cannot/will not develop significant alliances with 
PREOs or with other commercial actors, e.g. TNCs, due to their conservative activities. 
This issue is amplified where TNC operations in the wider economy are manufacturing 
branch plant in orientation.  
 
Public initiatives can be developed in efforts to address many of these issues, e.g. 
PREO-based infrastructural and skills developments can be sought to facilitate 
significant increases in intra- and inter-institutional exchanges of personnel, 
competences and resources. Inter-actor sectoral networks can indeed surge as a result of 
such initiatives, and may superficially resemble networking patterns found in the hub 
bio-sectors, e.g. the advanced research activities in the post-initiative research institutes 
and their close proximity to their 'parent' university have facilitated significant spillover 
developments, and have impacted on the bio-sector value chain by facilitating an 
increased level of commercial activities and developments, i.e. the post-initiative bio-
firm developments in the Irish bio-sector.  
 
However, where such initiatives are introduced in a top-down manner and have no 
explicit/defined network elements, established and entrenched institutional and actor 
characteristics will mean limited intra- or inter-institutional collaborations will occur. 
Such a scenario can develop as the interactive nature of the sectoral value chain is often 
ignored and/or misunderstood, i.e. Government agencies can seek to develop inter-actor 
collaborations, not as part of a defined collaborative networking programme, but 
through using funding to essentially force actors to collaborate, predominantly so as to 
facilitate more optimal and efficient uses of personnel and resources. As such alliances 
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are not trust-based, they typically end once a project ends due to their contractual 
nature.  
 
As a result, the deeply ingrained institutional inertia, and the virtual absence of an 
existing interactive mind frame/culture in a bio-sector, will not be addressed. Such 
issues will feedback through the sectoral value chain, meaning that new bio-firms will 
emerge into a compromised value chain which presents few opportunities for 
downstream collaborations. This means that the bio-sector's network structure will 
remain characterised by groupings of conservatively structured actors which engender 
limited spillovers, while alliances will continue to be sought with non-local actors as 
they continue to seek to by-pass on-going shortcomings of the indigenous bio-sector. 
 
9.2.3 An analysis of agglomerations in the bio-cluster case studies and the Irish bio-
sector 
Hub bio-sectors form dense geographic concentrations of actors, partly due to the 
importance of spatially sticky tacit knowledge transfers between PREO and commercial 
actors through informal networks. These dense network structures are spatially 
concentrated in what are identified as bio-clusters.  
 
Only five locations in the international bio-sector have developed bio-clusters to date, 
i.e. San Francisco, Boston, San Diego, Cambridge and Munich. Each bio-cluster 
underwent its own unique development trajectory and trigger process, indeed the 
presence of proto bio-clusters/non-hub bio-sectors in countries with bio-clusters 
emphasises the distinct spatial specificity of the issues which underline bio-cluster 
developments. However, commonalities can be identified in the elements which 
facilitate a bio-cluster's emergence, as detailed in Table 9.3. 
 
Outside of the bio-clusters, similar features and elements can be identified in non-hubs, 
which can be termed proto bio-clusters (PBCs). For place specific reasons, they fail to 
develop a critical mass of entrepreneurial developments, and/or a suitable interactive 
system which drives and facilitates entrepreneurial developments. As such, negative 
spillovers occur which undermine their trigger processes and development trajectories. 
The PBCs are lagging behind due to their disjointed and suboptimal entrepreneurial and 
innovative infrastructures, resources and capabilities, and their compromised 
development trajectories. 
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Table 9.3: The main contributions of the international bio-sector's bio-cluster analysis to the Irish bio-sector 
The bio-clusters emerged in the context of similar positive pre-conditions and seeds, e.g. established PREOs and the presence of related industries, 
e.g. TNCs. The bio-clusters emerged through the development of place specific trigger processes, i.e. complex processes which build upon and 
prime a bio-sector's substantial and positive pre-conditions and seeds and engender positive systemic path dependence and development trajectory.  
Positive systemic path dependence and development trajectory facilitated the formation of a critical mass of entrepreneurial and innovative activity, 
i.e. a bio-cluster's trigger event, which emerges over an extended period of time and depends on the form, nature and character of a system's 
entrepreneurial and innovative support ecosystem and case specific information spillovers. There are three identifiable trigger event forms in the 
international bio-clusters:  
 the San Francisco and Boston bio-clusters emerged due to spontaneous trigger events, where the critical mass formed through private actor 
developments in an absence of public policy interventions,  
 the San Diego and Cambridge bio-clusters emerged through hybrid trigger events, i.e. their systems emerge through private actor developments, 
yet the trigger event was sparked by direct/indirect public actor initiatives, and 
 the Munich bio-cluster emerged due to a planned trigger event, where the system's trigger process and event was overwhelmingly driven by 
public actor initiatives. 
The character of a bio-cluster's trigger event determines the nature of its structure, the entrepreneurial and innovative features of its constituent 
actors, and a bio-cluster's typical business structure. This is reflected in the EU bio-clusters, which are more entrepreneurially conservative then the 
US bio-clusters due to the planned nature of element of their trigger processes, while their system structures are characterised as having limited 
inter-actor networks and systemic spillover events due to the continuing impacts of their limited pre-conditions and existing systemic path 
dependences.  
Following a bio-cluster's emergence, its sustainability, in relation to how it extends and consolidates its competitive advantage(s), is determined by 
how it is subject to a continual, structured and self-reinforcing process of growth and development through on-going innovative and entrepreneurial 
activities. The case specific nature of bio-cluster systems means a limited number of themes can be derived from the bio-cluster case studies, i.e. 
second generation (spin-off) firm developments (particularly evident in the San Francisco bio-cluster) and an influx of non-local actors, in 
particular TNCs and VCs. 
The bio-clusters are driving sectoral developments and activities in the internal bio-sector due to their intense private actor dominated 
entrepreneurial and innovative systems. Essentially, the bio-clusters are advancing rapidly, relative to the remainder of the international bio-sector, 
due to the magnetism, deep entrepreneurial capabilities and low entry barriers of their systems. 
(Chiaroni, and Chiesa, 2006; Romanelli and Feldman’s, 2007; Feldman and 
Braunerhjelm, 2007; Wolfe and Gertler, 2007; Bresnahan et al, 2001; Engel and Del-
Palacio, 2011) 
 
Where a bio-sector experiences long-term cumulative infrastructural and actor 
weaknesses, its compromised path dependence and development trajectory will result in 
a fragmented and restricted value chain. Essentially, these issues mean that a suitable 
collaborative environment, i.e. an established networked sectoral structure, cannot and 
will not develop. In combination, these issues mean that the conditions required to 
facilitate the development of a systemic trigger process will not form, as 
entrepreneurial/innovative and spillover developments will be undermined by negative 
systemic developments.  
 
Such issues will be strongly determined by the policy environment in which a bio-sector 
emerges and develops. Where a Government formulates its policies without private 
actor involvement, and implements its initiatives in a top down manner, its policies will 
be reactive in nature and they can fail to address (and may even entrench) sectoral 
issues through being poorly designed and/or unsuitable for sectoral activities. This issue 
can be demonstrated by the presence of disjointed industrial and STI policy streams and 
the presence of an innovation paradox in the wider industrial base, while an interactive 
environment which facilitates systemic developments will not form where inter-actor 
networks or interactive structures are not defined elements of public initiatives. 
 
Additionally, where a country's Government is centralist in structure, i.e. where 
Government structures do not have implicit/defined regional structures, differences in 
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regional development trajectories will be ignored. This creates and engrains regional 
imbalances in how a national bio-sector develops, i.e. locations with relatively more 
complex endowments of infrastructures, skills and resources will experience more 
substantial spillover developments and will advance at a greater rate relative to less 
endowed regions. This will undermine a national bio-sector's development trajectory, as 
the less endowed regions will experience cumulative disadvantages as the more 
advanced regions will draw away skills and resources from them.  
 
9.2.4 An analysis of the policy themes of the international case studies and the Irish 
bio-sector  
There are an enormous range of policy forms and approaches in the international bio-
sector due to different Government structures and case specific historical issues. For 
ease of presentation purposes, Table 9.4 discusses generalised policy themes that are 
observable in the hub/bio-cluster case studies. 
 
Where a bio-sector emerges and develops in the context of a policy environment that is 
shaped by disjointed policy themes, the legacy of long-term protectionist policies, and a 
pronounced (and on-going) FDI-centred orientation to industrial development policies, 
its development trajectory will be restricted by the resultant limitations and conservative 
natures of its actor types, their limited entrepreneurial and innovative activities, and the 
disjointed and limited nature of the sectoral value chain these features engender.  
 
Where Governments introduce development initiatives to advance the activities of their 
indigenous bio-sectors, these initiatives will typically be developed from snapshots of 
leading international bio-sectors, i.e. they are derived from observable positive aspects 
of hub bio-sectors/bio-clusters. Policies derived from 'snap shots' of hub bio-sectors are 
poorly developed as they ignore important elements and features of their case study bio-
sector(s) and of their indigenous bio-sectors. Such initiatives typically result in the 
adoption of top down policies that seek to engender large scale developments, e.g. 
advanced sector wide commercial developments solely through PREO-centred 
investments. This ultimately and unintentionally results in the staged introduction of 
uncoordinated initiatives over a series of stages (over an extended period of time) that 
focus on addressing specific big issue topics. They typically have clearly defined 
timeframes and funding amounts, and will focus on engendering 'quick' results, so as to 
justify the sometimes substantial investments made by these initiatives. 
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Table 9.4: Review of the international bio-sector's policy themes 
The US bio-sector emerged in the context of substantial Federal Government investments, particularly the Cold War era PREO funding initiatives, 
which did not focus on a particular sector, but on the wider economy and industrial base. They seeded extensive positive factor conditions and 
created the advanced entrepreneurial support ecosystem which subsequently exploited the commercial promise the PREO investments engendered. 
The entrepreneurial supports were also introduced to facilitate developments in the wider economy, and indirectly seeded a defined 
entrepreneurial/innovative culture which subsequently facilitated and optimised the US bio-sector's development trajectory following its emergence 
in the mid-1970s. A complex set of predominantly private actor driven, mutually reinforcing and aligned interests emerged, in the context of these 
indirect and aligned public interests and supports, which fostered the development of their value chains and enabled their trigger processes to 
engender a critical mass of entrepreneurial activity. Public policy measures in the bio-cluster, following their emergence, continue to focus on the 
wider industrial base. They are adaptive, responsive and attuned to the demands and needs of local actors through constant upgrading and 
development through advanced and evolving public/private actor dialogue processes at all Governance levels. 
While similar features can be observed in the EU hubs/bio-clusters to those in the US bio-clusters, their trigger processes developed in the contexts 
of different Government structures: 
 The UK's National Government introduced indirect policy initiatives in the 1960s that engendered a national PREO-orientated entrepreneurial 
environment. This facilitated the emergence of pharma-TNC and NICT/electronics agglomerations in the Cambridge area, in combination with 
the area's established PREOs, which the sector subsequently slotted into. By the late 1980s, the area had begun to develop a mass of 
entrepreneurial/innovative activity, yet this was constricted by investor actor limitations. 
 In Germany, prior to the emergence of its bio-sector, significant Federal and Land investments facilitated the development of an advanced PREO 
base, while an established TNC sector had also emerged. However, the German policy environment was not focused on engendering a similar 
pro-entrepreneurial environment as found in the US and the UK, e.g. defined structural rigidities between university and research institute actors 
undermined collaborative activities, while contractual restrictions inhibited alliances between PREO-based and commercial actors. In 
combination with the dominance of the indigenous TNCs, and the relative absence of a commercialisation culture or support infrastructures, 
minor entrepreneurial/innovative activities had occurred in the German bio-sector by the mid-1990s. 
Due to European Union driven efforts to encourage its member states to address the rising dominance of the US bio-sector in the mid-1990s, 
extensive policy initiatives were introduced throughout the EU to engender more advanced sectoral developments and activities. Both EU clusters 
emerged as a result of these actions. The Cambridge sector experienced a hybrid trigger event as the Department of Trade and Industry 
implemented various biotechnology initiatives to improve the competitiveness of the wider UK industry base through promoting biotechnology 
processes and practices in non-biotechnology sectors, while the Munich bio-sector experienced a planned trigger event through the extensive 
supports/infrastructures introduced by the Federal Government's BioRegio programme. The governance structures in the EU bio-clusters remain 
hierarchical/public actor dominated, and are disjointed in comparison to the US bio-sector's policy environment.  
The US bio-sector is the basis on which many of the policy forms and approaches of the non-hub bio-sectors are derived from due to the observable 
'hard' and 'soft' strengths of its bio-clusters, e.g. productivity advantages through specialised components and/or services inputs, collective 
marketing activities, intense innovative pressures due to geographic proximity between suppliers and customers, and business and innovation 
advantages created by the presence of multiple suppliers and institutions.  
The Munich bio-sector and the BioRegio programme, which was derived through an analysis of the US sector, have become the international 
templates for Governments designing comprehensive bio-cluster development programmes. The programme demonstrates that cluster specific 
policies must be substantial in shape and form in order to link in with existing preconditions and seeds, and to create an ecosystem that focuses on 
facilitating and driving entrepreneurial developments. Essentially, cluster specific policies must be co-ordinated, large scale, and adaptive and 
reactive in nature, through private actor involvement, so as to optimise their formulation, development and implementation. The ultimate aim of 
such policies must be on the long-term development and building up of seeds and preconditions, and addressing existing infrastructural, resource, 
skills and competence issues through cumulative positive spillover/externalities. 
The presence of PBCs in countries which have developed bio-clusters demonstrates that place specific issue play a central role in bio-cluster 
development and emergence. 
(Giesecke, 2000; Romanelli and Feldman’s, 2007; Feldman and Braunerhjelm, 2007; 
Wolfe and Gertler, 2007; Engel and Del-Palacio, 2011) 
 
Initially, such initiatives will focus on advancing the infrastructures and resources of 
PREOs in the anticipation/expectation that they will automatically drive sectoral 
developments by generating commercially viable research. Yet, limited innovative and 
commercial developments will ultimately emerge due to the absence of an 
entrepreneurial mindframe/culture in the PREOs and the limited availability of 
commercialisation supports. Subsequent initiatives will again be snapshot derived, and 
will seek to address limitations in sectoral commercialisation support infrastructures and 
resources, such as the absence of VC actors, in order to facilitate the emergence of 
commercial concerns. Yet, again, limited commercial developments will occur as the 
initiatives will not address entrenched structural or competence weaknesses. 
 
While such policies will seed positives, e.g. advanced infrastructures, and facilitate 
sectoral surges in entrepreneurial and innovative activities, significant sectoral 
developments will not materialise as the initiatives fail to fully account for and 
surmount existing structural weaknesses and/or sectoral actor path dependence issues. 
Indeed, such staged initiatives will result in a suboptimal sectoral development 
 262 
trajectory and can contribute to structural weaknesses. 
 
These issues demonstrate that seeking to develop an innovative industrial sector which 
is characterised by a complex Post-Fordist interactive structure, through snapshot-
derived initiatives, where an indigenous bio-sector is characterised as being 
entrepreneurially conservative and structurally fragmented, is problematic for a variety 
of reasons.  
 
Where sectoral actors are seen as being unique entities, not as active participants in an 
inherently interlinked value chain, development initiatives will fail to address the 
presence of a poor interactive environment, the absence of crucial collaborative skills 
and competences, and the presence of innovation and/or investment paradoxes. 
Furthermore, where such initiatives are formulated with limited private actor 
involvement and implemented in a top down manner, they will fail to address intricate 
and complex systemic weaknesses which can be embedded in the institutional 
characteristics of a bio-sector's actors through imposing impracticable and/or unsuitable 
initiatives.   
 
These issues demonstrate that where a country seeks to develop an internationally 
competitive bio-sector, in the context of the substantial cumulative strengths of hub bio-
sectors/bio-clusters and the distinct policy environments that characterise them, sectoral 
development initiatives need to be take the form of a comprehensive, long term co-
ordinated framework environment which addresses the inter-linked and inter-dependent 
elements of their sectoral innovation processes as a whole.  
 
Such an approach requires public actors to fully understand what they are seeking to 
develop, i.e. they must fully understand the exact needs requirements and demands of a 
bio-sector, how it is structured, how it functions, as well as the exact needs of its actors. 
This means that private actor involvement at the local level is required at all stages of 
initiative formulation and implementation. Failure to develop such an approach will 
mean that systemic/structural weaknesses will not be surmounted, due to poorly 
designed/unsuitable initiatives, and that sectoral development efforts will flounder. 
 
Initiatives must focus on creating the conditions which facilitate and drive 
entrepreneurship and innovative developments throughout a bio-sector's value chain. As 
 263 
such, a multi-element approach must be adopted which creates the necessary 
infrastructures, skills and competences to facilitate such developments. As stated, these 
initiatives must be informed and shaped by public/private dialogue processes and 
implemented in a manner which acknowledges and addresses regional differences in 
sectoral activity and development trajectories. Essentially, it is the process by which 
bio-sectors form and emerge, not the final 'result', which is important in relation to 
policy initiatives. This means that public actors should seek to become sectoral 
facilitators, not constructors, in the long-term, i.e. that private actors eventually direct 
and guide sectoral developments (Anderson et al., 2004; Martin and Sunley, 2001). 
 
9.3 DISCUSSION 
The international bio-sector case studies demonstrate that the vast majority of available 
academic and public actor literature on the international sector focuses on the hub 
sectors/bio-clusters. This focus reflects their more advanced activity levels and states of 
development, and also reflects the common use of these studies in determining what are 
perceived as being the optimal way/manner in which to advance the development of 
non-hub bio-sectors.  
 
Such studies typically focus on specific aspects of the value chains of the hub sectors, 
e.g. a specific relationship type, such as PREO/bio-firm relationships, and/or on specific 
policy approaches. As such, they can be characterised as being 'snapshot' analyses of 
aspects of sectoral structures and activities, i.e. they do not fully account for a bio-
sector's entire value chain, its actors or their characteristics, its on-going path 
dependence/development trajectory, its interactive nature, or its policy environment at 
different Governance levels. 
 
This delimited approach is questionable for two reasons. Firstly, as such studies 
selectively analyse elements or sections of a hub bio-sector, their findings can therefore 
be misinterpreted and/or skewed by being taken out of their proper context(s). Secondly, 
non-hub sectors share few common elements/features with hub bio-sectors, making the 
effectiveness of such comparisons ultimately questionable.  
 
The pronounced focus on hub bio-sectors reflects the little academic work which has 
been done on how non-hub bio-sectors can feed into our understanding of the hub bio-
sectors and the international bio-sector as a whole. Yet, the analysis of the Irish bio-
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sector, presented in chapters 5, 6, 7 and 8, demonstrates that analysing a non-hub sector 
in depth substantially contributes to and adds to the general understanding of the key 
concepts in the international bio-sector, and also shows that non-hub bio-sectors must be 
analysed on their own place specific terms, not only/solely in the context of hub sectors. 
Essentially, this analysis demonstrates that an opportunity exists to develop an area of 
economic geography that is specifically centred on non-hub sectors/PBCs. The 
principles underpinning this proposition are discussed below. 
 
The actor typology study of the Irish bio-sector demonstrates that while the value chain 
of hub sectors can be characterised as a tripartite relationship between PREOs, bio-firms 
and TNCs (with VCs, Government actors, and supply actors playing key facilitator 
roles), a hierarchy of specific actor types can be identified in non-hub sectors. Specific 
actors play more central roles in such value chains, i.e. RIs are the main PREO actor 
type, innovative developments are essentially confined to new bio-firm developments, 
while public VCs play key facilitator roles in entrepreneurial developments.  
 
The case study also shows that specific actors play relatively peripheral roles in non-
hubs, i.e. university- and research hospital-based research programmes are not key 
sources of commercial sectoral developments, regional associations and supply actors 
play limited roles due to limited sectoral activity levels, while the participation of TNC 
research elements occurs mainly through distant networking strategies. Furthermore, the 
Irish case study demonstrates the need for place specific approaches to sector actor 
analyses, as the Institutes of Technology do not appear in the PREO actor typologies 
presented in chapter 3  
 
However, the most important sectoral actor-related issue that the Irish study emphasises 
is that Government agencies and departments are typically the central/dominant actor 
type in non-hub sectors. Government agencies and departments seek to engender 
sectoral developments through introducing various initiatives (this is discussed further 
below), and their dominance reflects the extensive and engrained nature of private 
sector actor weaknesses and the disjointed manner of non-hub value chains.  
 
The Irish study also emphasises how the place specific nature of a non-hub sector's 
actors determines the nature and character of its formal and informal inter-actor 
networks and influences its entrepreneurial and innovative developments. As stated 
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above, non-hub sectors are essentially little more than combinations of co-locating 
actors that are grounded in regional ambitions to become significant players in the 
global bio-sector. Structural weaknesses, caused by place specific resource, skill and 
competence limitations of key value chain actors, inhibit crucial information transfers 
and innovative developments, even where significant sectoral advances occur. The 
specific nature of such issues demonstrates that in-depth analyses of the interactive 
structural characters of non-hub sectors must occur, so as to properly identify sector 
specific causes and impacts of structural weaknesses throughout a value chain.  
 
The Irish study shows that the formulation and implementation of public actor policy 
initiatives seeking to drive and facilitate non-hub sectoral developments must occur 
through an evolving and tailored process that addresses the place specific form, nature, 
and structures of a particular bio-sector. Using other sectors as templates or bench 
marks in formulating development initiatives is unrealistic, for several reasons. Aside 
from the selective nature of such studies making direct comparisons between hubs and 
non-hubs ineffective, as detailed above, 'snapshot' studies also set unrealistic 
development standards, i.e. non-hub sectors share only certain characteristics or features 
of hub sector actors, networks, development trajectories and/or innovative and 
entrepreneurial natures. Furthermore, deriving initiatives through studying bio-sectors 
which have emerged through planned initiatives is also problematic, as such sectors 
have developed through actions derived from hub sectors. Essentially this approach 
would entail a 'snapshot' analysis being derived from a 'snapshot' analysis, making such 
an approach particularly unsuitable. 
 
While 'snapshot' derived policies can seed sectoral strengths, e.g. they facilitate 
relatively more advanced PREO-based activities and firm developments, such initiatives 
only succeed in engendering disjointed and staggered developments as they fail to 
address pre-existing and entrenched structural and competence weaknesses which 
undermine entrepreneurial and innovative developments throughout a sectoral value 
chain, e.g. the limited involvement of TNCs in sectoral activities and the lack of an 
entrepreneurial culture among indigenous actors.  
 
The Irish study demonstrates that where a non-hub sector's government seeks to 
engender significant sectoral developments, a contextual, pluralist, and heterogeneous 
approach is required, one which is responsive, adaptable, and fine tuned to the needs, 
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demands and requirement of a sector's actors. Initiatives should seek to facilitate the 
emergence of a proactive and private actor driven entrepreneurial support infrastructure, 
and an entrepreneurial mindframe and culture in the sectoral value chain. As stated, 
entrepreneurship is an inherently localised phenomenon, and a system's propensity 
towards entrepreneurship is determined by past experiences and existing skills, 
competences and experiences.  
 
It is imperative that initiatives are developed in the context of a complete understanding 
of the place specific nature of a non-hub sector's actors, the structure and interactive 
nature of its value chain, and the spatial differences in sectoral development trajectories, 
at local and national levels. Essentially, initiatives must focus on building upon local 
strengths and addressing local weaknesses through a long-term, localised, systemic 
approach that is formulated through a public/private dialogue.  
 
Efforts to develop a non-hub bio-sector should focus on developing tailored 
entrepreneurial and innovative functional resource (EIFR) requirements (as detailed in 
chapter 3) that seek to facilitate and drive entrepreneurial/innovative developments 
along a sector's value chain over an extended period of time. An initial policy 
framework should be established through using the SWOT analysis tables presented in 
chapter 2. Essentially, initiatives should seek the development of place specific hard and 
soft infrastructures, resources, supports, skills and competences to form a tailored 
industrial environment that is adaptable and responsive to new entrepreneurial and 
innovative developments throughout a bio-sector's value chain. Successive long-term 
developments should be sought that engender positive feedback developments 
throughout a bio-sectors value chain, in order to optimise a bio-sector's development 
trajectory (Casper, 2007; Orsenigo, 2007; Rausser et al., 2000).   
 
The Irish study demonstrates that a hierarchy can be identified among the EIFRs as they 
apply to non-hubs, i.e. knowledge infrastructure, resources and skills (EIFR 1), 
entrepreneurial infrastructure, resources and skills (EIFR 2), and inter-actor networks 
(EIFR 3) are crucial requirements in facilitating and driving sectoral entrepreneurial and 
innovative developments. EIFR 2 is particularly important, as entrepreneurship is the 
main issue which determines the long-term success of a sector through facilitating 
spillover developments. Market information exchange resources (EIFR 4) should 
develop alongside the other EIFRs, yet it depends on a positive development trajectory 
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emerging, while such a development will ultimately feed into and drive actor and 
institutional density, and skill, competence and resource depth (EIFR 5).  
 
The study also demonstrates that non-hub sectors should seek to focus on developing 
place specific forms of competitive advantage. Internationally, non-hub sectors are 
focusing on competing in pharma-biotechnology related developments, which has 
resulted in the formation of a global mass of diagnostic and platform technology firm 
developments. Aside from the capacity issues this development raises, significant 
questions must be asked as to the long-term effectiveness of this approach in the context 
of the extensive positive spillovers hub sectors engender through their advanced 
entrepreneurial and innovative systems, i.e. non-hub sectors will essentially remain 
peripheral and reactive to current and future developments in pharmaceutical 
biotechnology. The opportunities Post-Fordism and biotechnology present to non-hubs 
in creating competitive advantages in niche areas in bio-sectors and related sectors are 
not being addressed by non-hub sectors. Essentially, non-hub sectors should tailor their 
policy initiatives towards their local strengths to develop 'niche' areas in which they 
possess/can develop competitive advantage(s).  
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CHAPTER 10: 
CONCLUSION 
 
10.1 INTRODUCTION 
Drawing from the theoretical framework of the thesis, this chapter synthesises the main 
material, under the main headings of sectoral actors, inter-actor networks, industrial 
clusters, and policy measures to facilitate their development, and also assesses what can 
be drawn from the interpretation of the material in light of the aims of the study. The 
chapter also discusses the contribution of this dissertation as a whole to the literature, 
and to efforts to optimise and facilitate the on-going development of the indigenous 
biotechnology sector (bio-sector).  
 
This chapter is divided into three sections. The first section presents a general 
discussion on the main findings of the thesis. The second section discusses the 
implications of these findings and makes recommendations relating to on-going and 
future policy initiatives. Finally, the third section discusses the contribution of the thesis 
to the academic literature in economic geography.  
 
10.2 SUMMARY OF THE MAIN FINDINGS OF THE THESIS 
The modern international bio-sector emerged in the mid 1970s following the 
establishment of Genentech in the San Francisco Bay Area. Genentech's formation and 
its rapid development established a biotechnology firm (bio-firm) development 
'template' that continues to shape the international bio-sector's main development 
pattern, i.e. the commercialisation of the explorative research programmes of Public 
Research and Education Organisations (PREOs) through the creation of a bio-firm, 
whose development is optimised through strategic alliances with a Venture Capital firm 
(VC), and which is floated on the stock market and/or enters into strategic alliances with 
a Transnational Corporation (TNC), so as to access the necessary knowledge sets and 
revenues required in bringing a product to the market place. 
 
This template established the tripartite nature of the bio-sector's value chain between 
PREOs, bio-firms (the value chain linchpin), and downstream commercial actors, e.g. 
TNCs. These actors create a non-linear, continuously interactive structure in which a 
hierarchy cannot typically form. Their interactions, which are supported and facilitated 
by region-specific support structures, act as feedback loops that update and alter the 
sectoral innovation process, optimising the process for the benefit of all network 
members (Malecki, 1997; Morgan and Nauwelaers, 1999a; Owen-Smith and Powell, 
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2007). 
 
The tripartite nature of the international bio-sector's value chain is an example of a 
complex network-based innovative high-tech Post-Fordist sector, i.e. the knowledge 
base from which biotechnology innovations draws upon is embedded in complex formal 
and informal networks between various actor types, including PREO and industrial 
actors, while the development of biotechnology-derived products and processes 
involves many different formal and informal actor alliances, which have different 
spatial patterns, that form at various stages of a product's and/or process's development.   
 
Networks can be generally classified as being either formal or informal in nature. 
Formal networks are rigidly structured relationship agreements in which actors agree to 
collaborate to achieve a common business goal or goals, or more sophisticated business 
practices than they can/could achieve independently. Due to their rigidly structured, 
sometimes contractual nature, only the members of a network benefit from these 
alliances. Formal alliances involve codified knowledge and information exchanges, i.e. 
knowledge/information embodied in machinery and equipment, which is codified through 
documentation, manuals, patents and scientific papers (NESC, 1996; Owen-Smith and 
Powell, 2004; Pitt et al., 2006) 
 
Informal networks are loosely structured social connections that primarily involve the 
diffusion and transfer of knowledge/information through face-to-face interactions 
between network members. They are heavily dependent on, and are regulated, by inter-
actor trust and reciprocity as they involve the diffusion of tacit knowledge, i.e. privately 
held knowledge and expertise accumulated by technical and research personnel through 
practice and experience gained at the interface between organisations, and which is 
optimised where close geographic proximity and relational norms exist between network 
members (NESC, 1996; Malecki, 1997; Delaney, 1993; Gaya and Dousset, 2005). 
 
The bio-sector's innovation process begins with PREO-based scientists engaging in 
collaborative and exploratory basic research programmes characterised by informal, 
strategic, exploratory, and exploitative networks that involve exchanges of filtered tacit 
and codified scientific and technical competences and research-related equipment and 
resources. Such networks develop through the under-graduate and post-graduate, and 
professional careers of academics, as well as through industrial and/or PREO work 
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placements and publications (Malecki, 1997; Owen-Smith and Powell, 2008; Prevezer 
and Swann, 1996).  
 
PREO organisational structures and research capabilities depend on their place specific 
research communities and infrastructures, which represent idiosyncratic and localised 
knowledge fields of researcher specific tacit knowledge. As such, PREO-generated 
knowledge can be characterised as being spatially 'sticky', due to its predominantly tacit 
nature and being closely tied to the location in which it is generated (Powell 1996; 
Malecki, 1997; Owen-Smith and Powell, 2008; Gertler and Levitte, 2005; Prevezer and 
Swann, 1996).  
 
PREOs proactively promote information transmission and dissemination through 
lecturing, publications, placements, and conference presentations. Research programme 
findings are ultimately codified through publications, or through a license developed by 
(a) commercially minded entrepreneurial academic scientist(s) that seeks to engender 
commercial developments, i.e. a patent development or start-up bio-firm development, 
where commercially viable Intellectual Property (IP) is generated (Casper and Murray, 
2005; Malecki, 1997; Smith and Powell, 2004).  
 
Where commercially minded academics seek to develop formal commercial alliances 
with commercial actors, i.e. bio-firms and TNCs, they seek to access the financial 
resources and technological capabilities of the commercial actors. These alliances also 
allow academics to gain insight into emerging industrial trends, needs and requirements 
(Casper and Murray, 2005; Smith and Powell, 2004; Giesecke, 2000; Lundberg and 
Andresen, 2012). 
 
PREO/bio-firm alliances represent the first stage of the biotechnology innovation 
process, i.e. research enters the product development process. As bio-firms are 
predominantly founded by entrepreneurial academics, as stated, they will typically 
locate in close proximity to their 'parent' PREO(s). Close relations with PREOs 
determines a bio-firm's research capabilities by optimising informal and formal 
alliances through reducing transaction costs and insecurities by minimising the distance 
over which interaction and communication are conducted. These elements are important 
due to the increasingly niche orientated nature of bio-firms, internationally, and enhance 
inter-actor task coordination, codified resource and knowledge transactions, and 
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engender crucial knowledge spillovers (Balconi et al., 2004; Sorenson, 2003; NESC, 
1996; Rowley et al., 2000; Uzzi, 1996).  
 
Bio-firms also seek to develop close networks with PREOs to source skilled human 
capital, while transfers of organisational routines may occur through formal business 
competence exchanges during a bio-firm’s initial set-up phase. This means they model 
their organisational routines and structures on those of their 'parent' PREO(s), which can 
facilitate increased network flows among the network members as the presence of 
common organisational forms means that structural similarities exist, i.e. mimetic 
isomorphism. Mimetic isomorphism facilitates organisational proximity and reduces 
perceptions of risk in alliances (Owen-Smith and Powell, 2008; Powell and Brantley, 
1992; Romanelli and Feldman, 2007; Zhang and Haiyang, 2011).  
 
Mimetic isomorphism can result in increased sectoral network density as, where actors 
face uncertainties, they model themselves on organisations they perceive as being 
successful. Those elements observed as being most efficient and effective are diffused, 
fine-tuned and replicated among network members, and gradually evolve into accepted 
routines and procedures that lead to a common vision, further advancing 
experimentation and adoption. This can place competitive pressure on similar actors in 
an area to do the same so as to improve their ability and suitability to form alliances, 
further engraining the non-reproducible, regional specific characteristics of a network's 
structure (Owen-Smith and Powell, 2007; Cooke, 2002; Slack and Hinings, 1994; Scott, 
2007).  
 
Alliances between bio-firms and downstream commercial actors, e.g. other bio-firms 
and TNCs, represent the second stage of the biotechnology innovation process, i.e. 
product development enters the clinical trials drug development process (Owen-Smith 
and Powell, 2007).  
 
Bio-firms traditionally seek formal financial, resource and business knowledge 
networks with VC firms so as to access the necessary funding and business skills they 
require to optimise their development trajectories. Such alliances facilitate strategic 
developments and re-modelling of bio-firm management structures in order to allow 
VCs optimise their chosen exit strategy, i.e. a stock market floatation and/or strategic 
alliances with a TNC.  
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Alliances with TNCs represent the final stage in the sectoral value chain. Such alliances 
constitute research and business networks that facilitate exchanges of tacit and codified 
scientific and technological competences and resources. TNCs access the scientific 
capabilities of bio-firms, i.e. their ability to evaluate external scientific knowledge, and 
also their technical capabilities, i.e. its ability to utilise external knowledge. Bio-firms 
access the established marketing, supply, manufacturing, sales, and distribution 
networks of the TNCs (Malecki, 1997; Powell and Brantley, 1992).  
 
The nature of downstream alliances in hub bio-sectors has stratified due to the 
increasingly niche orientated nature of bio-firm activities caused by the rising costs and 
durations of research programmes, due to increasing regulatory demands and 
commercial competition. As such, the relative size of bio-firms to TNCs have shrunk, 
making inter-firm alliances more equitable than those with TNCs. This has been 
facilitated by the establishment of bio-firm forms which focus on specialist 
technological and research support services, i.e. platform technology and product 
development firms. Additionally, second generation bio-firms have emerged, i.e. an 
established bio-firm spins-out a new bio-firm so as to continue (for example) a research 
programme which emerges within its existing activities but without stretching its finite 
resources (Powell and Brantley, 1992; Ernst and Young, 2001; McMillan et al., 2000; 
Giesecke, 2000).  
 
TNCs have responded to these developments by increasingly adopting biotechnology 
practices into their product development activities, establishing their own biotechnology 
research laboratories, and/or reorganising their operations to mimic bio-firm structures 
and locational patterns. As such, two main elements to the network structures of the 
leading bio-sectors can be observed, i.e. 'traditional' vertical innovation networks, where 
bio-firms act as the main mechanism between PREOs and TNCs, and horizontal product 
development networks between different forms of bio-firms, i.e. drug discovery and 
service/platform technology firms, and TNCs (Gertler and Levitte, 2006; Giesecke, 
2000; Owen-Smith and Powell, 2007). 
 
Geography plays a key role in determining how the bio-sector's innovation process is 
replicated internationally. Two broad sectoral forms can be identified, i.e. hub and non-
hub bio-sectors. These differences exist as regional endowments of actors, and their 
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ability to generate and assimilate locally- and externally-sourced knowledge, are not 
homogeneous. Furthermore, the non-structural underpinnings of the behavioural 
characteristics and social regulations of actors can also be region specific. As such, 
geography means that different regions have non-reproducible, regional specific 
organisational forms and targets that form a local knowledge community or 
organisational field, and which determines the innovative capabilities and development 
trajectory of a bio-sector (Owen-Smith and Powell, 2004; Ozman, 2006).  
 
Non-hub sectors can be characterised as being little more than combinations of co-
locating actors, principally bio-firms and PREOs, grounded in regional ambitions to 
become significant players in the global sector. Their network structures are poorly 
developed, and are characterised by limited innovation due to regional limitations in 
institutions, resources, and skills (Powell et al., 2002; Gertler and Levitte, 2005; 
Malecki, 1997).  
 
In comparison, the network structures of the hub sectors, i.e. San Francisco, Boston, and 
San Diego, and (outside the US) Munich and Cambridge, act as collective entrepreneurs 
where actors form dense regional specific concentrations/critical masses of complex and 
varied forms of skills, resources, information and networks that facilitate rapid transfers 
of information/knowledge and resources to engender sector-wide innovative 
developments, and the development of self-supporting and generating regional 
agglomerations (Anderson et al., 2004; Feldman, 2001; Malecki, 1997). 
 
The hub sectors form dense geographic concentrations of actors and network structures, 
partly due to the importance of tacit knowledge transfers between PREOs and 
commercial actors through informal networks, that can be identified as biotechnology 
clusters (bio-clusters). A bio-cluster can be conceived as a mode of organisation of a 
productive system that contributes to the innovation and competitiveness of its actors. 
The interdependencies/collaborative arrangements among actors are at the concept's 
centre. Bio-clusters are trust-based, voluntary, non-contractual systematic relationship 
arrangements that have no membership limits, in which actors collaborate and compete 
to facilitate acquisitions of wider competencies and to build competitive advantage in a 
local system of specialised sub-supply, service providers and institutes (Rosenfeld, 
1997; Porter 1998; vom Hofe and Chen, 2006). 
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The industrial cluster concept was developed by Michael Porter (1990), through his 
analysis of the factors determining national competitiveness. Porter argued that 
individual nations gain competitive advantage in particular industrial sectors that 
portray strong tendencies to concentrate within particular regions. At a national level, 
Porter conceived clusters as broad industry groups linked within the overall macro 
economy, at the regional level, constituent elements share common regional locations, 
including urban areas, labour markets, or other functional economic units (Porter, 1998).  
 
Porter focuses on the importance of close proximity in facilitating synergistic 
interactions between actors that generate innovations. Proximity stimulates innovation 
by facilitating knowledge and technology transfers through repeated trust-based 
exchanges, i.e. networks. Only through constant innovation and upgrading, including 
product and organisational methods innovation, can competitive advantage be attained 
and sustained.  
 
Porter proposed four broad determinants of national competitive advantage, i.e. factor 
conditions, demand conditions, related and supporting industries, and firm strategy, 
structure and rivalry, which form a mutually reinforcing system where the effects and 
influence of one determinant is dependent on the state of the others. How they interact, 
and the influence of two additional factors, i.e. chance, and the role of Government, 
create the context, individually and as a system, in which firms are created and compete, 
and determines why particular locations develop bio-clusters, and others do not. 
 
As stated, few locations have developed bio-clusters, which emerged in the context of 
similar positive pre-conditions and seeds, e.g. established PREOs and the presence of 
related industries. Yet, these elements alone cannot facilitate a bio-cluster's emergence. 
This occurs through a place specific trigger process, i.e. complex processes which build 
upon and prime a bio-sector's pre-conditions and seeds, and engenders positive systemic 
path dependence and development trajectories which facilitate the formation of a critical 
mass of entrepreneurial and innovative activity. This critical mass is a bio-cluster's 
trigger event, which emerges over an extended period of time, and depends on the form, 
nature and character of a system's entrepreneurial and innovative support ecosystem, 
and case specific information spillovers.  
 
There are three identifiable trigger event forms in the international bio-clusters:  
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 the San Francisco and Boston bio-clusters emerged due to spontaneous trigger 
events, where critical mass formed though private actor developments, in an 
absence of policy interventions,  
 the San Diego and Cambridge bio-clusters emerged through hybrid trigger 
events, i.e. their system's emerge through private actor developments, yet the 
trigger event was sparked by direct/indirect public initiatives, and 
 the Munich bio-cluster emerged due to a planned trigger event, where the 
system's trigger process and event was overwhelmingly driven by public 
initiatives. 
 
 
A trigger event's character determines the nature of a bio-cluster's structure, the 
entrepreneurial and innovative features of its constituent actors, and its business 
structure. A bio-cluster's trigger process reflects the policy environments within which it 
emerges.  
 
Due to the visible success of the bio-clusters, governments and supra-national 
organisations have sought to engender similar developments in their own economies, 
through strategy approaches typically derived from the observable patterns, processes 
and institutional arrangements in the bio-clusters. As such, they can be characterised as 
being reactive in nature, as public actors are directly removed from industrial development 
trends, while their essentially top down nature can fail to address intricate and complex 
systemic weaknesses through imposing impracticable and/or unsuitable initiatives. This 
means that the envisaged entrepreneurial developments fail to emerge, meaning that the 
development trajectories of the PBCs remain compromised and fail to result in the 
formation of critical masses of entrepreneurial and innovative developments.  
 
These issues can be identified in the Irish bio-sector. The Irish Government first identified 
biotechnology's importance for Ireland’s future development in the late 1970s, yet 
serious and sustained efforts to develop a significant indigenous bio-sector were not 
introduced until the late 1990s. Prior to the late 1990s, limited sectoral developments 
occurred due to inter-related issues along the sectoral value chain. A general absence of 
PREO activity occurred due to extremely limited infrastructural and skills investments 
by public actors. As such, limited transfers or spillover developments occurred where 
PREO-based actors sought to enter into or engender commercial developments. This 
was compounded by the relative absence of commercialisation skills and competences 
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among academic researchers and University administrators, and the limited and 
disjointed nature of commercialisation supports and infrastructures available to PREO 
actors.  
 
These issues impacted on sectoral commercial activities prior to the late 1990s. The bio-
firms which formed in this environment had very limited innovative capacities due to 
their inability to form substantial alliances with PREO actors, while the limited 
development supports, specifically dedicated VCs, meant they adopted conservative 
business models. As such, they had limited desire or capacity to enter into significant 
alliances with sectoral actors. It must be noted that opportunities to develop alliances 
with commercial actors were small due to the limited level of sectoral activity and the 
limited involvement of key actors, such as TNCs, in such activities. Overall, the bio-
sector's network structure was compromised by a lack of innovative activity, poor skills, 
competences and resources and the limited/conservative nature of many sectoral actors. 
 
These issues reflected national circumstances, particularly the various industrial and 
science, technology and innovation (STI) policies from the early 1920s onwards. Until 
the late 1950s, in the context of a protectionist policy environment, industrial policy 
focused predominantly on facilitating indigenous agriculture-related developments, 
while limited emphasis was placed on industrial or PREO-based developments. 
Furthermore, the industrial and STI policy strands were segmented. From the late 1950s 
onwards, more open economic measures were adopted as the emergence of high 
emigration rates and a balance of payments crisis undermined the protectionist 
approach. The industrial policy focus switched towards attracting foreign direct 
investment (FDI) branch plants into the country. Little emphasis continued to be placed 
on indigenous industrial developments, while the industrial and STI policy strand 
segmentation remained.  
 
By the early 1980s, significant issues began to undermine the FDI development 
approach, particularly the emergence of 'jobless growth', i.e. TNC branch plants 
increased productivity through adopting more automated production methods, not 
through expanding their workforce. Several Government sponsored reports 
subsequently highlighted the on-going innovative limitations in the indigenous industry 
base, e.g. the 'Telesis Report' in 1982, and the 'Culliton Report' in 1993, and called for 
and proposed measures to address this issue. However, no serious attempts have been 
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made to address this issue in the wider economy. Essentially, the overwhelming thrust 
of industrial policies remains focused on attracting FDI activities into the economy. 
 
However, the orientation of public industrial and STI policy altered in the late 1990s, 
when new information and communication technologies (NICTs) and biotechnology 
were identified as strategic technologies that would underpin existing and future sectors 
in the Irish economy. The Government introduced a series of development initiatives to 
enhance and ensure Ireland's future competitiveness in these areas. However, it must be 
noted that the Government's focus on facilitating the emergence of internationally 
competitive high-tech sectors was/is anomalous in the context of indigenous industrial 
development efforts in the wider economy. 
 
Initially, the bio-sector initiatives focused on addressing the poor state of the country's 
PREO infrastructures and capabilities, with the ultimate aim of driving commercial 
developments throughout the sector. This focus engendered significant developments, in 
particular the introduction of advanced research institutes (RIs), yet failed to result in a 
significant increase in commercialisation due to the presence of significant structural 
weaknesses. Subsequently, more substantial commercialisation supports, in particular 
VC funds, were introduced to facilitate the emergence of more complex and innovative 
commercial developments from the advanced PREO activities. This resulted in a surge 
of commercial activity in the context of the pre-initiative sector's activity levels. 
 
Yet, the on-going initiatives have not delivered the intended/expected level of sectoral 
developments, as numerous established structural issues have essentially created a 
PREO centred 'bubble' of sectoral activity, and restricted transfer of the advanced 
PREO-based activities into commercial developments. These issues include:  
 
 significant weaknesses in the commercial orientation of PREO academics and 
administrators,  
 limitations in the resources, skills and capabilities of the PREO-based 
technology transfer actors,  
 on-going limitations in the commercialisation supports available to sector actors. 
Despite the introduction of dedicated VC funds, their relative age, size and 
public nature means commercial developments are and will remain limited in 
scale and scope. Additionally, they are conservative in nature as they are 
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unproven investors in an unproven bio-sector, and thus seek conservatively 
structured business developments,  
 the limited nature of pre-initiative bio-firms not being targeted by, which means 
their ability to enter into sectoral alliances remains limited,  
 the post-initiative bio-firm developments are 'new' in terms of their innovative 
intensity and the manner of their origin, yet due to the conservative nature of the 
entrepreneurial supports and the entrepreneurial environment they have emerged 
into, they mimic the pre-initiative bio-firms by adopting conservative business 
models. This inhibits possible/potential upstream and downstream alliances 
within the sector's value chain. 
 the limited level of inter-actor networks among indigenous actors, and 
 the continuing limited involvement of Irish-based TNC operations in sectoral 
developments, due to their branch plant nature.  
 
These issues reflect the on-going segmented nature of the industry and STI policy 
strands, and the reactive and top down nature of the on-going initiatives, i.e. they are not 
attuned to the specifics of the indigenous bio-sector's value chain, and are not suitably 
addressing the long standing and complex nature of the interrelated sectoral weaknesses 
that inhibit and undermine commercial/entrepreneurial developments.  
 
10.3 POLICY IMPLICATIONS AND RECOMMENDATIONS 
In the context of the current state of the post-Celtic Tiger economy, efforts to engender the 
development of innovative indigenous industry are vital, as Ireland's continuing 
dependence on FDI is not conducive for the long-term development of a strong, vibrant 
and sustainable economy, even where increasingly high-tech intensive TNC elements are 
being attracted into the country. However, the current policies relating to innovative 
industrial developments in the bio-sector are not working optimally. The main issue 
undermining the sector’s development is the relative absence of entrepreneurial 
developments caused by the presence of inter-related structural weaknesses. These issues 
have not been addressed due to the uncoordinated manner of the on-going initiatives, and 
the top down manner in which they have been formulated and implemented.  
 
Essentially, there is a pressing need for the introduction of an overarching framework so as 
to create a support ecosystem that facilitates and drives entrepreneurial and innovative 
activities throughout the sector's value chain. Optimally, such a development requires a 
long-term approach that transcends election and business cycles, and involves substantial 
 279 
private actor input into their formulation and implementation so as to address information 
gaps and improve their accuracy.  
 
The on-going PREO developments must continue as a key policy focus, yet more 
advanced initiatives must be introduced to promote high-quality basic and applied research 
so as to further advance skills developments, and to retain and attract skilled researchers 
into the sector. In order to optimise infrastructural and skills development efforts, the 
different PREO actors should be remodelled so as to form more integrated structures. A 
more defined commercialisation mindframe must also be indoctrinated among 
administrators and academics in order to optimise commercial developments from the 
PREOs. Commercialisation skills development services should be introduced, in 
collaboration with more advanced commercialisation and entrepreneurial sectoral supports, 
to optimise new bio-firm developments.  
 
A key issue inhibiting the bio-sector’s development is the limited level of inter-actor 
networks in the indigenous value chain. The concept of networking has only entered the 
vernacular of Government agencies over the last 10 years, and despite the increased 
importance placed on the concept in Government publications, no defined network 
development programme has been introduced in any area of indigenous industry. A 
network development programme must be introduced, one that links into PREO-based 
structural and commercialisation-based resource developments, so as to facilitate 
increased inter-actor knowledge exchanges and to optimise sectoral spillover 
developments. This development would allow sectoral actors to better identify and 
exploit commercial opportunities which emerge in the sector, in combination with 
enhanced commercialisation supports.  
 
A network programme should link in with the development of information exchange 
services to facilitate the circulation of sectoral information, and to facilitate more 
informed strategic decisions by sectoral actors. Such services could facilitate the 
development of a sectoral brand that coordinates sectoral developments and attracts in 
non-local skills, competences and resources. 
 
The bio-sector's development could be orientated around an anchor actor. Different anchor 
strategy options exist, yet optimally the sector's development should be driven by 
indigenous commercial developments. While an anchor actor may originate from the 
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indigenous bio-sector, the wide reaching nature of the science of biotechnology means 
alternative anchor actors may be found in other areas of the indigenous economy where 
potential biotechnology-derived applications may be developed. The niche areas 
identified in chapter 8 represent a significant opportunity to expand the range of 
biotechnology applications in the indigenous industrial base, and would facilitate the 
development of a more complex bio-sector. 
 
These ecosystem suggestions, individually or in combination, would require a shift in 
the current orientation of the Government's industrial policies, in particular the 
suggestion to focus on indigenous industrial innovative developments instead of FDI. 
An additional challenge for public actors would be the development of tailored regional 
initiatives to optimise the development of the three identifiable 'hub' locations in the 
indigenous bio-sector, as detailed in chapter 7, due to the established centralist structures 
of the Irish Government and the absence of defined regional aspects to Government 
policies or programmes. Spatial differences in accumulations and endowments of firms, 
institutions, and social capital exist, which mean that regional differences in development 
trajectories will continue.  
 
Region specific and tailored systems-based initiatives might engender the conditions that 
ultimately facilitate bio-cluster emergence. Yet, while the possibility of bio-cluster 
emergence is essentially impossible to gauge, particularly in the context of the bio-sector's 
current state, focusing on engendering an entrepreneurial and innovative ecosystem will 
optimise the indigenous bio-sector's development trajectory, and may engender bio-cluster 
emergence by creating a diverse economic base that supports new markets and internal 
diversification, though only through a long-term development process.  
 
10.4 CONTRIBUTION TO THE LITERATURE 
This thesis represents an in depth study of the evolution and development of an 
emerging sector in the Irish economy, the indigenous bio-sector. The study presents an 
analysis of the nature and capabilities of the bio-sector's actors, the formal and informal 
inter-actor networking arrangements found in the sector's value chain, and the policy 
environment within which the bio-sector has developed.  
 
These elements have been analysed through a review of the actor types, collaborative 
inter-actor network structures, and geographic locational trends found in international 
bio-sector case studies, i.e. hub sectors/bio-clusters and non-hub sectors/proto bio-
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clusters. Additionally, the analysis reviewed the nature of the entrepreneurial and 
innovation support environment provided by public and private actors in these different 
bio-sectors, and the main policy measure themes which influence(d) their development.  
 
The study found that the vast majority of academic and public actor literature on 
international sectors focuses on the hub sectors/bio-clusters. This reflects their more 
advanced activity levels and states of development, and also their common use in 
determining what are perceived as being the optimal way/manner in which to advance 
the development of non-hub bio-sectors. Typically, such studies analyse selective 
elements or sections of a hub bio-sector, and do not fully account for a bio-sector's actor 
characteristics, its on-going path dependence/development trajectory, its interactive 
nature, or its policy environment at different governance levels. This delimited approach 
is questionable, as their findings can be misinterpreted and/or skewed by being taken 
out of their proper context(s), while non-hub sectors share few common 
elements/features with hubs. 
 
The pronounced focus on hub bio-sectors reflects the little academic work which has 
been done on how non-hub sectors contribute to our understanding of the hub bio-
sectors and the international bio-sector as a whole. The analysis of the Irish bio-sector 
shows that non-hub sectors must be analysed on their own place specific terms, not 
only/solely in the context of hub sectors. Essentially, the analysis demonstrates that an 
opportunity exists to develop an area of economic geography that is specifically centred 
on non-hub sectors/PBCs. The principles underpinning this proposition are discussed 
below. 
 
Space has a significant impact on how sectors form, function and develop. Place 
specific constructions of competencies, actors, supporting institutions, and 
organisational structures occur under idiosyncratic natural, cultural, social and 
economic conditions that are “shaped and constrained by past decisions, chance events, 
and accidents of history” (Wolfe and Gertler, 2007: 244), and which involve complex 
inter-actions of heterogeneous public and private actors (Orsenigo, 2007; Swann and 
Prevezer, 1998).  
 
The Irish bio-sector actor typology study demonstrates that a hierarchy of actor types 
can be identified in non-hub sectors, i.e. RIs are the main PREO actor type, innovative 
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developments are essentially confined to post-initiative bio-firms, while public VCs 
play key facilitator roles in entrepreneurial developments. The largest role in non-hub 
sectoral activities is that of Government agencies and departments due to the presence 
of extensive and engrained private sector actor weaknesses, and the desire of the public 
actors to facilitate sectoral advances due to the strategic importance placed on 
biotechnology in the country's future economic performance. 
 
The study also demonstrates that certain actors play relatively peripheral roles in non-
hubs, e.g. university- and research hospital-based research programmes are not key 
sources of commercial sectoral developments, while the participation of TNC research 
elements occurs mainly through distant networking strategies. Furthermore, the 
presence of an actor type not found in the actor typologies presented in chapter 3, i.e. 
the Institutes of Technology, emphasises the need for place specific approaches to sector 
actor analyses. 
 
The study emphasises the inherent role of inter-actor networks in the functioning of a 
bio-sector's value chain, and demonstrates how they are determined by place specific 
factors, including the prevailing nature of actor competences, skills and resources, and 
structural weaknesses which influence entrepreneurial and innovative developments, 
and inhibit network formations. The place specific nature of these issues demonstrates 
that in-depth analyses of the interactive structural characters of non-hub sectors must 
occur, so as to properly identify sector specific causes and impacts of structural 
weaknesses throughout a value chain. 
 
The study adds to our understanding of the difficulties and issues non-hub bio-sectors 
face when attempting to establish themselves in a highly-competitive high-tech global 
industry, particularly where they operate in a small open economy characterised by 
limited indigenous industrial activities and a high dependence on inward investment 
from Transnational Corporations. Using other bio-sectors as templates or bench marks 
on which to develop policy sectoral development initiatives in non-hub sectors can seed 
sectoral strengths, yet such an approach ultimately fails to address pre-existing and 
entrenched structural and competence weaknesses which undermine entrepreneurial and 
innovative developments.  
 
The study demonstrates that sectoral developments should optimally be engendered 
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through an evolving and tailored process that addresses the place specific form, nature, 
and structures of a particular bio-sector. The study provides a detailed series of policy 
suggestions for both the Irish government, and for governments in non-hub sectors 
elsewhere, in terms of the range and nature of measures that are required to optimally 
develop indigenous biotechnology industries, the approach with which such measures 
should optimally be formulated and applied, and the prospects for success of such 
measures.  
 
The formulation and implementation of policy initiatives seeking to drive and facilitate 
sectoral developments should optimally occur through a contextual, pluralist, and 
heterogeneous approach. It is crucial that initiatives are developed in the context of a 
complete understanding of the place specific nature of a bio-sector's actors, the structure 
and interactive nature of its value chain, and the spatial differences in sectoral 
development trajectories, at local and national levels. This means a public/private 
dialogue process, which involves sectoral actors, is required to ensure a long-term, 
systemic approach to policy development and implementation is developed.  
 
Initiatives should seek to facilitate the emergence of a private actor driven 
entrepreneurial support infrastructure, and an entrepreneurial mindframe and culture 
among the sectoral value chain. Ultimately, initiatives should seek the development of 
hard and soft infrastructures, resources, supports, skills and competences that form a 
tailored industrial environment that is adaptable and responsive to new entrepreneurial 
and innovative developments. Successive long-term developments should be sought that 
engender positive feedback developments throughout a bio-sector by building on local 
strengths and addressing local weaknesses through a systemic approach based upon 
entrepreneurial and innovative functional resource (EIFR) requirements.  
 
The study demonstrates that a hierarchy can be identified among the EIFRs as they 
apply to non-hub bio-sectors. Three EIFRs, i.e. knowledge infrastructure, resources and 
skills (EIFR 1), entrepreneurial infrastructure, resources and skills (EIFR 2), and inter-
actor networks (EIFR 3), are particularly important in establishing positive path 
dependence in a value chain. EIFR 1 determines the strength of the technological 
foundation on which sectoral developments occur. EIFRs 2 and 3 are crucial 
requirements in facilitating and driving sectoral entrepreneurial and innovative 
developments. EIFR 2 is particularly important, as entrepreneurship determines the 
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long-term success of a sector through facilitating spillover developments.  
 
In contrast, market information exchange resources (EIFR 4) develop alongside the 
other EIFRs, yet ultimately depend on a positive development trajectory emerging. Such 
a development will ultimately contributes to and drive actor and institutional density, 
and skill, competence and resource depth (EIFR 5).  
 
The ultimate development of dense agglomerations of sectoral activity, and the 
likelihood of bio-cluster emergence, depend on the engenderment of a positive place 
specific trigger process and the cumulative development of actor and institutional 
density through the EIFRs. Bio-cluster developments are impossible to predict, yet 
clustering can be used as a long-term target on which sectoral development initiatives 
can be orientated.  
 
The study also demonstrates that development initiatives should ultimately seek to focus 
on developing place specific forms of competitive advantage in niche areas through 
exploiting the opportunities that Post-Fordism and biotechnology present. By tailoring 
their policy initiatives towards their local strengths to develop 'niche' areas in which 
they possess/can develop competitive advantage(s), non-hub sectors can address the 
formation of a global mass of diagnostic and platform technology firm developments, 
which has emerged due to the main focus of the international bio-sector being on 
pharma-biotechnology related developments. 
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APPENDIX A: 
QUESTIONNAIRE AND EXPLAINATION 
 
A.1 QUESTIONNAIRE 
 
Networks in the Irish Biotechnology 
Industry 
 
 
 
 
 Questionnaire Survey 
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Q.1 What is the name of your firm/plant? 
 
 
 
Q.2 What is the nationality of this firm/plant?  
 
 
 
Q.3 How many people does this firm/plant employ? 
 
 
 
Q.4 Of this number, what proportion are scientists/technologists? 
 
 
 
Q.5 In the following table, please list your firm’s/plant’s main products in the 
first 
column, and for each, indicate (approximately) the proportion of that 
product’s 
output which goes to each of the indicated market categories. 
 
Q.6 Where products are sold to other firms for further processing, are these:  
(a) standard commercial contracts?            
Yes       No 
(b) OR do any involve some form of special collaborative arrangement?  
Yes       No 
 
If you answer No for either part, please give details. 
 
 
 
 
Products Market category % of output 
Product 1: Consumer market  
Corporate market  
Further processing  
Other (Specify)  
Product 2: Consumer market  
Corporate market  
Further processing  
Other (Specify)  
Product 3: Consumer market  
Corporate market  
Further processing  
Other (Specify)  
  
START HERE 
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Q.7 In the following table, please indicate if any of your main products are 
produced with outside 
collaboration.   
 
Form of collaboration Details 
 
Other biotechnology 
firm* 
 
 
 
 
 
 
International 
corporation* 
 
 
 
 
 
 
University 
 
 
 
 
 
 
Research Institute 
 
 
 
 
 
 
Other (please specify) 
 
 
 
 
 
*  “biotechnology firm” refers to a specialised biotechnology  firm.   
*  “international corporation” refers to a large corporation, typically with a 
     pharmaceutical or biopharmaceutical division, which operates on an 
     international scale. 
 
Q.8 In the following table, list your firm’s main inputs (in value terms) and 
  where they are sourced (as indicated). Inputs include both materials 
and services. 
 
Input Type of input Mainly sourced in 
Ireland? 
If not Ireland, where is input 
sourced? 
1  
 
Yes 
 
No 
  
2  
 
Yes 
 
No 
  
3  
 
Yes 
 
No 
  
4  
 
Yes 
 
No 
  
5  
 
Yes 
 
No 
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Q.9 Are any of your inputs supplied through collaborative arrangements with 
other firms or 
institutions (please give details, including locations/nationalities of other 
firms/institutions)? 
 
 
 
 
 
 
 
 
 
 
 
 
Q.10 Is your firm engaged in any other collaborative arrangements apart from  
those covered by earlier questions?   
 
To assist in answering this question, four separate tables follow referring, 
respectively, to Other Biotechnology Firms, International Corporations, 
Universities and Research Institutes.  
 
Please complete each table as appropriate: 
 
 (A) COLLABORATIONS WITH OTHER BIOTECHNOLOGY FIRMS 
Names/locations of 
firms 
 Firm’s name Location (country) 
1  
2  
3  
How long has your firm 
been collaborating with 
each of these firms? 
 
1  
2  
3  
What is the nature of 
your firm’s relationship 
with these firms? 
 
1  
2  
3  
If the nature of your 
firm’s relationships with 
any of these firms has 
changed over time, 
please indicate the 
nature of these 
changes? 
1  
2  
3  
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 (B) COLLABORATIONS WITH INTERNATIONAL CORPORATIONS 
Names/locations of 
Corporations  
 Firm’s name Location (country) 
1  
2  
3  
How long has your 
firm been 
collaborating with 
each of these 
Corporations? 
 
 
1  
2  
3  
What is the nature of 
your firm’s relationship 
with these 
Corporations? 
 
 
 
1  
2  
3  
If the nature of your 
firm’s relationships with 
these Corporations has 
changed over time, 
please indicate the 
nature of these 
changes? 
1  
2  
3  
 
 (C) COLLABORATIONS WITH OTHER UNIVERSITIES 
Names/locations of 
Universities 
 Firm’s name Location (country) 
1  
2  
3  
How long has your firm 
been collaborating with 
each of these 
Universities? 
 
 
 
1  
2  
3  
What is the nature of 
your firm’s relationship 
with these 
Universities? 
 
 
 
1  
2  
3  
 Continued on the following page 
 332 
2 
 
 
 
 
If the nature of your 
firm’s relationships with 
these Universities has 
changed over time, 
please indicate the 
nature of these 
changes? 
1  
2  
3  
 
 (D) COLLABORATIONS WITH OTHER RESEARCH INSTITUTES 
Names/locations of 
Institutes 
 Firm’s name Location (country) 
1  
2  
3  
How long has your 
firm been 
collaborating with 
each of these 
Institutes? 
 
 
1  
2  
3  
What is the nature of 
your firm’s relationship 
with these Institutes? 
 
 
 
1  
2  
3  
If the nature of your 
firm’s relationships with 
these Institutes has 
changed over time, 
please indicate the 
nature of these 
changes? 
1  
2  
3  
 
 
Q.11 Has your firm experienced any difficulties in forming 
alliances/collaborations 
with other firms/institutions?  
   Yes  No 
If Yes, please elaborate. 
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 Q.11b What do you think needs to be done to get over such difficulties? 
 
 
 
 
 
 
 
 
 
 
 
 
 
Q.12 Has your firm’s ownership structure changed since its foundation? 
Yes  No 
 
If yes, please indicate the nature of the change from the following table: 
 
  Details 
Internal change of ownership  
Partial takeover by international 
corporation 
 
Complete takeover by 
international corporation 
 
Partial takeover by other biotech 
firm 
 
Complete takeover by other 
biotech firm 
 
 
Merger with other firm 
 
 
Joint venture with other firm 
 
 
Other  
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Q.13 Have Venture Capital funds played a role in the formation/development of 
your 
firm? 
Yes          No 
If Yes, please elaborate on their role. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Q.14 Does being located in Ireland create any operational problems for 
your firm? 
 Yes         No 
 If Yes, please elaborate. 
 
 
 
 
 
 
 
 
 
 
 
 
Q.15 In your opinion, what are the issues that need to be addressed in order for 
the 
  Irish biotechnology sector to optimise its potential? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for your co-operation and for taking the time to fill out this survey. 
Please return the survey in the enclosed S.A.E. or send it to: 
John O’Byrne, 
Dept. of Geography, 
N.U.I. Maynooth, 
Maynooth, 
Co. Kildare 
Please be assured that the contents of this survey will be treated in strict confidence. If you have any queries, please do 
not hesitate to contact me at 
john.p.obyrne@nuim.ie or at 01 7086208 
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A.2 QUESTIONNAIRE STRUCTURE AND CONTENT 
The following section presents the sequence of questions used in the 
questionnaire, and the rationale underlying these questions. 
 
Q. 1 What is the name of your firm/plant? 
While the identity of the biotechnology firm (bio-firm) in question would 
have been determined before the survey was issued, the rationale behind this 
question was to gently lead the respondent into the questionnaire. It was also 
included to establish if any changes of name had occurred, which might 
indicate a change of ownership, and allowed for an up-to-date list of the bio-
firms comprising the indigenous biotechnology sector (bio-sector) to be 
completed. 
 
Q. 2 What is the nationality of this firm/plant?  
Prior to the issuing of the survey, it was assumed that the vast majority of the 
bio-firms surveyed would be Irish-owned. However, limited information 
existed to support this assumption. This question sought to establish just how 
many of the bio-sector's bio-firms were indeed Irish-owned. 
 
Q. 3 How many people does this firm/plant employ? 
Literature on the indigenous biotechnology sector's bio-firms, in particular the 
InterTradeIreland report, portrayed them as being small in size with an 
average of 20 employees per firm. No detailed figures beyond sectoral 
averages, or breakdowns in activity-based employment trends were presented 
in the available literature. This question sought to establish more detailed 
information on firm employment numbers, to identify possible employment 
patterns, and to establish whether any significant sectoral employment 
developments had occurred. 
 
Q. 4 Of this number, what proportion are scientists/technologists? 
A bio-firm with a high proportion of scientists/technologists would reflect a 
high level of research being conducted by that firm. This question sought to 
establish more detailed information on firm employment numbers, yet in 
particular sought to identify whether the indigenous bio-firms were still 
heavily engaged in research, as had been indicated in the literature pertaining 
to the sector, or whether any significant changes had occurred in this respect. 
 
Q. 5 In the following table, please list your firm’s/plant’s main products, 
and for each, indicate (approximately) the proportion of that product’s 
output which goes to each of the indicated market categories. 
Details on three products were asked for, and the four market categories used 
were: Consumer market; Corporate market; Further processing; and Other 
(Specify). The amount asked was in “% of output”. 
 
This question sought to establish the stage in the production process (as 
detailed in chapter 3) occupied by the respondent bio-firms. The literature on 
the indigenous sector indicated that a very limited number of products were 
being produced in the indigenous sector, and that these were mainly to be 
found among the diagnostic bio-firms. Where products were being produced, 
this question also sought to determine the target markets for these products. 
From the four categories it would be possible to identify formal downstream 
linkages  firms had established  in the bio-sector,  a task that would have been 
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 impossible relying on existing literature. This information would then be 
used in the interview stage of the project. 
 
Q. 6 Where products are sold to other firms for further processing, are 
these: (a) standard commercial contracts, or (b) do any involve some 
form of special collaborative agreement?  
Yes/No options were provided for both parts. If the respondent answered 
“No” to either part, space was provided for the respondent to elaborate.  
 
As information on specific collaborative arrangements was difficult to find in 
the literature on the sector, this question sought to establish the forms/types of 
formal arrangements/collaborations which bio-firms had formed where 
products were being produced. Space was provided for the respondent to 
detail any other arrangements that may have been set up between the 
respondent bio-firm and its collaborators. This question, once again, would 
allow for a more informed interview stage/process. 
 
Q. 7 In the following table, please indicate if any of your main products 
are produced with outside collaboration? 
Five outside collaborator types were listed as options: Other Biotechnology 
Firms; International Corporation; University; Research Institute; and Other 
(please specify).  
Definitions of what was meant by “Biotechnology Firm” and “International 
Corporation” were provided to remove/reduce possible ambiguity in 
interpretation. 
 
The five choices presented to the respondent were perceived as being the 
more likely formal collaborators available to the indigenous bio-firms, based 
on the completed sectoral profile and the actor typologies developed by 
Barley et al. (1992). Space was provided to allow the respondent to detail the 
form(s) of the collaboration(s). 
 
Q. 8 In the following table, list your firm’s main inputs (in value terms) 
and where they are sourced (as indicated). Inputs include both materials 
and services. 
Five input categories were provided for (“Type of input”). These five inputs 
(details to be identified by the respondent) were individually queried: “Mainly 
sourced in Ireland, Yes/No; If not in Ireland, where is input sourced?”  
 
As little information existed on how dependent Irish bio-firms were/are on 
indigenous inputs, this question sought to establish how interlinked the 
surveyed bio-firms were with other indigenous sectors. Identifying the main 
inputs of the bio-firms and where these were sourced would identify areas of 
strength or weakness in the indigenous sector, e.g. whether specific inputs 
were consistently being sourced indigenously, or outside of Ireland. The value 
of the inputs was sought in order to identify any major trends regarding the 
inputs sourced abroad or in Ireland. In asking where non-Irish inputs were 
sourced, follow-up questions in the interview process were to be conducted to 
establish the rationale behind the input sourced used. 
 
Q. 9 Are any of your inputs supplied through collaborative arrangements 
with other firms or institutions (please give details, including 
locations/nationalities of other firms/institutions)? 
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Collaborative inputs would indicate that the respondent firms required 
specialist inputs, and would also allow the identification of vital formal 
collaborations/alliances that the bio-firms had established. This question 
provided space for the respondent to elaborate. In the cases where a basic 
answer was provided, a follow-up question was to be included in the 
interview process.  
 
Q. 10 Is your firm engaged in any other collaborative arrangements 
apart from those covered by earlier questions? 
To assist in answering this question, four separate tables followed referring, 
respectively, to Other Biotechnology Firms, International Corporations, 
Universities and Research Institutes. 
 
Existing information on collaborative arrangements in the sector is minimal. 
Answers to this question were categorised according to the four main actor 
types in the sector's innovation process, as identified by Barley et al. (1992). 
The decision to limit the actor options was based on discussions with 
individuals with extensive sector knowledge. For each category, information 
was sought on collaborators, their country of origin (to measure Ireland’s 
interconnectedness with the global sector), the nature of the collaboration, and 
whether the form of collaboration had changed over time to see if trends, such 
as increased interdependence, were apparent in the bio-sector. 
 
Q. 11 Has your firm experienced any difficulties in forming 
alliances/collaborations with other firms/institutions?  
Yes/No options were provided. If the respondent answered “Yes”, they were 
asked to elaborate. 
 
This question sought to detail issues which the respondent bio-firms faced in 
forming alliances/collaborations. This information would be vital in gaining a 
full understanding of the workings of the bio-sector and would identify issues 
requiring further investigation. Allowing the respondent to elaborate would 
facilitate the specific detailing of issues that affected the bio-firm, and would 
potentially identify general sectoral issues. 
 
Q. 11b What do you think needs to be done to get over such difficulties?  
Space was supplied to allow the respondent elaborate. 
 
The second part of this question sought to identify possible solutions the 
respondents might have for addressing the issues raised by the first part of the 
question. This part of the question would then provide possible avenues of 
investigation in the interview stage of the project. 
 
Q. 12 Has your firm’s ownership structure changed since its foundation?  
Yes/No options were provided. If the respondent answered “Yes”, they were 
asked to indicate the nature of change from a table that contained eight 
options: 
 
 Internal change of ownership, 
 Partial takeover by international corporation, 
 Complete takeover by international corporation, 
 Partial takeover by other biotechnology firms, 
 Merger with another firm, 
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 Joint venture with another firm, and 
 Other.  
 
Space was provided for the respondent to elaborate. 
 
It was important to establish the details regarding changes to a bio-firms’ 
ownership structure. This information would highlight if a bio-firm was 
autonomous or if its activities were decided by another actor. In the cases 
where a respondent bio-firm indicated a change in ownership, a follow-up 
question was included in the interview stage of the research. 
 
Q. 13 Have Venture Capital funds played a role in the 
formation/development of your firm?  
Yes/No options were provided. If the respondent answered “Yes”, space was 
provided to allow the respondent to elaborate. 
 
VC involvement in the indigenous bio-sector, according to the literature 
reviewed, is limited. The question sought to establish the overall level of VC 
involvement in the indigenous sector, and, where possible, identify if 
involvement came from foreign VC sources.  
 
Q. 14 Does being located in Ireland create any operational problems for 
your firm?  
Yes/No options were provided. If the respondent answered “Yes”, space was 
provided to allow the respondent to elaborate. 
 
Q. 15 In your opinion, what are the issues that need to be addressed in 
order for the Irish biotechnology sector to optimise its potential?  
Space was provided to allow the respondent elaborate. 
 
Once again, as literature on sectoral weaknesses is limited, this question 
sought to identify pressing or general sectoral issues with which the survey 
bio-firms were confronted.  
 
 
National University of Maynooth 
Co. Kildare, Ireland 
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APPENDIX B:  
LETTERS AND OTHER CONTACTS WITH TARGET 
BIOTECHNOLOGY FIRMS 
 
 
 
 
 
 
Dear Mr. Doe 
 
I am currently conducting a study of networks and interlinkages between firms in 
the Irish biotechnology industry.  International studies have highlighted the 
importance of such networks and linkages in the development of the industry.  This 
study, which is sponsored by the National Institute for Regional and Spatial 
Analysis (NIRSA), seeks to optimize the development of the biotechnology industry 
in Ireland through enhancing the formation and functioning of networks among the 
sector’s actors. 
 
As part of this study, I will be sending you, in the next few days, a questionnaire 
survey form relating to your own firm’s networking arrangements.  I would be very 
grateful if you would take the time to complete this survey which will assist in the 
formulation of effective policies for the development of the Irish biotechnology 
industry.  
 
Thank you for your time and consideration. I look forward to receiving your 
assistance in the completion of this study. 
 
Yours sincerely, 
 
 
______________ 
John O’Byrne 
Doctoral Research Fellow, NIRSA  
 
 
 
 
 
 
 
 
 
 
 
 
 
Tel: +353 (0)1 7086208 
E Mail: john.p.obyrne@nuim.ie 
 
National University of Maynooth 
Co. Kildare, Ireland 
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Biotechnology Company 
Ireland 
 
Dear Mr. Doe 
 
In the last few days you should have received a letter from me requesting your 
assistance in completing a questionnaire survey relating to networks in the Irish 
biotechnology industry. This study is sponsored by the National Institute for 
Regional and Spatial Analysis (NIRSA), and is primarily aimed at optimizing the 
development of the biotechnology industry through enhancing the formation and 
functioning of networks among the sector’s actors. As you will know, biotechnology 
has been identified by the Irish government as playing a key role in the future 
development of the Irish economy. 
 
The survey is concerned with collaborative or networking arrangements that may 
exist between your firm and other actors in the biotech industry.  Such 
arrangements are formed in order to achieve shared objectives or benefits and 
include (for example) joint marketing or the exchange of skills, equipment, and 
information.  The survey mainly consists of a series of open-ended questions that 
allow you to elaborate on your firm’s specific experiences in forming networks with 
sector actors in the Irish biotechnology industry.  
 
I would be very grateful if you could take the time to complete the enclosed survey 
form. The successful completion of this study is dependent on you completing this 
survey and sharing your experiences of working within the Irish biotechnology 
sector. Completion of the survey should take no more than 10 minutes. Your 
answers will be kept completely confidential and the survey results will be 
released only in summary form so no individual's answers can be identified. 
 
If you have any questions or comments about this study, I would be happy to talk 
with you. You can contact me at the addresses or number on the letterhead. A 
summary of the survey findings will be sent to all participating firms. 
 
Thank you very much for helping us with this important study. 
 
Yours sincerely, 
 
______________ 
John O’Byrne 
Research Fellow, NIRSA 
 
 
 
 
 
 
 
 
 
  
Tel: +353 (0)1 7086208 
E Mail: john.p.obyrne@nuim.ie 
 
National University of Maynooth 
Co. Kildare, Ireland 
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3rd August, 2004         
   
 
Last month a survey form on networks in the Irish biotechnology sector was 
posted to you. 
 
If you have already completed and returned the survey to me, please accept 
my sincere thanks. If not, could you please do so today. I am especially 
grateful for your help because it is only through you, sharing your 
experiences of networks among Irish biotechnology firms that this study can 
be successfully completed.  
 
If you did not receive a survey form, or it was misplaced, please call me at 
01-7086208 or e-mail me at john.p.obyrne@may.ie and I will get another 
one in the post to you today. 
 
 
John O’Byrne  
Research Fellow 
NIRSA 
NUI Maynooth 
Co. Kildare 
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Dear Mr. Doe 
 
 
I am writing to you to thank you for completing my questionnaire survey form 
(relating to your own firm’s networking arrangements) which I sent out to you over 
a month ago. I gratefully appreciate your response.  
 
Please note that your answers will be kept completely confidential and the 
survey results will be released only in summary form so no individual's answers 
can be identified. 
 
If you have any questions or comments about this study, I would be happy to talk 
with you. A summary of the survey findings will be sent to all participating firms. 
 
Thank you very much for helping with this important study. 
 
 
Yours sincerely, 
 
 
______________ 
John O’Byrne 
Doctoral Research Fellow, NIRSA  
 
 
 
 
 
 
 
 
 
 
Tel: +353 (0)1 7086208 
E Mail: john.p.obyrne@nuim.ie 
 
 
National University of Maynooth 
Co. Kildare, Ireland 
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Dear Mr. Doe 
 
In the last month or so, you should have received a letter from me requesting your 
assistance in completing a questionnaire survey relating to networks in the Irish 
biotechnology industry. This study is sponsored by the National Institute for 
Regional and Spatial Analysis (NIRSA), and is primarily aimed at optimizing the 
development of the biotechnology industry through enhancing the formation and 
functioning of networks among the sector’s actors. As you will know, biotechnology 
has been identified by the Irish government as playing a key role in the future 
development of the Irish economy. 
 
The survey is concerned with collaborative or networking arrangements that may 
exist between your firm and other actors in the biotech industry.  Such 
arrangements are formed in order to achieve shared objectives or benefits and 
include (for example) joint marketing or the exchange of skills, equipment, and 
information.  The survey mainly consists of a series of open-ended questions that 
allow you to elaborate on your firm’s specific experiences in forming networks with 
sector actors in the Irish biotechnology industry.  
 
I would be very grateful if you could take the time to complete the enclosed survey 
form. The successful completion of this study is dependent on you completing this 
survey and sharing your experiences of working within the Irish biotechnology 
sector. Completion of the survey should take no more than 10 minutes. Your 
answers will be kept completely confidential and the survey results will be released 
only in summary form so no individual's answers can be identified. 
 
If you have any questions or comments about this study, I would be happy to talk 
with you. You can contact me at the addresses or number on the letterhead. A 
summary of the survey findings will be sent to all participating firms. 
 
Thank you very much for helping us with this important study. 
 
Yours sincerely, 
 
______________ 
John O’Byrne 
Research Fellow, NIRSA 
 
 
 
 
 
 
 
 
 
 
 
  
Tel: +353 (0)1 7086208 
E Mail: john.p.obyrne@nuim.ie 
 
 
National University of Maynooth 
Co. Kildare, Ireland 
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Dear Mr. Doe, 
 
My name is John O'Byrne, I am currently engaged in research for my PhD thesis 
entitled "Networks and the development of the Irish biotechnology sector" at the 
NUI, Maynooth. 
My study, which is sponsored by the Irish Research Council for the Humanities and 
the Social Sciences (IRCHSS) and the National Institute for Regional and Spatial 
Analysis (NIRSA), seeks to optimise the development of the biotechnology industry 
in Ireland through enhancing the formation and functioning of networks among the 
sector's actors. 
I am presently conducting a study of networks and interlinkages between 
universities and the Irish biotechnology industry, and as such, I would like to 
interview key university staff members who are involved in collaborations/alliances 
(research based, or otherwise) with biotechnology firms, corporations (e.g. 
pharmaceutical companies) and other universities. 
I am curious if it would be possible for me to set up an interview with you to explore 
your experiences in facilitating University/biotechnology firm 
alliances/collaborations? 
Please note that any information received during any correspondence will be 
treated with the utmost confidentiality. 
 
Yours sincerely, 
John O'Byrne 
 
Doctoral Research Fellow 
 
Irish Research Council for the Humanities and the Social Sciences 
http://www.irchss.ie/ 
 
National Institute for Regional and Spatial Analysis 
http://www.nuim.ie/nirsa/ 
 
NIRSA 
John Hume Building 
National University of Ireland, Maynooth 
Co. Kildare 
Ireland 
Tel: + 353 - 1 - 7086208 
Email: john.p.obyrne@nuim.ie 
 
 
 
Tel: +353 (0)1 7086208 
E Mail: john.p.obyrne@nuim.ie 
 
 
National University of Maynooth 
Co. Kildare, Ireland 
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Dear Mr. Doe, 
 
My name is John O'Byrne, I am currently engaged in research for my PhD thesis 
entitled "Networks and the development of the Irish biotechnology sector" at the 
NUI, Maynooth. 
My study, which is sponsored by the Irish Research Council for the Humanities and 
the Social Sciences (IRCHSS) and the National Institute for Regional and Spatial 
Analysis (NIRSA), seeks to optimise the development of the biotechnology industry 
in Ireland through enhancing the formation and functioning of networks among the 
sector's actors. 
I am presently conducting a study of networks and interlinkages that exist between 
indigenous biotechnology companies and the Irish biotechnology industry. 
As such, I would like to interview key firm members who are involved in 
collaborations/alliances (research based, or otherwise) with university based 
researchers, corporations (e.g. pharmaceutical companies) and other indigenous 
biotechnology firms. 
I am curious if it would be possible for me to set up an interview with you to explore 
your experiences in relation to your firms networking activities? 
Please note that any information received during any correspondence will be 
treated with the utmost confidentiality. 
 
Yours sincerely, 
John O'Byrne 
 
Doctoral Research Fellow 
 
Irish Research Council for the Humanities and the Social Sciences 
http://www.irchss.ie/ 
 
National Institute for Regional and Spatial Analysis 
http://www.nuim.ie/nirsa/ 
 
NIRSA 
John Hume Building 
National University of Ireland, Maynooth 
Co. Kildare 
Ireland 
Tel: + 353 - 1 - 7086208 
Email: john.p.obyrne@nuim.ie 
Tel: +353 (0)1 7086208 
E Mail: john.p.obyrne@nuim.ie 
 
 
National University of Maynooth 
Co. Kildare, Ireland 
 346 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dear Mr. Doe, 
 
My name is John O'Byrne, I am currently engaged in research for my PhD thesis 
entitled "Networks and the development of the Irish biotechnology sector". My 
study, which is sponsored by the Irish Research Council for the Humanities and the 
Social Sciences (IRCHSS) and the National Institute for Regional and Spatial 
Analysis (NIRSA), seeks to optimise the development of the biotechnology industry 
in Ireland through enhancing the formation and functioning of networks among the 
sector's actors.  
I am presently conducting a detailed study of existing networks and interlinkages 
between all sectoral actors in the domestic biotechnology sector, and as such, I 
would like to interview key staff members of agencies that are involved in the 
sector.  
I am curious if it would be possible for me to set up an interview in order to explore 
your experiences/views/opinions in relation to the domestic biotechnology sector?  
Please note that any information received during any correspondence will be 
treated with the utmost confidentiality.  
 
Yours sincerely,  
John O'Byrne 
 
Doctoral Research Fellow 
 
Irish Research Council for the Humanities and the Social Sciences 
http://www.irchss.ie/ 
 
National Institute for Regional and Spatial Analysis 
http://www.nuim.ie/nirsa/ 
 
NIRSA 
John Hume Building 
National University of Ireland, Maynooth 
Co. Kildare 
Ireland 
Tel: + 353 - 1 - 7086208 
Email: john.p.obyrne@nuim.ie Tel: +353 (0)1 7086208 
E Mail: john.p.obyrne@nuim.ie 
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APPENDIX C:  
BIOTECHNOLOGY/BIOTECHNOLOGY-RELATED  
DEPARTMENTS IN IRISH UNIVERSITIES 
  
This appendix details and discusses the various biotechnology/biotechnology-related 
departmental and educational activities conducted by Irish university 
biotechnology/biotechnology-related departments and faculties.  
 
There are eight Universities in Ireland: 
 
 Dublin City University (DCU) 
 University College Cork (UCC) 
 University College Dublin (UCD) 
 National University of Ireland Galway (NUIG) 
 National University of Ireland Maynooth (NUI, Maynooth) 
 Trinity College Dublin (TCD) 
 the University of Limerick (UL), and  
 the Royal College of Surgeons, Ireland 
 
C.1 DUBLIN CITY UNIVERSITY 
Founded in 1980 as a technical college, Dublin City University (DCU) was awarded 
university status in 1989. DCU was the first Irish University to establish an 
undergraduate degree in Biotechnology in the mid 1980s (Dublin City University, 
2005).  
 
C.1.1 DCU Faculties 
C.1.1.1 Faculty of Science and Health 
The six schools of DCU’s Faculty of Science and Health’s teaching and research 
activities are inter-disciplinary focused. Among the teaching aspect of the various 
faculty school programmes are physical and biological sciences (Dublin City 
University, 2007a).  
 
C.1.1.1.1 School of Biotechnology 
DCU’s School of Biotechnology incorporates teaching and research facilities in a single 
departmental unit for Process Engineers, Biochemists, Microbiologists, Geneticists and 
Pharmacologists. The school has established basic and applied research collaborative 
links with national and international research laboratories and has developed close 
alliances with DCU based research centres (discussed in further detail in Appendix D) 
such as the National Institute for Cellular Biotechnology (NICB) and the National 
Centre for Sensor Research (NCSR) (Dublin City University, 2005).  
 
The School’s undergraduate programme includes four year B.Sc. degrees in 
Biotechnology, Environmental Science & Health, and Genetics and Cell Biology. The 
School’s postgraduate degree programmes include a M.Sc. in Bioinformatics, and a 
GDip/MSc in Biomedical Diagnostics (Dublin City University, 2007b, 2007c, 2007d, 
2007e, 2007f). 
 
C.1.1.1.2 School of Chemical Sciences 
The School of Chemical Sciences research activities include environmental and 
analytical chemistry, combinatorial synthesis, nanotechnology, photochemistry and 
spectroscopy research programmes. Close research collaborations have developed 
between the school and the NICB and the NCSR. The School’s teaching programmes 
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include B.Sc. degrees in Analytical Science, Chemical and Pharmaceutical Sciences 
(Dublin City University, 2007g, 2007h, 2007i).  
 
 
C.2 UNIVERSITY COLLEGE CORK   
University College Cork (UCC) was founded in 1845 and is the second largest 
university in Ireland (University College Cork, 2007).  
 
C.2.1 UCC Faculties 
UCC’s College of Science, Engineering and Food Science comprises of the Faculties of 
Science, Engineering, and Food Science and Technology (University College Cork, 
2006a).  
 
C.2.1.1 The Faculty of Science  
UCC’s Faculty of Science includes the Departments of Biochemistry, Chemistry, 
Microbiology, Zoology, Ecology, and Plant Science (University College Cork, 2007). 
 
C.2.1.1.1 The Department of Biochemistry  
Established in 1945, the Department of Biochemistry is engaged in molecular and 
cellular education, training and research. The Department of Biochemistry’s 
undergraduate programmes include a four year B.Sc. in Biochemistry, this degree 
focuses on the biological and chemical sciences. The degree involves courses on 
Structural Biochemistry, Membrane Biochemistry, Cell Signalling, Biochemical 
Immunology, Principles of Medical Genetics, and Bioinformatics. The Department it is 
also involved in the Biomedical Sciences degree, the BSc in Genetics, the preclinical 
years of the medical degree (MB, BCh, BAO), dental degree (BDS) courses in the 
medical foundation year, and the BSc in chemistry of pharmaceutical compounds. The 
Department’s postgraduate degree programmes include Higher Diploma in Applied 
Science (Biotechnology), and a M.Sc. degree in Applied Science (Biotechnology) 
(University College Cork, 2003a, 2006b)  
 
C.2.1.1.2 The Department of Microbiology   
The Department of Microbiology is a member of two UCC Faculties, the faculty of 
Science and Food Science and Technology and the Faculty of Medicine. The 
Department has established close research and teaching ties with UCC departments, 
including the Department of Food Science and Technology, the Department of 
Medicine. Extensive collaborations have developed with Teagasc’s Dairy Products 
Centre in Moorepark, Fermoy. The department’s research programmes include topics in 
Genomics and Molecular Biology (University College Cork, 2005).  
 
The Department’s undergraduate programme includes a B.Sc. in Biology that has six 
possible specialisations: Microbiology, Plant and Microbial Biotechnology, Biomedical 
Sciences, Food Sciences, Food Technology, and Genetics. The Department’s 
postgraduate degree programmes include a research based M.Sc. degree. This is based 
upon a research project completed under the supervision of a faculty member 
(University College Cork, 2005).  
 
C.2.1.1.3 The Department of Zoology, Ecology, and Plant Science 
The Department of Zoology, Ecology, and Plant Science (ZEPS) was formed in 2002 
with the amalgamation of UCC’s Departments of Zoology and Animal Ecology, and 
Plant Science. The Department’s research activities are in the areas of marine, terrestrial 
and freshwater animal/plant ecology, environmental plant biotechnology, and population 
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genetics (University College Cork, 2003b).  
 
The Department’s undergraduate degree programmes include B.Sc. degrees in Zoology, 
Applied Ecology, and Environmental Plant Biotechnology. The Department’s 
postgraduate degree programmes include s a two year M.Sc. in Ecosystem Conservation 
and Landscape Management (University College Cork, 2007, 2006c).  
 
 
C.2.1.2 The Faculty of Food Science and Technology 
The Faculty of Food Science and Technology’s activities are focuses on the areas of 
Dairy and Food Science education and research, including Food Biotechnology. There 
are 5 Departments in the Faculty including the Departments of Food, Business and 
Development, Microbiology (discussed above), Food and Nutritional Science, and 
Process and Chemical Engineering. The Faculty has developed close connections with 
the National Food Biotechnology Centre (NFBC) (University College Cork, 2006a). 
 
C.2.1.2.1 The Department of Food, Business and Development 
The Department is focused on research relating to the agri-food industry, including 
developing current agricultural practices, to food processing. The research activities of 
the Department are focused on three general topics, Food Business, co-operative 
Business, and Rural Development.  
 
The Department’s undergraduate programmes include a 2 year B.Sc. in Food Business. 
This degree combines Food Business and Food Science and Technology courses. 
Business and marketing skills are combined with knowledge of food products and 
processes. The Department’s postgraduate degree programmes include a range of 
postgraduate courses and research programmes are offered by the department. Ph.D. and 
MSc research programmes in Food Chemistry, Food Economics, Food Engineering, 
Food Technology, Microbiology and Nutrition are available (University College Cork, 
2007d, 2007e).  
 
C.2.1.2.2 The Department of Physiology 
The Department of Physiology brings together academics from the fields of physiology, 
pharmacology, biochemistry, molecular biology and clinical research. The Department’s 
research involves programmes in the fields of Cell, Molecular and Integrative 
Physiology. Collaborative research projects are conducted with researchers from the 
Departments of Microbiology and Anatomy, and the Biosciences Research Institute 
(University College Cork, 2007f, 2007g).  
 
C.3 UNIVERSITY COLLEGE DUBLIN   
University College Dublin (UCD) was originally established in 1854. UCD is Ireland’s 
largest university with 5 Colleges and 35 Schools. The University’s biotechnology and 
biotechnology-related research is conducted in the Departments of Medicine, Veterinary 
Medicine and Agriculture as well the Department of Biochemistry, Industrial 
Microbiology, Botany, Zoology, Microbiology and Pharmacology, yet the main activity 
is carried out in the faculty of Science where research efforts focus on microbiology, 
molecular genetics, toxicology, immunology, drug design, biodiversity, industrial 
microbiology, pharmacology and zoology (Burke at al., 2003).  
 
C.3.1 College of Engineering, Mathematical and Physical Sciences 
There are 7 schools in the College of Engineering, Mathematical and Physical Sciences, 
including the School of Chemical and Bioprocess Engineering (University College 
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Dublin, 2007a). 
 
C.3.1.1 The UCD School of Chemical and Bioprocess Engineering 
The School of Chemical and Bioprocess Engineering is engaged in research in the areas 
of Bioprocess engineering, Cell biology, Biofilm Engineering, and Animal Cell Culture 
Technology. The School’s teaching programmes include a 4 year B.E. in Chemical 
Engineering or Bioprocess Engineering and taught and research MEngSc degrees 
(University College Dublin, 2006, 2007b, 2007c). 
 
C.3.2 The College of Life Sciences 
The College of Life Science comprises eight scientific schools, and the UCD Veterinary 
Hospital (University College Dublin, 2007d). 
 
C.3.2.1 School of Agriculture, Food Science and Veterinary Medicine 
The school engages in research and teaching programmes focused on animal health and 
welfare, human health, food systems and agriculture. The School’s undergraduate 
degree programmes include B.Sc. degrees in Food Science, Food & Agri-Business 
Management, Agri-Environmental Sciences, Animal & Crop Production, Animal 
Science, and in Engineering Technology. The School’s postgraduate degree include 
research M.Sc. degrees in Science, Science (Agriculture), Agricultural Science, Animal 
Science, Engineering Science, and in Veterinary Medicine. The School also offers 
taught M.Sc. degrees in Engineering Science: Food Engineering, and Engineering 
Technology (University College Dublin, 2007e, 2007f, 2007g, 2007h). 
 
C.3.2.2 UCD School of Biology and Environmental Science 
The school engages in teaching and research in the areas of modern biology and 
environmental science, these include programmes in botany, cell and molecular biology, 
environmental science, genetics, and zoology. The school’s research programmes cover 
a wide range of areas: general zoology, animal behaviour, biodiversity, bioremediation, 
cell biology, developmental biology, genetics, and marine fisheries (University College 
Dublin, 2007i).  
 
C.3.2.3 UCD School of Biomolecular and Biomedical Science 
The School brings together academics different disciplines including Biochemistry, 
Microbiology, Pharmacology and Physiology. The school’s research and teaching 
programmes are focused biological systems at molecular, cellular and whole organism 
levels. The school is part of the Conway Institute of Biomolecular and Biomedical 
Research (University College Dublin, 2007j).  
 
The School’s undergraduate programmes include B.Sc. (Honours) and B.Sc. (General) 
degrees in Biochemistry, Microbiology, Pharmacology and Physiology. B.Sc. (Joint 
Honours) programmes are also available to prospective students, which can be 
combined with degrees in other disciplines including Chemistry and Molecular Genetics 
(University College Dublin, 2007k).  
 
C.3.2.4 UCD School of Chemistry and Chemical Biology 
The School is home to 24 research groups with interests spanning a wide range of 
chemical sciences. The School opened the Centre for Synthesis and Chemical Biology 
(CSCB) in 2005. The School of Chemistry and Chemical Biology’s teaching 
programmes include a 4 year B.Sc. in Medicinal Chemistry & Chemical Biology that 
was introduced in 2007 (University College Dublin, 2007l, 2007m). 
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C.3.2.5 UCD School of Medicine and Medical Science 
The School has developed clinical research programs in six Dublin partner hospitals: 
 
 the Mater Misericordiae University Hospital;  
 St. Vincent's University Hospital;  
 the National Maternity Hospital;  
 the Coombe Women's Hospital;  
 Our Lady's Hospital for Sick Children; and  
 the Children's University Hospital at Temple Street.  
 
The school’s research programmes range from fundamental biology through 
translational research to population and clinical research. The school has extensive 
collaborations with the Conway Institute of Biomolecular and Biomedical Sciences and 
the Dublin Molecular Medicine Centre. The School’s teaching programmes include a 
B.Sc. in Biomedical Health and Life Sciences as well as taught and research 
postgraduate level M.Sc. degrees (University College Dublin, 2007n, 2007o). 
 
 
C.4 NATIONAL UNIVERSITY OF IRELAND, GALWAY    
The National University of Ireland at Galway (NUIG) was originally founded in 1845, 
and became one of the National Universities of Ireland in 1997 (National University of 
Ireland, Galway, 2007a).  
 
C.4.1 The Faculty of Medicine, Nursing, and Health Sciences 
C.4.1.1 The Department of Bacteriology 
The Department hosts the National Salmonella Reference Laboratory for Ireland, while 
its research activities include Antimicrobial Resistance in Human and Animal 
Pathogens. The department is closely associated with the Department of Medical 
Microbiology at NUIG’s University College Hospital. The Department of 
Bacteriology’s Bacteriology course begins in the final term of the Third Medical year. 
The Department also runs a Mechanisms of Disease course jointly with the Department 
of Pathology (National University of Ireland, Galway, 2007b, 2007c). 
 
C.4.2 The Faculty of Science 
The Faculty of Science’s department include the Department of Biochemistry, 
Chemistry, Microbiology, and Pharmaceutical and Therapeutics. The faculty of science 
offers two types of B.Sc. degrees, the undenominated programme (a three year degree 
that has a general focus to allow students to identify the area they are most interested in) 
and the denominated programme (this has a specific focus and is four years long) 
(National University of Ireland, Galway, 2003, 2007d).  
 
C.4.2.1 The Department of Biochemistry 
The Department of Biochemistry was established in 1963. The department’s activities 
involve activities in the areas of genetics, immunology, cell biology and structural 
biology. The Department’s undergraduate programmes include a B.Sc. in Biochemistry. 
The Department of Biochemistry, in collaboration with the Departments of 
Microbiology and Medicine, offers a B.Sc. in Biotechnology. The B.Sc. in 
Biotechnology is a four year degree in which students specialise in one of the following 
subject areas: Anatomy, Physiology or Biochemistry. The degree also includes an annual 
ICT module, the aim being to produce graduates with the necessary skills needed in 
industry (National University of Ireland, Galway, 2007e, 2007f).  
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C.4.2.2 The Department of Chemistry 
The Department of Chemistry was founded in 1849, its research activities include 
Environmental Chemistry, Chemical Synthesis, and Bioanalytical Chemistry. The 
Department offers a four year B.Sc. Programme, and a H.Dip. in Analytical Chemistry 
and Biochemistry (National University of Ireland, Galway, 2007g, 2007h).  
 
C.4.2.3 The Department of Botany 
The Department of Botany offers Botany B.Sc. degrees at general and honours level. 
The first year of the degree entails an extensive course in basic Biology (no prior 
knowledge of biology is necessary for students). The second and third years of the 
degree become more specialized in their focus. Only in the fourth year (when a student 
has qualified to complete an honours degree) is Botany studied exclusively. The Botany 
Department also contributes extensively to the Denominated B.Sc. Degrees in Marine 
and Environmental Science (National University of Ireland, Galway, 2007i). 
 
C.4.2.4 The Department of Microbiology 
The Department of Microbiology was established in 1965. The department’s research 
focuses are in the areas of biotechnology, environmental microbiology, aquaculture, 
marine sciences, genetics and bacterial pathogenesis (National University of Ireland, 
Galway, 2007j).  
 
C.4.2.5 The Department of Pharmacology  
The Department was formed in 1974, its research activities focus on the central nervous 
system, in particular the mechanism of action of antidepressants and drugs of abuse. 
The Department’s undergraduate programmes include courses on Medicine, and B.Sc. 
degrees in Biotechnology, Biomedical Science and Nursing (National University of 
Ireland, Galway, 2007k).  
 
C.5 NATIONAL UNIVERSITY OF IRELAND, MAYNOOTH 
The National University of Ireland at Maynooth (NUIM) was established as a university 
in 1997 (National University of Maynooth, 2007a).  
 
C.5.1 The Faculty of Science & Engineering  
C.5.1.1 The Department of Biology 
Established in 1970, the Department of Biology has grown into one of the largest 
departments in the university. The Department of Biology’s research focus is in the 
areas of Biological Control, Immunology, Medical Mycology, Molecular Genetics and 
Plant Biotechnology (National University of Maynooth, 2007b).  
 
The Department of Biology offers prospective students several four year B.Sc. degree 
courses; a BSc (Single Honours)/ BSc (Double Honours) (in which students are 
educated in a wide educational range in modern biological activities, including 
Evolutionary Biology, Microbiology, Plant Biology, Bioethics and Biotechnology), a 
Denominated Honours Degree in Biotechnology, and Denominated Honours Degree in 
Genetics & Bioinformatics. The postgraduate degree options available through the 
department include a taught MSc in Immunology & Global Health, and research MSc 
and PhD degrees (National University of Maynooth, 2007c).  
 
C.6 TRINITY COLLEGE DUBLIN 
Trinity College Dublin (TCD) is Ireland’s oldest university, being established in 1592. 
There are five academic faculties in TCD, two of which are related to biotechnology 
(Trinity College Dublin, 2007a). 
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C.6.1 The Faculty of Health Science 
The Faculty of Health Sciences brings together four schools, the schools of Medicine, 
Dental Science, Pharmacy and Pharmaceutical Sciences, and Nursing and Midwifery. 
The faculty has close alliances with two Dublin teaching hospitals; St James's Hospital 
and the Adelaide and Meath Hospital, Dublin incorporating the National Children's 
Hospital (AMNCH) at Tallaght (Trinity College Dublin, 2007b).  
 
C.6.1.1 The School of Pharmacy and Pharmaceutical Sciences 
Established in 1977, the School of Pharmacy and Pharmaceutical Sciences offers 
prospective students a B.Sc. in Pharmacy, and several postgraduate degree types: M.Sc. 
and Diplomas in Pharmaceutical Manufacturing Technology and Pharmaceutical 
Analysis, and a M.Sc. in Pharmaceutical Technology (Trinity College Dublin, 2007c, 
2007d). 
 
C.6.2 The Faculty of Science 
The Faculty of Science facilities include the East End Building, located on the main 
TCD campus. This building houses the School of Pharmacy, the Smurfit Institute of 
Genetics, and the Biology Teaching centre (Trinity College Dublin, 2007e).  
 
C.6.2.1 The School of Biochemistry and Immunology  
The School of Biochemistry and Immunology was established in 2005 through the 
joining of the existing disciplines of Biochemistry and Immunology. The school’s 
research programmes include Folic Acid Biochemistry, Structural Biology, 
Neurochemistry, Biotechnology and Vaccines. The school offer three undergraduate 
degree programmes to prospective students in Biochemistry with Structural Biology, 
Biochemistry with Cell Biology and Biochemistry with Immunology. The School also 
offers a research M.Sc. (Trinity College Dublin, 2007f, 2007g, 2007h, 2007i).  
 
C.6.3 The Vice-Deanery of Genetics & Microbiology  
This Vice-Deanery of Genetics & Microbiology comprises the Smurfit Institute of 
Genetics, and the Department of Microbiology (Trinity College Dublin, 2007j). 
 
C.6.3.1 The Smurfit Institute of Genetics 
Established in 1998, the research and teaching programmes of the Institute of Genetics 
encompasses molecular, cellular, developmental, behavioural, medical, psychiatric, 
population and quantitative genetics. The institute offers two B.A. undergraduate degree 
programmes in Genetics and Human Genetics (Trinity College Dublin, 2007k, 2007l). 
 
C.6.3.2 The Department of Microbiology 
The Department’s research topics include molecular biology of pathogenic microbes, 
preventive medicine, and microbial systems biology. The Department has established 
extensive research alliances with the Unit of Clinical Microbiology at St. James's 
Hospital. The Department’s undergraduate programme is a 4 year B.A. in Microbiology. 
The Department’s postgraduate programmes include research M.Sc. and Ph.D. 
programmes (Trinity College Dublin, 2007m).  
 
C.7 UNIVERSITY OF LIMERICK    
The University of Limerick (UL) was established in 1972, it became a university in 
1989 (University of Limerick, 2006). 
 
C.7.1 The College of Science 
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The College of Science includes extensive teaching and research programmes in a wide 
Sciences, 
Pharmaceutical and Industrial Chemistry, and Food Science & Health. The College’s 
research focus includes the environment and biosciences (University of Limerick, 
2007a). 
 
C.7.1.1 The Department of Chemical & Environmental Sciences  
The Department’s research activities include electrochemistry, organic chemistry and 
industrial biochemistry. The Department offers undergraduate B.Sc. degree courses in 
Pharmaceutical and Industrial Chemistry, Industrial Biochemistry, and Environmental 
Science (University of Limerick, 2003: 2007b).  
 
C.7.1.2 The Department of Life Sciences 
The Department BSc degree courses in Food Technology, and Equine Science 
(University of Limerick, 2007c, 2007d).  
 
C.8 THE ROYAL COLLEGE OF SURGEONS, IRELAND  
The Royal College of Surgeons (RCSI) was established in 1784. Since 1977 it has 
recognised as one of the National University of Ireland colleges (Royal College of 
Surgeons, Ireland, 2007a, 2007b).  
 
C.8.1 The School of Medicine and Health Sciences 
C.8.1.1 The Department of Clinical Microbiology 
The Department of Clinical Microbiology was established in 1965, it is located in the 
RCSI Education and Research Centre and the Smurfit Building on the Beaumont 
Hospital campus. The department’s research programmes includes basic and clinical 
research, with particular focus on the genetics of bacterial virulence factors and the 
surveillance and treatment of antibiotic resistant pathogens. The department conducts 
undergraduate and postgraduate teaching of medical, pharmacy and nursing students 
(Royal College of Surgeons, Ireland, 2003).  
 
C.8.1.2 The Department of Molecular and Cellular Therapeutics 
The Department was established in 2006 through the amalgamation of the Departments 
of Biochemistry and Clinical Pharmacology. The Department is engaged in wide 
reaching teaching and research programmes that cover the preclinical and clinical 
domains of the college. The Department is located on the main RCSI campus and 
additional facilities at Beaumont Hospital. The Department’s research activities include 
molecular and population genetic aspects of inherited disease, metabolic diseases, 
cardiovascular medicine and neuroscience (Royal College of Surgeons, 2007c).  
 
C.8.2 The School of Pharmacy 
The School is engaged in biopharmaceutical science research, and offers a four year 
B.Sc. in Pharmacy as well as a M.Sc. in Industrial Pharmaceutical Sciences (Royal 
College of Surgeons, 2007d).  
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APPENDIX D:  
BIOTECHNOLOGY/BIOTECHNOLOGY-RELATED THIRD 
LEVEL RESEARCH INSTITUTES 
 
This appendix details and discusses the various biotechnology/biotechnology-related 
research institutes (RIs) that are located in Ireland’s Universities (Part A), and Institutes 
of Technology (Part B), and the main biotechnology-related research and teaching 
hospitals affiliated to Irish universities (Part C), as mentioned in Chapter 6.  
 
D.1 UNIVERSITY RESEARCH INSTITUTES 
D.1.1 Dublin City University 
D.1.1.1 The National Cell and Tissue Culture Centre   
The National Cell and Tissue Culture Centre (NCTCC) was established in 1987. It is 
one of the five Enterprise Ireland Biotechnology Directorate (EIBD) RIs. The centre’s 
research focus is on animal cell biotechnology, its basic and applied research activities 
include Multi-drug resistance research, Cell Therapy & Tissue Engineering, Monoclonal 
and polyclonal antibody development, and In vitro screening of pharmacological agents. 
As with all of the EIBD RIs, one of the stated objectives of the centre is to 
commercialise its research through patenting commercial orientated research and 
through developing close interlinkages with indigenous and international firms. The 
NCTCC’s research has led to the development of one indigenous biotechnology firm 
(bio-firm) spin-out, Archport (National Cell and Tissue Culture Centre, 2003a). 
 
Several research groups have been established as off shoots from the NCTCC: 
 
 The NCTCC Immunology Group: this group is engaged in research to develop 
and produce polyclonal and monoclonal antibodies,  
 The NCTCC In Vitro Toxicology Group: this group specialises in cell culture 
and toxicology,  
 The NCTCC Differentiation & Proteomics Group: this group is engaged in 
researching the process through which lung cells acquire their definitive form 
and function,   
 The NCTCC Molecular Biology Group: this group is focused on the modelling 
and prediction of biological processes through the use of recent computer hard- 
and soft-ware developments.  
 The NCTCC Diabetes Group: this group is engaged in research to find new 
treatments for type I diabetes through cell generation (National Cell and Tissue 
Culture Centre, 2003b, 2003c, 2003d).  
 
D.1.1.2 The National Agriculture and Veterinary Biotechnology Centre 
The National Agriculture and Veterinary Biotechnology Centre was established in 1987 
as one of the five BioResearch Ireland RIs. Its research focus is on genomics, 
neurobiology, plant biotechnology, fungal biotechnology and vaccines (BioResearch 
Ireland, 2001j).  
 
D.1.1.3 The National Institute for Cellular Biotechnology 
The National Institute for Cellular Biotechnology (NICB) was established in 2002. Its 
partner institutes are the National University of Ireland, Maynooth (NUIM), and the IT 
Tallaght, and draws together researchers from the fields of Cellular Biotechnology, 
Molecular Cell Biology and Biological Chemistry, and Computer scientists. The NICB 
is engaged in cellular research at the molecular level, the institute’s research 
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programmes aim to develop new therapeutic targets and diagnostic methods for specific 
diseases such as cancer, microbial diseases and diabetes (Dublin City University, 2004: 
Higher Education Authority, 2006). 
 
D.1.1.4 The National Centre for Sensor Research 
The National Centre for Sensor Research was established in 1999 through funding from 
the Programme for Research in Third Level Iinstitutes (PRTLI), the National 
Development Plan (NDP) and the European Union (EU). Its partner institute is the IT 
Tallaght. It is a multidisciplinary RI that brings together physicists, chemists, 
biotechnologists and mechanical engineers in eight research clusters (Dublin City 
University, 2004: Higher Education Authority, 2006). 
 
D.1.1.5 The Materials Processing Research Centre  
The Materials Processing Research Centre (MPRC) was founded 1990. The Centre is 
engaged in collaborative research with the University's School of Mechanical & 
Manufacturing Engineering. The centre is engaged in basic and applied material science 
and material processing technique research. Among its research programmes is the 
Polymers and Biomedical Devices programme (Materials Processing Research Centre, 
2004a, 2004b).  
 
D.1.1.6 The Vascular Health Research Centre 
The Vascular Health Research Centre was established in 2005 through funding received 
from the Wellcome Trust, the US Department of Health and Human Services National 
Institutes of Health, the American Heart Association, and the (Irish) Health Research 
Board.  The centre’s research focus is in the areas of Vascular and developmental 
biology, Vascular disease and diabetes, and Vascular genomics and proteomics. The 
centre aims to develop new therapeutic treatments to address diseases using molecular 
and cellular biology techniques, in combination with functional genomics and 
proteomics strategies (Dublin City University, 2005).  
 
D.1.1.7 The Centre for Bioanalytical Science  
The Centre for Bioanalytical Science was established in 2007 as a joint-venture between 
Dublin City University (DCU), the National University of Ireland, Galway (NUIG) and 
Bristol-Myers Squibb. The centre was established to facilitate collaborations between 
research teams in the National Centre for Sensor Research, the National Institute for 
Cellular Biotechnology, and DCU’s Schools of Biotechnology and Chemical Sciences. 
The Centre’s research focus is in the area of bio-fermentation processes (Dublin City 
University, 2005).  
 
D.1.1.8 The Biomedical Diagnostic Institute  
The Biomedical Diagnostic Institute was established in 2006 through funding from 
Science Foundation Ireland and six industrial partners: Åmic, Analog Devices, Becton 
Dickinson, Enfer Scientific, Hospira, and Inverness Medical Innovations/Unipath. The 
institute aims to produce cancer, heart disease and diabetes diagnostic devices. The 
institute brings together researchers from the Royal College of Surgeons (RCSI), NUIG, 
and the University College Cork (Dublin City University, 2006). 
 
D.1.2 University College Cork 
D.1.2.1 The Biosciences Institute 
The Biosciences Institute, located at University College Cork (UCC), was established 
through SFI and PRTLI funding in 2002. The Institute is partnered with NUIG, RCSI, 
NUIM, Queens University (Belfast), and UL. The institute promotes interdisciplinary 
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research collaboration through bringing together researchers from several of the 
university’s biomedical and life sciences departments in the areas of cell, molecular and 
tissue biology (Biosciences Institute, 2007a: Higher Education Authority, 2006). 
 
The Institute’s research programmes include: 
 
 The Research-Neuroscience/Anatomy programme: this is focused on cancer, 
blindness and neurodegenerative disease such as Parkinson's disease and 
Alzheimer’s disease,    
 The Cancer Biology programme: this programme is focused on cancer and 
degenerative diseases research, in collaborations with the Cork Cancer Research 
Centre,  
 The Cell Signalling Research Programme: this programme is focused on 
research on the signalling interactions between foetal and maternal tissues in 
order to understand human reproductive disorders,  
 The Research-Food and Health programme: this programme focuses on the roles 
of food and lifestyle on disease prevention, as well as their therapeutic potential 
for neurodegenerative disorders (Biosciences Institute, 2007b).  
 
D.1.2.2 The Analytical and Biological Chemistry Research Facility 
The Analytical and Biological Chemistry Research Facility was established in 2003 
through PRTLI funding totalling €7.7M. The facility draws from the disciplines of 
Chemistry and Biology. Its activities include measuring dioxin levels in the 
environment, Testing cell viability with ultra-sensitive Bioassays, and Stress response 
proteins using proteomic technology (Higher Education Authority, 2006: Analytical and 
Biological Chemistry Research, 2007). 
 
D.1.2.3 The National Food Biotechnology Centre 
The National Food Biotechnology Centre (NFBC) is one of the five Enterprise Ireland 
Biotechnology Directorate RIs. The centre is a multidisciplinary RI that is focused on 
the development of services and technology for the food and related industries. The 
NFBC has played an important role in the formation of two indigenous spin-out bio-
firms: Hibergen, and Alimentary Health (BiotechnologyIreland, 2007: University 
College Cork, 2001).  
 
D.1.2.4 The BIOMERIT Research Centre 
The BIOMERIT Research Centre (BRC) was established in 1991. The centre is based in 
UCC’s Microbiology Department and has the aim of developing education and research 
programmes in innovative biotechnology. Among the centre’s facilities are state-of-the-
art proteomic and genomic research facilities. The centre’s cross-disciplinary research 
programmes include Immunogenetics and Microbial Pathogenesis, and Environmental 
Biotechnology (BIOMERIT Research Centre, 2007a, 2007b).  
 
D.1.3 University College Dublin 
D.1.3.1 The Conway Institute of Biomolecular and Biomedical Research 
The Conway Institute of Biomolecular and Biomedical Research opened in 2003 
through funding from the PRTLI programme, the Wellcome Trust, the Health Research 
Board, SFI and the EU. Its is partnered with TCD, and the RCSI and has established 
research links with three major centres: Centre for Synthesis and Biology (CSCB) (a 
University College Dublin-Trinity College Dublin-Royal College of Surgeons, Ireland 
joint venture), the Centre for Integrative Biology (CIB), and the Dublin Molecular 
Medicine Centre (DMMC) (Conway Institute, 2004a, 2004b: Higher Education 
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Authority, 2006). 
 
D.1.3.2 The Centre for Synthesis and Chemical Biology 
The Centre for Synthesis and Chemical Biology was established in 2001. The centre is 
funded through the PRTLI programme, the NDP, and the EU. It is partnered with TCD, 
and the RCSI. The Centre is one of the three constituent RIs of the Conway Institute. 
The centre’s research programme involves chemical biology research that focuses on 
the development and use of biological tools for chemistry, biology and medicine, and 
has developed extensive collaborations with the Dublin Molecular Medicine Centre 
(DMMC) and the Biopharmaceutical Sciences Network (BSN) at the RCSI (Centre for 
Synthesis and Chemical Biology, 2007a, 2007b: Higher Education Authority, 2006). 
 
D.1.3.3 National Institute for Bioprocessing Research and Training 
The National Institute for Bioprocessing Research and Training (NIBRT) was launched 
in 2004 in order to providing training and research for the Bioprocessing Industry in 
Ireland. The NIBRT is located at UCD and is run in collaboration between UCD, TCD, 
DCU and IT Sligo and has extensive alliances with industry partners. The NIBRT has 
three main activities: to provide training and education in all aspects of Bioprocessing 
Technology, to provide research facilities for key aspects of Bioprocessing Technology 
and Biotechnology, and to provide pilot-plant facilities for scale-up operations (Higher 
Education Authority, 2006; University College Dublin, 2005). 
 
D.1.4 National University of Ireland, Galway (NUIG) 
D.1.4.1 The National Centre for Biomedical Engineering Science 
The National Centre for Biomedical Engineering Science was established in NUIG in 
1999 through PRTLI funding and private donations. The centre combines the skills of 
engineers, IT specialists, physicians and scientists in order to research cardiovascular 
disease, reproductive biology, cancer, neurobiology, infectious diseases, biomaterials 
and biomechanics. The Centre has developed extensive collaborations with its partners 
UCC, UL, UCD, TCD, GMIT, IT Sligo, Athlone IT (National Centre for Biomedical 
Engineering Science, 2007a, 2007b: Higher Education Authority, 2006). 
 
D.1.4.2 The National Diagnostics Centre 
The National Diagnostics Centre was established in 1987 as one of the five BioResearch 
Ireland RIs. The Centre is an applied Bio-Sciences Research and Development Centre, 
its activities are focused in the areas of Immunodiagnostics, Nucleic acid-based 
diagnostics, and Gene regulation and differential expression (National Diagnostics 
Centre, 2007). 
  
D.1.4.3 The Martin Ryan Institute  
The Martin Ryan Institute was established in 1992 through private donations from the 
Martin Ryan University Foundation and funding from the EU’s STRIDE Operational 
Programme. The centre’s research is focused on marine and freshwater resource studies, 
in particular in the areas of biology, ecology, physiology and genetics of pelagic and 
benthic organisms, fisheries biology and economics, physical and chemical 
oceanography, and marine biotechnology (Martin Ryan Institute, 2007).  
 
D.1.4.4 The Environmental Change Institute  
The Environmental Change Institute (ECI) was founded in 2000 through private source 
and PRTLI funding. The Institute is a member of NUIG’s Institute for Environmental 
Studies. Its research focus is in the areas of Biodiversity, Climate Change, Marine 
Environment, and Waste (Environmental Change Institute, 2007: The Irish Scientist, 
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2002). 
 
D.1.5 National University of Ireland, Maynooth (NUIM) 
D.1.5.1 The Institute of Immunology 
The Institute of Immunology was created in 2003 through a PRTLI investment of €5.5 
million. The Institute is engaged in research in the area of immunology, its research 
themes include Immunity to infectious diseases, Neuroimmunology and inflammation, 
and Lymphocyte biology (Higher Education Authority, 2006: Institute of Immunology, 
2007a, 2007b). 
 
D.1.5.2 The Institute of Bioengineering and Agroecology 
The Institute of Bioengineering and Agroecology was established in 2000 through the 
PRTLI funding programme. The institute brings together six collaborating research 
laboratories whose research foci include Genetics, Developmental biology, and stress 
physiology, genetic modification of plants. The Institute’s partner institutions are the 
Dublin Institute of Technology, GMIT, and WIT (Higher Education Authority, 2006: 
Institute of Bioengineering and Agroecology, 2007). 
 
D.1.6 Trinity College Dublin 
D.1.6.1 Trinity Centre for Bio-Engineering 
The Trinity Centre for Bio-Engineering was established in 2002 through PRTLI 
funding. Its partner institute is the National Centre for Biomedical Engineering Science 
located in NUIG. The centre is focused in biomechanics, specifically relating to skeletal 
diseases (Tissue Engineering and Mechano-Biology) as well as Pre-clinical testing of 
implants and medical devices (Higher Education Authority, 2006). 
 
D.1.6.2 The National Pharmaceutical Biotechnology Centre 
The National Pharmaceutical Biotechnology Centre was established in 1987 as one of 
the five BioResearch Ireland RIs. Its research focus is on vaccines, inflammation and 
cancer, pharmaceuticals, nutriceuticals, bioinformatics and services (BioResearch 
Ireland, 2001n). 
 
D.1.6.3 Trinity College Institute of Neuroscience and National Neuroscience Network 
The Trinity College Institute of Neuroscience and National Neuroscience Network was 
established in 2002 through PRTLI funding. The Institutes partner institutes include the 
Trinity College Institute of Neuroscience, UCC, and UCD. The institute is engaged in 
research in the areas of brain disease, brain damage and brain ageing (Higher Education 
Authority, 2006). 
 
D.1.6.4 The Sami Nasr Institute for Advanced Materials Science 
The Sami Nasr Institute for Advanced Materials Science was established in 2001 
through PRTLI funding, it was established in partnership with DCU. The Institute draws 
together researchers from a wide range of disciplines including physicists, chemists, 
engineers, clinicians and pharmaceutics. The institute is engaged in research in the areas 
of supramolecular nanometric magnetic materials, t-lymphatic cell movement on micro-
textured surfaces, and Dynamic properties of colloidal suspensions of nano-particles 
(Higher Education Authority, 2006).  
 
D.1.6.5 The Centre for Research on Adaptive Nanostructures and Nanodevices  
The Centre for Research on Adaptive Nanostructures and Nanodevices (CRANN) was 
established in 2006 through SFI funding. CRANN is a science and engineering 
technology centre and was created in partnership with UCD and UCC. The centre has 
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close collaborations with several industry partners including Intel, Hewlett Packard, and 
many Irish firms. The research topics in the centre are conducted with the centre’s 
researchers and industrial partners across three research areas in the field of nanoscience 
including Magnetic Structures and Devices, Bottom-Up Fabrication and Testing of 
Nanoscale Integrated Devices, and Nano-Biology of Cell Surface Interactions 
(CRANN, 2007a, 2007b).  
 
D.1.6.6 The Institute of Molecular Medicine 
The Institute of Molecular Medicine was established in 2003 through PRTLI funding. 
Its partner institutes are UCD and RCSI. The centre is located on the campus of St 
James’s Hospital, and is dedicated to research into the molecular basis of human 
disease, in particular cancer and leukaemia, through the sequencing of genes in order to 
understand the development of human disease (Institute of Molecular Medicine, 2007a, 
2007b).  
 
D.1.7 The University of Limerick  
D.1.7.1 The Materials and Surface Science Institute 
The Materials and Surface Science Institute (MSSI) was established in 1998. It has 
received €15.7 million in PRTLI funding. The Institute’s partners are the Waterford 
Institute of Technology, NUIG, and UCC. The institute’s research is focused on 
Structural materials, Interfacial science, and Catalysis (Higher Education Authority, 
2006). 
 
D.1.7.2 The Centre for Applied Biomedical Engineering Research 
The Centre for Applied Biomedical Engineering Research (CABER) was established as 
part of the University of Limerick's (UL) Department of Mechanical and Aeronautical 
Engineering in 2004 through funding received from the EU, the NDP, and NUIG’s 
Materials and Surface Science Institute. This multidisciplinary centre brings together 
researchers in the field of biomedical engineering, and has established collaborations 
with the Mid-Western Regional Hospital Limerick. The centre’s research programmes 
include cardiovascular biomechanics, tissue engineering, and orthopaedic biomechanics 
(Centre for Applied Biomedical Engineering Research, 2004).  
 
D.1.7.3 The Centre for Environmental Research 
The Centre for Environmental Research was established in 1994, it is a 
multidisciplinary centre which draws together research experience from chemistry, 
biochemistry and biology. It has developed alliances with UCC’s Environmental 
Research Institute (Centre for Environmental Research, 2007: University College Cork, 
2007). 
 
D.1.8 The Royal College of Surgeons, Ireland 
D.1.8.1 The RCSI Research Institute 
The RCSI Research Institute is a multi-site research infrastructure that encompasses the 
entire research activities of the RCSI, it is located in the RCSI and the Education and 
Research Centre and the Clinical Research Centre at Beaumont Hospital. The Institute 
integrates basic and clinical research to facilitate the transfer of medical science 
developments into patient treatments. The institute’s core facilities include mass 
spectrometry, proteomics and genotyping, and bioinformatics. The institute’s research 
programmes include The Programme for Human Genomics, run in partnership with 
DMMC (RCSI Research Institute, 2007a, 2007b).   
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D.1.8.2 The Programme for Human Genomics  
The Programme for Human Genomics was established in 2003 through one of the 
largest single PRTLI funding awards. The programme is focused on human disease, in 
particular in the areas of cancer, cardiovascular disease, inflammation and therapeutics. 
The Programme’s partner institutions include TCD, and UCD (Higher Education 
Authority, 2006).  
 
D.1.8.3 The Biopharmaceutical Sciences Network 
The Biopharmaceutical Sciences Network was created in 1999 through PRTLI funding. 
It is located at the RCSI’s Clinical Research Centre at Beaumont Hospital, and is 
engaged in collaborative programmes with RCSI, TCD, UCC, and NUIM. The hospital 
based centre is engaged in evaluating innovative therapies in order to improve the 
quality of patient (Higher Education Authority, 2006).  
 
D.1.8.4 The Clinical Research Centre  
The Clinical Research Centre was established in 2000, partly through PRTLI funding. It 
is located at the RCSI’s research teaching facility at Beaumont Hospital. The Centre 
provides state of the art research equipment and facilities to academic and industrial 
partnerships in order to develop new therapies through clinical trials and basic research 
(Clinical Research Centre. 2007: The Irish Scientist, 2001). 
 
D.1.8.5 Biopharmaceutical Sciences Network 
The Biopharmaceutical Sciences Network (BSN) was established in 2000 through 
PRTLI funding. The BSN is a collaboration between the RCSI, TCD, UCC and NUIM. 
The BSN developed from a RCSI pharmacogenics programme, it now includes a series 
of research cores:  
 
 The National Transgenic Centre: located in TCD, this is Irelands first transgenic 
facility,  
 The National Probiotics Centre: based in UCC, this centre’s research is focused 
on probiotic bacteria in order to develop treatments for inflammatory bowel 
diseases and infections, 
 The Centre of Advanced Drug Delivery: this centre researches new drug 
delivery methods using gene therapy constructs,  
 The Virtual Institute of Bioinformatics in Éire: this is a cross-institution institute 
between the RCSI, NUIM, TCD, and UCD. The institute combines 
bioinformatic research activities of the host universities (VIBE, 2007, Royal 
college of Surgeons, Ireland, 2007, The Irish Scientist, 2000). 
 
D.2 UNIVERSITY AFFILIATED RESEARCH INSTITUTES 
D.2.1 Dublin Molecular Medicine Centre 
The Dublin Molecular Medicine Centre (DMMC) was established in 2002 through 
funding received from the PRTLI programme and the NDP. The centre is an 
independent partnership between RCSI’s Programme for Human Genomics, the Durkan 
Institute at TCD, UCD’s Conway Institute, and six Dublin based hospitals. The 
DMMC’s activities are focused on four biomedical areas: Cancer, Infection, 
Inflammation and Immunity, Neuroscience, and Vascular biology (Higher Education 
Authority, 2006). 
 
The centre conducts five research programmes: 
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 The Programme for Human Genomics: funded by the HEA, this is a cross-
institutional and translational research programme between the DMMC and 
researchers in the Royal College of Surgeons, Ireland and Trinity College Dublin 
(TCD). As the DMMC’s activities are based around medicine and 
pharmaceutical-related research, areas in which genomic research (as stated in 
chapter 1) could potentially have enormous impacts, this programme is expected 
to develop into a significant research area in the coming years,  
 The Prostate Cancer Research Consortium: this consortium brings together 
researchers from the partner universities and hospitals in research to identify 
disease biomarkers for improved detection and prognosis,   
 The All Ireland Cystic Fibrosis Research Consortium: this consortium is 
engaged in collaborative research between Irish and US researchers in order to 
develop Cystic Fibrosis pattern overviews and to develop improved screening 
services, and 
 The Breast Cancer Research Consortium: this consortium involves 
collaborations between the partner institutions researchers to establish a 
common research infrastructure to facilitated the establishment of a biobank of 
serum and tissue material drawn from a patient population (Dublin Molecular 
Medicine Centre, 2007a). 
 
The DMMC is hosts the Gene Archive of Ireland. Established between the DMMC and 
the RCSI through PRTLI funding, this aims to assist in the development, diagnosis and 
treatment of diseases at partner institutions (Dublin Molecular Medicine Centre, 2007b).  
 
D.2.3 Centres for Science, Engineering & Technology 
SFI established the Centres for Science, Engineering & Technology (CSETs) university-
industry partnerships in 2003. The CSET centres are designed to assist the development 
of alliances between academic (scientific and engineering) researchers in partnerships 
with industry in order to facilitate the development of new and existing Irish 
technology-based companies. CSET grants are competitive in nature and range from €1 
to €5 million per year for up to ten years. 
 
There are eight CSET centres biotechnology/biotechnology-related CSET centres, the 
following four are engaged in biotechnology/biotechnology-related activities: 
 
 The Alimentary Pharmabiotic Centre (APC): APC was established in 2003 and 
is based at UCC. The APC draws together scientists and clinicians from several 
UCC faculties including medicine, science, food science and nutrition, and is 
partnered with Teagasc, Alimentary Health, Procter & Gamble Co and 
GlaxoSmithKline. The APC’s research activities are in the areas of intestinal 
bacterial influences on health, developing therapies for gastrointestinal diseases 
such as gastroenteritis and Crohn’s disease, and exploring commercial 
opportunities in both the pharma and functional food sector. 
 The Centre for Research on Adaptive Nanostructure & Nanodevice (CRANN): 
CRANN is based at TCD, it was established in 2004. Its partner universities are 
UCC and UCD, its principal industry partners are Intel Ireland and Hewlett-
Packard. The centre brings together researchers from physics, chemistry, and 
biology in the area of nanoscience to develop new products and processes in 
microelectronics and drug delivery systems. 
 Regenerative Medicine Institute (REMEDI): REMEDI is located in NUIG and 
was established in 2003. The centre is engaged in research focused at developing 
techniques for tissues and organs repair. The Centre’s industrial partners are 
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Medtronic Vascular (Galway), and Charles rivers Laboratories. 
 Biomedical Diagnostic Institute (BDI): The BDI was established in 2005, it is 
primarily located in DCU. It is partnered with the National Centre for Sensor 
Research in DCU, the National Centre for Biomedical Engineering Science at 
NUIG, the RCSI, and the Tyndall National Institute at UCC. The Institute is 
engaged in research that is focused on developing biomedical diagnostic devices 
for a wide range of chronic diseases including cancer, and cardiovascular 
diseases. The BDI’s industrial partners include Analog Devices, Inverness 
Medical Innovations, and Enfer Technologies (Alimentary Pharmabiotic Centre, 
2007: Forfás, 2004: The Irish Scientist, 2003: University College Cork, 2003: 
Science foundation Ireland, 2002, 2007).  
 
D.2.3 Teagasc's Rresearch Institutes 
Teagasc, the Irish Agriculture and Food Development Authority, has 9 RIs (Centre of 
Excellence), the following centres are engaged in biotechnology or biotechnology-
related research:  
 
 The Moorepark Dairy Production Research Centre and Food Research Centre: 
The Moorepark Centres are engaged in research and the provision of 
technological services to the Irish dairy processing and food ingredients sectors, 
as well as research in dairy processing, food ingredients, and nutritional foods. 
The Food Research Centre is engaged in collaborative research with UCC’s 
alimentary pharmabiotic research centre,  
 The Kinsealy Research Centre: The Kinsealy Centre is engaged in research and 
technical development for the Irish horticultural industry, providing relevant 
technological data to optimise the competitiveness of the sector. The Centre’s 
research includes biotechnology, forestry, protected food and vegetable crop 
programmes,  
 The Grange Research Centre: The Grange Centre is engaged in research relating 
to beef production systems, and houses the Blood Laboratory which provides a 
national blood service to farmers,   
 The Oak Park Research Centre: The Oak Park Centre is focused in arable crop 
research. Teagasc’s Plant Biotechnology Unit is located in the Centre (where the 
first Irish trials of genetically modified crop trials were carried out in 1997 in 
collaboration with Monsanto), and 
 The Johnstown Castle Environment Research Centre: The Johnstown Castle 
centre is engaged in research on soils and the environment, it is home to the 
Teagasc Analytical Services Laboratory for soil, herbage, water and general 
agricultural materials (Teagasc, 1999, 2005a, 2005b, 2006). 
 
Two minor RIs (Belclare and Athenry) conduct biotechnology research as part of the 
Teagasc Beef Research Programme. This programme aims to develop “...the base of 
expertise and information in generic technologies to assist the Irish food industry to 
achieve...product and process innovations” (Teagasc, 2005, 2006). 
 
D.3 INSTITUTE OF TECHNOLOGY RESEARCH INSTITUTES 
D.3.1 Athlone Institute of Technology 
D.3.1.1 Centre for Biopolymer and Biomolecular Research 
The Centre for Biopolymer and Biomolecular Research was established in 2000 through 
PRTLI funding. Its partner institutes are NUIG, and the University of Ulster, Colrane. 
The centre’s research is focused on the areas of biopolymers and biomolecular research 
(Higher Education Authority, 2006). 
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D.3.2 Dublin Institute of Technology 
D.3.2.1 The Facility for Optical Characterisation and Spectroscopy 
The Facility for Optical Characterisation and Spectroscopy was established in 2002 
through PRTLI funding totaling €10.4M. The Facility is formed by 6 interdisciplinary 
research groups in physics, chemistry and materials science whose research is focused 
on Pharmaceuticals, Urban Air Pollution, Radiation, Optical Sensing, Optoelectronics, 
and Nanotechnology (Higher Education Authority, 2006). 
 
D.4 RESEARCH AND TEACHING HOSPITALS 
D.4.1 Beaumont Hospital 
Beaumont Hospital opened in 1987, it is the National Referral Centre for Neurosciences 
and Renal Transplantation. It has developed research alliances with the RCSI in relation 
to neurosciences research. Located at Beaumont Hospital are the RCSI Medical School. 
This is overseen by the Department of Medicine in Beaumont Hospital, clinical teaching 
for approximately two thirds of third and final year medical students of the RSCI 
Department of Surgery are conducted at the school, with research being conducted in 
the areas of cancer research (in collaboration with DCU’s National Institute for Cellular 
Biology) cardiology, respiratory medicine, gastroenterology, nephrology and 
endocrinology (Beaumont Hospital, 2000a, 200b: Irish Press Releases, 2007; National 
Institute for Cellular Biology, 2007; The Irish Scientist, 2001). 
 
D.4.2 Blackrock Clinic 
Established in 1984, Blackrock Clinic’s facilities include a coronary care unit, an 
intensive care unit, and two Cardiac Cathterisation Laboratories. The Clinic has 
developed education programmes the RCSI and UCD, and is engaged in molecular 
cancer research with the National Institute for Cellular Biotechnology (Blackrock 
Clinic, 2007; Molecular Cancer, 2006). 
 
D.4.3 Mater Misericordiae University Hospital 
The Mater Misericordiae University Hospital was established in 1861. The hospital has 
two national specialities, cardiothoracic surgery (including transplantation) and spinal 
injuries, while also providing cardiology, renal services, general and vascular surgery, 
urology and orthopaedics services. The Mater houses a Medical School (affiliated to 
UCD and the RCSI), a Centre for Nurse Education in partnership with the School of 
Nursing UCD, a School of Physiotherapy affiliated to UCD, an Institute of Radiological 
Science, and the Catherine McAuley Education and Research Centre (a collaborative RI 
formed in alliance with UCD, with linkages with the genome resource unit of the 
Dublin Molecular Medicine Centre). The hospital has also developed collaborative 
research programmes in cancer research with UCD’s Conway Institute (Dublin 
Molecular Medicine Centre, 2004; Mater Misericordiae University Hospital, 2004: 
Mater Private hospital, 2007a, 2007b).  
 
D.4.4 St. James's Hospital 
St. James's Hospital was established in 1971 through the amalgamation of smaller 
voluntary hospitals in Dublin. Located in St. James's Hospital is a teaching hospital for 
TCD and a Teaching Centre, opened in 1994, that incorporates the clinical departments 
of the medical school, the unit for dietetics and nutrition, the nursing school, the 
postgraduate centre and the library of the Faculty of Health Sciences (St. James's 
Hospital, 2007a).  
 
The St. James Biochemistry Department is the national centre for investigation and 
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diagnosis of Porphyria (enzyme disorders) and provides an extensive range of 
endocrinology assays to a variety of Irish hospitals including the Meath Hospital, the 
Adelaide Hospital and the National Children's Hospital (St. James's Hospital, 2007b). 
 
Located at St. James’s are a Bio-incubator and clinical trial facilities. The bioincubator 
was launched in 2006 by the hospital and EI in order to assist the formation of 
laboratory and serviced biotechnology companies. Two EI supported firms, Opsona 
Therapeutics and Cellix, are located at the incubator. The clinical trial facilities were 
opened in 2002 by the Dublin Molecular Medicine Centre (DMMC), in collaboration 
with the Health Research Board (HRB) and the Wellcome Trust (Department of 
Enterprise, Trade and Employment, 2006).  
 
D.4.4 St Patrick's Hospital 
St Patrick's Hospital has developed a wide ranging clinical research programme with the 
Academic Psychiatric Unit at St James's Hospital. The Depression Research Unit is 
engaged in a wide variety of research themes including diagnostic sensitivity and 
therapeutic effectiveness research in Alzheimer's disease (St Patrick's Hospital, 2004).  
 
D.4.5 St. Vincent’s University Hospital 
St Vincent’s University Hospital was originally opened in 1934, since 1999 it has acted 
as a major academic teaching hospital affiliated to University College Dublin. St. 
Vincent's Education and Research Centre is one of the main Biomedical RIs in Ireland. 
The centre’s research programmes complement the clinical and treatments conducted in 
the Hospital, these include the National Liver Transplant Programme, National Early 
Arthritis Clinic, part of the National Breast Screening Programme, and a clinical centre 
for Hepatitis C. The hospital’s Centre for Colorectal Disease was established to provide 
clinical care for the hospital’s patients, it is engaged in collaborative research 
programmes with the Biotechnology Centre of UCD, the RCSI and UCC (St. Vincent’s 
University Hospital, 2007).  
 
In 2007, St Vincent’s formed, in collaboration with the Mater University Hospital and 
UCD’s School of Medicine and Medical Science, Ireland’s first academic medical 
clinical care centre; Dublin Academic Health Care Centre. This centre is engaged in 
clinical care, teaching and research, aims to facilitate rapid and effective transfer of 
research ideas into clinical practice (University college Dublin, 2007) 
 
D.4.6 Adelaide and Meath Hospital (incorporating the National Children’s Hospital) 
in Tallaght 
The Adelaide and Meath Hospital is one of the main general teaching hospitals of TCD. 
The TCD Centre for Health Sciences at Tallaght houses the academic Departments of 
Paediatrics, academic clinical units of Clinical Medicine, Surgery, Gynaecology, 
Psychiatry, the hospital library and College of Nursing, and research laboratories 
(Adelaide and Meath Hospital, 2007).  
 
D.4.7 Temple Street Children's University Hospital 
Founded in 1872, the Temple Street Children's University Hospital is an Acute 
Paediatric Hospital. The Hospital is home to a variety of National Centres, including the 
National Centre for Inherited Metabolic Disorders, the National Screening Laboratory, 
and the National Centre for Paediatric Ophthalmology. The Hospital has teaching 
alliances with the RCSI and UCD in the areas of Radiography, Physiotherapy, 
Psychology, Psychiatric and Medical Social Work (Children's University Hospital, 
2007). 
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D.4.8 Merlin Park Regional Hospital 
Merlin Park Regional Hospital is a member of the Galway Regional Hospitals Group 
with Galway University Hospital, as such it has extensive alliances with the NUIG. The 
hospital is a regional centre for a wide range of specialties including Cardiology, 
Respiratory Medicine, Plastic Surgery, Vascular Surgery, and Neurology. The hospital is 
engaged in biotechnology-related research with NUIG’s REMEDI Clinical Research 
Facility (Western Health Board, 2007b). 
 
D.4.9 Galway University Hospital 
Galway University Hospital is located adjacent to NUIG, it is a specialist hospital and 
the main teaching hospital of NUIG’s Medical School. The Hospital includes NUIG’s 
Clinical Science Institute which contains the Hospital’s laboratories. The hospital has 
developed extensive collaborations with NUIG’s REMEDI clinical research facility in 
the areas of genomic based molecular research, cancer and regenerative medicine 
research (REMEDI, 2007; Western Health Board, 2007a).  
 
D.4.10 Cork University Hospital 
Cork University Hospital was purpose built in 1979, it houses Departments of 
Medicine, Surgery, Obstetrics/ Gynaecology, Paediatrics, Pathology and Psychiatry. It is 
the principal teaching hospital attached to UCC. The hospital is part of a city-wide 
group of hospitals which includes, St. Finbarr’s Hospital, Erinville Hospital and St. 
Mary’s Orthopaedic Hospital (Southern Health Board, 2006).  
 
D.4.11 Mercy Hospital 
The Mercy Hospital plays an active part in the undergraduate and postgraduate medical 
and nursing teaching programmes of University College Cork and has a number of 
research programmes including the Cork Cancer Research Charity Laboratory (Mercy 
Hospital, 2004).  
National University of Maynooth 
Co. Kildare, Ireland 
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APPENDIX B:  
LETTERS AND OTHER CONTACTS WITH TARGET 
BIOTECHNOLOGY FIRMS 
 
 
 
 
 
 
Dear Mr. Doe 
 
I am currently conducting a study of networks and interlinkages between firms in 
the Irish biotechnology industry.  International studies have highlighted the 
importance of such networks and linkages in the development of the industry.  This 
study, which is sponsored by the National Institute for Regional and Spatial 
Analysis (NIRSA), seeks to optimize the development of the biotechnology industry 
in Ireland through enhancing the formation and functioning of networks among the 
sector’s actors. 
 
As part of this study, I will be sending you, in the next few days, a questionnaire 
survey form relating to your own firm’s networking arrangements.  I would be very 
grateful if you would take the time to complete this survey which will assist in the 
formulation of effective policies for the development of the Irish biotechnology 
industry.  
 
Thank you for your time and consideration. I look forward to receiving your 
assistance in the completion of this study. 
 
Yours sincerely, 
 
 
______________ 
John O’Byrne 
Doctoral Research Fellow, NIRSA  
 
 
 
 
 
 
 
 
 
 
 
 
 
Tel: +353 (0)1 7086208 
E Mail: john.p.obyrne@nuim.ie 
 
National University of Maynooth 
Co. Kildare, Ireland 
 340 
 
 
 
 
 
 
 
Biotechnology Company 
Ireland 
 
Dear Mr. Doe 
 
In the last few days you should have received a letter from me requesting your 
assistance in completing a questionnaire survey relating to networks in the Irish 
biotechnology industry. This study is sponsored by the National Institute for 
Regional and Spatial Analysis (NIRSA), and is primarily aimed at optimizing the 
development of the biotechnology industry through enhancing the formation and 
functioning of networks among the sector’s actors. As you will know, biotechnology 
has been identified by the Irish government as playing a key role in the future 
development of the Irish economy. 
 
The survey is concerned with collaborative or networking arrangements that may 
exist between your firm and other actors in the biotech industry.  Such 
arrangements are formed in order to achieve shared objectives or benefits and 
include (for example) joint marketing or the exchange of skills, equipment, and 
information.  The survey mainly consists of a series of open-ended questions that 
allow you to elaborate on your firm’s specific experiences in forming networks with 
sector actors in the Irish biotechnology industry.  
 
I would be very grateful if you could take the time to complete the enclosed survey 
form. The successful completion of this study is dependent on you completing this 
survey and sharing your experiences of working within the Irish biotechnology 
sector. Completion of the survey should take no more than 10 minutes. Your 
answers will be kept completely confidential and the survey results will be 
released only in summary form so no individual's answers can be identified. 
 
If you have any questions or comments about this study, I would be happy to talk 
with you. You can contact me at the addresses or number on the letterhead. A 
summary of the survey findings will be sent to all participating firms. 
 
Thank you very much for helping us with this important study. 
 
Yours sincerely, 
 
______________ 
John O’Byrne 
Research Fellow, NIRSA 
 
 
 
 
 
 
 
 
 
  
Tel: +353 (0)1 7086208 
E Mail: john.p.obyrne@nuim.ie 
 
National University of Maynooth 
Co. Kildare, Ireland 
 341 
 
 
 
 
 
 
 
 
 
 
 
3rd August, 2004         
   
 
Last month a survey form on networks in the Irish biotechnology sector was 
posted to you. 
 
If you have already completed and returned the survey to me, please accept 
my sincere thanks. If not, could you please do so today. I am especially 
grateful for your help because it is only through you, sharing your 
experiences of networks among Irish biotechnology firms that this study can 
be successfully completed.  
 
If you did not receive a survey form, or it was misplaced, please call me at 
01-7086208 or e-mail me at john.p.obyrne@may.ie and I will get another 
one in the post to you today. 
 
 
John O’Byrne  
Research Fellow 
NIRSA 
NUI Maynooth 
Co. Kildare 
 
 
 
 
 
 
 
 
 
 
 
 
National University of Maynooth 
Co. Kildare, Ireland 
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Dear Mr. Doe 
 
 
I am writing to you to thank you for completing my questionnaire survey form 
(relating to your own firm’s networking arrangements) which I sent out to you over 
a month ago. I gratefully appreciate your response.  
 
Please note that your answers will be kept completely confidential and the 
survey results will be released only in summary form so no individual's answers 
can be identified. 
 
If you have any questions or comments about this study, I would be happy to talk 
with you. A summary of the survey findings will be sent to all participating firms. 
 
Thank you very much for helping with this important study. 
 
 
Yours sincerely, 
 
 
______________ 
John O’Byrne 
Doctoral Research Fellow, NIRSA  
 
 
 
 
 
 
 
 
 
 
Tel: +353 (0)1 7086208 
E Mail: john.p.obyrne@nuim.ie 
 
 
National University of Maynooth 
Co. Kildare, Ireland 
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Dear Mr. Doe 
 
In the last month or so, you should have received a letter from me requesting your 
assistance in completing a questionnaire survey relating to networks in the Irish 
biotechnology industry. This study is sponsored by the National Institute for 
Regional and Spatial Analysis (NIRSA), and is primarily aimed at optimizing the 
development of the biotechnology industry through enhancing the formation and 
functioning of networks among the sector’s actors. As you will know, biotechnology 
has been identified by the Irish government as playing a key role in the future 
development of the Irish economy. 
 
The survey is concerned with collaborative or networking arrangements that may 
exist between your firm and other actors in the biotech industry.  Such 
arrangements are formed in order to achieve shared objectives or benefits and 
include (for example) joint marketing or the exchange of skills, equipment, and 
information.  The survey mainly consists of a series of open-ended questions that 
allow you to elaborate on your firm’s specific experiences in forming networks with 
sector actors in the Irish biotechnology industry.  
 
I would be very grateful if you could take the time to complete the enclosed survey 
form. The successful completion of this study is dependent on you completing this 
survey and sharing your experiences of working within the Irish biotechnology 
sector. Completion of the survey should take no more than 10 minutes. Your 
answers will be kept completely confidential and the survey results will be released 
only in summary form so no individual's answers can be identified. 
 
If you have any questions or comments about this study, I would be happy to talk 
with you. You can contact me at the addresses or number on the letterhead. A 
summary of the survey findings will be sent to all participating firms. 
 
Thank you very much for helping us with this important study. 
 
Yours sincerely, 
 
______________ 
John O’Byrne 
Research Fellow, NIRSA 
 
 
 
 
 
 
 
 
 
 
 
  
Tel: +353 (0)1 7086208 
E Mail: john.p.obyrne@nuim.ie 
 
 
National University of Maynooth 
Co. Kildare, Ireland 
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Dear Mr. Doe, 
 
My name is John O'Byrne, I am currently engaged in research for my PhD thesis 
entitled "Networks and the development of the Irish biotechnology sector" at the 
NUI, Maynooth. 
My study, which is sponsored by the Irish Research Council for the Humanities and 
the Social Sciences (IRCHSS) and the National Institute for Regional and Spatial 
Analysis (NIRSA), seeks to optimise the development of the biotechnology industry 
in Ireland through enhancing the formation and functioning of networks among the 
sector's actors. 
I am presently conducting a study of networks and interlinkages between 
universities and the Irish biotechnology industry, and as such, I would like to 
interview key university staff members who are involved in collaborations/alliances 
(research based, or otherwise) with biotechnology firms, corporations (e.g. 
pharmaceutical companies) and other universities. 
I am curious if it would be possible for me to set up an interview with you to explore 
your experiences in facilitating University/biotechnology firm 
alliances/collaborations? 
Please note that any information received during any correspondence will be 
treated with the utmost confidentiality. 
 
Yours sincerely, 
John O'Byrne 
 
Doctoral Research Fellow 
 
Irish Research Council for the Humanities and the Social Sciences 
http://www.irchss.ie/ 
 
National Institute for Regional and Spatial Analysis 
http://www.nuim.ie/nirsa/ 
 
NIRSA 
John Hume Building 
National University of Ireland, Maynooth 
Co. Kildare 
Ireland 
Tel: + 353 - 1 - 7086208 
Email: john.p.obyrne@nuim.ie 
 
 
 
Tel: +353 (0)1 7086208 
E Mail: john.p.obyrne@nuim.ie 
 
 
National University of Maynooth 
Co. Kildare, Ireland 
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Dear Mr. Doe, 
 
My name is John O'Byrne, I am currently engaged in research for my PhD thesis 
entitled "Networks and the development of the Irish biotechnology sector" at the 
NUI, Maynooth. 
My study, which is sponsored by the Irish Research Council for the Humanities and 
the Social Sciences (IRCHSS) and the National Institute for Regional and Spatial 
Analysis (NIRSA), seeks to optimise the development of the biotechnology industry 
in Ireland through enhancing the formation and functioning of networks among the 
sector's actors. 
I am presently conducting a study of networks and interlinkages that exist between 
indigenous biotechnology companies and the Irish biotechnology industry. 
As such, I would like to interview key firm members who are involved in 
collaborations/alliances (research based, or otherwise) with university based 
researchers, corporations (e.g. pharmaceutical companies) and other indigenous 
biotechnology firms. 
I am curious if it would be possible for me to set up an interview with you to explore 
your experiences in relation to your firms networking activities? 
Please note that any information received during any correspondence will be 
treated with the utmost confidentiality. 
 
Yours sincerely, 
John O'Byrne 
 
Doctoral Research Fellow 
 
Irish Research Council for the Humanities and the Social Sciences 
http://www.irchss.ie/ 
 
National Institute for Regional and Spatial Analysis 
http://www.nuim.ie/nirsa/ 
 
NIRSA 
John Hume Building 
National University of Ireland, Maynooth 
Co. Kildare 
Ireland 
Tel: + 353 - 1 - 7086208 
Email: john.p.obyrne@nuim.ie 
Tel: +353 (0)1 7086208 
E Mail: john.p.obyrne@nuim.ie 
 
 
National University of Maynooth 
Co. Kildare, Ireland 
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Dear Mr. Doe, 
 
My name is John O'Byrne, I am currently engaged in research for my PhD thesis 
entitled "Networks and the development of the Irish biotechnology sector". My 
study, which is sponsored by the Irish Research Council for the Humanities and the 
Social Sciences (IRCHSS) and the National Institute for Regional and Spatial 
Analysis (NIRSA), seeks to optimise the development of the biotechnology industry 
in Ireland through enhancing the formation and functioning of networks among the 
sector's actors.  
I am presently conducting a detailed study of existing networks and interlinkages 
between all sectoral actors in the domestic biotechnology sector, and as such, I 
would like to interview key staff members of agencies that are involved in the 
sector.  
I am curious if it would be possible for me to set up an interview in order to explore 
your experiences/views/opinions in relation to the domestic biotechnology sector?  
Please note that any information received during any correspondence will be 
treated with the utmost confidentiality.  
 
Yours sincerely,  
John O'Byrne 
 
Doctoral Research Fellow 
 
Irish Research Council for the Humanities and the Social Sciences 
http://www.irchss.ie/ 
 
National Institute for Regional and Spatial Analysis 
http://www.nuim.ie/nirsa/ 
 
NIRSA 
John Hume Building 
National University of Ireland, Maynooth 
Co. Kildare 
Ireland 
Tel: + 353 - 1 - 7086208 
Email: john.p.obyrne@nuim.ie Tel: +353 (0)1 7086208 
E Mail: john.p.obyrne@nuim.ie 
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APPENDIX C:  
BIOTECHNOLOGY/BIOTECHNOLOGY-RELATED  
DEPARTMENTS IN IRISH UNIVERSITIES 
  
This appendix details and discusses the various biotechnology/biotechnology-related 
departmental and educational activities conducted by Irish university 
biotechnology/biotechnology-related departments and faculties.  
 
There are eight Universities in Ireland: 
 
 Dublin City University (DCU) 
 University College Cork (UCC) 
 University College Dublin (UCD) 
 National University of Ireland Galway (NUIG) 
 National University of Ireland Maynooth (NUI, Maynooth) 
 Trinity College Dublin (TCD) 
 the University of Limerick (UL), and  
 the Royal College of Surgeons, Ireland 
 
C.1 DUBLIN CITY UNIVERSITY 
Founded in 1980 as a technical college, Dublin City University (DCU) was awarded 
university status in 1989. DCU was the first Irish University to establish an 
undergraduate degree in Biotechnology in the mid 1980s (Dublin City University, 
2005).  
 
C.1.1 DCU Faculties 
C.1.1.1 Faculty of Science and Health 
The six schools of DCU’s Faculty of Science and Health’s teaching and research 
activities are inter-disciplinary focused. Among the teaching aspect of the various 
faculty school programmes are physical and biological sciences (Dublin City 
University, 2007a).  
 
C.1.1.1.1 School of Biotechnology 
DCU’s School of Biotechnology incorporates teaching and research facilities in a single 
departmental unit for Process Engineers, Biochemists, Microbiologists, Geneticists and 
Pharmacologists. The school has established basic and applied research collaborative 
links with national and international research laboratories and has developed close 
alliances with DCU based research centres (discussed in further detail in Appendix D) 
such as the National Institute for Cellular Biotechnology (NICB) and the National 
Centre for Sensor Research (NCSR) (Dublin City University, 2005).  
 
The School’s undergraduate programme includes four year B.Sc. degrees in 
Biotechnology, Environmental Science & Health, and Genetics and Cell Biology. The 
School’s postgraduate degree programmes include a M.Sc. in Bioinformatics, and a 
GDip/MSc in Biomedical Diagnostics (Dublin City University, 2007b, 2007c, 2007d, 
2007e, 2007f). 
 
C.1.1.1.2 School of Chemical Sciences 
The School of Chemical Sciences research activities include environmental and 
analytical chemistry, combinatorial synthesis, nanotechnology, photochemistry and 
spectroscopy research programmes. Close research collaborations have developed 
between the school and the NICB and the NCSR. The School’s teaching programmes 
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include B.Sc. degrees in Analytical Science, Chemical and Pharmaceutical Sciences 
(Dublin City University, 2007g, 2007h, 2007i).  
 
 
C.2 UNIVERSITY COLLEGE CORK   
University College Cork (UCC) was founded in 1845 and is the second largest 
university in Ireland (University College Cork, 2007).  
 
C.2.1 UCC Faculties 
UCC’s College of Science, Engineering and Food Science comprises of the Faculties of 
Science, Engineering, and Food Science and Technology (University College Cork, 
2006a).  
 
C.2.1.1 The Faculty of Science  
UCC’s Faculty of Science includes the Departments of Biochemistry, Chemistry, 
Microbiology, Zoology, Ecology, and Plant Science (University College Cork, 2007). 
 
C.2.1.1.1 The Department of Biochemistry  
Established in 1945, the Department of Biochemistry is engaged in molecular and 
cellular education, training and research. The Department of Biochemistry’s 
undergraduate programmes include a four year B.Sc. in Biochemistry, this degree 
focuses on the biological and chemical sciences. The degree involves courses on 
Structural Biochemistry, Membrane Biochemistry, Cell Signalling, Biochemical 
Immunology, Principles of Medical Genetics, and Bioinformatics. The Department it is 
also involved in the Biomedical Sciences degree, the BSc in Genetics, the preclinical 
years of the medical degree (MB, BCh, BAO), dental degree (BDS) courses in the 
medical foundation year, and the BSc in chemistry of pharmaceutical compounds. The 
Department’s postgraduate degree programmes include Higher Diploma in Applied 
Science (Biotechnology), and a M.Sc. degree in Applied Science (Biotechnology) 
(University College Cork, 2003a, 2006b)  
 
C.2.1.1.2 The Department of Microbiology   
The Department of Microbiology is a member of two UCC Faculties, the faculty of 
Science and Food Science and Technology and the Faculty of Medicine. The 
Department has established close research and teaching ties with UCC departments, 
including the Department of Food Science and Technology, the Department of 
Medicine. Extensive collaborations have developed with Teagasc’s Dairy Products 
Centre in Moorepark, Fermoy. The department’s research programmes include topics in 
Genomics and Molecular Biology (University College Cork, 2005).  
 
The Department’s undergraduate programme includes a B.Sc. in Biology that has six 
possible specialisations: Microbiology, Plant and Microbial Biotechnology, Biomedical 
Sciences, Food Sciences, Food Technology, and Genetics. The Department’s 
postgraduate degree programmes include a research based M.Sc. degree. This is based 
upon a research project completed under the supervision of a faculty member 
(University College Cork, 2005).  
 
C.2.1.1.3 The Department of Zoology, Ecology, and Plant Science 
The Department of Zoology, Ecology, and Plant Science (ZEPS) was formed in 2002 
with the amalgamation of UCC’s Departments of Zoology and Animal Ecology, and 
Plant Science. The Department’s research activities are in the areas of marine, terrestrial 
and freshwater animal/plant ecology, environmental plant biotechnology, and population 
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genetics (University College Cork, 2003b).  
 
The Department’s undergraduate degree programmes include B.Sc. degrees in Zoology, 
Applied Ecology, and Environmental Plant Biotechnology. The Department’s 
postgraduate degree programmes include s a two year M.Sc. in Ecosystem Conservation 
and Landscape Management (University College Cork, 2007, 2006c).  
 
 
C.2.1.2 The Faculty of Food Science and Technology 
The Faculty of Food Science and Technology’s activities are focuses on the areas of 
Dairy and Food Science education and research, including Food Biotechnology. There 
are 5 Departments in the Faculty including the Departments of Food, Business and 
Development, Microbiology (discussed above), Food and Nutritional Science, and 
Process and Chemical Engineering. The Faculty has developed close connections with 
the National Food Biotechnology Centre (NFBC) (University College Cork, 2006a). 
 
C.2.1.2.1 The Department of Food, Business and Development 
The Department is focused on research relating to the agri-food industry, including 
developing current agricultural practices, to food processing. The research activities of 
the Department are focused on three general topics, Food Business, co-operative 
Business, and Rural Development.  
 
The Department’s undergraduate programmes include a 2 year B.Sc. in Food Business. 
This degree combines Food Business and Food Science and Technology courses. 
Business and marketing skills are combined with knowledge of food products and 
processes. The Department’s postgraduate degree programmes include a range of 
postgraduate courses and research programmes are offered by the department. Ph.D. and 
MSc research programmes in Food Chemistry, Food Economics, Food Engineering, 
Food Technology, Microbiology and Nutrition are available (University College Cork, 
2007d, 2007e).  
 
C.2.1.2.2 The Department of Physiology 
The Department of Physiology brings together academics from the fields of physiology, 
pharmacology, biochemistry, molecular biology and clinical research. The Department’s 
research involves programmes in the fields of Cell, Molecular and Integrative 
Physiology. Collaborative research projects are conducted with researchers from the 
Departments of Microbiology and Anatomy, and the Biosciences Research Institute 
(University College Cork, 2007f, 2007g).  
 
C.3 UNIVERSITY COLLEGE DUBLIN   
University College Dublin (UCD) was originally established in 1854. UCD is Ireland’s 
largest university with 5 Colleges and 35 Schools. The University’s biotechnology and 
biotechnology-related research is conducted in the Departments of Medicine, Veterinary 
Medicine and Agriculture as well the Department of Biochemistry, Industrial 
Microbiology, Botany, Zoology, Microbiology and Pharmacology, yet the main activity 
is carried out in the faculty of Science where research efforts focus on microbiology, 
molecular genetics, toxicology, immunology, drug design, biodiversity, industrial 
microbiology, pharmacology and zoology (Burke at al., 2003).  
 
C.3.1 College of Engineering, Mathematical and Physical Sciences 
There are 7 schools in the College of Engineering, Mathematical and Physical Sciences, 
including the School of Chemical and Bioprocess Engineering (University College 
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Dublin, 2007a). 
 
C.3.1.1 The UCD School of Chemical and Bioprocess Engineering 
The School of Chemical and Bioprocess Engineering is engaged in research in the areas 
of Bioprocess engineering, Cell biology, Biofilm Engineering, and Animal Cell Culture 
Technology. The School’s teaching programmes include a 4 year B.E. in Chemical 
Engineering or Bioprocess Engineering and taught and research MEngSc degrees 
(University College Dublin, 2006, 2007b, 2007c). 
 
C.3.2 The College of Life Sciences 
The College of Life Science comprises eight scientific schools, and the UCD Veterinary 
Hospital (University College Dublin, 2007d). 
 
C.3.2.1 School of Agriculture, Food Science and Veterinary Medicine 
The school engages in research and teaching programmes focused on animal health and 
welfare, human health, food systems and agriculture. The School’s undergraduate 
degree programmes include B.Sc. degrees in Food Science, Food & Agri-Business 
Management, Agri-Environmental Sciences, Animal & Crop Production, Animal 
Science, and in Engineering Technology. The School’s postgraduate degree include 
research M.Sc. degrees in Science, Science (Agriculture), Agricultural Science, Animal 
Science, Engineering Science, and in Veterinary Medicine. The School also offers 
taught M.Sc. degrees in Engineering Science: Food Engineering, and Engineering 
Technology (University College Dublin, 2007e, 2007f, 2007g, 2007h). 
 
C.3.2.2 UCD School of Biology and Environmental Science 
The school engages in teaching and research in the areas of modern biology and 
environmental science, these include programmes in botany, cell and molecular biology, 
environmental science, genetics, and zoology. The school’s research programmes cover 
a wide range of areas: general zoology, animal behaviour, biodiversity, bioremediation, 
cell biology, developmental biology, genetics, and marine fisheries (University College 
Dublin, 2007i).  
 
C.3.2.3 UCD School of Biomolecular and Biomedical Science 
The School brings together academics different disciplines including Biochemistry, 
Microbiology, Pharmacology and Physiology. The school’s research and teaching 
programmes are focused biological systems at molecular, cellular and whole organism 
levels. The school is part of the Conway Institute of Biomolecular and Biomedical 
Research (University College Dublin, 2007j).  
 
The School’s undergraduate programmes include B.Sc. (Honours) and B.Sc. (General) 
degrees in Biochemistry, Microbiology, Pharmacology and Physiology. B.Sc. (Joint 
Honours) programmes are also available to prospective students, which can be 
combined with degrees in other disciplines including Chemistry and Molecular Genetics 
(University College Dublin, 2007k).  
 
C.3.2.4 UCD School of Chemistry and Chemical Biology 
The School is home to 24 research groups with interests spanning a wide range of 
chemical sciences. The School opened the Centre for Synthesis and Chemical Biology 
(CSCB) in 2005. The School of Chemistry and Chemical Biology’s teaching 
programmes include a 4 year B.Sc. in Medicinal Chemistry & Chemical Biology that 
was introduced in 2007 (University College Dublin, 2007l, 2007m). 
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C.3.2.5 UCD School of Medicine and Medical Science 
The School has developed clinical research programs in six Dublin partner hospitals: 
 
 the Mater Misericordiae University Hospital;  
 St. Vincent's University Hospital;  
 the National Maternity Hospital;  
 the Coombe Women's Hospital;  
 Our Lady's Hospital for Sick Children; and  
 the Children's University Hospital at Temple Street.  
 
The school’s research programmes range from fundamental biology through 
translational research to population and clinical research. The school has extensive 
collaborations with the Conway Institute of Biomolecular and Biomedical Sciences and 
the Dublin Molecular Medicine Centre. The School’s teaching programmes include a 
B.Sc. in Biomedical Health and Life Sciences as well as taught and research 
postgraduate level M.Sc. degrees (University College Dublin, 2007n, 2007o). 
 
 
C.4 NATIONAL UNIVERSITY OF IRELAND, GALWAY    
The National University of Ireland at Galway (NUIG) was originally founded in 1845, 
and became one of the National Universities of Ireland in 1997 (National University of 
Ireland, Galway, 2007a).  
 
C.4.1 The Faculty of Medicine, Nursing, and Health Sciences 
C.4.1.1 The Department of Bacteriology 
The Department hosts the National Salmonella Reference Laboratory for Ireland, while 
its research activities include Antimicrobial Resistance in Human and Animal 
Pathogens. The department is closely associated with the Department of Medical 
Microbiology at NUIG’s University College Hospital. The Department of 
Bacteriology’s Bacteriology course begins in the final term of the Third Medical year. 
The Department also runs a Mechanisms of Disease course jointly with the Department 
of Pathology (National University of Ireland, Galway, 2007b, 2007c). 
 
C.4.2 The Faculty of Science 
The Faculty of Science’s department include the Department of Biochemistry, 
Chemistry, Microbiology, and Pharmaceutical and Therapeutics. The faculty of science 
offers two types of B.Sc. degrees, the undenominated programme (a three year degree 
that has a general focus to allow students to identify the area they are most interested in) 
and the denominated programme (this has a specific focus and is four years long) 
(National University of Ireland, Galway, 2003, 2007d).  
 
C.4.2.1 The Department of Biochemistry 
The Department of Biochemistry was established in 1963. The department’s activities 
involve activities in the areas of genetics, immunology, cell biology and structural 
biology. The Department’s undergraduate programmes include a B.Sc. in Biochemistry. 
The Department of Biochemistry, in collaboration with the Departments of 
Microbiology and Medicine, offers a B.Sc. in Biotechnology. The B.Sc. in 
Biotechnology is a four year degree in which students specialise in one of the following 
subject areas: Anatomy, Physiology or Biochemistry. The degree also includes an annual 
ICT module, the aim being to produce graduates with the necessary skills needed in 
industry (National University of Ireland, Galway, 2007e, 2007f).  
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C.4.2.2 The Department of Chemistry 
The Department of Chemistry was founded in 1849, its research activities include 
Environmental Chemistry, Chemical Synthesis, and Bioanalytical Chemistry. The 
Department offers a four year B.Sc. Programme, and a H.Dip. in Analytical Chemistry 
and Biochemistry (National University of Ireland, Galway, 2007g, 2007h).  
 
C.4.2.3 The Department of Botany 
The Department of Botany offers Botany B.Sc. degrees at general and honours level. 
The first year of the degree entails an extensive course in basic Biology (no prior 
knowledge of biology is necessary for students). The second and third years of the 
degree become more specialized in their focus. Only in the fourth year (when a student 
has qualified to complete an honours degree) is Botany studied exclusively. The Botany 
Department also contributes extensively to the Denominated B.Sc. Degrees in Marine 
and Environmental Science (National University of Ireland, Galway, 2007i). 
 
C.4.2.4 The Department of Microbiology 
The Department of Microbiology was established in 1965. The department’s research 
focuses are in the areas of biotechnology, environmental microbiology, aquaculture, 
marine sciences, genetics and bacterial pathogenesis (National University of Ireland, 
Galway, 2007j).  
 
C.4.2.5 The Department of Pharmacology  
The Department was formed in 1974, its research activities focus on the central nervous 
system, in particular the mechanism of action of antidepressants and drugs of abuse. 
The Department’s undergraduate programmes include courses on Medicine, and B.Sc. 
degrees in Biotechnology, Biomedical Science and Nursing (National University of 
Ireland, Galway, 2007k).  
 
C.5 NATIONAL UNIVERSITY OF IRELAND, MAYNOOTH 
The National University of Ireland at Maynooth (NUIM) was established as a university 
in 1997 (National University of Maynooth, 2007a).  
 
C.5.1 The Faculty of Science & Engineering  
C.5.1.1 The Department of Biology 
Established in 1970, the Department of Biology has grown into one of the largest 
departments in the university. The Department of Biology’s research focus is in the 
areas of Biological Control, Immunology, Medical Mycology, Molecular Genetics and 
Plant Biotechnology (National University of Maynooth, 2007b).  
 
The Department of Biology offers prospective students several four year B.Sc. degree 
courses; a BSc (Single Honours)/ BSc (Double Honours) (in which students are 
educated in a wide educational range in modern biological activities, including 
Evolutionary Biology, Microbiology, Plant Biology, Bioethics and Biotechnology), a 
Denominated Honours Degree in Biotechnology, and Denominated Honours Degree in 
Genetics & Bioinformatics. The postgraduate degree options available through the 
department include a taught MSc in Immunology & Global Health, and research MSc 
and PhD degrees (National University of Maynooth, 2007c).  
 
C.6 TRINITY COLLEGE DUBLIN 
Trinity College Dublin (TCD) is Ireland’s oldest university, being established in 1592. 
There are five academic faculties in TCD, two of which are related to biotechnology 
(Trinity College Dublin, 2007a). 
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C.6.1 The Faculty of Health Science 
The Faculty of Health Sciences brings together four schools, the schools of Medicine, 
Dental Science, Pharmacy and Pharmaceutical Sciences, and Nursing and Midwifery. 
The faculty has close alliances with two Dublin teaching hospitals; St James's Hospital 
and the Adelaide and Meath Hospital, Dublin incorporating the National Children's 
Hospital (AMNCH) at Tallaght (Trinity College Dublin, 2007b).  
 
C.6.1.1 The School of Pharmacy and Pharmaceutical Sciences 
Established in 1977, the School of Pharmacy and Pharmaceutical Sciences offers 
prospective students a B.Sc. in Pharmacy, and several postgraduate degree types: M.Sc. 
and Diplomas in Pharmaceutical Manufacturing Technology and Pharmaceutical 
Analysis, and a M.Sc. in Pharmaceutical Technology (Trinity College Dublin, 2007c, 
2007d). 
 
C.6.2 The Faculty of Science 
The Faculty of Science facilities include the East End Building, located on the main 
TCD campus. This building houses the School of Pharmacy, the Smurfit Institute of 
Genetics, and the Biology Teaching centre (Trinity College Dublin, 2007e).  
 
C.6.2.1 The School of Biochemistry and Immunology  
The School of Biochemistry and Immunology was established in 2005 through the 
joining of the existing disciplines of Biochemistry and Immunology. The school’s 
research programmes include Folic Acid Biochemistry, Structural Biology, 
Neurochemistry, Biotechnology and Vaccines. The school offer three undergraduate 
degree programmes to prospective students in Biochemistry with Structural Biology, 
Biochemistry with Cell Biology and Biochemistry with Immunology. The School also 
offers a research M.Sc. (Trinity College Dublin, 2007f, 2007g, 2007h, 2007i).  
 
C.6.3 The Vice-Deanery of Genetics & Microbiology  
This Vice-Deanery of Genetics & Microbiology comprises the Smurfit Institute of 
Genetics, and the Department of Microbiology (Trinity College Dublin, 2007j). 
 
C.6.3.1 The Smurfit Institute of Genetics 
Established in 1998, the research and teaching programmes of the Institute of Genetics 
encompasses molecular, cellular, developmental, behavioural, medical, psychiatric, 
population and quantitative genetics. The institute offers two B.A. undergraduate degree 
programmes in Genetics and Human Genetics (Trinity College Dublin, 2007k, 2007l). 
 
C.6.3.2 The Department of Microbiology 
The Department’s research topics include molecular biology of pathogenic microbes, 
preventive medicine, and microbial systems biology. The Department has established 
extensive research alliances with the Unit of Clinical Microbiology at St. James's 
Hospital. The Department’s undergraduate programme is a 4 year B.A. in Microbiology. 
The Department’s postgraduate programmes include research M.Sc. and Ph.D. 
programmes (Trinity College Dublin, 2007m).  
 
C.7 UNIVERSITY OF LIMERICK    
The University of Limerick (UL) was established in 1972, it became a university in 
1989 (University of Limerick, 2006). 
 
C.7.1 The College of Science 
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The College of Science includes extensive teaching and research programmes in a wide 
Sciences, 
Pharmaceutical and Industrial Chemistry, and Food Science & Health. The College’s 
research focus includes the environment and biosciences (University of Limerick, 
2007a). 
 
C.7.1.1 The Department of Chemical & Environmental Sciences  
The Department’s research activities include electrochemistry, organic chemistry and 
industrial biochemistry. The Department offers undergraduate B.Sc. degree courses in 
Pharmaceutical and Industrial Chemistry, Industrial Biochemistry, and Environmental 
Science (University of Limerick, 2003: 2007b).  
 
C.7.1.2 The Department of Life Sciences 
The Department BSc degree courses in Food Technology, and Equine Science 
(University of Limerick, 2007c, 2007d).  
 
C.8 THE ROYAL COLLEGE OF SURGEONS, IRELAND  
The Royal College of Surgeons (RCSI) was established in 1784. Since 1977 it has 
recognised as one of the National University of Ireland colleges (Royal College of 
Surgeons, Ireland, 2007a, 2007b).  
 
C.8.1 The School of Medicine and Health Sciences 
C.8.1.1 The Department of Clinical Microbiology 
The Department of Clinical Microbiology was established in 1965, it is located in the 
RCSI Education and Research Centre and the Smurfit Building on the Beaumont 
Hospital campus. The department’s research programmes includes basic and clinical 
research, with particular focus on the genetics of bacterial virulence factors and the 
surveillance and treatment of antibiotic resistant pathogens. The department conducts 
undergraduate and postgraduate teaching of medical, pharmacy and nursing students 
(Royal College of Surgeons, Ireland, 2003).  
 
C.8.1.2 The Department of Molecular and Cellular Therapeutics 
The Department was established in 2006 through the amalgamation of the Departments 
of Biochemistry and Clinical Pharmacology. The Department is engaged in wide 
reaching teaching and research programmes that cover the preclinical and clinical 
domains of the college. The Department is located on the main RCSI campus and 
additional facilities at Beaumont Hospital. The Department’s research activities include 
molecular and population genetic aspects of inherited disease, metabolic diseases, 
cardiovascular medicine and neuroscience (Royal College of Surgeons, 2007c).  
 
C.8.2 The School of Pharmacy 
The School is engaged in biopharmaceutical science research, and offers a four year 
B.Sc. in Pharmacy as well as a M.Sc. in Industrial Pharmaceutical Sciences (Royal 
College of Surgeons, 2007d).  
 
 
 
